

Ki67 expression in breast cancer

Journal of King Abdulaziz University, Islamic Economics
37, 137-141

DOI: [10.15537/smj.2016.2.12285](https://doi.org/10.15537/smj.2016.2.12285)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Regulation of somatic growth by the p160 coactivator p/CIP. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 13549-13554.	3.3	176
2	Does massively parallel transcriptome analysis signify the end of cancer histopathology as we know it?. Genome Biology, 2000, 1, reviews1021.1.	13.9	16
3	Tamoxifen Resistance in Breast Cancer. Drugs, 2001, 61, 1721-1733.	4.9	87
4	Characterization of adjacent breast tumors using oligonucleotide microarrays. Breast Cancer Research, 2001, 3, 336-41.	2.2	36
5	Applications of microarray technology in breast cancer research. Breast Cancer Research, 2001, 3, 158-75.	2.2	70
6	More breast cancer genes?. Breast Cancer Research, 2001, 3, 154-7.	2.2	9
7	Molecular profiling of breast cancer: portraits but not physiognomy. Breast Cancer Research, 2001, 3, 77.	2.2	32
8	Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biology, 2001, 2, research0041.1.	13.9	304
9	Expression Profiling of Human Tumors: The End of Surgical Pathology?. Journal of Molecular Diagnostics, 2001, 3, 92-97.	1.2	33
10	Molecular Signatures of Sepsis. American Journal of Pathology, 2001, 159, 1199-1209.	1.9	190
11	Comparative Genome-Scale Analysis of Gene Expression Profiles in T Cell Lymphoma Cells during Malignant Progression Using a Complementary DNA Microarray. American Journal of Pathology, 2001, 158, 1231-1237.	1.9	62
12	Expression Profiling of Ductal Carcinoma in Situ by Laser Capture Microdissection and High-Density Oligonucleotide Arrays. American Journal of Pathology, 2001, 158, 2005-2010.	1.9	116
13	Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 10869-10874.	3.3	9,721
14	Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 13790-13795.	3.3	2,270
15	A Streamlined Process to Phenotypically Profile Heterologous cDNAs in Parallel Using Yeast Cell-Based Assays. Genome Research, 2001, 11, 1899-1912.	2.4	30
16	Progress in the application of DNA microarrays.. Environmental Health Perspectives, 2001, 109, 881-891.	2.8	59
17	Toxicogenomics: "the call of the wild chip".. Environmental Health Perspectives, 2001, 109, A8-11.	2.8	20
18	Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer. Journal of Clinical Pathology, 2001, 54, 281-284.	2.1	13

#	ARTICLE	IF	CITATIONS
19	Identification of Disease-specific Genes in Chronic Pancreatitis Using DNA Array Technology. <i>Annals of Surgery</i> , 2001, 234, 769-779.	2.1	55
20	Biomarker Identification by Feature Wrappers. <i>Genome Research</i> , 2001, 11, 1878-1887.	2.4	243
21	Identification and Classification of Differentially Expressed Genes in Renal Cell Carcinoma by Expression Profiling on a Global Human 31,500-Element cDNA Array. <i>Genome Research</i> , 2001, 11, 1861-1870.	2.4	184
22	Multiclass cancer diagnosis using tumor gene expression signatures. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 15149-15154.	3.3	1,885
23	Phosphatidylinositol 3' kinase signaling in mammary tumorigenesis. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2001, 6, 83-99.	1.0	34
24	Molecular Genetics of Ovarian Cancer. <i>Molecular Biotechnology</i> , 2001, 19, 013-028.	1.3	2
25	CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. <i>British Journal of Cancer</i> , 2001, 85, 422-427.	2.9	129
26	Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. <i>Nature Medicine</i> , 2001, 7, 673-679.	15.2	2,352
27	PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors. <i>Oncogene</i> , 2001, 20, 626-633.	2.6	111
28	Genetic programs of epithelial cell plasticity directed by transforming growth factor- β . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 6686-6691.	3.3	505
29	Molecular characteristics of non-small cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 15203-15208.	3.3	119
30	Papillomavirus Type 16 Oncogenes Downregulate Expression of Interferon-Responsive Genes and Upregulate Proliferation-Associated and NF- κ B-Responsive Genes in Cervical Keratinocytes. <i>Journal of Virology</i> , 2001, 75, 4283-4296.	1.5	345
31	Science, medicine, and the future: DNA microarrays in medical practice. <i>BMJ: British Medical Journal</i> , 2001, 323, 611-615.	2.4	75
32	Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features. <i>British Journal of Cancer</i> , 2001, 85, 538-545.	2.9	17
33	Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 9754-9759.	3.3	363
34	Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 1124-1129.	3.3	266
35	Ceramic Capillaries for Use in Microarray Fabrication. <i>Genome Research</i> , 2001, 11, 1780-1783.	2.4	16
36	Comparative expressed sequence hybridization to chromosomes for tumor classification and identification of genomic regions of differential gene expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 9197-9202.	3.3	53

#	ARTICLE	IF	CITATIONS
37	Architectural Transcription Factor HMGI(Y) Promotes Tumor Progression and Mesenchymal Transition of Human Epithelial Cells. <i>Molecular and Cellular Biology</i> , 2001, 21, 575-594.	1.1	228
38	Diversity of gene expression in adenocarcinoma of the lung. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 13784-13789.	3.3	1,151
39	Diversity, topographic differentiation, and positional memory in human fibroblasts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 12877-12882.	3.3	983
40	External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 12747-12752.	3.3	63
41	A Highly Reproducible, Linear, and Automated Sample Preparation Method for DNA Microarrays. <i>Genome Research</i> , 2002, 12, 976-984.	2.4	41
42	Initiating oncogenic event determines gene-expression patterns of human breast cancer models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 6967-6972.	3.3	192
43	Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 10008-10013.	3.3	246
44	Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 10335-10340.	3.3	312
45	Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 2830-2835.	3.3	83
46	Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 12963-12968.	3.3	1,098
47	Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. <i>British Journal of Cancer</i> , 2002, 86, 1457-1464.	2.9	58
48	Molecular classification of selective oestrogen receptor modulators on the basis of gene expression profiles of breast cancer cells expressing oestrogen receptor β . <i>British Journal of Cancer</i> , 2002, 87, 449-456.	2.9	30
49	Analysis of repeatability in spotted cDNA microarrays. <i>Nucleic Acids Research</i> , 2002, 30, 3235-3244.	6.5	49
50	Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 16203-16208.	3.3	166
51	Identification of Genes Periodically Expressed in the Human Cell Cycle and Their Expression in Tumors. <i>Molecular Biology of the Cell</i> , 2002, 13, 1977-2000.	0.9	1,352
52	An assessment of Motorola CodeLink TM microarray performance for gene expression profiling applications. <i>Nucleic Acids Research</i> , 2002, 30, 30e-30.	6.5	178
53	A protein disulfide isomerase expressed in the embryonic midline is required for left/right asymmetries. <i>Genes and Development</i> , 2002, 16, 2518-2529.	2.7	37
54	BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 7560-7565.	3.3	224

#	ARTICLE	IF	CITATIONS
55	In Vivo Regulation of Human Skeletal Muscle Gene Expression by Thyroid Hormone. <i>Genome Research</i> , 2002, 12, 281-291.	2.4	143
56	Fully Automatic Quantification of Microarray Image Data. <i>Genome Research</i> , 2002, 12, 325-332.	2.4	303
57	Transcript Profiling of Functionally Related Groups of Genes During Conditional Differentiation of a Mammalian Cochlear Hair Cell Line. <i>Genome Research</i> , 2002, 12, 1091-1099.	2.4	58
58	Detection of genes expressed in primary colon cancers by in situ hybridisation: overexpression of RACK 1. <i>Journal of Clinical Pathology</i> , 2002, 55, 34-39.	2.1	30
59	Differential Gene Expression Patterns in HER2/neu-Positive and -Negative Breast Cancer Cell Lines and Tissues. <i>American Journal of Pathology</i> , 2002, 161, 1171-1185.	1.9	97
60	Software Tools for High-Throughput Analysis and Archiving of Immunohistochemistry Staining Data Obtained with Tissue Microarrays. <i>American Journal of Pathology</i> , 2002, 161, 1557-1565.	1.9	194
61	Expression Profiling of Synovial Sarcoma by cDNA Microarrays. <i>American Journal of Pathology</i> , 2002, 161, 1587-1595.	1.9	173
62	Genes Involved in Breast Cancer Progression. <i>American Journal of Pathology</i> , 2002, 161, 1973-1977.	1.9	3
63	Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome. <i>American Journal of Pathology</i> , 2002, 161, 1991-1996.	1.9	494
64	Quantitative Assessment of Promoter Hypermethylation during Breast Cancer Development. <i>American Journal of Pathology</i> , 2002, 160, 605-612.	1.9	210
65	Insights from gene arrays on the development and growth regulation of uterine leiomyomata. <i>Fertility and Sterility</i> , 2002, 78, 114-121.	0.5	173
66	Expression profiling to predict outcome in breast cancer: the influence of sample selection. <i>Breast Cancer Research</i> , 2002, 5, 23-6.	2.2	35
67	The importance of being a myoepithelial cell. <i>Breast Cancer Research</i> , 2002, 4, 224-30.	2.2	131
68	Within the fold: assessing differential expression measures and reproducibility in microarray assays. <i>Genome Biology</i> , 2002, 3, research0062.1.	13.9	195
69	Have microarrays failed to deliver for developmental biology?. <i>Genome Biology</i> , 2002, 3, comment2009.1.	13.9	16
70	Transcriptional programs activated by exposure of human prostate cancer cells to androgen. <i>Genome Biology</i> , 2002, 3, research0032.1.	13.9	158
71	Physical mapping of genes in somatic cell radiation hybrids by comparative genomic hybridization to cDNA microarrays. <i>Genome Biology</i> , 2002, 3, research0026.1.	13.9	7
72	Microarray profile of differentially expressed genes in a monkey model of allergic asthma. <i>Genome Biology</i> , 2002, 3, research0020.1.	13.9	80

#	ARTICLE	IF	CITATIONS
73	Microarrays and molecular markers for tumor classification. <i>Genome Biology</i> , 2002, 3, comment2005.1.	13.9	15
74	Vector algebra in the analysis of genome-wide expression data. <i>Genome Biology</i> , 2002, 3, research0011.1.	13.9	45
75	Gene Expression Patterns in Human Liver Cancers. <i>Molecular Biology of the Cell</i> , 2002, 13, 1929-1939.	0.9	779
76	Gene Expression Phenotype in Heterozygous Carriers of Ataxia Telangiectasia. <i>American Journal of Human Genetics</i> , 2002, 71, 791-800.	2.6	50
77	Microarray Analysis of B-Cell Lymphoma Cell Lines with the t(14;18). <i>Journal of Molecular Diagnostics</i> , 2002, 4, 123-136.	1.2	22
78	Insulin-Like Growth Factor-1 Incribes a Gene Expression Profile for Angiogenic Factors and Cancer Progression in Breast Epithelial Cells. <i>Neoplasia</i> , 2002, 4, 204-217.	2.3	52
79	Core Biopsies Can Be Used to Distinguish Differences in Expression Profiling by cDNA Microarrays. <i>Journal of Molecular Diagnostics</i> , 2002, 4, 30-36.	1.2	41
80	Application of a Multigene Reverse Transcription-PCR Assay for Detection of Mammaglobin and Complementary Transcribed Genes in Breast Cancer Lymph Nodes. <i>Clinical Chemistry</i> , 2002, 48, 1225-1231.	1.5	54
81	Clustering of the SOM easily reveals distinct gene expression patterns: results of a reanalysis of lymphoma study. <i>BMC Bioinformatics</i> , 2002, 3, 36.	1.2	99
82	Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis. <i>BMC Genomics</i> , 2002, 3, 31.	1.2	124
83	The organizing principle: microenvironmental influences in the normal and malignant breast. <i>Differentiation</i> , 2002, 70, 537-546.	1.0	542
84	Quantitative assessment of the use of modified nucleoside triphosphates in expression profiling: differential effects on signal intensities and impacts on expression ratios. <i>BMC Biotechnology</i> , 2002, 2, 14.	1.7	4
85	The transcriptional response of human macrophages to murabutide reflects a spectrum of biological effects for the synthetic immunomodulator. <i>Clinical and Experimental Immunology</i> , 2002, 128, 474-482.	1.1	15
86	Identifying pre-post chemotherapy differences in gene expression in breast tumours: a statistical method appropriate for this aim. <i>British Journal of Cancer</i> , 2002, 86, 1093-1096.	2.9	23
87	Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence. <i>British Journal of Cancer</i> , 2002, 87, 1105-1111.	2.9	57
88	Expression profiling with oligonucleotide arrays: technologies and applications for neurobiology. <i>Neurochemical Research</i> , 2002, 27, 1005-1026.	1.6	10
89	Expression Profiling of Human Breast Cancers and Gene Regulation by Progesterone Receptors. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2003, 8, 257-268.	1.0	53
90	Interrogating Mouse Mammary Cancer Models: Insights from Gene Expression Profiling. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2003, 8, 321-334.	1.0	11

#	ARTICLE	IF	CITATIONS
91	Laser Capture Microdissection and Advanced Molecular Analysis of Human Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2003, 8, 335-345.	1.0	44
92	Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003, 442, 271-277.	1.4	118
93	Not just for housekeeping: protein initiation and elongation factors in cell growth and tumorigenesis. <i>Journal of Molecular Medicine</i> , 2003, 81, 536-548.	1.7	119
94	Neural network analysis of lymphoma microarray data: prognosis and diagnosis near-perfect. <i>BMC Bioinformatics</i> , 2003, 4, 13.	1.2	74
95	Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification. <i>BMC Cancer</i> , 2003, 3, 3.	1.1	85
96	Gene expression analysis on small numbers of invasive cells collected by chemotaxis from primary mammary tumors of the mouse. <i>BMC Biotechnology</i> , 2003, 3, 13.	1.7	37
97	Examination of tumour histopathology and gene expression in a neu/S100A4 transgenic model of metastatic breast cancer. <i>International Journal of Experimental Pathology</i> , 2003, 84, 173-184.	0.6	8
98	Regulation of human breast epithelial stem cells. <i>Cell Proliferation</i> , 2003, 36, 45-58.	2.4	109
99	Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept. <i>Cell Proliferation</i> , 2003, 36, 73-84.	2.4	122
100	Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling. <i>British Journal of Cancer</i> , 2003, 88, 510-515.	2.9	81
101	Protein expression profiling arrays: tools for the multiplexed high-throughput analysis of proteins. <i>Proteome Science</i> , 2003, 1, 3.	0.7	35
102	From peas to "chips" - the new millennium of molecular biology: a primer for the surgeon. <i>World Journal of Surgical Oncology</i> , 2003, 1, 21.	0.8	4
103	Multiple mutations and cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 776-781.	3.3	657
104	Tissue Microarray Validation of Epidermal Growth Factor Receptor and SALL2 in Synovial Sarcoma with Comparison to Tumors of Similar Histology. <i>American Journal of Pathology</i> , 2003, 163, 1449-1456.	1.9	133
105	Amplification of a 280-Kilobase Core Region at the ERBB2 Locus Leads to Activation of Two Hypothetical Proteins in Breast Cancer. <i>American Journal of Pathology</i> , 2003, 163, 1979-1984.	1.9	90
106	Differential Expression of Metallothionein 1 and 2 Isoforms in Breast Cancer Lines with Different Invasive Potential. <i>American Journal of Pathology</i> , 2003, 163, 2009-2019.	1.9	61
107	Gene Expression Patterns and Gene Copy Number Changes in Dermatofibrosarcoma Protuberans. <i>American Journal of Pathology</i> , 2003, 163, 2383-2395.	1.9	142
108	Identification of Novel Cellular Targets in Biliary Tract Cancers Using Global Gene Expression Technology. <i>American Journal of Pathology</i> , 2003, 163, 217-229.	1.9	117

#	ARTICLE	IF	CITATIONS
109	Expression Profiling of Mouse Endometrial Cancers Microdissected from Ethanol-Fixed, Paraffin-Embedded Tissues. <i>American Journal of Pathology</i> , 2003, 162, 755-762.	1.9	32
110	Gene Expression Patterns in Renal Cell Carcinoma Assessed by Complementary DNA Microarray. <i>American Journal of Pathology</i> , 2003, 162, 925-932.	1.9	247
111	Repeated observation of breast tumor subtypes in independent gene expression data sets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 8418-8423.	3.3	4,849
112	Malignancy-Associated Regions of Transcriptional Activation: Gene Expression Profiling Identifies Common Chromosomal Regions of a Recurrent Transcriptional Activation in Human Prostate, Breast, Ovarian, and Colon Cancers. <i>Neoplasia</i> , 2003, 5, 218-228.	2.3	31
113	Microarrays bring new insights into understanding of breast cancer metastasis to bone. <i>Breast Cancer Research</i> , 2003, 6, 61.	2.2	38
114	Models of breast cancer: quo vadis, animal modeling?. <i>Breast Cancer Research</i> , 2003, 6, 31-8.	2.2	56
115	The diagnosis and management of pre-invasive breast disease: Promise of new technologies in understanding pre-invasive breast lesions. <i>Breast Cancer Research</i> , 2003, 5, 320-8.	2.2	22
116	Differential gene-expression patterns in genital fibroblasts of normal males and 46,XY females with androgen insensitivity syndrome: evidence for early programming involving the androgen receptor. <i>Genome Biology</i> , 2003, 4, R37.	13.9	45
117	MicroSAGE is highly representative and reproducible but reveals major differences in gene expression among samples obtained from similar tissues. <i>Genome Biology</i> , 2003, 4, R17.	13.9	36
118	Identification of expressed genes linked to malignancy of human colorectal carcinoma by parametric clustering of quantitative expression data. <i>Genome Biology</i> , 2003, 4, R21.	13.9	59
119	Breast cancer classification and prognosis based on gene expression profiles from a population-based study. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 10393-10398.	3.3	1,796
120	Gene expression profiles of primary breast tumors maintained in distant metastases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 15901-15905.	3.3	404
121	Fluorescent labelling of cRNA for microarray applications. <i>Nucleic Acids Research</i> , 2003, 31, 20e-20.	6.5	92
122	Ligand-independent activation of estrogen receptor \hat{A} by XBP-1. <i>Nucleic Acids Research</i> , 2003, 31, 5266-5274.	6.5	112
123	Variation in Gene Expression Patterns in Human Gastric Cancers. <i>Molecular Biology of the Cell</i> , 2003, 14, 3208-3215.	0.9	285
124	A Classification-Based Machine Learning Approach for the Analysis of Genome-Wide Expression Data. <i>Genome Research</i> , 2003, 13, 503-512.	2.4	40
125	Variation in gene expression patterns in follicular lymphoma and the response to rituximab. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 1926-1930.	3.3	144
126	Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 15853-15858.	3.3	486

#	ARTICLE	IF	CITATIONS
127	A neural survival factor is a candidate oncogene in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10931-10936.	3.3	118
128	EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11606-11611.	3.3	1,482
129	Salivary gland-like tumours of the breast: surgical and molecular pathology. Journal of Clinical Pathology, 2003, 56, 497-506.	1.0	170
130	Purified malignant mammary epithelial cells maintain hormone responsiveness in culture. British Journal of Cancer, 2003, 88, 1071-1076.	2.9	15
131	Epstein-Barr virus gene expression in human breast cancer: protagonist or passenger?. British Journal of Cancer, 2003, 89, 113-119.	2.9	60
132	Gene expression array profile of human osteosarcoma. British Journal of Cancer, 2003, 89, 2284-2288.	2.9	31
133	Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 13350-13355.	3.3	608
134	Transcriptional network controlled by the trithorax-group gene ash2 in Drosophila melanogaster. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3293-3298.	3.3	21
135	Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2532-2537.	3.3	182
136	Extending the utility of gene profiling data by bridging microarray platforms. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10585-10587.	3.3	13
137	Genomewide view of gene silencing by small interfering RNAs. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6343-6346.	3.3	283
138	Gene Expression Patterns in Ovarian Carcinomas. Molecular Biology of the Cell, 2003, 14, 4376-4386.	0.9	302
139	Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9608-9613.	3.3	184
140	Discovery of the breast cancer gene BASE using a molecular approach to enrich for genes encoding membrane and secreted proteins. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 1099-1104.	3.3	55
141	Spurious spatial periodicity of co-expression in microarray data due to printing design. Nucleic Acids Research, 2003, 31, 4425-4433.	6.5	39
142	Demystified ... Tissue microarray technology. Journal of Clinical Pathology, 2003, 56, 198-204.	2.1	116
143	Expression of P-cadherin, but not E-cadherin or N-cadherin, relates to pathological and functional differentiation of breast carcinomas. Journal of Clinical Pathology, 2003, 56, 318-322.	2.1	53
144	Validation of cDNA microarray gene expression data obtained from linearly amplified RNA. Journal of Clinical Pathology, 2003, 56, 307-312.	2.1	51

#	ARTICLE	IF	CITATIONS
145	Prediction of Toxicant-Specific Gene Expression Signatures after Chemotherapeutic Treatment of Breast Cell Lines. <i>Environmental Health Perspectives</i> , 2004, 112, 1607-1613.	2.8	17
146	DNA amplification method tolerant to sample degradation. <i>Genome Research</i> , 2004, 14, 2357-2366.	2.4	79
147	Different Gene Expression Patterns in Invasive Lobular and Ductal Carcinomas of the Breast. <i>Molecular Biology of the Cell</i> , 2004, 15, 2523-2536.	0.9	540
148	Genomic DNA as a cohybridization standard for mammalian microarray measurements. <i>Nucleic Acids Research</i> , 2004, 32, e81-e81.	6.5	33
149	Gene Expression in the Normal Adult Human Kidney Assessed by Complementary DNA Microarray. <i>Molecular Biology of the Cell</i> , 2004, 15, 649-656.	0.9	97
150	Design of a real time quantitative PCR assay to assess global mRNA amplification of small size specimens for microarray hybridisation. <i>Journal of Clinical Pathology</i> , 2004, 57, 1278-1287.	1.0	4
151	BRCA1 functions as a breast stem cell regulator. <i>Journal of Medical Genetics</i> , 2004, 41, 1-5.	1.5	146
152	Quantitative assessment of a novel flow-through porous microarray for the rapid analysis of gene expression profiles. <i>Nucleic Acids Research</i> , 2004, 32, e123-e123.	6.5	45
153	Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 8431-8436.	3.3	200
154	From The Cover: The host response to smallpox: Analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 15190-15195.	3.3	111
155	Gene expression profiles of epithelial cells microscopically isolated from a breast-invasive ductal carcinoma and a nodal metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 18147-18152.	3.3	97
156	LSimpute: accurate estimation of missing values in microarray data with least squares methods. <i>Nucleic Acids Research</i> , 2004, 32, 34e-34.	6.5	291
157	Selective Gene Expression in Magnocellular Neurons in Rat Supraoptic Nucleus. <i>Journal of Neuroscience</i> , 2004, 24, 7174-7185.	1.7	36
158	Forkhead Box Transcription Factor FOXO3a Regulates Estrogen Receptor Alpha Expression and Is Repressed by the Her-2/neu/Phosphatidylinositol 3-Kinase/Akt Signaling Pathway. <i>Molecular and Cellular Biology</i> , 2004, 24, 8681-8690.	1.1	150
159	The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 4158-4163.	3.3	288
160	NF- κ B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 10137-10142.	3.3	426
161	Coexpression Analysis of Human Genes Across Many Microarray Data Sets. <i>Genome Research</i> , 2004, 14, 1085-1094.	2.4	688
162	Differential gene-expression profiles associated with gastric adenoma. <i>British Journal of Cancer</i> , 2004, 90, 216-223.	2.9	23

#	ARTICLE	IF	CITATIONS
163	Cellular responses to ErbB-2 overexpression in human mammary luminal epithelial cells: comparison of mRNA and protein expression. <i>British Journal of Cancer</i> , 2004, 90, 173-181.	2.9	43
164	Metagenes and molecular pattern discovery using matrix factorization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 4164-4169.	3.3	1,649
165	Gold nanoparticle probe-based gene expression analysis with unamplified total human RNA. <i>Nucleic Acids Research</i> , 2004, 32, e137-e137.	6.5	84
166	A Versatile Assay for High-Throughput Gene Expression Profiling on Universal Array Matrices. <i>Genome Research</i> , 2004, 14, 878-885.	2.4	165
167	Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds. <i>PLoS Biology</i> , 2004, 2, e7.	2.6	824
168	RNA expression microarrays (REMs), a high-throughput method to measure differences in gene expression in diverse biological samples. <i>Nucleic Acids Research</i> , 2004, 32, e120-e120.	6.5	11
169	Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry. <i>British Journal of Cancer</i> , 2004, 90, 1422-1428.	2.9	32
170	Tests for finding complex patterns of differential expression in cancers: towards individualized medicine. <i>BMC Bioinformatics</i> , 2004, 5, 110.	1.2	38
171	Cancer characterization and feature set extraction by discriminative margin clustering. <i>BMC Bioinformatics</i> , 2004, 5, 21.	1.2	25
172	Multiclass discovery in array data. <i>BMC Bioinformatics</i> , 2004, 5, 70.	1.2	11
173	A comparative analysis of data generated using two different target preparation methods for hybridization to high-density oligonucleotide microarrays. <i>BMC Genomics</i> , 2004, 5, 2.	1.2	38
174	Universal Reference RNA as a standard for microarray experiments. <i>BMC Genomics</i> , 2004, 5, 20.	1.2	140
175	CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. <i>BMC Cancer</i> , 2004, 4, 73.	1.1	199
176	The Genetic Epidemiology of Breast Cancer Genes. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2004, 9, 221-236.	1.0	210
177	High density peptide microarrays. In situ synthesis and applications. <i>Molecular Diversity</i> , 2004, 8, 177-187.	2.1	36
178	In situ hybridization in the pathology laboratory: General principles, automation, and emerging research applications for tissue-based studies of gene expression. <i>Journal of Molecular Histology</i> , 2004, 35, 595-601.	1.0	12
179	Use of Three-Dimensional Basement Membrane Cultures to Model Oncogene-Induced Changes in Mammary Epithelial Morphogenesis. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2004, 9, 297-310.	1.0	126
181	Biomolecular features of clinical relevance in breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, S3-S14.	3.3	13

#	ARTICLE	IF	CITATIONS
182	Statistics in clinical trials. <i>Current Oncology Reports</i> , 2004, 6, 36-41.	1.8	3
183	The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. <i>Journal of Clinical Pathology</i> , 2004, 57, 1009-1014.	1.0	636
184	Gene expression profiling identifies clinically relevant subtypes of prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 811-816.	3.3	1,175
185	Genetic alteration and gene expression modulation during cancer progression. <i>Molecular Cancer</i> , 2004, 3, 9.	7.9	108
186	Methods to find out the expression of activated genes. <i>Reproductive Biology and Endocrinology</i> , 2004, 2, 68.	1.4	6
187	The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. <i>Breast Cancer Research</i> , 2004, 6, 240-5.	2.2	163
188	Recent translational research: microarray expression profiling of breast cancer "beyond classification and prognostic markers?". <i>Breast Cancer Research</i> , 2004, 6, 192-200.	2.2	21
189	S100A7 and the progression of breast cancer. <i>Breast Cancer Research</i> , 2004, 6, 153-9.	2.2	84
190	Prognostic molecular markers in early breast cancer. <i>Breast Cancer Research</i> , 2004, 6, 109-18.	2.2	197
191	Malignant myoepithelial cells are associated with the differentiated papillary structure and metastatic ability of a syngeneic murine mammary adenocarcinoma model. <i>Breast Cancer Research</i> , 2004, 6, R116-29.	2.2	11
192	Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer. <i>Breast Cancer Research</i> , 2004, 6, R46.	2.2	39
193	Statistical modeling for selecting housekeeper genes. <i>Genome Biology</i> , 2004, 5, R59.	13.9	155
194	ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform. <i>Neoplasia</i> , 2004, 6, 1-6.	2.3	3,212
195	Multi-Platform, Multi-Site, Microarray-Based Human Tumor Classification. <i>American Journal of Pathology</i> , 2004, 164, 9-16.	1.9	207
196	Quantitative Gene Expression Profiling in Formalin-Fixed, Paraffin-Embedded Tissues Using Universal Bead Arrays. <i>American Journal of Pathology</i> , 2004, 165, 1799-1807.	1.9	147
197	Genomic and proteomic approaches for studying human cancer: Prospects for true patient-tailored therapy. <i>Human Genomics</i> , 2004, 1, 134.	1.4	57
198	Isolation and characterization of human mammary stem cells. <i>Cell Proliferation</i> , 2005, 38, 375-386.	2.4	67
199	Genomic approaches in the management and treatment of breast cancer. <i>British Journal of Cancer</i> , 2005, 92, 618-624.	2.9	31

#	ARTICLE	IF	CITATIONS
200	Comparison of hypoxia transcriptome in vitro with in vivo gene expression in human bladder cancer. <i>British Journal of Cancer</i> , 2005, 93, 346-354.	2.9	64
201	No common denominator for breast cancer lymph node metastasis. <i>British Journal of Cancer</i> , 2005, 93, 924-932.	2.9	82
202	Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities. <i>EMBO Journal</i> , 2005, 24, 963-973.	3.5	149
203	Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor- β signaling in ErbB2/Neu-induced tumors from transgenic mice. <i>Oncogene</i> , 2005, 24, 5173-5190.	2.6	61
204	Genes that mediate breast cancer metastasis to lung. <i>Nature</i> , 2005, 436, 518-524.	13.7	2,581
205	Gene Expression Profiling of Breast Cancer in Ethnic Populations: An Aid to Gene Discovery for the Benefit of All. <i>Breast Journal</i> , 2005, 11, 89-91.	0.4	3
206	Sample phenotype clusters in high-density oligonucleotide microarray data sets are revealed using Isomap, a nonlinear algorithm. <i>BMC Bioinformatics</i> , 2005, 6, 195.	1.2	42
207	stam—a Bioconductor compliant R package for structured analysis of microarray data. <i>BMC Bioinformatics</i> , 2005, 6, 211.	1.2	3
208	An adaptive method for cDNA microarray normalization. <i>BMC Bioinformatics</i> , 2005, 6, 28.	1.2	26
209	An entropy-based gene selection method for cancer classification using microarray data. <i>BMC Bioinformatics</i> , 2005, 6, 76.	1.2	129
210	An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention. <i>BMC Bioinformatics</i> , 2005, 6, S7.	1.2	27
211	Gene expression signature of estrogen receptor \pm status in breast cancer. <i>BMC Genomics</i> , 2005, 6, 37.	1.2	126
212	Expression analysis of secreted and cell surface genes of five transformed human cell lines and derivative xenograft tumors. <i>BMC Genomics</i> , 2005, 6, 55.	1.2	8
213	A molecular analysis by gene expression profiling reveals Bik/NBK overexpression in sporadic breast tumor samples of Mexican females. <i>BMC Cancer</i> , 2005, 5, 93.	1.1	20
214	Gene expression profiling: cell cycle deregulation and aneuploidy do not cause breast cancer formation in WAP-SVT/t transgenic animals. <i>Journal of Molecular Medicine</i> , 2005, 83, 362-376.	1.7	24
215	p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005, 447, 688-694.	1.4	197
216	Gene expression profiling of primary breast cancer. <i>Current Oncology Reports</i> , 2005, 7, 38-44.	1.8	16
217	Stem/Progenitor Cells in Mouse Mammary Gland Development and Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2005, 10, 17-24.	1.0	67

#	ARTICLE	IF	CITATIONS
218	Epithelial Progenitors in the Normal Human Mammary Gland. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2005, 10, 49-59.	1.0	141
219	Maintenance of Cell Type Diversification in the Human Breast. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2005, 10, 61-74.	1.0	14
220	Intrauterine Breast Development and the Mammary Myoepithelial Lineage. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2005, 10, 199-210.	1.0	31
221	Myoepithelial Cells in the Control of Mammary Development and Tumorigenesis: Data From Genetically Modified Mice. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2005, 10, 211-219.	1.0	35
222	Myoepithelial Cells: Autocrine and Paracrine Suppressors of Breast Cancer Progression. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2005, 10, 249-260.	1.0	111
223	Myoepithelial Cells: Their Origin and Function in Breast Morphogenesis and Neoplasia. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2005, 10, 261-272.	1.0	225
224	A cell behavior screen: identification, sorting, and enrichment of cells based on motility. <i>BMC Cell Biology</i> , 2005, 6, 14.	3.0	18
225	A simplified immunoprecipitation method for quantitatively measuring antibody responses in clinical sera samples by using mammalian-produced Renilla luciferase-antigen fusion proteins. <i>BMC Biotechnology</i> , 2005, 5, 22.	1.7	96
226	Differential expression of alphaB-crystallin and Hsp27-1 in anaplastic thyroid carcinomas because of tumor-specific alphaB-crystallin gene (CRYAB) silencing. <i>Cell Stress and Chaperones</i> , 2005, 10, 171.	1.2	31
227	DNA Array-Based Gene Profiling. <i>Annals of Surgery</i> , 2005, 241, 16-26.	2.1	37
228	Gene Expression Profiling Predicts Survival in Conventional Renal Cell Carcinoma. <i>PLoS Medicine</i> , 2005, 3, e13.	3.9	182
229	Microarray Profiling of Lymphocytes in Internal Diseases With an Altered Immune Response: Potential and Methodology. <i>Mediators of Inflammation</i> , 2005, 2005, 317-330.	1.4	21
230	Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. <i>Neuro-Oncology</i> , 2005, 7, 20-31.	0.6	59
231	Multi-species microarrays reveal the effect of sequence divergence on gene expression profiles. <i>Genome Research</i> , 2005, 15, 674-680.	2.4	155
232	Resveratrol-Induced Gene Expression Profiles in Human Prostate Cancer Cells. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 596-604.	1.1	75
233	Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. <i>Bioinformatics</i> , 2005, 21, 4205-4208.	1.8	363
234	Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. <i>British Journal of Cancer</i> , 2005, 92, 147-155.	2.9	144
235	From The Cover: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 3738-3743.	3.3	934

#	ARTICLE	IF	CITATIONS
236	Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 5814-5819.	3.3	445
237	The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation. Molecular Systems Biology, 2005, 1, 2005.0022.	3.2	64
238	A unique gene expression signature discriminates familial Alzheimer's disease mutation carriers from their wild-type siblings. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14854-14859.	3.3	45
239	Redefinition of Affymetrix probe sets by sequence overlap with cDNA microarray probes reduces cross-platform inconsistencies in cancer-associated gene expression measurements. BMC Bioinformatics, 2005, 6, 107.	1.2	113
240	Breast Cancer Metastasis to the Central Nervous System. American Journal of Pathology, 2005, 167, 913-920.	1.9	375
241	Gene Expression Analysis of Immune-Mediated Arrest of Tumorigenesis in a Transgenic Mouse Model of HER-2/neu-Positive Basal-Like Mammary Carcinoma. American Journal of Pathology, 2005, 166, 1205-1216.	1.9	43
242	New Insights into the Tumor Metastatic Process Revealed by Gene Expression Profiling. American Journal of Pathology, 2005, 166, 1291-1294.	1.9	21
243	Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. Molecular Cancer, 2005, 4, 26.	7.9	25
244	Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures. Journal of Translational Medicine, 2005, 3, 32.	1.8	45
245	Simple decision rules for classifying human cancers from gene expression profiles. Bioinformatics, 2005, 21, 3896-3904.	1.8	348
246	Erythropoietin Abuse and Erythropoietin Gene Doping. Sports Medicine, 2005, 35, 831-840.	3.1	50
247	Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions. Breast Cancer Research, 2005, 7, 255-7.	2.2	5
248	Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Research, 2005, 7, R953-64.	2.2	659
249	Myoepithelial cells: good fences make good neighbors. Breast Cancer Research, 2005, 7, 190-7.	2.2	210
250	Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Research, 2005, 7, R634-44.	2.2	109
251	Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Research, 2005, 7, 143-8.	2.2	225
252	The promise of microarrays in the management and treatment of breast cancer. Breast Cancer Research, 2005, 7, 100-4.	2.2	25
253	Tumor microenvironments, the immune system and cancer survival. Genome Biology, 2005, 6, 211.	13.9	25

#	ARTICLE	IF	CITATIONS
254	A DNA microarray survey of gene expression in normal human tissues. <i>Genome Biology</i> , 2005, 6, R22.	13.9	198
255	GATA3 protein as a MUC1 transcriptional regulator in breast cancer cells. <i>Breast Cancer Research</i> , 2006, 8, R64.	2.2	28
256	Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. <i>Breast Cancer Research</i> , 2006, 8, R66.	2.2	123
257	CD44+/CD24-breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. <i>Breast Cancer Research</i> , 2006, 8, R59.	2.2	839
258	Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. <i>Breast Cancer Research</i> , 2006, 8, R58.	2.2	122
259	Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. <i>Breast Cancer Research</i> , 2006, 8, R34.	2.2	218
260	A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. <i>Breast Cancer Research</i> , 2006, 8, R25.	2.2	433
261	Dissection of a metastatic gene expression signature into distinct components. <i>Genome Biology</i> , 2006, 7, R117.	13.9	36
262	Variability in synovial inflammation in rheumatoid arthritis investigated by microarray technology. <i>Arthritis Research and Therapy</i> , 2006, 8, R47.	1.6	46
263	Prognostic Gene Expression Signatures Can Be Measured in Tissues Collected in RNAlater Preservative. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 31-39.	1.2	115
264	Exploring along a Crooked Path**â€œPreviously presented at the annual meeting of The American Society of Human Genetics, in Salt Lake City, on October 29, 2005.. <i>American Journal of Human Genetics</i> , 2006, 79, 429-433.	2.6	1
265	The Role of Nicotinamide Adenine Dinucleotide Phosphate Oxidase-Derived Reactive Oxygen Species in the Acquisition of Metastatic Ability of Tumor Cells. <i>American Journal of Pathology</i> , 2006, 169, 294-302.	1.9	49
266	ErbB2 Regulates Inflammation and Proliferation in the Skin after Ultraviolet Irradiation. <i>American Journal of Pathology</i> , 2006, 169, 1402-1414.	1.9	34
267	Evaluation of MetriGenix custom 4Dâ„¢ arrays applied for detection of breast cancer subtypes. <i>BMC Cancer</i> , 2006, 6, 59.	1.1	7
268	Gene Expression Profiling Reveals Stromal Genes Expressed in Common Between Barrett's Esophagus and Adenocarcinoma. <i>Gastroenterology</i> , 2006, 131, 925-933.	0.6	137
269	Heterogeneity of mammary lesions represent molecular differences. <i>BMC Cancer</i> , 2006, 6, 275.	1.1	32
270	Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters. <i>Molecular Cancer</i> , 2006, 5, 47.	7.9	23
271	A systems approach to clinical oncology: focus on breast cancer. <i>Proteome Science</i> , 2006, 4, 5.	0.7	43

#	ARTICLE	IF	CITATIONS
272	Identification of prognostic signatures in breast cancer microarray data using Bayesian techniques. <i>Journal of the Royal Society Interface</i> , 2006, 3, 367-381.	1.5	13
273	GATA-3 Maintains the Differentiation of the Luminal Cell Fate in the Mammary Gland. <i>Cell</i> , 2006, 127, 1041-1055.	13.5	576
274	Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers. <i>PLoS Medicine</i> , 2006, 3, e47.	3.9	536
275	Gene Expression Profiling in Hereditary, BRCA1-linked Breast Cancer: Preliminary Report. <i>Hereditary Cancer in Clinical Practice</i> , 2006, 4, 28.	0.6	12
276	Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 515-525.	0.7	46
277	Genetic regulators of large-scale transcriptional signatures in cancer. <i>Nature Genetics</i> , 2006, 38, 421-430.	9.4	204
278	Molecular subtypes of breast cancer and amplification of topoisomerase II α : predictive role in dose intensive adjuvant chemotherapy. <i>British Journal of Cancer</i> , 2006, 95, 1334-1341.	2.9	59
279	Heterogeneity of Breast Cancer among Patients and Implications for Patient Selection for Adjuvant Chemotherapy. <i>Pharmaceutical Research</i> , 2006, 23, 1951-1958.	1.7	11
280	The Role of the Epidermal Growth Factor Receptor in Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2006, 11, 3-11.	1.0	60
281	The ErbB2 Signaling Network as a Target for Breast Cancer Therapy. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2006, 11, 13-25.	1.0	65
282	Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. <i>Neurogenetics</i> , 2006, 7, 67-80.	0.7	308
283	Personalized medicine and development of targeted therapies: the upcoming challenge for diagnostic molecular pathology. A review. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 448, 744-755.	1.4	99
284	Proteomic analysis on metastasis-associated proteins of human hepatocellular carcinoma tissues. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 132, 92-98.	1.2	60
286	Gene expression in breast cancer. <i>Current Treatment Options in Oncology</i> , 2006, 7, 123-128.	1.3	21
287	Molecular Diagnostics in Sepsis: From Bedside to Bench. <i>Journal of the American College of Surgeons</i> , 2006, 203, 585-598.e1.	0.2	38
288	A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. <i>Cancer Cell</i> , 2006, 10, 515-527.	7.7	2,729
289	In vitro and in vivo MMP gene expression localisation by In Situ-RT-PCR in cell culture and paraffin embedded human breast cancer cell line xenografts. <i>BMC Cancer</i> , 2006, 6, 18.	1.1	14
290	Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. <i>BMC Cancer</i> , 2006, 6, 245.	1.1	120

#	ARTICLE	IF	CITATIONS
291	Gene expression patterns associated with p53 status in breast cancer. <i>BMC Cancer</i> , 2006, 6, 276.	1.1	128
292	Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. <i>BMC Medicine</i> , 2006, 4, 16.	2.3	47
293	Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. <i>BMC Bioinformatics</i> , 2006, 7, 197.	1.2	272
294	Missing value estimation for DNA microarray gene expression data by Support Vector Regression imputation and orthogonal coding scheme. <i>BMC Bioinformatics</i> , 2006, 7, 32.	1.2	103
295	Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. <i>BMC Genomics</i> , 2006, 7, 127.	1.2	314
296	Discovery and validation of breast cancer subtypes. <i>BMC Genomics</i> , 2006, 7, 231.	1.2	102
297	Converting a breast cancer microarray signature into a high-throughput diagnostic test. <i>BMC Genomics</i> , 2006, 7, 278.	1.2	429
298	Evaluation of reference-based two-color methods for measurement of gene expression ratios using spotted cDNA microarrays. <i>BMC Genomics</i> , 2006, 7, 35.	1.2	17
299	Novel patterns of genome rearrangement and their association with survival in breast cancer. <i>Genome Research</i> , 2006, 16, 1465-1479.	2.4	291
300	Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. <i>Journal of Clinical Pathology</i> , 2006, 60, 1006-1012.	1.0	93
301	Genome-Scale Identification of Membrane-Associated Human mRNAs. <i>PLoS Genetics</i> , 2006, 2, e11.	1.5	84
302	A Genome-Wide Screen for Promoter Methylation in Lung Cancer Identifies Novel Methylation Markers for Multiple Malignancies. <i>PLoS Medicine</i> , 2006, 3, e486.	3.9	228
303	Cyclin D1 Determines Mitochondrial Function InVivo. <i>Molecular and Cellular Biology</i> , 2006, 26, 5449-5469.	1.1	166
304	Genome-wide analysis of mRNAs bound to the histone stem-loop binding protein. <i>Rna</i> , 2006, 12, 1853-1867.	1.6	66
305	Gene Expression Signature in Organized and Growth-Arrested Mammary Acini Predicts Good Outcome in Breast Cancer. <i>Cancer Research</i> , 2006, 66, 7095-7102.	0.4	111
306	Gene expression patterns in human placenta. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 5478-5483.	3.3	383
307	Demystifying basal-like breast carcinomas. <i>Journal of Clinical Pathology</i> , 2006, 60, 1328-1332.	1.0	51
308	Towards a Holistic, Yet Gene-Centered Analysis of Gene Expression Profiles: A Case Study of Human Lung Cancers. <i>Journal of Biomedicine and Biotechnology</i> , 2006, 2006, 1-11.	3.0	47

#	ARTICLE	IF	CITATIONS
309	Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14842-14847.	3.3	264
310	Expression of oestrogen receptor- β in oestrogen receptor- α negative human breast tumours. British Journal of Cancer, 2006, 95, 616-626.	2.9	116
311	The impact of surgically induced ischaemia on protein levels in patients undergoing rectal cancer surgery. British Journal of Cancer, 2006, 95, 928-933.	2.9	11
312	Identification of alterations in DNA copy number in host stromal cells during tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19848-19853.	3.3	55
313	NF- κ B activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation. British Journal of Cancer, 2007, 97, 659-669.	2.9	86
314	HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?. British Journal of Cancer, 2007, 96, 654-659.	2.9	57
315	Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis. British Journal of Cancer, 2007, 97, 1165-1174.	2.9	64
316	PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of phospho-Akt-negative breast carcinomas. British Journal of Cancer, 2007, 97, 809-817.	2.9	45
317	Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin~Cyclophosphamide Regimen. PLoS Medicine, 2007, 4, e90.	3.9	144
318	Elucidating the Altered Transcriptional Programs in Breast Cancer using Independent Component Analysis. PLoS Computational Biology, 2007, 3, e161.	1.5	108
319	Validation of Computational Methods in Genomics. Current Genomics, 2007, 8, 1-19.	0.7	31
320	Let-7 expression defines two differentiation stages of cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 11400-11405.	3.3	434
321	Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human <i>BRCA1</i> -mutated basal-like breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12111-12116.	3.3	428
322	Functional Analysis of the Human N-Acetyltransferase 1 Major Promoter: Quantitation of Tissue Expression and Identification of Critical Sequence Elements. Drug Metabolism and Disposition, 2007, 35, 1649-1656.	1.7	49
323	Breast Cancer Molecular Signatures as Determined by SAGE: Correlation with Lymph Node Status. Molecular Cancer Research, 2007, 5, 881-890.	1.5	99
324	Molecular restoration of archived transcriptional profiles by complementary-template reverse-transcription (CT-RT). Nucleic Acids Research, 2007, 35, e94-e94.	6.5	27
325	Parallels between Global Transcriptional Programs of Polarizing Caco-2 Intestinal Epithelial Cells In Vitro and Gene Expression Programs in Normal Colon and Colon Cancer. Molecular Biology of the Cell, 2007, 18, 4245-4260.	0.9	114
326	Bystin in human cancer cells: intracellular localization and function in ribosome biogenesis. Biochemical Journal, 2007, 404, 373-381.	1.7	36

#	ARTICLE	IF	CITATIONS
327	Metastasis: recent discoveries and novel treatment strategies. <i>Lancet, The</i> , 2007, 369, 1742-1757.	6.3	650
328	A Perspective on DNA Microarrays in Pathology Research and Practice. <i>American Journal of Pathology</i> , 2007, 171, 375-385.	1.9	52
329	Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer. <i>Breast Cancer Research</i> , 2007, 9, 110.	2.2	18
330	Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. <i>Breast Cancer Research</i> , 2007, 9, R59.	2.2	64
331	Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. <i>Breast Cancer Research</i> , 2007, 9, R61.	2.2	126
332	Risk factors for breast cancer characterized by the estrogen receptor alpha A908G (K303R) mutation. <i>Breast Cancer Research</i> , 2007, 9, R36.	2.2	22
333	An oestrogen-dependent model of breast cancer created by transformation of normal human mammary epithelial cells. <i>Breast Cancer Research</i> , 2007, 9, R38.	2.2	45
334	TP53mutation status and gene expression profiles are powerful prognostic markers of breast cancer. <i>Breast Cancer Research</i> , 2007, 9, R30.	2.2	244
335	Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine. <i>Breast Cancer Research</i> , 2007, 9, 206.	2.2	36
336	Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. <i>Breast Cancer Research</i> , 2007, 9, R24.	2.2	154
337	The continuing search for cancer-causing somatic mutations. <i>Breast Cancer Research</i> , 2007, 9, 101.	2.2	3
338	Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas. <i>Breast Cancer Research</i> , 2007, 9, R5.	2.2	28
339	Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. <i>Breast Cancer Research</i> , 2007, 9, R16.	2.2	112
340	The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever. <i>Genome Biology</i> , 2007, 8, R174.	13.9	80
341	An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. <i>Genome Biology</i> , 2007, 8, R157.	13.9	433
342	Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. <i>Genome Biology</i> , 2007, 8, R76.	13.9	1,009
343	Evidence for a stem cell hierarchy in the adult human breast. <i>Journal of Cell Biology</i> , 2007, 177, 87-101.	2.3	331
344	Oncomine 3.0: Genes, Pathways, and Networks in a Collection of 18,000 Cancer Gene Expression Profiles. <i>Neoplasia</i> , 2007, 9, 166-180.	2.3	1,847

#	ARTICLE	IF	CITATIONS
345	Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1008-1014.	0.5	290
346	Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses. <i>Molecular Cancer</i> , 2007, 6, 2.	7.9	61
347	Transcriptional changes associated with breast cancer occur as normal human mammary epithelial cells overcome senescence barriers and become immortalized. <i>Molecular Cancer</i> , 2007, 6, 7.	7.9	44
348	Feature Selection and Molecular Classification of Cancer Using Genetic Programming. <i>Neoplasia</i> , 2007, 9, 292-IN3.	2.3	68
349	Gene Expression Patterns in Pancreatic Tumors, Cells and Tissues. <i>PLoS ONE</i> , 2007, 2, e323.	1.1	86
350	Virtual Northern Analysis of the Human Genome. <i>PLoS ONE</i> , 2007, 2, e460.	1.1	11
351	The Emerging Role of the LIV-1 Subfamily of Zinc Transporters in Breast Cancer. <i>Molecular Medicine</i> , 2007, 13, 396-406.	1.9	213
352	Strategic Plans to Promote Head and Neck Cancer Translational Research Within the Radiation Therapy Oncology Group: A Report From the Translational Research Program. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S67-S78.	0.4	13
353	Gene expression changes associated with Barrett's esophagus and Barrett's-associated adenocarcinoma cell lines after acid or bile salt exposure. <i>BMC Gastroenterology</i> , 2007, 7, 24.	0.8	16
354	The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. <i>Oncogene</i> , 2007, 26, 6469-6487.	2.6	867
355	Interpretation of microarray data in cancer. <i>British Journal of Cancer</i> , 2007, 96, 1155-1158.	2.9	84
356	Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. <i>BMC Cancer</i> , 2007, 7, 134.	1.1	316
357	Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer. <i>BMC Cancer</i> , 2007, 7, 182.	1.1	109
358	A new molecular breast cancer subclass defined from a large scale real-time quantitative RT-PCR study. <i>BMC Cancer</i> , 2007, 7, 39.	1.1	17
359	Identification of a robust gene signature that predicts breast cancer outcome in independent data sets. <i>BMC Cancer</i> , 2007, 7, 61.	1.1	33
360	Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. <i>BMC Cancer</i> , 2007, 7, 63.	1.1	63
361	Re-sampling strategy to improve the estimation of number of null hypotheses in FDR control under strong correlation structures. <i>BMC Bioinformatics</i> , 2007, 8, 157.	1.2	19
362	A feature selection approach for identification of signature genes from SAGE data. <i>BMC Bioinformatics</i> , 2007, 8, 169.	1.2	3

#	ARTICLE	IF	CITATIONS
363	Portraits of breast cancer progression. <i>BMC Bioinformatics</i> , 2007, 8, 291.	1.2	32
364	EGFR associated expression profiles vary with breast tumor subtype. <i>BMC Genomics</i> , 2007, 8, 258.	1.2	234
365	Non-coding antisense transcription detected by conventional and single-stranded cDNA microarray. <i>BMC Genomics</i> , 2007, 8, 295.	1.2	9
366	Integrated analysis of independent gene expression microarray datasets improves the predictability of breast cancer outcome. <i>BMC Genomics</i> , 2007, 8, 331.	1.2	22
367	Unravelling the hidden heterogeneities of diffuse large B-cell lymphoma based on coupled two-way clustering. <i>BMC Genomics</i> , 2007, 8, 332.	1.2	7
368	Molecular profiling in breast cancer. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2007, 8, 185-198.	2.6	35
369	Modeling Metastatic Breast Cancer in Mice. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2007, 12, 191-203.	1.0	55
370	Tumour vascularization: sprouting angiogenesis and beyond. <i>Cancer and Metastasis Reviews</i> , 2007, 26, 489-502.	2.7	464
371	Differential expression of hypoxia and (lymph)angiogenesis-related genes at different metastatic sites in breast cancer. <i>Clinical and Experimental Metastasis</i> , 2007, 24, 13-23.	1.7	23
372	Identification of estrogen-responsive genes involved in breast cancer metastases to the bone. <i>Clinical and Experimental Metastasis</i> , 2007, 24, 411-422.	1.7	30
373	P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 450, 73-80.	1.4	71
374	Functional pathway characterized by gene expression analysis of supraclavicular lymph node metastasis-positive breast cancer. <i>Journal of Human Genetics</i> , 2007, 52, 271-279.	1.1	32
375	The oestrogen-dependent biology of breast cancer. Sensitivity and resistance to aromatase inhibitors revisited: a molecular perspective. <i>Clinical and Translational Oncology</i> , 2007, 9, 752-759.	1.2	7
376	Epidemiology of basal-like breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 123-139.	1.1	747
377	Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics. <i>Familial Cancer</i> , 2008, 7, 83-89.	0.9	28
379	Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. <i>Clinical and Translational Oncology</i> , 2008, 10, 646-653.	1.2	52
380	Basal-like subtype and BRCA1 dysfunction in breast cancers. <i>International Journal of Clinical Oncology</i> , 2008, 13, 395-400.	1.0	32
381	SCC-112 gene is involved in tumor progression and promotes the cell proliferation in G2/M phase. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 453-462.	1.2	14

#	ARTICLE	IF	CITATIONS
382	The ubiquitin E3 ligase activity of BRCA1 and its biological functions. <i>Cell Division</i> , 2008, 3, 1.	1.1	100
383	Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer. <i>Cancer</i> , 2008, 113, 2638-2645.	2.0	585
384	The fibromatosis signature defines a robust stromal response in breast carcinoma. <i>Laboratory Investigation</i> , 2008, 88, 591-601.	1.7	100
385	Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. <i>British Journal of Cancer</i> , 2008, 99, 1729-1734.	2.9	46
386	Integrative approach for differentially overexpressed genes in gastric cancer by combining large-scale gene expression profiling and network analysis. <i>British Journal of Cancer</i> , 2008, 99, 1307-1315.	2.9	87
387	Missing value imputation for microarray gene expression data using histone acetylation information. <i>BMC Bioinformatics</i> , 2008, 9, 252.	1.2	42
388	Integrative bioinformatics analysis of transcriptional regulatory programs in breast cancer cells. <i>BMC Bioinformatics</i> , 2008, 9, 404.	1.2	31
389	A method for analyzing censored survival phenotype with gene expression data. <i>BMC Bioinformatics</i> , 2008, 9, 417.	1.2	13
390	A highly sensitive and specific system for large-scale gene expression profiling. <i>BMC Genomics</i> , 2008, 9, 9.	1.2	12
391	The transcription factor ATF3 acts as an oncogene in mouse mammary tumorigenesis. <i>BMC Cancer</i> , 2008, 8, 268.	1.1	53
392	Different gene-expression profiles for the poorly differentiated carcinoma and the highly differentiated papillary adenocarcinoma in mammary glands support distinct metabolic pathways. <i>BMC Cancer</i> , 2008, 8, 270.	1.1	10
393	The effects of timing of fine needle aspiration biopsies on gene expression profiles in breast cancers. <i>BMC Cancer</i> , 2008, 8, 277.	1.1	13
394	Amplification of HER2 is a marker for global genomic instability. <i>BMC Cancer</i> , 2008, 8, 297.	1.1	33
395	The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. <i>BMC Cancer</i> , 2008, 8, 307.	1.1	108
396	Identification and transcript analysis of a novel wallaby (<i>Macropus eugenii</i>) basal-like breast cancer cell line. <i>Molecular Cancer</i> , 2008, 7, 1.	7.9	44
397	Unlocking the power of cross-species genomic analyses: identification of evolutionarily conserved breast cancer networks and validation of preclinical models. <i>Breast Cancer Research</i> , 2008, 10, 213.	2.2	20
398	A gene signature of loss of oestrogen receptor (ER) function and oxidative stress links ER-positive breast tumours with an absent progesterone receptor and a poor prognosis. <i>Breast Cancer Research</i> , 2008, 10, 109.	2.2	13
399	Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. <i>Breast Cancer Research</i> , 2008, 10, R85.	2.2	113

#	ARTICLE	IF	CITATIONS
400	Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. <i>Breast Cancer Research</i> , 2008, 10, R87.	2.2	122
401	A candidate molecular signature associated with tamoxifen failure in primary breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R88.	2.2	54
402	Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study. <i>Breast Cancer Research</i> , 2008, 10, R6.	2.2	29
403	Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R3.	2.2	44
404	Noninvasive Monitoring of Breast Cancer during Neoadjuvant Chemotherapy Using Optical Tomography with Ultrasound Localization. <i>Neoplasia</i> , 2008, 10, 1028-1040.	2.3	83
405	Transcriptional Networks Inferred from Molecular Signatures of Breast Cancer. <i>American Journal of Pathology</i> , 2008, 172, 495-509.	1.9	13
406	Gene Expression Profiling of Breast Cancer. <i>Advances in Surgery</i> , 2008, 42, 249-260.	0.6	42
407	Early onset of breast cancer in a group of British black women. <i>British Journal of Cancer</i> , 2008, 98, 277-281.	2.9	135
408	Identification of cancer genes using a statistical framework for multiexperiment analysis of nondiscretized array CGH data. <i>Nucleic Acids Research</i> , 2008, 36, e13-e13.	6.5	62
409	Genome-wide transcriptional analysis of the human cell cycle identifies genes differentially regulated in normal and cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 955-960.	3.3	145
410	Differences in Estrogen Receptor Subtype According to Family History of Breast Cancer among Hispanic, but not Non-Hispanic White Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2700-2706.	1.1	21
411	MYC in breast tumor progression. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1689-1698.	1.1	128
412	Adjuvant Therapy of Breast Cancer: Can We Do Better?. <i>Breast Care</i> , 2009, 4, 8-8.	0.8	0
413	ATX-LPA receptor axis in inflammation and cancer. <i>Cell Cycle</i> , 2009, 8, 3695-3701.	1.3	95
414	Triple Receptor-Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes. <i>Journal of Clinical Oncology</i> , 2009, 27, 220-226.	0.8	115
415	Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition. <i>Cancer Research</i> , 2009, 69, 565-572.	0.4	340
416	Transforming growth factor- β signaling: emerging stem cell target in metastatic breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 453-495.	1.1	123
417	Indirect two-sided relative ranking: a robust similarity measure for gene expression data. <i>BMC Bioinformatics</i> , 2010, 11, 137.	1.2	3

#	ARTICLE	IF	CITATIONS
418	Improvement of tissue preparation for laser capture microdissection: application for cell type-specific miRNA expression profiling in colorectal tumors. <i>BMC Genomics</i> , 2010, 11, 163.	1.2	59
419	Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction. <i>British Journal of Cancer</i> , 2010, 102, 1503-1510.	2.9	12
420	Triple-negative breast carcinomas are a heterogeneous entity that differs between young and old patients. <i>Clinics</i> , 2010, 65, 1033-1036.	0.6	43
421	Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1821-1828.	0.8	128
422	¹⁸ F-FDG PET of Locally Invasive Breast Cancer and Association of Estrogen Receptor Status with Standardized Uptake Value: Microarray and Immunohistochemical Analysis. <i>Journal of Nuclear Medicine</i> , 2010, 51, 543-550.	2.8	86
423	Targeting Signal Transduction Pathways in Metastatic Breast Cancer: A Comprehensive Review. <i>Oncologist</i> , 2010, 15, 216-235.	1.9	47
424	Whole Blueberry Powder Modulates the Growth and Metastasis of MDA-MB-231 Triple Negative Breast Tumors in Nude Mice. <i>Journal of Nutrition</i> , 2011, 141, 1805-1812.	1.3	52
425	Pioneer transcription factors: establishing competence for gene expression. <i>Genes and Development</i> , 2011, 25, 2227-2241.	2.7	1,388
426	Nanomedicine: Application Areas and Development Prospects. <i>International Journal of Molecular Sciences</i> , 2011, 12, 3303-3321.	1.8	135
427	Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk. <i>Clinics</i> , 2011, 66, 607-612.	0.6	13
428	Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy. <i>Modern Pathology</i> , 2012, 25, 388-397.	2.9	69
429	Biomarkers in Breast Cancer – An Update. <i>Geburtshilfe Und Frauenheilkunde</i> , 2012, 72, 819-832.	0.8	38
430	Overcoming implementation challenges of personalized cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 542-548.	12.5	115
431	Emerging Concepts in Breast Cancer Risk Prediction. <i>Current Obstetrics and Gynecology Reports</i> , 2013, 2, 43-52.	0.3	8
432	The role of the pathologist in the decision-making process. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 23-26.	2.2	3
433	The FGF/FGF receptor axis as a therapeutic target in breast cancer. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 391-402.	1.2	56
434	New drugs, new knowledge, new targets. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 75-76.	12.5	9
435	Incorporate gene signature profiling into routine molecular testing. <i>Applied & Translational Genomics</i> , 2013, 2, 28-33.	2.1	3

#	ARTICLE	IF	CITATIONS
436	Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype. <i>Modern Pathology</i> , 2013, 26, 485-495.	2.9	83
437	From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis. <i>Microarrays (Basel, Switzerland)</i> , 2013, 2, 243-264.	1.4	5
438	Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. <i>BMC Medicine</i> , 2013, 11, 220.	2.3	109
439	Prognostic Value of Myeloid Differentiation Primary Response 88 and Toll-Like Receptor 4 in Breast Cancer Patients. <i>PLoS ONE</i> , 2014, 9, e111639.	1.1	27
440	FABP7 and HMGS2 Are Novel Protein Markers for Apocrine Differentiation Categorizing Apocrine Carcinoma of the Breast. <i>PLoS ONE</i> , 2014, 9, e112024.	1.1	23
441	Evaluation of Ki67 Expression across Distinct Categories of Breast Cancer Specimens: A Population-Based Study of Matched Surgical Specimens, Core Needle Biopsies and Tissue Microarrays. <i>PLoS ONE</i> , 2014, 9, e112121.	1.1	54
442	Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival. <i>PLoS ONE</i> , 2014, 9, e114900.	1.1	77
443	Advances in Proteomic Technologies and Its Contribution to the Field of Cancer. <i>Advances in Medicine</i> , 2014, 2014, 1-25.	0.3	31
444	Subtype Is a Predictive Factor of Nonsentinel Lymph Node Involvement in Sentinel Node-Positive Breast Cancer Patients. <i>Journal of Breast Cancer</i> , 2014, 17, 370.	0.8	19
445	Targeting the NFκB Signaling Pathways for Breast Cancer Prevention and Therapy. <i>Current Medicinal Chemistry</i> , 2014, 22, 264-289.	1.2	178
446	Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer. <i>OncoTargets and Therapy</i> , 2014, 7, 2205.	1.0	23
447	Expression of Angiogenesis Regulatory Proteins and Epithelial-Mesenchymal Transition Factors in Platelets of the Breast Cancer Patients. <i>Scientific World Journal, The</i> , 2014, 2014, 1-7.	0.8	15
448	Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine) Tj ETQq0 0 0 rgBT /Overlock 10 Tf, 50 262 Td	0.4	23
449	Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area. <i>Current Psychiatry Reviews</i> , 2014, 10, 118-132.	0.9	13
450	Tumor Infiltrating Lymphocytes â€œ The Next Step in Assessing Outcome and Response to Treatment in Patients with Breast Cancer. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2014, 05, .	0.3	3
451	MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. <i>Journal of Clinical Investigation</i> , 2014, 124, 398-412.	3.9	348
452	Resistance to HER2-targeted therapies: a potential role for FOXM1. <i>Breast Cancer Management</i> , 2014, 3, 423-431.	0.2	16
453	SLUG: Critical regulator of epithelial cell identity in breast development and cancer. <i>Cell Adhesion and Migration</i> , 2014, 8, 578-587.	1.1	108

#	ARTICLE	IF	CITATIONS
454	Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells. <i>Cell Cycle</i> , 2014, 13, 3191-3201.	1.3	30
455	L1CAM is expressed in triple-negative breast cancers and is inversely correlated with Androgen receptor. <i>BMC Cancer</i> , 2014, 14, 958.	1.1	38
456	Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells. <i>Breast Cancer Research</i> , 2014, 16, 489.	2.2	54
457	Making Breast Cancer Molecular Subtypes Robust?. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju386-dju386.	3.0	10
458	A framework for generalized subspace pattern mining in high-dimensional datasets. <i>BMC Bioinformatics</i> , 2014, 15, 355.	1.2	4
459	The clinical and biological significance of STAT1 in esophageal squamous cell carcinoma. <i>BMC Cancer</i> , 2014, 14, 791.	1.1	55
460	Resolving cancerâ€™stroma interfacial signalling and interventions with micropatterned tumourâ€™stromal assays. <i>Nature Communications</i> , 2014, 5, 5662.	5.8	45
461	Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 360.	1.3	70
462	Predicting Cancer Prognosis Using Functional Genomics Data Sets. <i>Cancer Informatics</i> , 2014, 13s5, CIN.S14064.	0.9	9
463	Emerging Understanding of Multiscale Tumor Heterogeneity. <i>Frontiers in Oncology</i> , 2014, 4, 366.	1.3	90
464	Loss of WAVE3 sensitizes triple-negative breast cancers to chemotherapeutics by inhibiting the STAT-HIF-1 α -mediated angiogenesis. <i>Jak-stat</i> , 2014, 3, e1009276.	2.2	16
465	Key Challenges in Rheumatic and Musculoskeletal Disease Translational Research. <i>EBioMedicine</i> , 2014, 1, 95-96.	2.7	1
466	Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. <i>Lancet Oncology</i> , The, 2014, 15, e625-e634.	5.1	186
467	Stromal Expression of miR-21 Identifies High-Risk Group in Triple-Negative Breast Cancer. <i>American Journal of Pathology</i> , 2014, 184, 3217-3225.	1.9	44
468	Novel neoadjuvant therapy paradigms for bladder cancer: Results from the National Cancer Center Institute Forum. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1108-1115.	0.8	24
469	Differentiation and Loss of Malignant Character of Spontaneous Pulmonary Metastases in Patient-Derived Breast Cancer Models. <i>Cancer Research</i> , 2014, 74, 7406-7417.	0.4	37
470	Correlation of Forkhead Box c2 with subtypes and invasive ability of invasive breast cancer. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2014, 34, 896-901.	1.0	5
471	Estrogen independent gene expression defines clinically relevant subgroups of estrogen receptor positive breast cancer. <i>BMC Cancer</i> , 2014, 14, 871.	1.1	4

#	ARTICLE	IF	CITATIONS
472	Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer. <i>BMC Cancer</i> , 2014, 14, 990.	1.1	49
473	Family history of breast and ovarian cancer and triple negative subtype in hispanic/latina women. <i>SpringerPlus</i> , 2014, 3, 727.	1.2	11
474	Molecular signatures of lymph node status by intrinsic subtype: gene expression analysis of primary breast tumors from patients with and without metastatic lymph nodes. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 116.	3.5	11
475	DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival. <i>Breast Cancer Research</i> , 2014, 16, 450.	2.2	76
476	Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer. <i>Breast Cancer Research</i> , 2014, 16, 464.	2.2	40
477	Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer. <i>Breast Cancer Research</i> , 2014, 16, 466.	2.2	35
478	Modulation of tumor fatty acids, through overexpression or loss of thyroid hormone responsive protein spot 14 is associated with altered growth and metastasis. <i>Breast Cancer Research</i> , 2014, 16, 481.	2.2	30
479	Standardized uptake value of 18F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden. <i>Breast Cancer Research</i> , 2014, 16, 502.	2.2	33
480	Approaches to uncovering cancer diagnostic and prognostic molecular signatures. <i>Molecular and Cellular Oncology</i> , 2014, 1, e957981.	0.3	1
481	Prognostic Factors in Operated Stage IIIc, Pathological N3a Breast Cancer Patients. <i>Breast Care</i> , 2014, 9, 1-1.	0.8	5
482	Mining genome sequencing data to identify the genomic features linked to breast cancer histopathology. <i>Journal of Pathology Informatics</i> , 2014, 5, 3.	0.8	22
483	A Novel Subset of Human tumors that Simultaneously Overexpress Multiple E2F-responsive Genes Found in Breast, Ovarian, and Prostate Cancers. <i>Cancer Informatics</i> , 2014, 13s5, CIN.S14062.	0.9	17
484	Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. <i>Annals of Oncology</i> , 2014, 25, 1128-1136.	0.6	157
485	Heterogeneity of breast cancer subtypes and survival among Hispanic women with invasive breast cancer in California. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 625-634.	1.1	52
486	Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E384-93.	3.3	165
487	Unbiased Approaches to Biomarker Discovery in Neurodegenerative Diseases. <i>Neuron</i> , 2014, 84, 594-607.	3.8	51
488	Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2014, 11, 400-410.	1.9	267
489	Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. <i>Genes and Diseases</i> , 2014, 1, 75-86.	1.5	78

#	ARTICLE	IF	CITATIONS
490	Molecular Heterogeneity of Triple-Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2014, 6, 154-158.	0.5	58
491	Adenoid cystic carcinoma of breast: Recent advances. <i>World Journal of Clinical Cases</i> , 2014, 2, 732.	0.3	71
492	Hereditary Breast Cancer: Clinical, Pathological and Molecular Characteristics. <i>Breast Cancer: Basic and Clinical Research</i> , 2014, 8, BCBCR.S18715.	0.6	71
493	eMBI: Boosting Gene Expression-based Clustering for Cancer Subtypes. <i>Cancer Informatics</i> , 2014, 13s2, CIN.S13777.	0.9	7
494	Comprehensive Evaluation of Composite Gene Features in Cancer Outcome Prediction. <i>Cancer Informatics</i> , 2014, 13s3, CIN.S14028.	0.9	2
495	Complex-based analysis of dysregulated cellular processes in cancer. <i>BMC Systems Biology</i> , 2014, 8, S1.	3.0	19
496	The inactive X chromosome is epigenetically unstable and transcriptionally labile in breast cancer. <i>Genome Research</i> , 2015, 25, 488-503.	2.4	106
497	Cell surface GRP78: A potential marker of good prognosis and response to chemotherapy in breast cancer. <i>Oncology Letters</i> , 2015, 10, 2149-2155.	0.8	30
498	Correlation of Various Biomarkers with Axillary Nodal Metastases: Can a Panel of Such Biomarkers Guide Selective Use of Axillary Surgery in T1 Breast Cancer?. <i>Indian Journal of Surgical Oncology</i> , 2015, 6, 346-351.	0.3	1
499	Genetics and Breast Cancer – Oncologists Perspectives. <i>Indian Journal of Surgical Oncology</i> , 2015, 6, 415-419.	0.3	2
500	Integrated analysis of differentially expressed genes in breast cancer pathogenesis. <i>Oncology Letters</i> , 2015, 9, 2560-2566.	0.8	15
501	Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast. <i>Breast Cancer Research</i> , 2015, 17, 80.	2.2	5
502	Triple Negative Breast Cancer versus Non-Triple Negative Breast Cancer Treated with Breast Conservation Surgery Followed by Radiotherapy: A Systematic Review and Meta-Analysis. <i>Breast Care</i> , 2015, 10, 413-416.	0.8	11
503	Clinicopathological Factors Related to the Prognosis of Metastatic Breast Cancer Patients after Development of Brain Metastasis. <i>Breast Care</i> , 2015, 10, 387-392.	0.8	6
504	Molecular portrait of breast cancer in China reveals comprehensive transcriptomic likeness to Caucasian breast cancer and low prevalence of luminal A subtype. <i>Cancer Medicine</i> , 2015, 4, 1016-1030.	1.3	31
505	Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer. <i>Cancer Medicine</i> , 2015, 4, 1344-1355.	1.3	13
506	Quantitative multigene FISH on breast carcinomas identifies der(1;16)(q10;p10) as an early event in luminal A tumors. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 235-248.	1.5	11
507	Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer. <i>Experimental and Therapeutic Medicine</i> , 2015, 10, 379-385.	0.8	8

#	ARTICLE	IF	CITATIONS
508	PKC δ Promotes Breast Cancer Invasion by Regulating Expression of E-cadherin and Zonula Occludens-1 (ZO-1) via NF κ B-p65. <i>Scientific Reports</i> , 2015, 5, 12520.	1.6	28
509	Exometabolom analysis of breast cancer cell lines: Metabolic signature. <i>Scientific Reports</i> , 2015, 5, 13374.	1.6	24
510	Molecular portraits revealing the heterogeneity of breast tumor subtypes defined using immunohistochemistry markers. <i>Scientific Reports</i> , 2015, 5, 14499.	1.6	29
511	Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling. <i>Scientific Reports</i> , 2014, 4, 6566.	1.6	61
512	Breast cancer metastasis and the lymphatic system. <i>Oncology Letters</i> , 2015, 10, 1233-1239.	0.8	58
513	An optimised direct lysis method for gene expression studies on low cell numbers. <i>Scientific Reports</i> , 2015, 5, 12859.	1.6	25
514	Biological determinants of bladder cancer gene expression subtypes. <i>Scientific Reports</i> , 2015, 5, 10957.	1.6	102
515	Identifying ultrasound and clinical features of breast cancer molecular subtypes by ensemble decision. <i>Scientific Reports</i> , 2015, 5, 11085.	1.6	61
516	Outcome of Epstein-Barr virus-associated primary breast cancer. <i>Molecular and Clinical Oncology</i> , 2015, 3, 295-298.	0.4	18
517	Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. <i>Clinical Medicine Insights Pathology</i> , 2015, 8, CPath.S31563.	0.6	312
518	Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer. <i>Genetics & Epigenetics</i> , 2015, 7, GEG.S35500.	2.5	80
519	Targeting Breast Cancer Metastasis. <i>Breast Cancer: Basic and Clinical Research</i> , 2015, 9s1, BCBCR.S25460.	0.6	145
520	Reference-free inference of tumor phylogenies from single-cell sequencing data. <i>BMC Genomics</i> , 2015, 16, S7.	1.2	10
521	2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses tumor progression and metastatic potential of breast cancer cells by inducing ubiquitin ligase CHIP. <i>Scientific Reports</i> , 2014, 4, 7095.	1.6	31
522	Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis. <i>Oncology Letters</i> , 2015, 9, 2825-2832.	0.8	8
523	A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer. <i>Advances in Therapy</i> , 2015, 32, 1237-1247.	1.3	32
524	Leveraging global gene expression patterns to predict expression of unmeasured genes. <i>BMC Genomics</i> , 2015, 16, 1065.	1.2	3
525	Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival. <i>BMC Cancer</i> , 2015, 15, 865.	1.1	36

#	ARTICLE	IF	CITATIONS
526	Cancer classification in the genomic era: five contemporary problems. <i>Human Genomics</i> , 2015, 9, 27.	1.4	48
527	Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer. <i>BMC Medicine</i> , 2015, 13, 254.	2.3	21
528	Mechanistic-enriched models: integrating transcription factor networks and metabolic deregulation in cancer. <i>Theoretical Biology and Medical Modelling</i> , 2015, 12, 16.	2.1	2
529	Trastuzumab and docetaxel in a preclinical organotypic breast cancer model using tissue slices from mammary fat pad: Translational relevance. <i>Oncology Reports</i> , 2015, 34, 1146-1152.	1.2	8
530	Diverse functions of miR-373 in cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 162.	1.8	79
531	Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. <i>SpringerPlus</i> , 2015, 4, 386.	1.2	27
532	ER, PgR, Ki67, p27Kip1, and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab. <i>BMC Cancer</i> , 2015, 15, 622.	1.1	48
533	Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study. <i>BMC Cancer</i> , 2015, 15, 697.	1.1	3
534	Immunohistochemical evaluation of ROCK activation in invasive breast cancer. <i>BMC Cancer</i> , 2015, 15, 943.	1.1	13
535	Gene-expression signature functional annotation of breast cancer tumours in function of age. <i>BMC Medical Genomics</i> , 2015, 8, 80.	0.7	6
536	CRABP1 is associated with a poor prognosis in breast cancer: adding to the complexity of breast cancer cell response to retinoic acid. <i>Molecular Cancer</i> , 2015, 14, 129.	7.9	59
537	Overexpression of G6PD is associated with high risks of recurrent metastasis and poor progression-free survival in primary breast carcinoma. <i>World Journal of Surgical Oncology</i> , 2015, 13, 323.	0.8	50
538	Mechanisms involved in breast cancer liver metastasis. <i>Journal of Translational Medicine</i> , 2015, 13, 64.	1.8	96
539	Assessing breast cancer cell lines as tumour models by comparison of mRNA expression profiles. <i>Breast Cancer Research</i> , 2015, 17, 114.	2.2	60
540	Transgelin gene is frequently downregulated by promoter DNA hypermethylation in breast cancer. <i>Clinical Epigenetics</i> , 2015, 7, 104.	1.8	34
541	The integrative epigenomic-transcriptomic landscape of ER positive breast cancer. <i>Clinical Epigenetics</i> , 2015, 7, 126.	1.8	24
542	Comprehensive prognostic analysis in breast cancer integrating clinical, tumoral, micro-environmental and immunohistochemical criteria. <i>SpringerPlus</i> , 2015, 4, 528.	1.2	7
543	High incidence of triple negative breast cancers following pregnancy and an associated gene expression signature. <i>SpringerPlus</i> , 2015, 4, 710.	1.2	31

#	ARTICLE	IF	CITATIONS
544	Her2 positivity and race predict higher mastectomy rates: a SEER database analysis. SpringerPlus, 2015, 4, 715.	1.2	1
545	Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay. Journal of Magnetic Resonance Imaging, 2015, 42, 1398-1406.	1.9	119
546	Runx1 is associated with breast cancer progression in MMTV- <i>PyMT</i> transgenic mice and its depletion in vitro inhibits migration and invasion. Journal of Cellular Physiology, 2015, 230, 2522-2532.	2.0	63
547	CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials. Clinical Cancer Research, 2015, 21, 4027-4029.	3.2	4
548	Racial/Ethnic and Socioeconomic Differences in Short-Term Breast Cancer Survival Among Women in an Integrated Health System. American Journal of Public Health, 2015, 105, 938-946.	1.5	49
549	Molecular heterogeneity in adjacent cells in triple-negative breast cancer. Breast Cancer: Targets and Therapy, 2015, 7, 231.	1.0	12
550	Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation. Oncotarget, 2015, 6, 15966-15983.	0.8	395
551	Reverse phase protein arrays in signaling pathways: a data integration perspective. Drug Design, Development and Therapy, 2015, 9, 3519.	2.0	40
552	Survival Improvement in Korean Breast Cancer Patients Due to Increases in Early-Stage Cancers and Hormone Receptor Positive/HER2 Negative Subtypes: A Nationwide Registry-Based Study. Journal of Breast Cancer, 2015, 18, 8.	0.8	12
553	Triple negative breast cancer: an Indian perspective. Breast Cancer: Targets and Therapy, 2015, 7, 239.	1.0	18
554	Whole-Exome Sequencing Identifies Novel Somatic Mutations in Chinese Breast Cancer Patients. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2015, 09, .	0.1	22
555	Genetic Programming Based Ensemble System for Microarray Data Classification. Computational and Mathematical Methods in Medicine, 2015, 2015, 1-11.	0.7	16
556	Age and the means of bypassing stasis influence the intrinsic subtype of immortalized human mammary epithelial cells. Frontiers in Cell and Developmental Biology, 2015, 3, 13.	1.8	25
557	Circulating MicroRNAs as Biomarkers and Mediators of Cell-Cell Communication in Cancer. Biomedicines, 2015, 3, 270-281.	1.4	10
558	Effects of Age on the Detection and Management of Breast Cancer. Cancers, 2015, 7, 908-929.	1.7	263
559	miRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer. International Journal of Molecular Sciences, 2015, 16, 28347-28376.	1.8	56
560	Claudin 1 in Breast Cancer: New Insights. Journal of Clinical Medicine, 2015, 4, 1960-1976.	1.0	50
561	Estrogen-Related Receptors in Breast Cancer and Prostate Cancer. Frontiers in Endocrinology, 2015, 6, 83.	1.5	56

#	ARTICLE	IF	CITATIONS
562	Insights into Orphan Nuclear Receptors as Prognostic Markers and Novel Therapeutic Targets for Breast Cancer. <i>Frontiers in Endocrinology</i> , 2015, 6, 115.	1.5	4
563	Unfolding the Role of Stress Response Signaling in Endocrine Resistant Breast Cancers. <i>Frontiers in Oncology</i> , 2015, 5, 140.	1.3	27
564	High Expression of Three-Gene Signature Improves Prediction of Relapse-Free Survival in Estrogen Receptor-Positive and Node-Positive Breast Tumors. <i>Biomarker Insights</i> , 2015, 10, BMI.S30559.	1.0	27
565	MicroRNAs and Growth Factors: An Alliance Propelling Tumor Progression. <i>Journal of Clinical Medicine</i> , 2015, 4, 1578-1599.	1.0	21
566	Breast Cancer Subtype as a Predictor of Lymph Node Metastasis according to the SEER Registry. <i>Journal of Breast Cancer</i> , 2015, 18, 143.	0.8	28
567	The Active Tamoxifen Metabolite Endoxifen (4OHNDtam) Strongly Down-Regulates Cytokeratin 6 (CK6) in MCF-7 Breast Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0122339.	1.1	3
568	Prediction of Breast Cancer Survival Using Clinical and Genetic Markers by Tumor Subtypes. <i>PLoS ONE</i> , 2015, 10, e0122413.	1.1	14
569	Prognostic Value of Tumor-Associated Macrophages According to Histologic Locations and Hormone Receptor Status in Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0125728.	1.1	98
570	Revealing the Molecular Portrait of Triple Negative Breast Tumors in an Understudied Population through Omics Analysis of Formalin-Fixed and Paraffin-Embedded Tissues. <i>PLoS ONE</i> , 2015, 10, e0126762.	1.1	18
571	The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set. <i>PLoS ONE</i> , 2015, 10, e0129711.	1.1	27
572	Perceived Stress Levels, Chemotherapy, Radiation Treatment and Tumor Characteristics Are Associated with a Persistent Increased Frequency of Somatic Chromosomal Instability in Women Diagnosed with Breast Cancer: A One Year Longitudinal Study. <i>PLoS ONE</i> , 2015, 10, e0133380.	1.1	22
573	Comparative Gene Expression Analyses Identify Luminal and Basal Subtypes of Canine Invasive Urothelial Carcinoma That Mimic Patterns in Human Invasive Bladder Cancer. <i>PLoS ONE</i> , 2015, 10, e0136688.	1.1	56
574	CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0139112.	1.1	78
575	Breast Cancer Cell Line Aggregate Morphology Does Not Predict Invasive Capacity. <i>PLoS ONE</i> , 2015, 10, e0139523.	1.1	22
576	Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0141763.	1.1	77
577	Non-Specific Blocking of miR-17-5p Guide Strand in Triple Negative Breast Cancer Cells by Amplifying Passenger Strand Activity. <i>PLoS ONE</i> , 2015, 10, e0142574.	1.1	23
578	GO-PCA: An Unsupervised Method to Explore Gene Expression Data Using Prior Knowledge. <i>PLoS ONE</i> , 2015, 10, e0143196.	1.1	29
579	Mutation Screening of 1,237 Cancer Genes across Six Model Cell Lines of Basal-Like Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0144528.	1.1	6

#	ARTICLE	IF	CITATIONS
580	MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer. <i>Theranostics</i> , 2015, 5, 1122-1143.	4.6	664
581	Evaluation of the pathological response and prognosis following neoadjuvant chemotherapy in molecular subtypes of breast cancer. <i>OncoTargets and Therapy</i> , 2015, 8, 1511.	1.0	17
582	Differences in Clinical Outcomes between Luminal A and B Type Breast Cancers according to the St. Gallen Consensus 2013. <i>Journal of Breast Cancer</i> , 2015, 18, 149.	0.8	39
583	Recent Advances in the Use of Metformin: Can Treating Diabetes Prevent Breast Cancer?. <i>BioMed Research International</i> , 2015, 2015, 1-13.	0.9	54
584	Heterogeneity of Breast Cancer Associations with Common Genetic Variants in <i>FGFR2</i> according to the Intrinsic Subtypes in Southern Han Chinese Women. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	15
585	Classification of Cancer Primary Sites Using Machine Learning and Somatic Mutations. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	20
586	The Influence of Socioeconomic Status on Racial/Ethnic Disparities among the ER/PR/HER2 Breast Cancer Subtypes. <i>Journal of Cancer Epidemiology</i> , 2015, 2015, 1-8.	0.5	25
587	Application of Metabolomics in Thyroid Cancer Research. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-13.	0.6	42
588	Identifying and Assessing Interesting Subgroups in a Heterogeneous Population. <i>BioMed Research International</i> , 2015, 2015, 1-13.	0.9	3
589	Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study. <i>Oncotarget</i> , 2015, 6, 22985-22995.	0.8	16
590	Biomarkers in triple negative breast cancer: A review. <i>World Journal of Clinical Oncology</i> , 2015, 6, 252.	0.9	97
591	Triple negative breast cancer: looking for the missing link between biology and treatments. <i>Oncotarget</i> , 2015, 6, 26560-26574.	0.8	133
592	Diagnosis of Basal-Like Breast Cancer Using a FOXC1-Based Assay. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	48
593	Genomic profiling of breast cancers. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 34-39.	0.9	19
594	Inhibition of Cancer Cell Proliferation and Breast Tumor Targeting of pHILIP-“Monomethyl Auristatin E Conjugates. <i>Molecular Pharmaceutics</i> , 2015, 12, 1250-1258.	2.3	52
595	Validation of an in vitro model of erbB2+ cancer cell redirection. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2015, 51, 776-786.	0.7	10
596	Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 541-552.	12.5	121
597	From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 153, 45-53.	1.2	47

#	ARTICLE	IF	CITATIONS
598	Relapse profile of early breast cancer according to immunohistochemical subtypes: guidance for patient's follow up?. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 144-152.	1.4	8
599	Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients. <i>Oncology Letters</i> , 2015, 9, 1046-1054.	0.8	22
600	The Roles of MicroRNAs in Breast Cancer. <i>Cancers</i> , 2015, 7, 598-616.	1.7	125
601	Genome-wide analysis of alternative transcripts in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 295-307.	1.1	26
602	OM.Breast Cancer in Very Young Women Aged 25 Year-Old or Below in the Center of Tunisia and Review of the Literature. <i>Pathology and Oncology Research</i> , 2015, 21, 553-561.	0.9	3
603	Myoepithelial and luminal breast cancer cells exhibit different responses to all-trans retinoic acid. <i>Cellular Oncology (Dordrecht)</i> , 2015, 38, 289-305.	2.1	15
604	Long non-coding RNA expression profiles predict metastasis in lymph node-negative breast cancer independently of traditional prognostic markers. <i>Breast Cancer Research</i> , 2015, 17, 55.	2.2	49
605	Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma. <i>British Journal of Cancer</i> , 2015, 113, 64-68.	2.9	40
606	The fate of chemoresistance in triple negative breast cancer (TNBC). <i>BBA Clinical</i> , 2015, 3, 257-275.	4.1	293
607	Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1039-1045.	1.1	95
608	Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. <i>Journal of Breast Health</i> , 2015, 11, 59-66.	0.9	177
609	P-Cadherin Linking Breast Cancer Stem Cells and Invasion: A Promising Marker to Identify an "Intermediate/Metastable"-EMT State. <i>Frontiers in Oncology</i> , 2014, 4, 371.	1.3	87
610	Prognostic Significance of Single Progesterone Receptor Positivity. <i>Medicine (United States)</i> , 2015, 94, e2066.	0.4	21
611	Associations among ancestry, geography and breast cancer incidence, mortality, and survival in Trinidad and Tobago. <i>Cancer Medicine</i> , 2015, 4, 1742-1753.	1.3	17
612	Altered intracellular region of MUC1 and disrupted correlation of polarity-related molecules in breast cancer subtypes. <i>Cancer Science</i> , 2015, 106, 307-314.	1.7	8
613	MEXPRESS: visualizing expression, DNA methylation and clinical TCGA data. <i>BMC Genomics</i> , 2015, 16, 636.	1.2	257
614	Gene expression profiling leads to discovery of correlation of matrix metalloproteinase 11 and heparanase 2 in breast cancer progression. <i>BMC Cancer</i> , 2015, 15, 473.	1.1	33
615	Unexpected features of breast cancer subtype. <i>World Journal of Surgical Oncology</i> , 2015, 13, 249.	0.8	3

#	ARTICLE	IF	CITATIONS
616	Developmental Insights into Breast Cancer Intratumoral Heterogeneity. <i>Trends in Cancer</i> , 2015, 1, 242-251.	3.8	16
617	Non-muscle myosin II in disease: mechanisms and therapeutic opportunities. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 1495-515.	1.2	107
618	Plasma Autoantibodies Associated with Basal-like Breast Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1332-1340.	1.1	42
619	Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. <i>BMC Medicine</i> , 2015, 13, 303.	2.3	113
620	Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short report. <i>Cellular Oncology (Dordrecht)</i> , 2015, 38, 485-491.	2.1	23
621	Vascular Targeting of a Gold Nanoparticle to Breast Cancer Metastasis. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 2600-2610.	1.6	46
622	Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. <i>Breast Care</i> , 2015, 10, 168-172.	0.8	19
623	Down-regulation of PAR1 activity with a pHLIP-based allosteric antagonist induces cancer cell death. <i>Biochemical Journal</i> , 2015, 472, 287-295.	1.7	21
624	A Long-Lived Luminal Subpopulation Enriched with Alveolar Progenitors Serves as Cellular Origin of Heterogeneous Mammary Tumors. <i>Stem Cell Reports</i> , 2015, 5, 60-74.	2.3	18
625	Correlation Between Clinical-Pathologic Factors and Long-Term Follow-Up in Young Breast Cancer Patients. <i>Translational Oncology</i> , 2015, 8, 265-272.	1.7	10
626	Molecular characteristics of recurrent triple-negative breast cancer. <i>Molecular Medicine Reports</i> , 2015, 12, 7326-7334.	1.1	18
627	HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. <i>Breast Cancer Research</i> , 2015, 17, 149.	2.2	42
628	Phloroglucinol suppresses metastatic ability of breast cancer cells by inhibition of epithelial-mesenchymal cell transition. <i>Cancer Science</i> , 2015, 106, 94-101.	1.7	53
629	Insulin-Like Growth Factor-1 Receptor Signaling Increases the Invasive Potential of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Cells via Src-Focal Adhesion Kinase and Forkhead Box Protein M1. <i>Molecular Pharmacology</i> , 2015, 87, 150-161.	1.0	46
630	Basaloid carcinoma of the pancreas-clinopathological presentation and oncogenetic snapshot of a rare entity. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 237-241.	1.4	2
631	Evaluation of the Stage IB Designation of the American Joint Committee on Cancer Staging System in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1119-1127.	0.8	36
632	Animal models for exploring the pharmacokinetics of breast cancer therapies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 221-230.	1.5	47
633	Patient-derived xenograft models of breast cancer and their predictive power. <i>Breast Cancer Research</i> , 2015, 17, 17.	2.2	225

#	ARTICLE	IF	CITATIONS
634	Triple-negative breast cancer in African-American women: disparities versus biology. <i>Nature Reviews Cancer</i> , 2015, 15, 248-254.	12.8	342
635	Assessing the Role of Platinum Agents in Aggressive Breast Cancers. <i>Current Oncology Reports</i> , 2015, 17, 3.	1.8	30
636	Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients. <i>Tumor Biology</i> , 2015, 36, 5451-5457.	0.8	22
637	Identification of Metastasis-Suppressive microRNAs in Primary Melanoma. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	47
638	Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models. <i>Journal of Controlled Release</i> , 2015, 208, 59-66.	4.8	34
639	Computational and analytical challenges in single-cell transcriptomics. <i>Nature Reviews Genetics</i> , 2015, 16, 133-145.	7.7	1,043
640	Decreased BECN1 mRNA Expression in Human Breast Cancer is Associated With Estrogen Receptor-Negative Subtypes and Poor Prognosis. <i>EBioMedicine</i> , 2015, 2, 255-263.	2.7	95
641	Metabolic signatures of human breast cancer. <i>Molecular and Cellular Oncology</i> , 2015, 2, e992217.	0.3	56
642	Intrinsic cancer subtypes-next steps into personalized medicine. <i>Cellular Oncology (Dordrecht)</i> , 2015, 38, 3-16.	2.1	24
643	The future of breast cancer systemic therapy: the next 10Âyears. <i>Journal of Molecular Medicine</i> , 2015, 93, 119-125.	1.7	19
644	Pharmacological Profiling of Kinase Dependency in Cell Lines across Triple-Negative Breast Cancer Subtypes. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 298-306.	1.9	14
645	The Osteogenic Niche Promotes Early-Stage Bone Colonization of Disseminated Breast Cancer Cells. <i>Cancer Cell</i> , 2015, 27, 193-210.	7.7	308
646	Epigenetic and metabolic regulation of breast cancer stem cells. <i>Journal of Zhejiang University: Science B</i> , 2015, 16, 10-17.	1.3	23
647	RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer. <i>Cell Cycle</i> , 2015, 14, 109-122.	1.3	33
648	Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 425-437.	1.1	29
649	Role of Positron Emission Tomography for the Monitoring of Response to Therapy in Breast Cancer. <i>Oncologist</i> , 2015, 20, 94-104.	1.9	53
650	Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast. <i>Journal of Histochemistry and Cytochemistry</i> , 2015, 63, 408-416.	1.3	19
651	Diagnostic significance of alternative splice variants of REST and DOPEY1 in the peripheral blood of patients with breast cancer. <i>Tumor Biology</i> , 2015, 36, 2473-2480.	0.8	3

#	ARTICLE	IF	CITATIONS
652	Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 145-155.	2.7	264
653	Hypoxia-induced nitric oxide release by luminal cells stimulates proliferation and uPA secretion of myoepithelial cells in a bicellular murine mammary tumor. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1727-1738.	1.2	2
654	Targeting a cell state common to triple-negative breast cancers. <i>Molecular Systems Biology</i> , 2015, 11, 789.	3.2	21
655	The origin of breast tumor heterogeneity. <i>Oncogene</i> , 2015, 34, 5309-5316.	2.6	125
656	The role of the insulin-like growth factor-1 system in breast cancer. <i>Molecular Cancer</i> , 2015, 14, 43.	7.9	287
657	The 21-Gene Recurrence Score and Locoregional Recurrence in Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2015, 22, 1088-1094.	0.7	28
658	Genetic variation in estrogen and progesterone pathway genes and breast cancer risk: an exploration of tumor subtype-specific effects. <i>Cancer Causes and Control</i> , 2015, 26, 121-131.	0.8	17
659	Precision Medicine in Breast Cancer: Genes, Genomes, and the Future of Genomically Driven Treatments. <i>Current Oncology Reports</i> , 2015, 17, 15.	1.8	29
660	Crosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironment. <i>Expert Reviews in Molecular Medicine</i> , 2015, 17, e3.	1.6	65
661	Utility of 18F FDG-PET/CT for predicting prognosis of luminal-type breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 209-217.	1.1	60
662	Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. <i>Oncologist</i> , 2015, 20, 713-718.	1.9	19
663	Functional and therapeutic significance of protein kinase D enzymes in invasive breast cancer. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 4369-4382.	2.4	35
664	Form and Function: how Estrogen and Progesterone Regulate the Mammary Epithelial Hierarchy. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2015, 20, 9-25.	1.0	100
665	Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2772-2779.	0.8	141
666	Gene expression profiling offers insights into the role of innate immune signaling in SSc. <i>Seminars in Immunopathology</i> , 2015, 37, 501-509.	2.8	24
667	Metabolomic profiling of hormone-dependent cancers: a bird's eye view. <i>Trends in Endocrinology and Metabolism</i> , 2015, 26, 477-485.	3.1	42
668	Inhibition of the autocrine IL-6/JAK2-STAT3-calprotectin axis as targeted therapy for HR ⁺ /HER2 ⁺ breast cancers. <i>Genes and Development</i> , 2015, 29, 1631-1648.	2.7	94
669	Significance of Rat Mammary Tumors for Human Risk Assessment. <i>Toxicologic Pathology</i> , 2015, 43, 145-170.	0.9	65

#	ARTICLE	IF	CITATIONS
670	A new role of SNAI2 in postlactational involution of the mammary gland links it to luminal breast cancer development. <i>Oncogene</i> , 2015, 34, 4777-4790.	2.6	12
671	Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor in a Multiethnic Asian Country. <i>World Journal of Surgery</i> , 2015, 39, 2450-2458.	0.8	10
672	Prevalence of molecular subtypes of invasive breast cancer: A retrospective study. <i>Medical Journal Armed Forces India</i> , 2015, 71, 254-258.	0.3	34
673	Association between 18F-FDG uptake and molecular subtype of breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1371-1377.	3.3	62
674	Application of a 70-Gene Expression Profile to Japanese Breast Cancer Patients. <i>Breast Care</i> , 2015, 10, 118-122.	0.8	5
675	Presence of Insulin-Like Growth Factor Binding Proteins Correlates With Tumor-Promoting Effects of Matrix Metalloproteinase 9 in Breast Cancer. <i>Neoplasia</i> , 2015, 17, 421-433.	2.3	28
676	Spatiotemporal Targeting of a Dual-Ligand Nanoparticle to Cancer Metastasis. <i>ACS Nano</i> , 2015, 9, 8012-8021.	7.3	107
677	A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer. <i>Cancer Biology and Therapy</i> , 2015, 16, 225-232.	1.5	22
678	Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. <i>Cell Reports</i> , 2015, 12, 511-524.	2.9	39
679	Subclonal diversification of primary breast cancer revealed by multiregion sequencing. <i>Nature Medicine</i> , 2015, 21, 751-759.	15.2	711
680	Fertility preservation and breast cancer: a review. <i>Ecancermedicalscience</i> , 2015, 9, 503.	0.6	34
681	A novel embryonic plasticity gene signature that predicts metastatic competence and clinical outcome. <i>Scientific Reports</i> , 2015, 5, 11766.	1.6	36
682	Perturbation-Expression Analysis Identifies RUNX1 as a Regulator of Human Mammary Stem Cell Differentiation. <i>PLoS Computational Biology</i> , 2015, 11, e1004161.	1.5	22
683	Systemic Treatment Approaches in her2-Negative Advanced Breast Cancer – Guidance on the Guidelines. <i>Current Oncology</i> , 2015, 22, 29-42.	0.9	18
684	The role of non-coding RNAs in the regulation of stem cells and progenitors in the normal mammary gland and in breast tumors. <i>Frontiers in Genetics</i> , 2015, 6, 72.	1.1	44
685	Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes. <i>Molecular Oncology</i> , 2015, 9, 877-888.	2.1	16
686	The Proteomic Landscape of Triple-Negative Breast Cancer. <i>Cell Reports</i> , 2015, 11, 630-644.	2.9	179
687	Krüppel-like factor 4 induces apoptosis and inhibits tumorigenic progression in SK-BR-3 breast cancer cells. <i>FEBS Open Bio</i> , 2015, 5, 147-154.	1.0	36

#	ARTICLE	IF	CITATIONS
688	Tumour and patient factors in renal cell carcinoma towards personalized therapy. <i>Nature Reviews Urology</i> , 2015, 12, 253-262.	1.9	22
689	Cell signaling events differentiate ER-negative subtypes from ER-positive breast cancer. <i>Medical Oncology</i> , 2015, 32, 142.	1.2	7
690	Therapies for triple negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 983-998.	0.9	85
691	Clinical management of breast cancer heterogeneity. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 381-394.	12.5	400
692	Zinc distribution within breast cancer tissue: A possible marker for histological grading?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1321-1331.	1.2	39
693	Retrospective analysis of metastatic behaviour of breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 547-557.	1.1	141
694	MUC1-mediated motility in breast cancer: a review highlighting the role of the MUC1/ICAM-1/Src signaling triad. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 393-403.	1.7	37
695	Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 647-664.	1.5	40
696	Pseudogenes transcribed in breast invasive carcinoma show subtype-specific expression and ceRNA potential. <i>BMC Genomics</i> , 2015, 16, 113.	1.2	35
697	A functional in vitro model of heterotypic interactions reveals a role for interferon-positive carcinoma associated fibroblasts in breast cancer. <i>BMC Cancer</i> , 2015, 15, 130.	1.1	16
698	Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers. <i>BMC Medicine</i> , 2015, 13, 46.	2.3	27
699	Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer the INNODIAG study. <i>BMC Medical Genomics</i> , 2015, 8, 3.	0.7	13
700	Integrative analysis of survival-associated gene sets in breast cancer. <i>BMC Medical Genomics</i> , 2015, 8, 11.	0.7	17
701	Drug sensitivity in cancer cell lines is not tissue-specific. <i>Molecular Cancer</i> , 2015, 14, 40.	7.9	39
702	High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients. <i>Hereditary Cancer in Clinical Practice</i> , 2015, 13, 7.	0.6	21
703	Invasive lobular carcinoma of the breast: morphology, biomarkers and omics. <i>Breast Cancer Research</i> , 2015, 17, 12.	2.2	256
704	Molecular subtyping for clinically defined breast cancer subgroups. <i>Breast Cancer Research</i> , 2015, 17, 29.	2.2	51
705	Prognostic stromal gene signatures in breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 23.	2.2	67

#	ARTICLE	IF	CITATIONS
706	FOXF2 deficiency promotes epithelial-mesenchymal transition and metastasis of basal-like breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 30.	2.2	55
707	A case-control analysis of oral contraceptive use and breast cancer subtypes in the African American Breast Cancer Epidemiology and Risk Consortium. <i>Breast Cancer Research</i> , 2015, 17, 22.	2.2	47
708	Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. <i>Breast Cancer Research</i> , 2015, 17, 43.	2.2	248
709	Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing. <i>Human Genomics</i> , 2015, 9, 2.	1.4	36
710	Characterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian Women. <i>Annals of Surgical Oncology</i> , 2015, 22, 3831-3835.	0.7	27
711	Revisiting the transcriptional analysis of primary tumours and associated nodal metastases with enhanced biological and statistical controls: application to thyroid cancer. <i>British Journal of Cancer</i> , 2015, 112, 1665-1674.	2.9	54
712	Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. <i>Oncologist</i> , 2015, 20, 474-482.	1.9	145
713	Molecular characterization and targeted therapeutic approaches in breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 60.	2.2	132
714	Overexpression of chromosome 14 open reading frame 166 correlates with disease progression and poorer prognosis in human NPC. <i>Tumor Biology</i> , 2015, 36, 7977-7986.	0.8	8
715	The role of Tcfap2c in tumorigenesis and cancer growth in an activated Neu model of mammary carcinogenesis. <i>Oncogene</i> , 2015, 34, 6105-6114.	2.6	22
716	Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 237-51.	1.2	154
717	Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1220-9.	3.3	72
718	High tumor budding stratifies breast cancer with metastatic properties. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 363-371.	1.1	62
719	Global Analysis of Protein Folding Thermodynamics for Disease State Characterization. <i>Journal of Proteome Research</i> , 2015, 14, 2287-2297.	1.8	28
720	Genotype/Phenotype Correlations in Patients with Hereditary Breast Cancer. <i>Breast Care</i> , 2015, 10, 22-26.	0.8	17
721	Ki67: no evidence for its use in node-positive breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 296-301.	12.5	58
722	Landscape of Neoadjuvant Therapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 1408-1415.	0.7	47
723	Racial Variation in Breast Tumor Promoter Methylation in the Carolina Breast Cancer Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 921-930.	1.1	41

#	ARTICLE	IF	CITATIONS
724	Transgelin: a potentially useful diagnostic marker differentially expressed in triple-negative and non-triple-negative breast cancers. <i>Human Pathology</i> , 2015, 46, 876-883.	1.1	20
725	PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 569-579.	1.1	17
726	TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2722-2729.	3.2	57
727	Chemotherapy for Metastatic Breast Cancer – An Anachronism in the Era of Personalised and Targeted Oncological Therapy?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 574-583.	0.8	19
728	Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network. <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 41-50.	0.8	75
729	Prognostic Relevance of Circulating Tumor Cells in Molecular Subtypes of Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 232-237.	0.8	19
730	Prognostic Factors for Local, Loco-regional and Systemic Recurrence in Early-stage Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 710-718.	0.8	16
731	4-IHC classification of breast cancer subtypes in a large cohort of a clinical cancer registry: use in clinical routine for therapeutic decisions and its effect on survival. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 647-658.	1.1	51
732	CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer. <i>Cell</i> , 2015, 163, 174-186.	13.5	346
733	The possible role of EZH2 and DNMT1 polymorphisms in sporadic triple-negative breast carcinoma in southern Chinese females. <i>Tumor Biology</i> , 2015, 36, 9849-9855.	0.8	21
734	The changing role of ER in endocrine resistance. <i>Breast</i> , 2015, 24, S60-S66.	0.9	97
735	Methylation biomarkers for pleomorphic lobular breast cancer - a short report. <i>Cellular Oncology (Dordrecht)</i> , 2015, 38, 397-405.	2.1	10
736	A retrospective analysis of breast cancer subtype based on ER/PR and HER2 status in Ghanaian patients at the Korle Bu Teaching Hospital, Ghana. <i>BMC Clinical Pathology</i> , 2015, 15, 14.	1.8	31
737	Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers. <i>Cellular Oncology (Dordrecht)</i> , 2015, 38, 433-442.	2.1	59
738	Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53. <i>Molecular Cancer Research</i> , 2015, 13, 493-501.	1.5	53
739	Post-diagnosis adiposity and survival among breast cancer patients: influence of breast cancer subtype. <i>Cancer Causes and Control</i> , 2015, 26, 1803-1811.	0.8	22
740	Interferons and the Immunogenic Effects of Cancer Therapy. <i>Trends in Immunology</i> , 2015, 36, 725-737.	2.9	107
741	Tumor characterization and stratification by integrated molecular profiles reveals essential pan-cancer features. <i>BMC Genomics</i> , 2015, 16, 503.	1.2	32

#	ARTICLE	IF	CITATIONS
742	A Gene Regulatory Program in Human Breast Cancer. <i>Genetics</i> , 2015, 201, 1341-1348.	1.2	14
743	FAS Death Receptor: A Breast Cancer Subtype-Specific Radiation Response Biomarker and Potential Therapeutic Target. <i>Radiation Research</i> , 2015, 184, 456.	0.7	26
744	Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis. <i>Breast Cancer Research</i> , 2015, 17, 98.	2.2	76
745	Breast cancer survival in African-American women by hormone receptor subtypes. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 211-218.	1.1	22
746	Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer. <i>Drugs</i> , 2015, 75, 1311-1321.	4.9	5
747	Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome. <i>Epigenetics</i> , 2015, 10, 903-912.	1.3	30
748	Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. <i>Nature</i> , 2015, 525, 119-123.	13.7	284
749	APC selectively mediates response to chemotherapeutic agents in breast cancer. <i>BMC Cancer</i> , 2015, 15, 457.	1.1	36
750	Mitochondrial Genetics Regulate Breast Cancer Tumorigenicity and Metastatic Potential. <i>Cancer Research</i> , 2015, 75, 4429-4436.	0.4	58
751	Classical pathology and mutational load of breast cancer – integration of two worlds. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 225-238.	1.3	91
752	Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. <i>Investigational New Drugs</i> , 2015, 33, 1108-1114.	1.2	44
753	Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomas. <i>BMC Cancer</i> , 2015, 15, 524.	1.1	20
754	Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. <i>BMC Medical Genomics</i> , 2015, 8, 54.	0.7	352
755	Modelling breast cancer requires identification and correction of a critical cell lineage-dependent transduction bias. <i>Nature Communications</i> , 2015, 6, 6927.	5.8	20
756	Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 81-88.	1.1	17
757	Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers. <i>BMC Cancer</i> , 2015, 15, 506.	1.1	12
758	The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer. <i>Biochemical and Biophysical Research Communications</i> , 2015, 467, 1070-1075.	1.0	17
759	Regulation of triple-negative breast cancer cell metastasis by the tumor-suppressor liver kinase B1. <i>Oncogenesis</i> , 2015, 4, e168-e168.	2.1	30

#	ARTICLE	IF	CITATIONS
760	Inferring pathway dysregulation in cancers from multiple types of omic data. <i>Genome Medicine</i> , 2015, 7, 61.	3.6	13
761	Of Mice and Women: A Comparative Tissue Biology Perspective of Breast Stem Cells and Differentiation. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2015, 20, 51-62.	1.0	44
762	Patterns of Chromosomal Aberrations in Solid Tumors. <i>Recent Results in Cancer Research</i> , 2015, 200, 115-142.	1.8	44
763	MicroRNA letâ€b regulates genomic balance by targeting Aurora B kinase. <i>Molecular Oncology</i> , 2015, 9, 1056-1070.	2.1	21
764	The mammary stem cell hierarchy: a looking glass into heterogeneous breast cancer landscapes. <i>Endocrine-Related Cancer</i> , 2015, 22, T161-T176.	1.6	45
765	Identifying and targeting tumor-initiating cells in the treatment of breast cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, R135-R155.	1.6	42
766	Molecular portraits: the evolution of the concept of transcriptome-based cancer signatures. <i>Briefings in Bioinformatics</i> , 2015, 16, 1000-1007.	3.2	9
767	Genome-wide analysis of microRNA and mRNA expression signatures in cancer. <i>Acta Pharmacologica Sinica</i> , 2015, 36, 1200-1211.	2.8	63
768	Mechanisms of Cancer Cell Dormancyâ€”Another Hallmark of Cancer?. <i>Cancer Research</i> , 2015, 75, 5014-5022.	0.4	168
769	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. <i>Cancer Gene Therapy</i> , 2015, 22, 417-430.	2.2	112
770	Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 607-616.	1.1	22
771	Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer. <i>Cell Stem Cell</i> , 2015, 17, 260-271.	5.2	328
772	Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. <i>Autophagy</i> , 2015, 11, 1878-1890.	4.3	91
773	Associations between sociodemographic and clinicopathological factors and breast cancer subtypes in a population-based study. <i>Cancer Causes and Control</i> , 2015, 26, 1737-1750.	0.8	18
774	Gene mutations in gastric cancer: a review of recent next-generation sequencing studies. <i>Tumor Biology</i> , 2015, 36, 7385-7394.	0.8	46
775	A tumour through time. <i>Nature</i> , 2015, 527, S102-S103.	13.7	12
776	Folate-dependent hydrolysis of acetyl-coenzyme A by recombinant human and rodent arylamine N-acetyltransferases. <i>Biochemistry and Biophysics Reports</i> , 2015, 3, 45-50.	0.7	28
777	Individuality and Variation of Personal Regulomes in Primary Human T Cells. <i>Cell Systems</i> , 2015, 1, 51-61.	2.9	128

#	ARTICLE	IF	CITATIONS
778	A phase 1 trial of preoperative partial breast radiation therapy: Patient selection, target delineation, and dose delivery. <i>Practical Radiation Oncology</i> , 2015, 5, e513-e520.	1.1	26
779	SETD1A modulates cell cycle progression through a miRNA network that regulates p53 target genes. <i>Nature Communications</i> , 2015, 6, 8257.	5.8	47
780	Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition. <i>Molecular and Cellular Biology</i> , 2015, 35, 4069-4082.	1.1	33
781	Elevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: a retrospective study. <i>BMC Cancer</i> , 2015, 15, 548.	1.1	14
782	Loss of Estrogen-Regulated microRNA Expression Increases HER2 Signaling and Is Prognostic of Poor Outcome in Luminal Breast Cancer. <i>Cancer Research</i> , 2015, 75, 436-445.	0.4	75
783	Epigenetics in Breast and Prostate Cancer. <i>Methods in Molecular Biology</i> , 2015, 1238, 425-466.	0.4	81
784	NF κ B affects estrogen receptor expression and activity in breast cancer through multiple mechanisms. <i>Molecular and Cellular Endocrinology</i> , 2015, 418, 235-239.	1.6	46
785	Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer. <i>Modern Pathology</i> , 2015, 28, 677-685.	2.9	28
786	BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function. <i>Oncogene</i> , 2015, 34, 4333-4346.	2.6	63
787	Wip1 phosphatase in breast cancer. <i>Oncogene</i> , 2015, 34, 4429-4438.	2.6	40
788	Chemotherapy benefit for $\hat{\epsilon}$ ER-positive $\hat{\epsilon}$ ™ breast cancer and contamination of Nonluminal subtypes $\hat{\epsilon}$ ™waiting for TAILORx and RxPONDER. <i>Annals of Oncology</i> , 2015, 26, 70-74.	0.6	11
789	Ki67 expression in breast cancer. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2016, 37, 137-141.	0.5	3,048
790	TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. <i>Oncotarget</i> , 2016, 7, 32731-32753.	0.8	30
791	Cell Fate Decisions During Breast Cancer Development. <i>Journal of Developmental Biology</i> , 2016, 4, 4.	0.9	22
792	Molecular expression of vascular endothelial growth factor, prokineticin receptor-1 and other biomarkers in infiltrating canalicular carcinoma of the breast. <i>Oncology Letters</i> , 2016, 12, 2720-2727.	0.8	6
793	The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1298.	1.8	35
794	High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer. <i>Oncotarget</i> , 2016, 7, 64900-64909.	0.8	41
795	Molecular biology of breast tumors and prognosis. <i>F1000Research</i> , 2016, 5, 711.	0.8	6

#	ARTICLE	IF	CITATIONS
796	Patients with Concordant Triple-Negative Phenotype between Primary Breast Cancers and Corresponding Metastases Have Poor Prognosis. <i>Journal of Breast Cancer</i> , 2016, 19, 268.	0.8	5
797	Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6119-6125.	1.0	13
798	Targeting Oncogenes into a Defined Subset of Mammary Cells Demonstrates That the Initiating Oncogenic Mutation Defines the Resulting Tumor Phenotype. <i>International Journal of Biological Sciences</i> , 2016, 12, 381-388.	2.6	9
799	Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer. <i>Journal of Cancer</i> , 2016, 7, 167-173.	1.2	98
800	Association of PTP1B with Outcomes of Breast Cancer Patients who Underwent Neoadjuvant Chemotherapy. <i>Breast Cancer: Basic and Clinical Research</i> , 2016, 10, BCBCR.S40934.	0.6	4
801	Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives. <i>Pharmacogenomics and Personalized Medicine</i> , 2016, 9, 7.	0.4	20
802	Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis. <i>OncoTargets and Therapy</i> , 2016, 9, 431.	1.0	50
804	Antibody Therapeutics in Oncology. <i>Immunotherapy (Los Angeles, Calif)</i> , 2016, 02, .	0.1	17
805	Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy. <i>Yonsei Medical Journal</i> , 2016, 57, 1192.	0.9	17
806	Ki-67 as a prognostic marker according to breast cancer molecular subtype. <i>Cancer Biology and Medicine</i> , 2016, 13, 496.	1.4	161
807	Breast Cancer Mortality among Asian-American Women in California: Variation according to Ethnicity and Tumor Subtype. <i>Journal of Breast Cancer</i> , 2016, 19, 112.	0.8	17
808	A preliminary study of pamidronic acid downregulation of angiogenic factors IGF-1/PECAM-1 expression in circulating level in bone metastatic breast cancer patients. <i>OncoTargets and Therapy</i> , 2016, 9, 3147.	1.0	4
809	Function of AURKA protein kinase in the formation of vasculogenic mimicry in triple-negative breast cancer stem cells. <i>OncoTargets and Therapy</i> , 2016, 9, 3473.	1.0	8
810	Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer. <i>Oncotarget</i> , 2016, 7, 53230-53244.	0.8	30
811	Identifying molecular genetic features and oncogenic pathways of clear cell renal cell carcinoma through the anatomical (PADUA) scoring system. <i>Oncotarget</i> , 2016, 7, 10006-10014.	0.8	4
812	Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment. <i>Cancer Research and Treatment</i> , 2016, 48, 1363-1372.	1.3	40
813	Male Breast Cancer. <i>Journal of Breast Health</i> , 2016, 12, 1-8.	0.9	76
814	Dysregulation of the BRCA1/long non-coding RNA NEAT1 signaling axis contributes to breast tumorigenesis. <i>Oncotarget</i> , 2016, 7, 65067-65089.	0.8	80

#	ARTICLE	IF	CITATIONS
815	Curcumin and Resveratrol as Promising Natural Remedies with Nanomedicine Approach for the Effective Treatment of Triple Negative Breast Cancer. <i>Journal of Oncology</i> , 2016, 2016, 1-13.	0.6	55
816	Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients. <i>Mediators of Inflammation</i> , 2016, 2016, 1-12.	1.4	4
817	The Role of Forkhead Box Protein M1 in Breast Cancer Progression and Resistance to Therapy. <i>International Journal of Breast Cancer</i> , 2016, 2016, 1-8.	0.6	47
818	Associations of Genetic Variants at Nongenetic Susceptibility Loci with Breast Cancer Risk and Heterogeneity by Tumor Subtype in Southern Han Chinese Women. <i>BioMed Research International</i> , 2016, 2016, 1-9.	0.9	5
819	Biologic subtype is a more important prognostic factor than nodal involvement in patients with stages I and II breast carcinoma. <i>Annals of Surgical Treatment and Research</i> , 2016, 90, 1.	0.4	9
820	Human plasma metabolomics for identifying differential metabolites and predicting molecular subtypes of breast cancer. <i>Oncotarget</i> , 2016, 7, 9925-9938.	0.8	90
821	Epithelial-Mesenchymal Transition and Breast Cancer. <i>Journal of Clinical Medicine</i> , 2016, 5, 13.	1.0	160
822	Long non-coding RNAs as prognostic markers in human breast cancer. <i>Oncotarget</i> , 2016, 7, 20584-20596.	0.8	133
823	Targeting FOSB with a cationic antimicrobial peptide, TP4, for treatment of triple-negative breast cancer. <i>Oncotarget</i> , 2016, 7, 40329-40347.	0.8	41
824	Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2016, 6, 205.	1.3	35
825	Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women. <i>Frontiers in Oncology</i> , 2016, 6, 241.	1.3	23
826	Dissecting the Biology of Menstrual Cycle-Associated Breast Cancer Risk. <i>Frontiers in Oncology</i> , 2016, 6, 267.	1.3	37
827	Mammary Development and Breast Cancer: A Wnt Perspective. <i>Cancers</i> , 2016, 8, 65.	1.7	91
828	TÎ²RIII Expression in Human Breast Cancer Stroma and the Role of Soluble TÎ²RIII in Breast Cancer Associated Fibroblasts. <i>Cancers</i> , 2016, 8, 100.	1.7	9
829	Androgen Receptor: A Complex Therapeutic Target for Breast Cancer. <i>Cancers</i> , 2016, 8, 108.	1.7	49
830	Implications of Hypoxia in Breast Cancer Metastasis to Bone. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1669.	1.8	52
831	The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures. <i>BMC Cancer</i> , 2016, 16, 555.	1.1	9
832	Single-Cell Co-expression Analysis Reveals Distinct Functional Modules, Co-regulation Mechanisms and Clinical Outcomes. <i>PLoS Computational Biology</i> , 2016, 12, e1004892.	1.5	36

#	ARTICLE	IF	CITATIONS
833	The Circadian Rhythm Gene Arntl2 Is a Metastasis Susceptibility Gene for Estrogen Receptor-Negative Breast Cancer. <i>PLoS Genetics</i> , 2016, 12, e1006267.	1.5	57
834	Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0156323.	1.1	44
835	Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0158461.	1.1	17
836	Dissecting the Origin of Breast Cancer Subtype Stem Cell and the Potential Mechanism of Malignant Transformation. <i>PLoS ONE</i> , 2016, 11, e0165001.	1.1	11
837	The highly expressed 5â€™ TM isomiR of hsa-miR-140-3p contributes to the tumor-suppressive effects of miR-140 by reducing breast cancer proliferation and migration. <i>BMC Genomics</i> , 2016, 17, 566.	1.2	85
838	Transcriptional Network Architecture of Breast Cancer Molecular Subtypes. <i>Frontiers in Physiology</i> , 2016, 7, 568.	1.3	48
839	Molecular Classification of Triple-Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2016, 19, 223.	0.8	111
840	Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells. <i>Breast Cancer: Targets and Therapy</i> , 2017, Volume 9, 9-19.	1.0	40
841	Triple-negative breast cancer: treatment challenges and solutions. <i>Breast Cancer: Targets and Therapy</i> , 2016, 8, 93.	1.0	201
842	Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. <i>Journal of Cancer</i> , 2016, 7, 1281-1294.	1.2	300
843	Comprehensive landscape of subtype-specific coding and non-coding RNA transcripts in breast cancer. <i>Oncotarget</i> , 2016, 7, 68851-68863.	0.8	19
844	Identification of lncRNA FAM83H-AS1 as a novel prognostic marker in luminal subtype breast cancer. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7039-7045.	1.0	35
845	HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase <i>in vitro</i> and <i>in vivo</i>. <i>Oncotarget</i> , 2016, 7, 45186-45198.	0.8	58
846	Expression profile analysis of long noncoding RNA in HER-2-enriched subtype breast cancer by next-generation sequencing and bioinformatics. <i>OncoTargets and Therapy</i> , 2016, 9, 761.	1.0	79
847	The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0161731.	1.1	15
848	EGFR and HER2 signaling in breast cancer brain metastasis. <i>Frontiers in Bioscience - Elite</i> , 2016, 8, 245-263.	0.9	30
849	Micro RNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR. <i>Oncotarget</i> , 2016, 7, 5702-5714.	0.8	67
850	Therapeutic effect of taxanes on metastatic breast cancer of various immunohistochemical subtypes. <i>Oncology Letters</i> , 2016, 12, 663-669.	0.8	4

#	ARTICLE	IF	CITATIONS
851	Laser Direct Write Onto Live Tissues: A Novel Model for Studying Cancer Cell Migration. <i>Journal of Cellular Physiology</i> , 2016, 231, 2333-2338.	2.0	34
853	Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification. <i>Breast Cancer Research</i> , 2016, 18, 68.	2.2	77
854	Proteomic analysis of breast tumors confirms the mRNA intrinsic molecular subtypes using different classifiers: a large-scale analysis of fresh frozen tissue samples. <i>Breast Cancer Research</i> , 2016, 18, 69.	2.2	9
855	The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression. <i>Cellular Signalling</i> , 2016, 28, 1502-1519.	1.7	29
856	Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide. <i>Oncology Letters</i> , 2016, 11, 2320-2326.	0.8	4
857	Pathway Oriented Therapy in Breast Cancer - a Light at the End of the Tunnel!. <i>Breast Care</i> , 2016, 11, 382-383.	0.8	0
858	Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers. <i>Breast Cancer Research</i> , 2016, 18, 118.	2.2	65
859	SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016). <i>Clinical and Translational Oncology</i> , 2016, 18, 1197-1205.	1.2	10
860	The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 575-588.	2.7	237
861	Long intergenic non-coding RNA expression signature in human breast cancer. <i>Scientific Reports</i> , 2016, 6, 37821.	1.6	26
862	FAT4 functions as a tumor suppressor in triple-negative breast cancer. <i>Tumor Biology</i> , 2016, 37, 16337-16343.	0.8	34
863	mRNA expression of delta-HER2 and its clinicopathological correlation in HER2-overexpressing breast cancer. <i>Molecular Medicine Reports</i> , 2016, 14, 5104-5110.	1.1	2
864	Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer. <i>World Journal of Surgical Oncology</i> , 2016, 14, 244.	0.8	19
865	Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer. <i>Journal of Translational Medicine</i> , 2016, 14, 227.	1.8	56
866	How interacting pathways are regulated by miRNAs in breast cancer subtypes. <i>BMC Bioinformatics</i> , 2016, 17, 348.	1.2	20
867	Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53 deficient mammary cancers. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 749-57.	1.2	25
868	Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups. <i>Breast Cancer Research</i> , 2016, 18, 74.	2.2	75
869	Study design requirements for RNA sequencing-based breast cancer diagnostics. <i>Scientific Reports</i> , 2016, 6, 20200.	1.6	2

#	ARTICLE	IF	CITATIONS
870	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). <i>Npj Breast Cancer</i> , 2016, 2, .	2.3	80
871	Tumour biomarkers: homeostasis as a novel prognostic indicator. <i>Open Biology</i> , 2016, 6, 160254.	1.5	21
872	Pan-cancer subtyping in a 2D-map shows substructures that are driven by specific combinations of molecular characteristics. <i>Scientific Reports</i> , 2016, 6, 24949.	1.6	21
873	Identifying biological mechanisms for favorable cancer prognosis using non-hypothesis-driven iterative survival analysis. <i>Npj Systems Biology and Applications</i> , 2016, 2, 16037.	1.4	12
874	Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro. <i>BMC Cancer</i> , 2016, 16, 951.	1.1	50
875	Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic features. <i>BMC Women's Health</i> , 2016, 16, 68.	0.8	12
876	Patient-derived xenograft (PDX) models in basic and translational breast cancer research. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 547-573.	2.7	189
877	Gene expression in local stroma reflects breast tumor states and predicts patient outcome. <i>Scientific Reports</i> , 2016, 6, 39240.	1.6	11
878	Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. <i>Journal of Translational Medicine</i> , 2016, 14, 173.	1.8	103
879	Inherent variability of cancer-specific aneuploidy generates metastases. <i>Molecular Cytogenetics</i> , 2016, 9, 90.	0.4	33
880	Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. <i>Breast Care</i> , 2016, 11, 315-322.	0.8	6
881	Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase III β . <i>Molecular and Clinical Oncology</i> , 2016, 4, 383-389.	0.4	6
882	Biological Subtypes and Distant Relapse Pattern in Breast Cancer Patients After Curative Surgery (Study of Anatolian Society of Medical Oncology). <i>Breast Care</i> , 2016, 11, 248-252.	0.8	15
883	A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment. <i>Scientific Reports</i> , 2016, 6, 33825.	1.6	26
884	Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. <i>Cancer Research</i> , 2016, 76, 2301-2313.	0.4	509
885	Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5864-5875.	3.2	99
886	Proteogenomics connects somatic mutations to signalling in breast cancer. <i>Nature</i> , 2016, 534, 55-62.	13.7	1,384
887	Rho GTPase Transcriptome Analysis Reveals Oncogenic Roles for Rho GTPase-Activating Proteins in Basal-like Breast Cancers. <i>Cancer Research</i> , 2016, 76, 3826-3837.	0.4	60

#	ARTICLE	IF	CITATIONS
888	18F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1937-1944.	3.3	53
889	Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 521-550.	1.7	30
890	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 674-690.	12.5	1,938
891	High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. <i>Clinical Cancer Research</i> , 2016, 22, 5068-5078.	3.2	38
892	Urothelial carcinoma management in elderly or unfit patients. <i>European Journal of Cancer, Supplement</i> , 2016, 14, 1-20.	2.2	45
893	Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5362-5369.	3.2	73
894	Aromatase expression and regulation in breast and endometrial cancer. <i>Journal of Molecular Endocrinology</i> , 2016, 57, R19-R33.	1.1	148
895	Signatures of breast cancer metastasis at a glance. <i>Journal of Cell Science</i> , 2016, 129, 1751-8.	1.2	52
896	Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 117-131.	1.1	18
897	Differential expression of the epigenetic methylation-related protein DNMT1 by breast cancer molecular subtype and stromal histology. <i>Journal of Translational Medicine</i> , 2016, 14, 87.	1.8	41
898	The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair. <i>Cancer Letters</i> , 2016, 376, 249-258.	3.2	99
899	Increased Proportion of Variance Explained and Prediction Accuracy of Survival of Breast Cancer Patients with Use of Whole-Genome Multiomic Profiles. <i>Genetics</i> , 2016, 203, 1425-1438.	1.2	49
900	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). <i>Journal of Clinical Oncology</i> , 2016, 34, 2602-2609.	0.8	101
901	CoINclDE: A framework for discovery of patient subtypes across multiple datasets. <i>Genome Medicine</i> , 2016, 8, 27.	3.6	29
902	Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, 783-796.	1.6	31
903	MicroRNA expression and gene regulation drive breast cancer progression and metastasis in PyMT mice. <i>Breast Cancer Research</i> , 2016, 18, 75.	2.2	14
904	Minireview: The Link Between ER α Corepressors and Histone Deacetylases in Tamoxifen Resistance in Breast Cancer. <i>Molecular Endocrinology</i> , 2016, 30, 965-976.	3.7	48
905	Identification of novel susceptibility markers for the risk of overall breast cancer as well as subtypes defined by hormone receptor status in the Chinese population. <i>Journal of Human Genetics</i> , 2016, 61, 1027-1034.	1.1	9

#	ARTICLE	IF	CITATIONS
906	Height and Body Size in Childhood, Adolescence, and Young Adulthood and Breast Cancer Risk According to Molecular Subtype in the Nurses' Health Studies. <i>Cancer Prevention Research</i> , 2016, 9, 732-738.	0.7	29
907	Clinicopathological relevance of kinesin family member 18A expression in invasive breast cancer. <i>Oncology Letters</i> , 2016, 12, 1909-1914.	0.8	35
908	Intrinsic subtypes and bladder cancer metastasis. <i>Asian Journal of Urology</i> , 2016, 3, 260-267.	0.5	31
909	Multiple Natural and Experimental Inflammatory Rabbit Lacrimal Gland Phenotypes. <i>Ocular Surface</i> , 2016, 14, 460-483.e3.	2.2	3
910	Antibody-Guided In Vivo Imaging for Early Detection of Mammary Gland Tumors. <i>Translational Oncology</i> , 2016, 9, 295-305.	1.7	25
911	Axillary lymph node micrometastases decrease triple-negative early breast cancer survival. <i>British Journal of Cancer</i> , 2016, 115, 1024-1031.	2.9	23
912	The impact of breast cancer biological subtyping on tumor size assessment by ultrasound and mammography - a retrospective multicenter cohort study of 6543 primary breast cancer patients. <i>BMC Cancer</i> , 2016, 16, 459.	1.1	33
913	Epigenetic regulation of glycosylation and the impact on chemo-resistance in breast and ovarian cancer. <i>Epigenetics</i> , 2016, 11, 845-857.	1.3	39
914	Involvement of microRNAs in HER2 signaling and trastuzumab treatment. <i>Tumor Biology</i> , 2016, 37, 15437-15446.	0.8	15
915	Gene expression profiling identifies distinct molecular subgroups of leiomyosarcoma with clinical relevance. <i>British Journal of Cancer</i> , 2016, 115, 1000-1007.	2.9	4
916	Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. <i>EBioMedicine</i> , 2016, 12, 105-117.	2.7	257
917	The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers. <i>Seminars in Cell and Developmental Biology</i> , 2016, 58, 108-117.	2.3	10
918	The Estrogen Receptor \pm -Cistrome Beyond Breast Cancer. <i>Molecular Endocrinology</i> , 2016, 30, 1046-1058.	3.7	20
919	Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer. <i>Cell Reports</i> , 2016, 16, 2032-2046.	2.9	36
920	Hereditary breast and ovarian cancer: new genes in confined pathways. <i>Nature Reviews Cancer</i> , 2016, 16, 599-612.	12.8	305
921	Data on alteration of hormone and growth factor receptor profiles over progressive passages of breast cancer cell lines representing different clinical subtypes. <i>Data in Brief</i> , 2016, 8, 944-947.	0.5	6
922	Exploring circulating microRNA in the neoadjuvant treatment of breast cancer. <i>International Journal of Cancer</i> , 2016, 139, 12-22.	2.3	40
923	Translating cancer genomes and transcriptomes for precision oncology. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 75-88.	157.7	133

#	ARTICLE	IF	CITATIONS
924	Loss of the oncogenic phosphatase PRL-3 promotes a TNF-R1 feedback loop that mediates triple-negative breast cancer growth. <i>Oncogenesis</i> , 2016, 5, e255-e255.	2.1	12
925	SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer. <i>EBioMedicine</i> , 2016, 11, 183-198.	2.7	23
926	The calcium pump plasma membrane Ca ²⁺ -ATPase 2 (PMCA2) regulates breast cancer cell proliferation and sensitivity to doxorubicin. <i>Scientific Reports</i> , 2016, 6, 25505.	1.6	53
927	Gene expression profiling of breast cancer in Lebanese women. <i>Scientific Reports</i> , 2016, 6, 36639.	1.6	41
928	The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population. <i>Npj Breast Cancer</i> , 2016, 2, 16022.	2.3	21
929	Associations of parity-related reproductive histories with ER [±] and HER2 [±] receptor-specific breast cancer aetiology. <i>International Journal of Epidemiology</i> , 2016, 46, dyw286.	0.9	14
930	Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. <i>Npj Breast Cancer</i> , 2016, 2, .	2.3	266
931	Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. <i>Npj Breast Cancer</i> , 2016, 2, 16036.	2.3	127
933	Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications. <i>Tumor Biology</i> , 2016, 37, 14479-14499.	0.8	13
934	Targeting the androgen receptor in triple-negative breast cancer. <i>Current Problems in Cancer</i> , 2016, 40, 141-150.	1.0	70
935	Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 429-449.	1.4	31
936	Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. <i>BMC Cancer</i> , 2016, 16, 734.	1.1	126
937	Prognostic impact of total and tyrosine phosphorylated GIV/Girdin in breast cancers. <i>FASEB Journal</i> , 2016, 30, 3702-3713.	0.2	11
938	Concepts and targets in triple-negative breast cancer: recent results and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 351-359.	1.4	24
939	Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 545-554.	1.1	64
940	Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences. <i>Journal of Proteome Research</i> , 2016, 15, 3225-3240.	1.8	43
941	Biology and Management of Patients With Triple-Negative Breast Cancer. <i>Oncologist</i> , 2016, 21, 1050-1062.	1.9	220
942	Massive and parallel expression profiling using microarrayed single-cell sequencing. <i>Nature Communications</i> , 2016, 7, 13182.	5.8	44

#	ARTICLE	IF	CITATIONS
943	Gene Expression Profiling of Breast Cancer Brain Metastasis. <i>Scientific Reports</i> , 2016, 6, 28623.	1.6	51
944	A network-based phenotype mapping approach to identify genes that modulate drug response phenotypes. <i>Scientific Reports</i> , 2016, 6, 37003.	1.6	9
945	Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency. <i>Scientific Reports</i> , 2016, 6, 33035.	1.6	24
946	The rise of genomic profiling in ovarian cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1337-1351.	1.5	18
947	Suppression of Spry1 inhibits triple-negative breast cancer malignancy by decreasing EGF/EGFR mediated mesenchymal phenotype. <i>Scientific Reports</i> , 2016, 6, 23216.	1.6	22
948	microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. <i>Scientific Reports</i> , 2016, 6, 25997.	1.6	132
949	TRPV4 Regulates Breast Cancer Cell Extravasation, Stiffness and Actin Cortex. <i>Scientific Reports</i> , 2016, 6, 27903.	1.6	98
950	Breast cancer subtype predictors revisited: from consensus to concordance?. <i>BMC Medical Genomics</i> , 2016, 9, 26.	0.7	6
951	Recent perspectives of breast cancer prognosis and predictive factors. <i>Oncology Letters</i> , 2016, 12, 3674-3678.	0.8	19
952	Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy. <i>Scientific Reports</i> , 2016, 6, 30934.	1.6	29
953	Portraying breast cancers with long noncoding RNAs. <i>Science Advances</i> , 2016, 2, e1600220.	4.7	102
955	The SIRT2 Deacetylase Stabilizes Slug to Control Malignancy of Basal-like Breast Cancer. <i>Cell Reports</i> , 2016, 17, 1302-1317.	2.9	85
956	Aryl Hydrocarbon Receptor Activates NDRG1 Transcription under Hypoxia in Breast Cancer Cells. <i>Scientific Reports</i> , 2016, 6, 20808.	1.6	19
957	Exploring the intrinsic differences among breast tumor subtypes defined using immunohistochemistry markers based on the decision tree. <i>Scientific Reports</i> , 2016, 6, 35773.	1.6	17
958	Robust homology-directed repair within mouse mammary tissue is not specifically affected by Brca2 mutation. <i>Nature Communications</i> , 2016, 7, 13241.	5.8	36
959	Lgr6 labels a rare population of mammary gland progenitor cells that are able to originate luminal mammary tumours. <i>Nature Cell Biology</i> , 2016, 18, 1346-1356.	4.6	75
960	Classification of breast cancer patients using somatic mutation profiles and machine learning approaches. <i>BMC Systems Biology</i> , 2016, 10, 62.	3.0	54
961	The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. <i>Nature Communications</i> , 2016, 7, 12791.	5.8	196

#	ARTICLE	IF	CITATIONS
962	Optimal Trend Tests for Genetic Association Studies of Heterogeneous Diseases. <i>Scientific Reports</i> , 2016, 6, 27821.	1.6	10
963	Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer. <i>Scientific Reports</i> , 2016, 6, 19435.	1.6	102
964	Glycosyltransferase Gene Expression Profiles Classify Cancer Types and Propose Prognostic Subtypes. <i>Scientific Reports</i> , 2016, 6, 26451.	1.6	63
965	Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis. <i>Scientific Reports</i> , 2016, 6, 26456.	1.6	37
966	Primary breast cancer cell culture yields intra-tumor heterogeneous subpopulations expressing exclusive patterns of receptor tyrosine kinases. <i>BMC Cancer</i> , 2016, 16, 740.	1.1	12
967	Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting. <i>Bladder Cancer</i> , 2016, 2, 37-47.	0.2	184
968	Association of <i>MTHFR</i> (C677T) Gene Polymorphism with Breast Cancer in North India. <i>Biomarkers in Cancer</i> , 2016, 8, BIC.S40446.	3.6	19
969	Evolutionary science as a method to facilitate higher level thinking and reasoning in medical training. <i>Evolution, Medicine and Public Health</i> , 2016, 2016, 358-368.	1.1	12
970	Joint estimation of precision matrices in heterogeneous populations. <i>Electronic Journal of Statistics</i> , 2016, 10, 1341-1392.	0.4	35
971	Tamoxifen Action in ER-Negative Breast Cancer. <i>Signal Transduction Insights</i> , 2016, 5, STI.S29901.	2.0	70
972	Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10s1, CMO.S34540.	0.6	121
973	Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers. <i>Biomarkers in Cancer</i> , 2016, 8s1, BIC.S34417.	3.6	27
974	Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes. <i>Cancer & Metabolism</i> , 2016, 4, 12.	2.4	57
975	Ras protein expression as a marker for breast cancer. <i>Oncology Letters</i> , 2016, 11, 3637-3642.	0.8	16
976	Should Sentinel Lymph Node Biopsy for Patients with Early Breast Cancer be Abandoned? Not So Fast. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10, CMO.S32817.	0.6	0
977	Reproductive risk factors in relation to molecular subtypes of breast cancer: Results from the nurses' health studies. <i>International Journal of Cancer</i> , 2016, 138, 2346-2356.	2.3	92
978	Mutated Pathways as a Guide to Adjuvant Therapy Treatments for Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 184-189.	1.9	2
979	MYC Is a Crucial Mediator of TGF β ² -Induced Invasion in Basal Breast Cancer. <i>Cancer Research</i> , 2016, 76, 3520-3530.	0.4	12

#	ARTICLE	IF	CITATIONS
980	Snail-induced epithelial-to-mesenchymal transition of MCF-7 breast cancer cells: systems analysis of molecular changes and their effect on radiation and drug sensitivity. <i>BMC Cancer</i> , 2016, 16, 236.	1.1	38
981	Impact of central obesity on prognostic outcome of triple negative breast cancer in Chinese women. <i>SpringerPlus</i> , 2016, 5, 594.	1.2	30
982	Discriminatory power of common genetic variants in personalized breast cancer diagnosis. , 2016, 9787, .		2
983	Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 691-705.	12.5	47
984	High prevalence of luminal B breast cancer intrinsic subtype in Colombian women. <i>Carcinogenesis</i> , 2016, 37, 669-676.	1.3	39
985	RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. <i>Nature Medicine</i> , 2016, 22, 933-939.	15.2	224
986	Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. <i>Cancer Research</i> , 2016, 76, 4948-4958.	0.4	147
987	Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 179-187.	1.1	42
988	Reproductive Factors and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer Among Multiethnic Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1297-1304.	1.1	33
989	The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expressionâ€Based Meta-Analysis. <i>Clinical Cancer Research</i> , 2016, 22, 6039-6050.	3.2	48
990	Alkaline hydrolysis to remove potentially infectious viral RNA contaminants from DNA. <i>Virology Journal</i> , 2016, 13, 88.	1.4	20
991	The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase 18F-FDG PET/CT. <i>Nuclear Medicine and Molecular Imaging</i> , 2016, 50, 246-254.	0.6	10
992	The Nuclear Receptor, ROR β , Regulates Pathways Necessary for Breast Cancer Metastasis. <i>EBioMedicine</i> , 2016, 6, 59-72.	2.7	40
993	Stochastic epigenetic outliers can define field defects in cancer. <i>BMC Bioinformatics</i> , 2016, 17, 178.	1.2	36
994	The prognostic value of stromal and epithelial periostin expression in human breast cancer: correlation with clinical pathological features and mortality outcome. <i>BMC Cancer</i> , 2016, 16, 95.	1.1	27
995	Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma. <i>BMC Cancer</i> , 2016, 16, 248.	1.1	78
996	The voltage gated Ca ²⁺ -channel Cav3.2 and therapeutic responses in breast cancer. <i>Cancer Cell International</i> , 2016, 16, 24.	1.8	34
997	Iteratively refining breast cancer intrinsic subtypes in the METABRIC dataset. <i>BioData Mining</i> , 2016, 9, 2.	2.2	16

#	ARTICLE	IF	CITATIONS
998	ELF5 isoform expression is tissue-specific and significantly altered in cancer. <i>Breast Cancer Research</i> , 2016, 18, 4.	2.2	37
999	An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells. <i>Breast Cancer Research</i> , 2016, 18, 27.	2.2	67
1000	Genomic alterations and molecular subtypes of gastric cancers in Asians. <i>Chinese Journal of Cancer</i> , 2016, 35, 42.	4.9	20
1001	Metabolomics in epidemiology: from metabolite concentrations to integrative reaction networks. <i>International Journal of Epidemiology</i> , 2016, 45, 1319-1328.	0.9	40
1002	Informative gene selection and the direct classification of tumors based on relative simplicity. <i>BMC Bioinformatics</i> , 2016, 17, 44.	1.2	23
1003	EPIG-Seq: extracting patterns and identifying co-expressed genes from RNA-Seq data. <i>BMC Genomics</i> , 2016, 17, 255.	1.2	16
1004	Alcohol and breast cancer tumor subtypes in a Spanish Cohort. <i>SpringerPlus</i> , 2016, 5, 39.	1.2	13
1006	HIF1 α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3735-44.	3.3	62
1007	Identification of Optimal Mouse Models of Systemic Sclerosis by Interspecies Comparative Genomics. <i>Arthritis and Rheumatology</i> , 2016, 68, 2003-2015.	2.9	35
1008	Pathogenesis of Breast Cancer Metastasis to Brain: a Comprehensive Approach to the Signaling Network. <i>Molecular Neurobiology</i> , 2016, 53, 446-454.	1.9	17
1009	Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer. <i>Medical Molecular Morphology</i> , 2016, 49, 11-21.	0.4	43
1010	Epidemiological risk factors associated with inflammatory breast cancer subtypes. <i>Cancer Causes and Control</i> , 2016, 27, 359-366.	0.8	38
1011	Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 669-678.	1.2	14
1012	Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression. <i>Clinical Cancer Research</i> , 2016, 22, 2950-2959.	3.2	21
1013	Ki-67 is a prognostic marker for hormone receptor positive tumors. <i>Clinical and Translational Oncology</i> , 2016, 18, 996-1002.	1.2	17
1014	The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 235-251.	1.1	18
1015	Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. <i>Cell</i> , 2016, 164, 293-309.	13.5	399
1016	Breast Cancer Subtypes: Morphologic and Biologic Characterization. <i>Women's Health</i> , 2016, 12, 103-119.	0.7	38

#	ARTICLE	IF	CITATIONS
1017	The immune microenvironment of breast ductal carcinoma in situ. <i>Modern Pathology</i> , 2016, 29, 249-258.	2.9	119
1018	Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer. <i>British Journal of Cancer</i> , 2016, 114, 14-20.	2.9	51
1019	Noncoding RNAs in breast cancer. <i>Briefings in Functional Genomics</i> , 2016, 15, 200-221.	1.3	41
1020	Pharmacogenomics. <i>Urologic Clinics of North America</i> , 2016, 43, 77-86.	0.8	9
1021	PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. <i>Human Pathology</i> , 2016, 47, 52-63.	1.1	284
1022	Down-regulated ECRG4 expression in breast cancer and its correlation with tumor progression and poor prognosis - A short Report. <i>Cellular Oncology (Dordrecht)</i> , 2016, 39, 89-95.	2.1	17
1023	Tamoxifen induces hepatotoxicity and changes to hepatocyte morphology at the early stage of endocrinotherapy in mice. <i>Biomedical Reports</i> , 2016, 4, 102-106.	0.9	32
1024	FOXC1-induced Gli2 activation: A non-canonical pathway contributing to stemness and anti-Hedgehog resistance in basal-like breast cancer. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1131668.	0.3	10
1025	Manganese Superoxide Dismutase Acetylation and Dysregulation, Due to Loss of SIRT3 Activity, Promote a Luminal B-Like Breast Carcinogenic-Permissive Phenotype. <i>Antioxidants and Redox Signaling</i> , 2016, 25, 326-336.	2.5	36
1026	Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. <i>Journal of Translational Medicine</i> , 2016, 14, 46.	1.8	31
1027	Kaiso depletion attenuates transforming growth factor- β^2 signaling and metastatic activity of triple-negative breast cancer cells. <i>Oncogenesis</i> , 2016, 5, e208-e208.	2.1	33
1028	Role of dietary bioactive natural products in estrogen receptor-positive breast cancer. <i>Seminars in Cancer Biology</i> , 2016, 40-41, 170-191.	4.3	51
1029	EJE PRIZE 2016: Mechanisms of oestrogen receptor (ER) gene regulation in breast cancer. <i>European Journal of Endocrinology</i> , 2016, 175, R41-R49.	1.9	68
1030	Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 16.	2.2	22
1031	Patterns in target-directed breast cancer research. <i>SpringerPlus</i> , 2016, 5, 109.	1.2	1
1032	Expression of ROR1 has prognostic significance in triple negative breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 589-595.	1.4	63
1033	STAT1 and NF- κ B Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells. <i>Molecular Cancer Research</i> , 2016, 14, 482-492.	1.5	34
1034	New insight on the biological role of p53 protein as a tumor suppressor: re-evaluation of its clinical significance in triple-negative breast cancer. <i>Tumor Biology</i> , 2016, 37, 11017-11024.	0.8	20

#	ARTICLE	IF	CITATIONS
1035	Biomarkers of residual disease after neoadjuvant therapy for breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 487-503.	12.5	43
1036	¹⁸ F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 34S-39S.	2.8	91
1037	Performance of Three-Biomarker Immunohistochemistry for Intrinsic Breast Cancer Subtyping in the AMBER Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 470-478.	1.1	53
1038	Î±B-crystallin: Portrait of a malignant chaperone as a cancer therapeutic target. , 2016, 160, 1-10.		35
1039	Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer. <i>Tumor Biology</i> , 2016, 37, 8159-8168.	0.8	62
1040	Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. <i>BMC Cancer</i> , 2016, 16, 143.	1.1	55
1041	Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. <i>Nature Medicine</i> , 2016, 22, 369-378.	15.2	572
1043	An unsupervised MVA method to compare specific regions in human breast tumor tissue samples using ToF-SIMS. <i>Analyst</i> , The, 2016, 141, 1947-1957.	1.7	19
1044	Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications. <i>Breast Cancer Research</i> , 2016, 18, 26.	2.2	25
1045	c-Met and ER ^{Î²} expression differences in basal-like and non-basal-like triple-negative breast cancer. <i>Tumor Biology</i> , 2016, 37, 11385-11395.	0.8	12
1046	Dogs as a Model for Cancer. <i>Annual Review of Animal Biosciences</i> , 2016, 4, 199-222.	3.6	138
1047	Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers. <i>British Journal of Cancer</i> , 2016, 114, 298-304.	2.9	7
1048	Reproducibility of Differential Proteomic Technologies in CPTAC Fractionated Xenografts. <i>Journal of Proteome Research</i> , 2016, 15, 691-706.	1.8	44
1049	MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells. <i>Tumor Biology</i> , 2016, 37, 8825-8839.	0.8	41
1050	HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR. <i>Oncogene</i> , 2016, 35, 4244-4255.	2.6	64
1051	Proteomic maps of breast cancer subtypes. <i>Nature Communications</i> , 2016, 7, 10259.	5.8	256
1052	The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients. <i>Tumor Biology</i> , 2016, 37, 7675-7684.	0.8	11
1053	An Update in Breast Cancer Screening and Management. <i>Women's Health</i> , 2016, 12, 229-239.	0.7	16

#	ARTICLE	IF	CITATIONS
1054	miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2016, 76, 927-939.	0.4	128
1055	Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming. <i>Molecular Cancer Research</i> , 2016, 14, 141-162.	1.5	25
1056	Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 1104-1110.	0.7	116
1057	ADRA2A Germline Gene Polymorphism is Associated to the Severity, but not to the Risk, of Breast Cancer. <i>Pathology and Oncology Research</i> , 2016, 22, 357-365.	0.9	14
1058	Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer. <i>Oncogene</i> , 2016, 35, 1877-1887.	2.6	116
1059	Meta-Analytic Framework for Sparse t -Means to Identify Disease Subtypes in Multiple Transcriptomic Studies. <i>Journal of the American Statistical Association</i> , 2016, 111, 27-42.	1.8	22
1060	A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. <i>European Urology</i> , 2016, 69, 855-862.	0.9	228
1061	Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics. <i>Molecular Cancer Research</i> , 2016, 14, 3-13.	1.5	230
1062	ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. <i>Oncogene</i> , 2016, 35, 3201-3208.	2.6	430
1063	Is there an association between invasive lobular carcinoma of the breast and a family history of gastric cancer?. <i>Familial Cancer</i> , 2016, 15, 41-47.	0.9	3
1064	Comprehensive profiling of biological processes reveals two major prognostic subtypes in breast cancer. <i>Tumor Biology</i> , 2016, 37, 3365-3370.	0.8	0
1065	Secreted factors derived from obese visceral adipose tissue regulate the expression of breast malignant transformation genes. <i>International Journal of Obesity</i> , 2016, 40, 514-523.	1.6	31
1066	Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs. <i>Oncogene</i> , 2016, 35, 1743-1749.	2.6	13
1067	Luminal epithelial cells within the mammary gland can produce basal cells upon oncogenic stress. <i>Oncogene</i> , 2016, 35, 1461-1467.	2.6	30
1068	Dysregulated protease activated receptor 1 (PAR1) promotes metastatic phenotype in breast cancer through HMGA2. <i>Oncogene</i> , 2016, 35, 1529-1540.	2.6	38
1069	Defining the optimal sequence for the systemic treatment of metastatic breast cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 149-161.	1.2	24
1070	Cancer-selective death of human breast cancer cells by leelamine is mediated by bax and bak activation. <i>Molecular Carcinogenesis</i> , 2017, 56, 337-348.	1.3	17
1071	Statistical Significance for Hierarchical Clustering. <i>Biometrics</i> , 2017, 73, 811-821.	0.8	122

#	ARTICLE	IF	CITATIONS
1072	Endometrial Cancer Risk Factors, Hormone Receptors, and Mortality Prediction. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 727-735.	1.1	42
1073	Fusion RNA profiling provides hints on cell of origin of mysterious tumor. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1263714.	0.3	3
1074	TRIM28 interacts with EZH2 and SWI/SNF to activate genes that promote mammosphere formation. <i>Oncogene</i> , 2017, 36, 2991-3001.	2.6	48
1075	Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis. <i>Oncogene</i> , 2017, 36, 3553-3561.	2.6	11
1076	Profiling of microRNA in tumor interstitial fluid of breast tumors – a novel resource to identify biomarkers for prognostic classification and detection of cancer. <i>Molecular Oncology</i> , 2017, 11, 220-234.	2.1	50
1077	Integrated analysis of differentially expressed genes and pathways in triple-negative breast cancer. <i>Molecular Medicine Reports</i> , 2017, 15, 1087-1094.	1.1	10
1078	First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases. <i>BMC Women's Health</i> , 2017, 17, 3.	0.8	30
1079	Comparison of Core Needle Biopsy and Excision Specimens for the Accurate Evaluation of Breast Cancer Molecular Markers: a Report of 1003 Cases. <i>Pathology and Oncology Research</i> , 2017, 23, 769-775.	0.9	18
1080	Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients. <i>Bioengineered</i> , 2017, 8, 383-392.	1.4	11
1081	Imaging Surveillance After Primary Breast Cancer Treatment. <i>American Journal of Roentgenology</i> , 2017, 208, 676-686.	1.0	59
1082	MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation. <i>Modern Pathology</i> , 2017, 30, 682-697.	2.9	59
1083	P-cadherin: a useful biomarker for axillary-based breast cancer decisions in the clinical practice. <i>Modern Pathology</i> , 2017, 30, 698-709.	2.9	18
1084	IGF-IR cooperates with ER α to inhibit breast cancer cell aggressiveness by regulating the expression and localisation of ECM molecules. <i>Scientific Reports</i> , 2017, 7, 40138.	1.6	29
1085	Genomic pathways modulated by Twist in breast cancer. <i>BMC Cancer</i> , 2017, 17, 52.	1.1	15
1086	Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program. <i>Breast Cancer Research</i> , 2017, 19, 10.	2.2	77
1087	Prognostic significance of Ki67 in Chinese women diagnosed with ER+/HER2 α breast cancers by the 2015 St. Gallen consensus classification. <i>BMC Cancer</i> , 2017, 17, 28.	1.1	6
1088	Insights from Global Analyses of Long Noncoding RNAs in Breast Cancer. <i>Current Pathobiology Reports</i> , 2017, 5, 23-34.	1.6	15
1089	Understanding breast cancer – The long and winding road. <i>BBA Clinical</i> , 2017, 7, 64-77.	4.1	145

#	ARTICLE	IF	CITATIONS
1090	Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 119-130.	1.1	29
1091	Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. <i>Oncologist</i> , 2017, 22, 286-292.	1.9	54
1092	INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC. <i>Molecular Cancer Research</i> , 2017, 15, 765-775.	1.5	26
1093	The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. <i>Endocrine-Related Cancer</i> , 2017, 24, R123-R144.	1.6	64
1094	A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth. <i>Scientific Reports</i> , 2017, 7, 42555.	1.6	51
1095	The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. <i>Trends in Cancer</i> , 2017, 3, 39-55.	3.8	206
1096	The Opportunity of Precision Medicine for Breast Cancer With Context-Sensitive Tumor Suppressor Maspin. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 1639-1647.	1.2	12
1097	Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1145-1154.	3.3	65
1098	Prediction of years of life after diagnosis of breast cancer using omics and omic-by-treatment interactions. <i>European Journal of Human Genetics</i> , 2017, 25, 538-544.	1.4	28
1099	DCYTB is a predictor of outcome in breast cancer that functions via iron-independent mechanisms. <i>Breast Cancer Research</i> , 2017, 19, 25.	2.2	34
1100	Antitumor effects of naturally occurring cardiac glycosides convallatoxin and peruvoside on human ER+ and triple-negative breast cancers. <i>Cell Death Discovery</i> , 2017, 3, 17009.	2.0	35
1101	Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry. <i>Cancer Biology and Therapy</i> , 2017, 18, 205-213.	1.5	73
1102	Featured Article: Downregulation of transgelin blocks interleukin-8 utilization and suppresses vasculogenic mimicry in breast cancer cells. <i>Experimental Biology and Medicine</i> , 2017, 242, 573-583.	1.1	24
1103	Roles of FoxM1 in cell regulation and breast cancer targeting therapy. <i>Medical Oncology</i> , 2017, 34, 41.	1.2	31
1104	Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype. <i>Scientific Reports</i> , 2017, 7, 41960.	1.6	73
1105	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. <i>Cancer Research</i> , 2017, 77, 2213-2221.	0.4	168
1106	ZNF503 drives aggressive breast cancer progression by down-regulation of GATA3 expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3169-3174.	3.3	32
1107	Identifying relations between imaging phenotypes and molecular subtypes of breast cancer: Model discovery and external validation. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 1017-1027.	1.9	78

#	ARTICLE	IF	CITATIONS
1108	MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 511-521.	1.1	48
1109	Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 439-450.	1.1	47
1110	MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib. <i>British Journal of Cancer</i> , 2017, 116, 742-751.	2.9	13
1111	Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 221-229.	1.1	8
1112	Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells. <i>Npj Breast Cancer</i> , 2017, 3, 9.	2.3	47
1113	A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2 ⁻ early breast cancer. <i>Scientific Reports</i> , 2017, 7, 45554.	1.6	26
1114	Breast cancers are rare diseases ^{â€} and must be treated as such. <i>Npj Breast Cancer</i> , 2017, 3, 11.	2.3	11
1115	Network-aided Bi-Clustering for discovering cancer subtypes. <i>Scientific Reports</i> , 2017, 7, 1046.	1.6	17
1116	Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival. <i>Clinical and Translational Oncology</i> , 2017, 19, 1232-1240.	1.2	25
1117	miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. <i>Genes and Development</i> , 2017, 31, 553-566.	2.7	87
1118	Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. <i>BMC Cancer</i> , 2017, 17, 241.	1.1	27
1119	Effect of Ki-67 assessment in the distribution of breast cancer subtypes: Evaluation in a cohort of Latin American patients. <i>Molecular and Clinical Oncology</i> , 2017, 6, 503-509.	0.4	11
1120	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017, 3, 1663.	3.4	219
1121	Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy. <i>Cancer Biology and Therapy</i> , 2017, 18, 369-378.	1.5	31
1122	Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target. <i>Archives of Toxicology</i> , 2017, 91, 2497-2513.	1.9	123
1123	Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine. <i>Npj Breast Cancer</i> , 2017, 3, 3.	2.3	17
1124	Deficiency of CCN5/WISP-2-Driven Program in breast cancer Promotes Cancer Epithelial cells to mesenchymal stem cells and Breast Cancer growth. <i>Scientific Reports</i> , 2017, 7, 1220.	1.6	27
1125	Expression and function of MutT homolog 1 in distinct subtypes of breast cancer. <i>Oncology Letters</i> , 2017, 13, 2161-2168.	0.8	20

#	ARTICLE	IF	CITATIONS
1126	The zinc-finger transcriptional factor Slug transcriptionally downregulates ER α by recruiting lysine-specific demethylase 1 in human breast cancer. <i>Oncogenesis</i> , 2017, 6, e330-e330.	2.1	28
1127	Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. <i>Neuro-Oncology</i> , 2017, 19, 1481-1493.	0.6	32
1128	Current Update of Patient-Derived Xenograft Model for Translational Breast Cancer Research. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2017, 22, 131-139.	1.0	35
1129	Usefulness of miRNA profiles for predicting pathological responses to neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer. <i>Oncology Letters</i> , 2017, 13, 1731-1740.	0.8	24
1130	Augmentation of the cytotoxic effects of zinc oxide nanoparticles by MTCP conjugation: Non-canonical apoptosis and autophagy induction in human adenocarcinoma breast cancer cell lines. <i>Materials Science and Engineering C</i> , 2017, 78, 949-959.	3.8	20
1131	Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity. <i>Npj Breast Cancer</i> , 2017, 3, 14.	2.3	115
1132	Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer. <i>Scientific Reports</i> , 2017, 7, 1134.	1.6	5
1133	Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer. <i>Scientific Reports</i> , 2017, 7, 1089.	1.6	19
1134	4-1BB α -Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells. <i>Cancer Immunology Research</i> , 2017, 5, 439-445.	1.6	45
1135	Recent advances of highly selective CDK4/6 inhibitors in breast cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 97.	6.9	126
1136	Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population. <i>Stem Cell Reports</i> , 2017, 8, 1392-1407.	2.3	62
1137	^{18}F -FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1420-1427.	3.3	40
1138	A PAM50-Based Chemoendocrine Score for Hormone Receptor α -Positive Breast Cancer with an Intermediate Risk of Relapse. <i>Clinical Cancer Research</i> , 2017, 23, 3035-3044.	3.2	28
1139	Subtype-Specific Radiation Response and Therapeutic Effect of FAS Death Receptor Modulation in Human Breast Cancer. <i>Radiation Research</i> , 2017, 188, 169.	0.7	4
1140	Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. <i>Drugs</i> , 2017, 77, 1313-1336.	4.9	39
1141	Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from ^{18}F -FDG PET/CT in operable triple-negative breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1787-1795.	3.3	13
1142	PSIP1/p75 promotes tumorigenicity in breast cancer cells by promoting the transcription of cell cycle genes. <i>Carcinogenesis</i> , 2017, 38, 966-975.	1.3	25
1143	Mystery of the brain metastatic disease in breast cancer patients: improved patient stratification, disease prediction and targeted prevention on the horizon?. <i>EPMA Journal</i> , 2017, 8, 119-127.	3.3	47

#	ARTICLE	IF	CITATIONS
1144	Molecular characterization of breast cancer cell lines by clinical immunohistochemical markers. <i>Oncology Letters</i> , 2017, 13, 4708-4712.	0.8	40
1145	Advancing Immunotherapy in Metastatic Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 35.	1.3	13
1146	Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field. <i>Oncologist</i> , 2017, 22, 1086-1093.	1.9	77
1147	Molecular genetics complexity impeding research progress in breast and ovarian cancers. <i>Molecular and Clinical Oncology</i> , 2017, 7, 3-14.	0.4	12
1148	The expression of keratin 6 is regulated by the activation of the ERK1/2 pathway in arsenite transformed human urothelial cells. <i>Toxicology and Applied Pharmacology</i> , 2017, 331, 41-53.	1.3	9
1149	Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas. <i>Modern Pathology</i> , 2017, 30, 1086-1099.	2.9	63
1150	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 904-916.	5.1	427
1151	Clinical utility of gene-expression signatures in early stage breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 595-610.	12.5	197
1152	Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification. <i>Nature Communications</i> , 2017, 8, 15657.	5.8	70
1153	The regulatory role of miRNAs on VDR in breast cancer. <i>Transcription</i> , 2017, 8, 232-241.	1.7	22
1154	Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	13
1155	Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	49
1156	Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. <i>European Urology</i> , 2017, 72, 354-365.	0.9	195
1157	Wnt signaling in triple-negative breast cancer. <i>Oncogenesis</i> , 2017, 6, e310-e310.	2.1	217
1158	Multicolor immunofluorescence reveals that p63- and/or K5-positive progenitor cells contribute to normal breast epithelium and usual ductal hyperplasia but not to low-grade intraepithelial neoplasia of the breast. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 493-504.	1.4	10
1159	Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging. <i>BMC Cancer</i> , 2017, 17, 210.	1.1	59
1160	<i>In vivo</i> models in breast cancer research: progress, challenges and future directions. <i>DMM Disease Models and Mechanisms</i> , 2017, 10, 359-371.	1.2	131
1161	Stepwise analysis of MIR9 loci identifies miR-9-5p to be involved in Oestrogen regulated pathways in breast cancer patients. <i>Scientific Reports</i> , 2017, 7, 45283.	1.6	45

#	ARTICLE	IF	CITATIONS
1162	Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. <i>Scientific Reports</i> , 2017, 7, 45411.	1.6	149
1163	A Bayesian semiparametric factor analysis model for subtype identification. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2017, 16, 145-158.	0.2	0
1164	Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. <i>Breast Cancer Research</i> , 2017, 19, 44.	2.2	85
1165	Glycoproteins in Claudin-Low Breast Cancer Cell Lines Have a Unique Expression Profile. <i>Journal of Proteome Research</i> , 2017, 16, 1391-1400.	1.8	7
1166	Down regulation of ADAM33 as a Predictive Biomarker of Aggressive Breast Cancer. <i>Scientific Reports</i> , 2017, 7, 44414.	1.6	17
1167	Biological Subtypes of Triple-Negative Breast Cancer. <i>Breast Care</i> , 2017, 12, 8-14.	0.8	85
1168	Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry. <i>Head and Neck Pathology</i> , 2017, 11, 288-294.	1.3	53
1169	Expression Profiling of Clinical Specimens Supports the Existence of Neural Progenitor-Like Stem Cells in Basal Breast Cancers. <i>Clinical Breast Cancer</i> , 2017, 17, 298-306.e7.	1.1	22
1170	MicroRNA-567 dysregulation contributes to carcinogenesis of breast cancer, targeting tumor cell proliferation, and migration. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 605-616.	1.1	32
1171	Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors. <i>British Journal of Cancer</i> , 2017, 116, 211-217.	2.9	69
1172	Disease Subtype-Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical Withaferin A. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw293.	3.0	28
1173	Cellular and molecular mechanisms underlying alcohol-induced aggressiveness of breast cancer. <i>Pharmacological Research</i> , 2017, 115, 299-308.	3.1	36
1174	The recurrent architecture of tumour initiation, progression and drug sensitivity. <i>Nature Reviews Cancer</i> , 2017, 17, 116-130.	12.8	170
1175	Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers. <i>Cancer Discovery</i> , 2017, 7, 202-217.	7.7	57
1176	Persistent homology index as a robust quantitative measure of immunohistochemical scoring. <i>Scientific Reports</i> , 2017, 7, 14002.	1.6	10
1177	Differential response to doxorubicin in breast cancer subtypes simulated by a microfluidic tumor model. <i>Journal of Controlled Release</i> , 2017, 266, 129-139.	4.8	54
1178	Lunatic Fringe and p53 Cooperatively Suppress Mesenchymal Stem-Like Breast Cancer. <i>Neoplasia</i> , 2017, 19, 885-895.	2.3	10
1179	Network-Based Coverage of Mutational Profiles Reveals Cancer Genes. <i>Cell Systems</i> , 2017, 5, 221-229.e4.	2.9	40

#	ARTICLE	IF	CITATIONS
1180	MCbiclust: a novel algorithm to discover large-scale functionally related gene sets from massive transcriptomics data collections. <i>Nucleic Acids Research</i> , 2017, 45, 8712-8730.	6.5	13
1181	Triple-negative breast cancer and the potential for targeted therapy. <i>Pharmacogenomics</i> , 2017, 18, 1595-1609.	0.6	165
1182	High expression of Ki-67 acts a poor prognosis indicator in locally advanced nasopharyngeal carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2017, 494, 390-396.	1.0	22
1183	Revisiting the impact of age and molecular subtype on overall survival after radiotherapy in breast cancer patients. <i>Scientific Reports</i> , 2017, 7, 12587.	1.6	19
1184	Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes. <i>Translational Oncology</i> , 2017, 10, 904-910.	1.7	22
1185	Functional proteomics outlines the complexity of breast cancer molecular subtypes. <i>Scientific Reports</i> , 2017, 7, 10100.	1.6	50
1186	High excision repair cross-complementation group 1 expression is associated with favorable prognostic factors in breast cancer. <i>Oncology Letters</i> , 2017, 14, 4995-5003.	0.8	5
1187	A Compendium of Co-regulated Protein Complexes in Breast Cancer Reveals Collateral Loss Events. <i>Cell Systems</i> , 2017, 5, 399-409.e5.	2.9	46
1188	Breast Cancer: Multiple Subtypes within a Tumor?. <i>Trends in Cancer</i> , 2017, 3, 753-760.	3.8	253
1189	A novel approach for data integration and disease subtyping. <i>Genome Research</i> , 2017, 27, 2025-2039.	2.4	139
1190	Induction of a novel isoform of the lncRNA HOTAIR in Claudin-low breast cancer cells attached to extracellular matrix. <i>Molecular Oncology</i> , 2017, 11, 1698-1710.	2.1	29
1191	Gene expression profiling of calcifications in breast cancer. <i>Scientific Reports</i> , 2017, 7, 11427.	1.6	21
1192	Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progesterone Receptor Status: Results from a Case-Control Study in Northern and Eastern China and Implications for Chemoprevention. <i>Oncologist</i> , 2017, 22, 1431-1443.	1.9	39
1193	Bifunctional Elastin-like Polypeptide Nanoparticles Bind Rapamycin and Integrins and Suppress Tumor Growth in Vivo. <i>Bioconjugate Chemistry</i> , 2017, 28, 2715-2728.	1.8	32
1194	Identifying DNase I hypersensitive sites as driver distal regulatory elements in breast cancer. <i>Nature Communications</i> , 2017, 8, 436.	5.8	22
1195	Nanogrid single-nucleus RNA sequencing reveals phenotypic diversity in breast cancer. <i>Nature Communications</i> , 2017, 8, 228.	5.8	105
1196	ω-3 free fatty acids and all-trans retinoic acid synergistically induce growth inhibition of three subtypes of breast cancer cell lines. <i>Scientific Reports</i> , 2017, 7, 2929.	1.6	28
1197	Ki-67 Expression in Breast Cancer Tissue Microarrays. <i>American Journal of Clinical Pathology</i> , 2017, 148, 108-118.	0.4	10

#	ARTICLE	IF	CITATIONS
1198	Conditional expression of Ki-RasG12V in the mammary epithelium of transgenic mice induces estrogen receptor alpha (ER α)-positive adenocarcinoma. <i>Oncogene</i> , 2017, 36, 6420-6431.	2.6	13
1199	Targeting the Stem Cell Properties of Adult Breast Cancer Cells: Using Combinatorial Strategies to Overcome Drug Resistance. <i>Current Molecular Biology Reports</i> , 2017, 3, 159-164.	0.8	11
1200	CPSF6 is a Clinically Relevant Breast Cancer Vulnerability Target. <i>EBioMedicine</i> , 2017, 21, 65-78.	2.7	38
1201	Triple negative invasive lobular carcinoma of the breast presents as small bowel obstruction. <i>International Journal of Surgery Case Reports</i> , 2017, 37, 79-82.	0.2	2
1202	The CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms. <i>Scientific Reports</i> , 2017, 7, 5480.	1.6	24
1203	Comparison of Oncotype DX $\hat{\text{A}}$ Recurrence Score $\hat{\text{A}}$ with other risk assessment tools including the Nottingham Prognostic Index in the identification of patients with low-risk invasive breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 321-328.	1.4	5
1204	Dissecting the Biological Heterogeneity within Hormone Receptor Positive HER2 Negative Breast Cancer by Gene Expression Markers Identifies Indolent Tumors within Late Stage Disease. <i>Translational Oncology</i> , 2017, 10, 699-706.	1.7	8
1205	A comparison of statistical methods for the study of etiologic heterogeneity. <i>Statistics in Medicine</i> , 2017, 36, 4050-4060.	0.8	16
1206	Advances in the development of improved animal-free models for use in breast cancer biomedical research. <i>Biophysical Reviews</i> , 2017, 9, 321-327.	1.5	6
1207	Pan-urolologic cancer genomic subtypes that transcend tissue of origin. <i>Nature Communications</i> , 2017, 8, 199.	5.8	49
1208	Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma. <i>Scientific Reports</i> , 2017, 7, 5568.	1.6	37
1209	Tumor LDH-A expression and serum LDH status are two metabolic predictors for triple negative breast cancer brain metastasis. <i>Scientific Reports</i> , 2017, 7, 6069.	1.6	66
1210	HER2-positive breast cancer is lost in translation: time for patient-centered research. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 669-681.	12.5	59
1211	Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 378-397.	157.7	551
1212	Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients. <i>International Journal of Oncology</i> , 2017, 51, 781-790.	1.4	46
1213	A comparative study of Ki-67 antigen expression between luminal A and triple-negative subtypes of breast cancer. <i>Medical Oncology</i> , 2017, 34, 156.	1.2	7
1214	NaviCom: a web application to create interactive molecular network portraits using multi-level omics data. <i>Database: the Journal of Biological Databases and Curation</i> , 2017, 2017, .	1.4	12
1215	Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report. <i>Oncology Letters</i> , 2017, 14, 1725-1730.	0.8	2

#	ARTICLE	IF	CITATIONS
1216	A novel FOXA1/ESR1 interacting pathway: A study of Oncomine [®] , breast cancer microarrays. <i>Oncology Letters</i> , 2017, 14, 1247-1264.	0.8	18
1217	Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine. <i>Genomics, Proteomics and Bioinformatics</i> , 2017, 15, 220-235.	3.0	96
1218	Bcl-2 antigen expression in luminal A and triple-negative breast cancer. <i>Medical Oncology</i> , 2017, 34, 161.	1.2	10
1219	Identification of cancer genes that are independent of dominant proliferation and lineage programs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E11276-E11284.	3.3	20
1220	Tumor-Suppressor Inactivation of GDF11 Occurs by Precursor Sequestration in Triple-Negative Breast Cancer. <i>Developmental Cell</i> , 2017, 43, 418-435.e13.	3.1	62
1221	Transforming Growth Factor-beta Regulation of Ephrin Type-A Receptor 4 Signaling in Breast Cancer Cellular Migration. <i>Scientific Reports</i> , 2017, 7, 14976.	1.6	33
1222	Metastasis of breast cancer cells to the bone, lung, and lymph nodes promotes resistance to ionizing radiation. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 848-855.	1.0	13
1223	A Comparative Study of Clinical Profile and Relapse Patterns in TRIPLE-NEGATIVE and Non-Triple-Negative Breast Cancer Patients Treated with Curative Intent. <i>Indian Journal of Surgical Oncology</i> , 2017, 8, 291-297.	0.3	1
1224	Genotranscriptomic meta-analysis of the CHD family chromatin remodelers in human cancers: initial evidence of an oncogenic role for CHD7. <i>Molecular Oncology</i> , 2017, 11, 1348-1360.	2.1	28
1225	Large-Scale Analysis of Breast Cancer-Related Conformational Changes in Proteins Using SILAC-SPROX. <i>Journal of Proteome Research</i> , 2017, 16, 3277-3286.	1.8	22
1226	Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells. <i>Cell Cycle</i> , 2017, 16, 1453-1464.	1.3	30
1227	Integrated analysis of the potential roles of miRNA-mRNA networks in triple negative breast cancer. <i>Molecular Medicine Reports</i> , 2017, 16, 1139-1146.	1.1	18
1228	Spectral clustering using Nyström approximation for the accurate identification of cancer molecular subtypes. <i>Scientific Reports</i> , 2017, 7, 4896.	1.6	2
1229	Epidemiological Study of Triple-Negative Breast Cancer Patients in North Indian Population: a Hospital-Based Study. <i>Indian Journal of Surgical Oncology</i> , 2017, 8, 279-283.	0.3	0
1230	DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis. <i>Cancer Biology and Therapy</i> , 2017, 18, 439-449.	1.5	21
1231	A novel pathway-based distance score enhances assessment of disease heterogeneity in gene expression. <i>BMC Bioinformatics</i> , 2017, 18, 309.	1.2	2
1232	The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion. <i>BMC Cancer</i> , 2017, 17, 329.	1.1	13
1233	Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index. <i>BMC Cancer</i> , 2017, 17, 354.	1.1	32

#	ARTICLE	IF	CITATIONS
1234	miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 72.	2.2	43
1235	Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression. <i>Oncogene</i> , 2017, 36, 5958-5968.	2.6	46
1236	Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 573-583.	1.1	149
1237	Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw207.	3.0	26
1238	The molecular basis of breast cancer pathological phenotypes. <i>Journal of Pathology</i> , 2017, 241, 375-391.	2.1	86
1239	Advancement of mass spectrometry-based proteomics technologies to explore triple negative breast cancer. <i>Molecular BioSystems</i> , 2017, 13, 42-55.	2.9	19
1240	TP53 Mutations in Breast and Ovarian Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a026252.	2.9	116
1241	Clustering of mRNA-Seq data based on alternative splicing patterns. <i>Biostatistics</i> , 2017, 18, 295-307.	0.9	7
1242	MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 143-155.	1.9	31
1243	Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression. <i>Oncogene</i> , 2017, 36, 1157-1166.	2.6	125
1244	Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes. <i>Journal of Human Genetics</i> , 2017, 62, 15-24.	1.1	122
1245	Dynamic 2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts. <i>Molecular Imaging and Biology</i> , 2017, 19, 271-279.	1.3	4
1246	Integrative clustering of multi-level omics data for disease subtype discovery using sequential double regularization. <i>Biostatistics</i> , 2017, 18, 165-179.	0.9	27
1247	Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu. <i>International Journal of Cancer</i> , 2017, 140, 495-503.	2.3	30
1248	The influence of breast cancer subtype on bone metastases development and survival in women with metastatic breast cancer. <i>Irish Journal of Medical Science</i> , 2017, 186, 97-102.	0.8	4
1249	Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 221-234.	12.5	89
1250	A comprehensive genomic pan-cancer classification using The Cancer Genome Atlas gene expression data. <i>BMC Genomics</i> , 2017, 18, 508.	1.2	145
1251	Bioinformatics analysis of gene expression profiles to identify causal genes in luminal B2 breast cancer. <i>Oncology Letters</i> , 2017, 14, 7880-7888.	0.8	10

#	ARTICLE	IF	CITATIONS
1252	Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer. <i>BMC Cancer</i> , 2017, 17, 604.	1.1	15
1253	Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series. <i>BMC Cancer</i> , 2017, 17, 804.	1.1	22
1254	Prognostic Significance of Low Claudin3 Expression in Luminal Breast Cancers. <i>Breast Cancer: Basic and Clinical Research</i> , 2017, 11, 117822341774585.	0.6	1
1255	Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors. <i>Oncology Letters</i> , 2017, 15, 129-136.	0.8	9
1256	Bioinformatics identification of dysregulated microRNAs in triple negative breast cancer based on microRNA expression profiling. <i>Oncology Letters</i> , 2018, 15, 3017-3023.	0.8	9
1257	Interface between breast cancer cells and the tumor microenvironment using platelet-rich plasma to promote tumor angiogenesis - influence of platelets and fibrin bundles on the behavior of breast tumor cells. <i>Oncotarget</i> , 2017, 8, 16851-16874.	0.8	26
1258	A nomogram to predict HER2 status in breast cancer patients with HER2-borderline disease as determined via immunohistochemistry. <i>Oncotarget</i> , 2017, 8, 93492-93501.	0.8	3
1259	Clut1 promotes cell proliferation, migration and invasion by regulating epidermal growth factor receptor and integrin signaling in triple-negative breast cancer cells. <i>BMB Reports</i> , 2017, 50, 132-137.	1.1	110
1260	Expression of sex-determining region Y-box protein 2 in breast cancer and its clinical significance. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2017, 38, 685-690.	0.5	7
1261	A Retrospective Survival Analysis of Anatomic and Prognostic Stage Group Based on the American Joint Committee on Cancer 8th Edition Cancer Staging Manual in Luminal B Human Epidermal Growth Factor Receptor 2-negative Breast Cancer. <i>Chinese Medical Journal</i> , 2017, 130, 1945-1952.	0.9	17
1262	Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study. <i>Oncotarget</i> , 2017, 8, 44800-44810.	0.8	4
1263	Triple negative breast cancer: the kiss of death. <i>Oncotarget</i> , 2017, 8, 46652-46662.	0.8	129
1264	Network Modularity in Breast Cancer Molecular Subtypes. <i>Frontiers in Physiology</i> , 2017, 8, 915.	1.3	53
1265	Clinical Impact of Sphingosine-1-Phosphate in Breast Cancer. <i>Mediators of Inflammation</i> , 2017, 2017, 1-9.	1.4	30
1266	Low Expression of Circulating MicroRNA-34c is Associated with Poor Prognosis in Triple-Negative Breast Cancer. <i>Yonsei Medical Journal</i> , 2017, 58, 697.	0.9	41
1267	Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3363-3372.	1.0	11
1268	Role of postmastectomy radiotherapy in early-stage (T1–2N–1M0) triple-negative breast cancer: a systematic review. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2009-2016.	1.0	4
1269	Associations between gene expression profiles of invasive breast cancer and Breast Imaging Reporting and Data System MRI lexicon. <i>Annals of Surgical Treatment and Research</i> , 2017, 93, 18.	0.4	7

#	ARTICLE	IF	CITATIONS
1270	Prognostic immune-related gene models for breast cancer: a pooled analysis. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4423-4433.	1.0	10
1271	NanoString nCounter [®] Approach in Breast Cancer: A Comparative Analysis with Quantitative Real-Time Polymerase Chain Reaction, <i>In Situ</i> Hybridization, and Immunohistochemistry. <i>Journal of Breast Cancer</i> , 2017, 20, 286.	0.8	17
1272	In vivo validation of metastasis-regulating microRNA-766 in human triple-negative breast cancer cells. <i>Laboratory Animal Research</i> , 2017, 33, 256.	1.1	14
1273	Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1851.	1.8	31
1274	Galectin-7 in Epithelial Homeostasis and Carcinomas. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2760.	1.8	33
1275	Metabolic Portraits of Breast Cancer by HR MAS MR Spectroscopy of Intact Tissue Samples. <i>Metabolites</i> , 2017, 7, 18.	1.3	35
1276	Breast Tissue Metabolism by Magnetic Resonance Spectroscopy. <i>Metabolites</i> , 2017, 7, 25.	1.3	35
1277	Metabolomics Applications in Precision Medicine: An Oncological Perspective. <i>Current Topics in Medicinal Chemistry</i> , 2017, 17, 2740-2751.	1.0	82
1278	Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer. <i>Cancers</i> , 2017, 9, 4.	1.7	52
1279	AR Signaling in Breast Cancer. <i>Cancers</i> , 2017, 9, 21.	1.7	81
1280	Systematic Identification and Assessment of Therapeutic Targets for Breast Cancer Based on Genome-Wide RNA Interference Transcriptomes. <i>Genes</i> , 2017, 8, 86.	1.0	12
1281	Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools. <i>Genes</i> , 2017, 8, 217.	1.0	24
1282	Review: Receptor Targeted Nuclear Imaging of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 260.	1.8	27
1283	Variability in DNA Repair Capacity Levels among Molecular Breast Cancer Subtypes: Triple Negative Breast Cancer Shows Lowest Repair. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1505.	1.8	13
1284	Transcriptome Profiling in Human Diseases: New Advances and Perspectives. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1652.	1.8	193
1285	Defining Genome-Wide Expression and Phenotypic Contextual Cues in Macrophages Generated by Granulocyte/Macrophage Colony-Stimulating Factor, Macrophage Colony-Stimulating Factor, and Heat-Killed Mycobacteria. <i>Frontiers in Immunology</i> , 2017, 8, 1253.	2.2	7
1286	Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 94.	1.3	19
1287	Ror2 Signaling and Its Relevance in Breast Cancer Progression. <i>Frontiers in Oncology</i> , 2017, 7, 135.	1.3	47

#	ARTICLE	IF	CITATIONS
1288	Metabolic Footprints and Molecular Subtypes in Breast Cancer. <i>Disease Markers</i> , 2017, 2017, 1-19.	0.6	52
1289	The Predictive Value of <i>PITX2</i> DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges. <i>Disease Markers</i> , 2017, 2017, 1-14.	0.6	18
1290	Epigallocatechin gallate inhibits the growth of MDA-MB-231 breast cancer cells via inactivation of the β -catenin signaling pathway. <i>Oncology Letters</i> , 2017, 14, 441-446.	0.8	58
1291	Cadherins Associate with Distinct Stem Cell-Related Transcription Factors to Coordinate the Maintenance of Stemness in Triple-Negative Breast Cancer. <i>Stem Cells International</i> , 2017, 2017, 1-13.	1.2	22
1292	Artonin E induces p53-independent G1 cell cycle arrest and apoptosis through ROS-mediated mitochondrial pathway and livin suppression in MCF-7 cells. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 865-879.	2.0	24
1293	Alcohol and Cancer Stem Cells. <i>Cancers</i> , 2017, 9, 158.	1.7	20
1294	Ganoderma spp.: A Promising Adjuvant Treatment for Breast Cancer. <i>Medicines (Basel, Switzerland)</i> , 2017, 4, 15.	0.7	21
1295	Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4869-4883.	1.0	26
1296	Mesenchymal phenotype of circulating tumor cells is associated with distant metastasis in breast cancer patients. <i>Cancer Management and Research</i> , 2017, Volume 9, 691-700.	0.9	31
1297	Current Progresses of Single Cell DNA Sequencing in Breast Cancer Research. <i>International Journal of Biological Sciences</i> , 2017, 13, 949-960.	2.6	15
1298	Targeting Intracellular Calcium Signaling ($[Ca^{2+}]_i$) to Overcome Acquired Multidrug Resistance of Cancer Cells: A Mini-Overview. <i>Cancers</i> , 2017, 9, 48.	1.7	45
1299	Comparative diagnostic accuracy of ^{18}F -FDG PET/CT for breast cancer recurrence. <i>Breast Cancer: Targets and Therapy</i> , 2017, Volume 9, 461-471.	1.0	12
1300	Network pharmacology-based and clinically relevant prediction of the active ingredients and potential targets of Chinese herbs in metastatic breast cancer patients. <i>Oncotarget</i> , 2017, 8, 27007-27021.	0.8	63
1301	The past and future of breast cancer treatment "from the papyrus to individualised treatment approaches. <i>Ecancermedicalscience</i> , 2017, 11, 746.	0.6	35
1302	Contribution of molecular analysis to the typification of the non-functioning pituitary adenomas. <i>PLoS ONE</i> , 2017, 12, e0180039.	1.1	18
1303	Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma. <i>PLoS ONE</i> , 2017, 12, e0188068.	1.1	61
1304	Expression and prognosis analyses of the Tob/BTG antiproliferative (APRO) protein family in human cancers. <i>PLoS ONE</i> , 2017, 12, e0184902.	1.1	21
1305	Interactions between the tumor and the blood systemic response of breast cancer patients. <i>PLoS Computational Biology</i> , 2017, 13, e1005680.	1.5	22

#	ARTICLE	IF	CITATIONS
1306	SIRT7 antagonizes TGF- β 2 signaling and inhibits breast cancer metastasis. <i>Nature Communications</i> , 2017, 8, 318.	5.8	162
1307	Targeting protein quality control pathways in breast cancer. <i>BMC Biology</i> , 2017, 15, 109.	1.7	27
1308	Validation and comparison of the molecular classifications of pancreatic carcinomas. <i>Molecular Cancer</i> , 2017, 16, 168.	7.9	38
1309	Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population. <i>Breast Cancer Research</i> , 2017, 19, 83.	2.2	27
1310	Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up. <i>Breast Cancer Research</i> , 2017, 19, 120.	2.2	93
1311	Obesity reversibly depletes the basal cell population and enhances mammary epithelial cell estrogen receptor alpha expression and progenitor activity. <i>Breast Cancer Research</i> , 2017, 19, 128.	2.2	31
1312	Insulin-like growth factor receptor and sphingosine kinase are prognostic and therapeutic targets in breast cancer. <i>BMC Cancer</i> , 2017, 17, 820.	1.1	11
1313	A kinetic model of multiple phenotypic states for breast cancer cells. <i>Scientific Reports</i> , 2017, 7, 9890.	1.6	20
1314	Using machine learning algorithms to identify genes essential for cell survival. <i>BMC Bioinformatics</i> , 2017, 18, 397.	1.2	5
1315	Analysis of breast cancer subtypes by AP-ISA biclustering. <i>BMC Bioinformatics</i> , 2017, 18, 481.	1.2	3
1316	Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study. <i>Oncotarget</i> , 2017, 8, 27990-27996.	0.8	242
1317	Significance of lung biopsy for the definitive diagnosis of lung nodules in breast cancer patients. <i>Molecular and Clinical Oncology</i> , 2017, 8, 250-256.	0.4	3
1318	Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancer. <i>Oncotarget</i> , 2017, 8, 51621-51629.	0.8	24
1319	Inflammation, phagocytosis and cancer: another step in the CD47 act. <i>Journal of Thoracic Disease</i> , 2017, 9, 2279-2282.	0.6	5
1320	The molecular understanding of cancer: from the unspeakable illness to a curable disease. <i>Ecancelmedscience</i> , 2017, 11, 747.	0.6	7
1321	No association between triple-negative breast cancer and prognosis of patients receiving breast-conserving treatment. <i>Oncology Letters</i> , 2017, 14, 7862-7872.	0.8	3
1322	Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 69-78.	0.4	21
1323	Eribulin Does Not Prevent Epithelial-to-Mesenchymal Transition in HT-29 Intestinal Epithelial Cells. <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 211-218.	0.8	1

#	ARTICLE	IF	CITATIONS
1324	A nomogram to predict the probability of axillary lymph node metastasis in female patients with breast cancer in China: A nationwide, multicenter, 10-year epidemiological study. <i>Oncotarget</i> , 2017, 8, 35311-35325.	0.8	29
1325	Phosphodiesterase type 5 and cancers: progress and challenges. <i>Oncotarget</i> , 2017, 8, 99179-99202.	0.8	42
1326	Clinicopathological characteristics and prognostic value of cancer stem cell marker CD133 in breast cancer: a meta-analysis. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 859-870.	1.0	11
1327	Estrogen receptor- α , progesterone receptor, and c-erbB/HER-family receptor mRNA detection and phenotype analysis in spontaneous canine models of breast cancer. <i>Journal of Veterinary Science</i> , 2017, 18, 149.	0.5	14
1328	Precision Medicine: Where have we reached and where are we headed?. <i>Sultan Qaboos University Medical Journal</i> , 2017, 17, e255-258.	0.3	13
1329	Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women. <i>Ethnicity and Disease</i> , 2017, 27, 169.	1.0	26
1330	Targeting the androgen receptor in triple-negative breast cancer: current perspectives. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4675-4685.	1.0	48
1331	The crossroads of breast cancer progression: insights into the modulation of major signaling pathways. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5491-5524.	1.0	56
1332	Profiling of gene expression regulated by 17β -estradiol and tamoxifen in estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines. <i>Breast Cancer: Targets and Therapy</i> , 2017, Volume 9, 537-550.	1.0	7
1333	Evaluation of the Expression of Amine Oxidase Proteins in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2775.	1.8	26
1334	Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients. <i>Oncotarget</i> , 2017, 8, 5309-5322.	0.8	30
1335	Doxycycline-Regulated p16 ^{MTS1} Expression Suppresses the Anchorage-Independence and Tumorigenicity of Breast Cancer Cell Lines that Lack Endogenous p16. <i>Journal of Cancer</i> , 2017, 8, 190-198.	1.2	5
1336	Bone metastasis risk factors in breast cancer. <i>Ecancermedicalscience</i> , 2017, 11, 715.	0.6	79
1337	Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry. <i>Oncotarget</i> , 2017, 8, 51416-51428.	0.8	16
1338	Biological specificity of CDK4/6 inhibitors: dose response relationship, <i>in vivo</i> signaling, and composite response signature. <i>Oncotarget</i> , 2017, 8, 43678-43691.	0.8	53
1339	Interaction of glycosphingolipids GD3 and GD2 with growth factor receptors maintains breast cancer stem cell phenotype. <i>Oncotarget</i> , 2017, 8, 47454-47473.	0.8	47
1340	A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer. <i>Oncotarget</i> , 2017, 8, 89284-89306.	0.8	52
1341	Mammary gland stem cells and their application in breast cancer. <i>Oncotarget</i> , 2017, 8, 10675-10691.	0.8	23

#	ARTICLE	IF	CITATIONS
1342	Comprehensive Analysis of the Unfolded Protein Response in Breast Cancer Subtypes. <i>JCO Precision Oncology</i> , 2017, 2017, 1-9.	1.5	6
1343	Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2141-2148.	0.8	283
1344	South African Breast Cancer and HIV Outcomes Study: Methods and Baseline Assessment. <i>Journal of Global Oncology</i> , 2017, 3, 114-124.	0.5	32
1345	Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A. <i>Oncotarget</i> , 2017, 8, 40434-40453.	0.8	59
1346	Estimation of Premature Deaths From Lack of Access to Anti-HER2 Therapy for Advanced Breast Cancer in the Brazilian Public Health System. <i>Journal of Global Oncology</i> , 2017, 3, 201-207.	0.5	20
1347	Relationship between LINC00341 expression and cancer prognosis. <i>Oncotarget</i> , 2017, 8, 15283-15293.	0.8	13
1348	Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer. <i>The Journal of Breast Health</i> , 2017, 13, 168-174.	0.4	66
1349	The transcription levels and prognostic values of seven proteasome alpha subunits in human cancers. <i>Oncotarget</i> , 2017, 8, 4501-4519.	0.8	28
1350	The WAVE3-YB1 interaction regulates cancer stem cells activity in breast cancer. <i>Oncotarget</i> , 2017, 8, 104072-104089.	0.8	25
1351	Are breast cancer stem cells the key to resolving clinical issues in breast cancer therapy?. <i>Gland Surgery</i> , 2017, 6, 82-88.	0.5	43
1352	Systematic review and meta-analysis of the efficacy of breast conservation therapy followed by radiotherapy in four breast cancer subtypes. <i>Oncotarget</i> , 2017, 8, 57414-57420.	0.8	8
1353	MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. <i>Oncotarget</i> , 2017, 8, 11641-11658.	0.8	81
1354	Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort. <i>Npj Breast Cancer</i> , 2018, 4, 5.	2.3	32
1355	Luminal A Breast Cancer and Molecular Assays: A Review. <i>Oncologist</i> , 2018, 23, 556-565.	1.9	135
1356	A hierarchical prognostic model for risk stratification in patients with early breast cancer according to ¹⁸ F-fluorodeoxyglucose uptake and clinicopathological parameters. <i>Cancer Medicine</i> , 2018, 7, 1127-1134.	1.3	7
1357	Data-Driven Tree Transforms and Metrics. <i>IEEE Transactions on Signal and Information Processing Over Networks</i> , 2018, 4, 451-466.	1.6	11
1358	Discoidin domain receptor 1 (DDR1) ablation promotes tissue fibrosis and hypoxia to induce aggressive basal-like breast cancers. <i>Genes and Development</i> , 2018, 32, 244-257.	2.7	54
1360	Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression. <i>Cell Death and Disease</i> , 2018, 9, 326.	2.7	78

#	ARTICLE	IF	CITATIONS
1361	Ultrasound-Activated Piezoelectric Nanoparticles Inhibit Proliferation of Breast Cancer Cells. <i>Scientific Reports</i> , 2018, 8, 6257.	1.6	78
1362	Specific breast cancer prognosisâ€‘subtype distinctions based on <scp>DNA</scp> methylation patterns. <i>Molecular Oncology</i> , 2018, 12, 1047-1060.	2.1	68
1363	Patterns of breast cancer relapse in accordance to biological subtype. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1347-1355.	1.2	60
1364	Contribution of three-dimensional architecture and tumor-associated fibroblasts to hepcidin regulation in breast cancer. <i>Oncogene</i> , 2018, 37, 4013-4032.	2.6	40
1365	microRNAâ€‘10b expression and its correlation with molecular subtypes of early invasive ductal carcinoma. <i>Experimental and Therapeutic Medicine</i> , 2018, 15, 2851-2859.	0.8	4
1366	Update on the Treatment of Early-Stage Triple-Negative Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 22.	1.3	60
1367	Reparameterization of PAM50 Expression Identifies Novel Breast Tumor Dimensions and Leads to Discovery of a Genome-Wide Significant Breast Cancer Locus at <i>12q15</i>. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 644-652.	1.1	9
1368	Outcomes and prognostic factors for surgically treated patients with breast cancer spine metastases. <i>Journal of Bone Oncology</i> , 2018, 12, 38-43.	1.0	15
1369	Single drug biomarker prediction for ERâ€‘ breast cancer outcome from chemotherapy. <i>Endocrine-Related Cancer</i> , 2018, 25, 595-605.	1.6	6
1370	A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 257-266.	1.1	41
1371	Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases. <i>Clinical Cancer Research</i> , 2018, 24, 2182-2193.	3.2	68
1372	Immune gene expression and response to chemotherapy in advanced breast cancer. <i>British Journal of Cancer</i> , 2018, 118, 480-488.	2.9	37
1373	Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. <i>Clinical Cancer Research</i> , 2018, 24, 1845-1852.	3.2	84
1374	The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 231-241.	1.1	60
1375	Isolation and characterization of the primary epithelial breast cancer cells and the adjacent normal epithelial cells from Iranian womenâ€‘s breast cancer tumors. <i>Cytotechnology</i> , 2018, 70, 625-639.	0.7	12
1376	Characterization of bone only metastasis patients with respect to tumor subtypes. <i>Npj Breast Cancer</i> , 2018, 4, 2.	2.3	40
1377	Matricellular CCN6 (WISP3) protein: a tumor suppressor for mammary metaplastic carcinomas. <i>Journal of Cell Communication and Signaling</i> , 2018, 12, 13-19.	1.8	14
1378	miR-539 acts as a tumor suppressor by targeting epidermal growth factor receptor in breast cancer. <i>Scientific Reports</i> , 2018, 8, 2073.	1.6	35

#	ARTICLE	IF	CITATIONS
1379	PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer. <i>Cancer Biology and Therapy</i> , 2018, 19, 373-380.	1.5	56
1380	Feature specific quantile normalization enables cross-platform classification of molecular subtypes using gene expression data. <i>Bioinformatics</i> , 2018, 34, 1868-1874.	1.8	53
1381	Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. <i>Nature Communications</i> , 2018, 9, 578.	5.8	60
1382	Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative. <i>British Journal of Surgery</i> , 2018, 105, e158-e168.	0.1	32
1383	Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: The Norwegian Women and Cancer Study. <i>International Journal of Cancer</i> , 2018, 142, 2293-2302.	2.3	31
1384	Protein biomarkers for subtyping breast cancer and implications for future research. <i>Expert Review of Proteomics</i> , 2018, 15, 131-152.	1.3	63
1385	Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis. <i>Genome Research</i> , 2018, 28, 159-170.	2.4	137
1386	Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. <i>Clinical and Translational Oncology</i> , 2018, 20, 815-826.	1.2	57
1387	Big Data Reveal Insights into Alopecia Areata Comorbidities. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2018, 19, S57-S61.	0.8	15
1388	Nuclear receptors in cancer – uncovering new and evolving roles through genomic analysis. <i>Nature Reviews Genetics</i> , 2018, 19, 160-174.	7.7	74
1389	Discovery of internalizing antibodies to basal breast cancer cells. <i>Protein Engineering, Design and Selection</i> , 2018, 31, 17-28.	1.0	4
1390	Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 493-500.	3.0	50
1391	Diagnostic and prognostic values of contrast-enhanced ultrasound combined with diffusion-weighted magnetic resonance imaging in different subtypes of breast cancer. <i>International Journal of Molecular Medicine</i> , 2018, 42, 105-114.	1.8	5
1392	Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs). <i>BMC Cancer</i> , 2018, 18, 174.	1.1	22
1393	Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality. <i>BMC Cancer</i> , 2018, 18, 119.	1.1	14
1394	Identification of methylation sites and signature genes with prognostic value for luminal breast cancer. <i>BMC Cancer</i> , 2018, 18, 405.	1.1	44
1395	Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa. <i>BMC Women's Health</i> , 2018, 18, 40.	0.8	39
1396	Iso citrate dehydrogenase 1's axis dysfunction significantly correlates with breast cancer prognosis and regulates cell invasion ability. <i>Breast Cancer Research</i> , 2018, 20, 25.	2.2	31

#	ARTICLE	IF	CITATIONS
1397	Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. <i>Nature Communications</i> , 2018, 9, 1793.	5.8	188
1398	Functional and genomic characterization of a xenograft model system for the study of metastasis in triple-negative breast cancer. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	1.2	23
1399	MVisAGE Identifies Concordant and Discordant Genomic Alterations of Driver Genes in Squamous Tumors. <i>Cancer Research</i> , 2018, 78, 3375-3385.	0.4	5
1400	Over-elongation of centrioles in cancer promotes centriole amplification and chromosome missegregation. <i>Nature Communications</i> , 2018, 9, 1258.	5.8	113
1401	The Role of Steroid Hormones in Breast and Effects on Cancer Stem Cells. <i>Current Stem Cell Reports</i> , 2018, 4, 81-94.	0.7	29
1402	Peptidylprolyl <i>cis/trans</i> isomerase Pin1 regulates withaferin A-mediated cell cycle arrest in human breast cancer cells. <i>Molecular Carcinogenesis</i> , 2018, 57, 936-946.	1.3	13
1403	MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 477-486.	1.1	77
1404	Apigenin, a dietary flavonoid, induces apoptosis, DNA damage, and oxidative stress in human breast cancer MCF-7 and MDA MB-231 cells. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2018, 391, 537-550.	1.4	58
1405	Nephronectin is Correlated with Poor Prognosis in Breast Cancer and Promotes Metastasis via its Integrin-Binding Motifs. <i>Neoplasia</i> , 2018, 20, 387-400.	2.3	26
1406	The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes. <i>British Journal of Cancer</i> , 2018, 118, 1115-1122.	2.9	43
1407	GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. <i>Nature Communications</i> , 2018, 9, 1059.	5.8	72
1408	Expression of reactive species related genes is associated with patient survival in luminal B breast cancer. <i>Free Radical Biology and Medicine</i> , 2018, 120, 170-180.	1.3	13
1409	Timosaponin A-II inhibits oncogenic phenotype via regulation of PcG protein BMI1 in breast cancer cells. <i>Molecular Carcinogenesis</i> , 2018, 57, 831-841.	1.3	22
1410	B49, a BST-2-based peptide, inhibits adhesion and growth of breast cancer cells. <i>Scientific Reports</i> , 2018, 8, 4305.	1.6	12
1411	Molecular classification of Crohn's disease reveals two clinically relevant subtypes. <i>Gut</i> , 2018, 67, 36-42.	6.1	89
1412	Prevention of breast cancer-induced osteolytic bone resorption by benzyl isothiocyanate. <i>Carcinogenesis</i> , 2018, 39, 134-145.	1.3	21
1413	Breast Cancer in Latinas: A Focus on Intrinsic Subtypes Distribution. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 3-10.	1.1	26
1414	Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 459-468.	1.1	82

#	ARTICLE	IF	CITATIONS
1415	Clinicopathological study of a dimorphic variant of breast carcinoma. <i>Breast Cancer</i> , 2018, 25, 151-158.	1.3	2
1416	A double dealing tale of p63: an oncogene or a tumor suppressor. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 965-973.	2.4	71
1417	Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes. <i>Modern Pathology</i> , 2018, 31, 299-306.	2.9	17
1418	Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial. <i>International Journal of Cancer</i> , 2018, 142, 618-628.	2.3	27
1419	Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. <i>Pathology and Oncology Research</i> , 2018, 24, 701-716.	0.9	17
1420	Cellular subtype may predict survival outcomes in salivary adenoid cystic carcinoma patients—a single-institution experience. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 505-512.	1.4	2
1421	Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice. <i>Clinical and Translational Oncology</i> , 2018, 20, 862-869.	1.2	3
1422	The GDNF Family: A Role in Cancer?. <i>Neoplasia</i> , 2018, 20, 99-117.	2.3	54
1423	Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2018, 8, 354-369.	7.7	62
1424	Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. <i>Nature Reviews Urology</i> , 2018, 15, 92-111.	1.9	139
1425	Targeting bromodomain and extraterminal proteins in breast cancer. <i>Pharmacological Research</i> , 2018, 129, 156-176.	3.1	38
1426	Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 107-115.	1.1	12
1427	Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. <i>Cancer Causes and Control</i> , 2018, 29, 25-32.	0.8	9
1428	Molecular Subtypes and Local-Regional Control of Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 95-120.	0.6	297
1429	Comparison of Receptor-Defined Breast Cancer Subtypes Between German and Sudanese Women: A Facility-Based Cohort Study. <i>Journal of Global Oncology</i> , 2018, 4, 1-12.	0.5	9
1430	Epidemiological, Clinical, and Histopathological Features of Breast Cancer in Haiti. <i>Journal of Global Oncology</i> , 2018, 4, 1-9.	0.5	13
1431	Intratumor heterogeneity of <i>HMCN1</i> mutant alleles associated with poor prognosis in patients with breast cancer. <i>Oncotarget</i> , 2018, 9, 33337-33347.	0.8	18
1432	SIK2 attenuates proliferation and survival of breast cancer cells with simultaneous perturbation of MAPK and PI3K/Akt pathways. <i>Oncotarget</i> , 2018, 9, 21876-21892.	0.8	24

#	ARTICLE	IF	CITATIONS
1433	Breast Cancer Research in the Caribbean: Analysis of Reports From 1975 to 2017. <i>Journal of Global Oncology</i> , 2018, 4, 1-21.	0.5	16
1434	Osteoporosis and musculoskeletal complications related to therapy of breast cancer. <i>Gland Surgery</i> , 2018, 7, 411-423.	0.5	19
1435	Methyl donor S-adenosylmethionine (SAM) supplementation attenuates breast cancer growth, invasion, and metastasis <i>in vivo</i> ; therapeutic and chemopreventive applications. <i>Oncotarget</i> , 2018, 9, 5169-5183.	0.8	48
1436	Prediction model of lymphovascular invasion based on clinicopathological factors in Chinese patients with invasive breast cancer. <i>Medicine (United States)</i> , 2018, 97, e12973.	0.4	13
1437	Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer – A Single Centre Prospective Observational Study. <i>In Vivo</i> , 2018, 32, 303-311.	0.6	15
1438	The growing role of precision and personalized medicine for cancer treatment. <i>Technology</i> , 2018, 06, 79-100.	1.4	237
1439	Predictors of lymphovascular invasion identified from pathological factors in Chinese patients with breast cancer. <i>Oncotarget</i> , 2018, 9, 2468-2474.	0.8	4
1440	Whole-Genome Multi-omic Study of Survival in Patients with Glioblastoma Multiforme. <i>G3: Genes, Genomes, Genetics</i> , 2018, 8, 3627-3636.	0.8	12
1441	Mouse models of breast cancer in preclinical research. <i>Laboratory Animal Research</i> , 2018, 34, 160.	1.1	53
1442	Sperm-associated antigen 5 is a potential biomarker for poor prognosis in breast cancer. <i>Oncology Letters</i> , 2018, 17, 1146-1152.	0.8	4
1443	A new risk score based on twelve hepatocellular carcinoma-specific gene expression can predict the patients' prognosis. <i>Aging</i> , 2018, 10, 2480-2497.	1.4	20
1444	Correlation of tumor uptake on breast-specific gamma imaging and fluorodeoxyglucose PET/CT with molecular subtypes of breast cancer. <i>Medicine (United States)</i> , 2018, 97, e12840.	0.4	9
1445	A testing based approach to the discovery of differentially correlated variable sets. <i>Annals of Applied Statistics</i> , 2018, 12, 1180-1203.	0.5	2
1446	SRC inhibition prevents P-cadherin mediated signaling and function in basal-like breast cancer cells. <i>Cell Communication and Signaling</i> , 2018, 16, 75.	2.7	14
1447	Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: Results from the New South Wales Cancer Lifestyle and Evaluation of Risk (CLEAR) study. <i>PLoS ONE</i> , 2018, 13, e0205034.	1.1	7
1448	NMT1 inhibition modulates breast cancer progression through stress-triggered JNK pathway. <i>Cell Death and Disease</i> , 2018, 9, 1143.	2.7	30
1449	Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer. <i>Oncotarget</i> , 2018, 9, 33762-33777.	0.8	17
1450	Gene prioritization, communality analysis, networking and metabolic integrated pathway to better understand breast cancer pathogenesis. <i>Scientific Reports</i> , 2018, 8, 16679.	1.6	29

#	ARTICLE	IF	CITATIONS
1451	Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy. <i>BMC Cancer</i> , 2018, 18, 1059.	1.1	51
1452	Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer. <i>Theranostics</i> , 2018, 8, 6386-6399.	4.6	26
1453	Importance of gene expression signatures in pancreatic cancer prognosis and the establishment of a prediction model. <i>Cancer Management and Research</i> , 2019, Volume 11, 273-283.	0.9	58
1454	Molecular subtypes are prognostic for N3 breast cancer patients in the modern therapeutic era. <i>Molecular and Clinical Oncology</i> , 2018, 10, 180-184.	0.4	2
1455	Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit. <i>Oncology Letters</i> , 2018, 17, 1812-1818.	0.8	3
1456	Integrating proteomic and phosphoproteomic data for pathway analysis in breast cancer. <i>BMC Systems Biology</i> , 2018, 12, 130.	3.0	7
1457	Gene Expression Analyses in Breast Cancer: Sample Matters. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky019.	1.4	0
1458	High Throughput Chemical Screening Reveals Multiple Regulatory Proteins on FOXA1 in Breast Cancer Cell Lines. <i>International Journal of Molecular Sciences</i> , 2018, 19, 4123.	1.8	9
1459	An Effect of Culture Media on Epithelial Differentiation Markers in Breast Cancer Cell Lines MCF7, MDA-MB-436 and SkBr3. <i>Medicina (Lithuania)</i> , 2018, 54, 11.	0.8	9
1460	Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants. <i>Cancers</i> , 2018, 10, 514.	1.7	141
1461	CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591881834.	1.4	33
1462	Protein expression profile and microRNA expression signature in estrogen receptor-positive and -negative breast cancers: report of two cases. <i>Breast Cancer: Targets and Therapy</i> , 2018, Volume 10, 195-199.	1.0	2
1463	Incidence and prognostic factors of patients with synchronous liver metastases upon initial diagnosis of breast cancer: a population-based study. <i>Cancer Management and Research</i> , 2018, Volume 10, 5937-5950.	0.9	35
1464	Systems biology approaches to identify disease mechanisms and facilitate targeted therapy in the management of glomerular disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2018, 27, 433-439.	1.0	6
1465	Prevalence of breast and ovarian cancer subtypes in Hispanic populations from Puerto Rico. <i>BMC Cancer</i> , 2018, 18, 1177.	1.1	3
1466	Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer. <i>Nature Communications</i> , 2018, 9, 5200.	5.8	71
1467	The Interleukin-17 Family of Cytokines in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3880.	1.8	50
1468	Integrated proteotranscriptomics of breast cancer reveals globally increased protein-mRNA concordance associated with subtypes and survival. <i>Genome Medicine</i> , 2018, 10, 94.	3.6	100

#	ARTICLE	IF	CITATIONS
1469	Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review. <i>Stem Cell Research and Therapy</i> , 2018, 9, 336.	2.4	86
1470	DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E11978-E11987.	3.3	40
1471	Is Axillary Sentinel Lymph Node Biopsy Required in Patients Who Undergo Primary Breast Surgery. <i>Breast Care</i> , 2018, 13, 324-330.	0.8	22
1472	Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. <i>Genome Medicine</i> , 2018, 10, 86.	3.6	14
1473	What Is the Best Management of cNOpN1(sn) Breast Cancer Patients. <i>Breast Care</i> , 2018, 13, 331-336.	0.8	13
1474	Recurrent copy number alterations in young women with breast cancer. <i>Oncotarget</i> , 2018, 9, 11541-11558.	0.8	12
1475	Development and validation of nomograms for predicting overall and breast cancer-specific survival among patients with triple-negative breast cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 5881-5894.	0.9	14
1476	Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity. <i>Frontiers in Oncology</i> , 2018, 8, 609.	1.3	17
1477	Rhomboid domain-containing protein 1 promotes breast cancer progression by regulating the p-Akt and CDK2 levels. <i>Cell Communication and Signaling</i> , 2018, 16, 65.	2.7	24
1478	Lymph node metastasis and high serum CEA are important prognostic factors in hormone receptor positive and HER2 negative breast cancer. <i>Molecular and Clinical Oncology</i> , 2018, 9, 566-574.	0.4	6
1479	The Unfolded Protein Response in Breast Cancer. <i>Cancers</i> , 2018, 10, 344.	1.7	62
1480	Hypoxia Induces the Acquisition of Cancer Stem-like Phenotype Via Upregulation and Activation of Signal Transducer and Activator of Transcription-3 (STAT3) in MDA-MB-231, a Triple Negative Breast Cancer Cell Line. <i>Cancer Microenvironment</i> , 2018, 11, 141-152.	3.1	26
1481	Identification of miR-200c and miR141-Mediated lncRNA-mRNA Crosstalks in Muscle-Invasive Bladder Cancer Subtypes. <i>Frontiers in Genetics</i> , 2018, 9, 422.	1.1	26
1482	MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers. <i>Frontiers in Oncology</i> , 2018, 8, 352.	1.3	13
1483	Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer. <i>Cancers</i> , 2018, 10, 342.	1.7	109
1484	Correlation of BMI with breast cancer subtype and tumour size. <i>Ecancermedicalscience</i> , 2018, 12, 845.	0.6	11
1485	Aurantioside C Targets and Induces Apoptosis in Triple Negative Breast Cancer Cells. <i>Marine Drugs</i> , 2018, 16, 361.	2.2	19
1486	The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge. <i>Journal of Breast Cancer</i> , 2018, 21, 233.	0.8	59

#	ARTICLE	IF	CITATIONS
1487	Formin Proteins FHOD1 and INF2 in Triple-Negative Breast Cancer: Association With Basal Markers and Functional Activities. <i>Breast Cancer: Basic and Clinical Research</i> , 2018, 12, 117822341879224.	0.6	16
1488	Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. <i>Oncotarget</i> , 2018, 9, 26406-26416.	0.8	136
1489	Clinical decision making in postmastectomy radiotherapy in node negative breast cancer. <i>Ecancermedicalsecience</i> , 2018, 12, 874.	0.6	1
1490	Distinct esophageal adenocarcinoma molecular subtype has subtype-specific gene expression and mutation patterns. <i>BMC Genomics</i> , 2018, 19, 769.	1.2	8
1491	The Hierarchical Modular Structure of HER2+ Breast Cancer Network. <i>Frontiers in Physiology</i> , 2018, 9, 1423.	1.3	40
1492	Single-Cell Transcriptomics in Cancer Immunobiology: The Future of Precision Oncology. <i>Frontiers in Immunology</i> , 2018, 9, 2582.	2.2	47
1493	Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. <i>BMC Cancer</i> , 2018, 18, 1051.	1.1	59
1494	Calein C, a Sesquiterpene Lactone Isolated From <i>Calea Pinnatifida</i> (Asteraceae), Inhibits Mitotic Progression and Induces Apoptosis in MCF-7 Cells. <i>Frontiers in Pharmacology</i> , 2018, 9, 1191.	1.6	7
1495	Molecular characterization of breast and lung tumors by integration of multiple data types with functional sparse-factor analysis. <i>PLoS Computational Biology</i> , 2018, 14, e1006520.	1.5	13
1496	mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3396.	1.8	35
1497	UNBS5162 induces growth inhibition and apoptosis via inhibiting PI3K/AKT/mTOR pathway in triple negative breast cancer MDA-MB-231 cells. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 3921-3928.	0.8	6
1498	Novel MicroRNA-Based Risk Score Identified by Integrated Analyses to Predict Metastasis and Poor Prognosis in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 4037-4046.	0.7	34
1499	Molecular determinants of post-mastectomy breast cancer recurrence. <i>Npj Breast Cancer</i> , 2018, 4, 34.	2.3	9
1500	Single molecule localization microscopy coupled with touch preparation for the quantification of trastuzumab-bound HER2. <i>Scientific Reports</i> , 2018, 8, 15154.	1.6	28
1501	Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre. <i>British Journal of Cancer</i> , 2018, 119, 922-927.	2.9	3
1502	Practical Consequences Resulting from the Analysis of a 21-Multigene Array in the Interdisciplinary Conference of a Breast Cancer Center. <i>International Journal of Breast Cancer</i> , 2018, 2018, 1-8.	0.6	1
1503	Screening of Additive Manufactured Scaffolds Designs for Triple Negative Breast Cancer 3D Cell Culture and Stem-Like Expansion. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3148.	1.8	23
1504	An assessment of prognostic immunity markers in breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 35.	2.3	41

#	ARTICLE	IF	CITATIONS
1505	The downregulation of WWOX induces epithelialâ€mesenchymal transition and enhances stemness and chemoresistance in breast cancer. <i>Experimental Biology and Medicine</i> , 2018, 243, 1066-1073.	1.1	9
1506	LncRNA BLAT1 is Upregulated in Basal-like Breast Cancer through Epigenetic Modifications. <i>Scientific Reports</i> , 2018, 8, 15572.	1.6	26
1507	Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence. <i>Cancer Management and Research</i> , 2018, Volume 10, 3083-3099.	0.9	21
1508	Differential expression and clinical significance of epithelial-mesenchymal transition markers among different histological types of triple-negative breast cancer. <i>Journal of Cancer</i> , 2018, 9, 604-613.	1.2	25
1509	Activation of pro-survival metabolic networks by 1,25(OH)2D3 does not hamper the sensitivity of breast cancer cells to chemotherapeutics. <i>Cancer & Metabolism</i> , 2018, 6, 11.	2.4	12
1510	Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer. <i>Cancer Letters</i> , 2018, 438, 165-173.	3.2	28
1511	Proteome-Wide Structural Biology: An Emerging Field for the Structural Analysis of Proteins on the Proteomic Scale. <i>Journal of Proteome Research</i> , 2018, 17, 3614-3627.	1.8	54
1512	Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: antitumor miR-204-5p targets AP1S3. <i>Journal of Human Genetics</i> , 2018, 63, 1197-1210.	1.1	41
1513	Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance. <i>Molecules</i> , 2018, 23, 2193.	1.7	122
1514	Stress signaling in breast cancer cells induces matrix components that promote chemoresistant metastasis. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	77
1515	Combination of SIRT1 and Src overexpression suggests poor prognosis in luminal breast cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2051-2061.	1.0	26
1516	Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 713-723.	1.1	78
1517	Tumorâ€stroma interactions differentially alter drug sensitivity based on the origin of stromal cells. <i>Molecular Systems Biology</i> , 2018, 14, e8322.	3.2	25
1518	Identification of the Thioredoxin-Like 2 Autoantibody as a Specific Biomarker for Triple-Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2018, 21, 87.	0.8	8
1519	Loss of Wwox drives metastasis in triple-negative breast cancer by JAK2/STAT3 axis. <i>Nature Communications</i> , 2018, 9, 3486.	5.8	92
1520	Multicenter Study Using Desorption-Electrospray-Ionization-Mass-Spectrometry Imaging for Breast-Cancer Diagnosis. <i>Analytical Chemistry</i> , 2018, 90, 11324-11332.	3.2	70
1521	RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF- κ B activation and EGFR signaling. <i>Oncogene</i> , 2018, 37, 5101-5114.	2.6	22
1522	Profiling human breast epithelial cells using single cell RNA sequencing identifies cell diversity. <i>Nature Communications</i> , 2018, 9, 2028.	5.8	256

#	ARTICLE	IF	CITATIONS
1523	MELK as a potential target to control cell proliferation in triple-negative breast cancer MDA-MB-231 cells. <i>Oncology Letters</i> , 2018, 15, 9934-9940.	0.8	14
1524	Splicing dysregulation as a driver of breast cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, R467-R478.	1.6	31
1525	The cancer-associated microprotein CASIMO1 controls cell proliferation and interacts with squalene epoxidase modulating lipid droplet formation. <i>Oncogene</i> , 2018, 37, 4750-4768.	2.6	111
1526	Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. <i>Genes and Diseases</i> , 2018, 5, 77-106.	1.5	714
1527	MiR-133b targets Sox9 to control pathogenesis and metastasis of breast cancer. <i>Cell Death and Disease</i> , 2018, 9, 752.	2.7	63
1528	Imaging and the completion of the omics paradigm in breast cancer. <i>Der Radiologe</i> , 2018, 58, 7-13.	1.7	14
1529	Molecularly-driven precision medicine for advanced bladder cancer. <i>World Journal of Urology</i> , 2018, 36, 1749-1757.	1.2	4
1530	High CD90 (THY-1) expression positively correlates with cell transformation and worse prognosis in basal-like breast cancer tumors. <i>PLoS ONE</i> , 2018, 13, e0199254.	1.1	13
1531	Precision Medicine for Breast Cancer: The Paths to Truly Individualized Diagnosis and Treatment. <i>International Journal of Breast Cancer</i> , 2018, 2018, 1-8.	0.6	27
1532	CXCR4/CXCL12 Signaling and Protumor Macrophages in Primary Tumors and Sentinel Lymph Nodes Are Involved in Luminal B Breast Cancer Progression. <i>Disease Markers</i> , 2018, 2018, 1-9.	0.6	10
1533	Natural Products for the Management and Prevention of Breast Cancer. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-23.	0.5	141
1534	LIPG signaling promotes tumor initiation and metastasis of human basal-like triple-negative breast cancer. <i>ELife</i> , 2018, 7, .	2.8	29
1535	Classifying tumors by supervised network propagation. <i>Bioinformatics</i> , 2018, 34, i484-i493.	1.8	34
1536	FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome. <i>Molecular Oncology</i> , 2018, 12, 1884-1894.	2.1	19
1537	DCE-MRI Pharmacokinetic-Based Phenotyping of Invasive Ductal Carcinoma: A Radiomic Study for Prediction of Histological Outcomes. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-11.	0.4	41
1538	Two critical positions in zinc finger domains are heavily mutated in three human cancer types. <i>PLoS Computational Biology</i> , 2018, 14, e1006290.	1.5	31
1539	Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program. <i>Nature Communications</i> , 2018, 9, 2547.	5.8	63
1540	Autophagy Modulation in Cancer: Current Knowledge on Action and Therapy. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-18.	1.9	154

#	ARTICLE	IF	CITATIONS
1541	Expression of Pentose Phosphate Pathway-Related Proteins in Breast Cancer. <i>Disease Markers</i> , 2018, 2018, 1-9.	0.6	34
1542	miRNA-135b Contributes to Triple Negative Breast Cancer Molecular Heterogeneity: Different Expression Profile in Basal-like Versus non-Basal-like Phenotypes. <i>International Journal of Medical Sciences</i> , 2018, 15, 536-548.	1.1	31
1543	Adhesion, proliferation, and apoptosis in different molecular portraits of breast cancer treated with silver nanoparticles and its pathway-network analysis. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 1081-1095.	3.3	14
1544	polyClustR: defining communities of reconciled cancer subtypes with biological and prognostic significance. <i>BMC Bioinformatics</i> , 2018, 19, 182.	1.2	1
1545	Development of a Novel Proteomic Risk-Classifer for Prognostication of Patients With Early-Stage Hormone Receptor-Positive Breast Cancer. <i>Biomarker Insights</i> , 2018, 13, 117727191878910.	1.0	18
1546	Imaging Phenotypes in Women at High Risk for Breast Cancer on Mammography, Ultrasound, and Magnetic Resonance Imaging Using the Fifth Edition of the Breast Imaging Reporting and Data System. <i>European Journal of Radiology</i> , 2018, 106, 150-159.	1.2	28
1547	A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 82.	2.2	44
1548	Multifactorial Modes of Action of Arsenic Trioxide in Cancer Cells as Analyzed by Classical and Network Pharmacology. <i>Frontiers in Pharmacology</i> , 2018, 9, 143.	1.6	17
1549	Effect of Propofol on breast Cancer cell, the immune system, and patient outcome. <i>BMC Anesthesiology</i> , 2018, 18, 77.	0.7	66
1550	Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing. <i>Journal of Cancer</i> , 2018, 9, 219-231.	1.2	21
1551	Cancer: From Wild-Type to Mutant Huntingtin. <i>Journal of Huntington's Disease</i> , 2018, 7, 201-208.	0.9	19
1552	Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date. <i>Breast Cancer: Targets and Therapy</i> , 2018, Volume 10, 23-29.	1.0	15
1553	The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 79.	2.2	41
1554	Synaptopodin-2 plays an important role in the metastasis of breast cancer via PI3K/Akt/mTOR pathway. <i>Cancer Management and Research</i> , 2018, Volume 10, 1575-1583.	0.9	17
1555	Crambesicidin 800, Isolated from the Marine Sponge <i>Monanchora viridis</i> , Induces Cell Cycle Arrest and Apoptosis in Triple-Negative Breast Cancer Cells. <i>Marine Drugs</i> , 2018, 16, 53.	2.2	30
1556	Integration of in vitro and in silico perspectives to explain chemical characterization, biological potential and anticancer effects of <i>Hypericum salugineum</i> : A pharmacologically active source for functional drug formulations. <i>PLoS ONE</i> , 2018, 13, e0197815.	1.1	27
1557	MicroRNA-150 suppresses triple-negative breast cancer metastasis through targeting HMGA2. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2319-2332.	1.0	36
1558	Altered Circadian Rhythms and Breast Cancer: From the Human to the Molecular Level. <i>Frontiers in Endocrinology</i> , 2018, 9, 219.	1.5	36

#	ARTICLE	IF	CITATIONS
1559	Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. <i>Frontiers in Genetics</i> , 2018, 9, 174.	1.1	46
1560	A Leveraged Signal-to-Noise Ratio (LSTNR) Method to Extract Differentially Expressed Genes and Multivariate Patterns of Expression From Noisy and Low-Replication RNAseq Data. <i>Frontiers in Genetics</i> , 2018, 9, 176.	1.1	13
1561	Personalizing Breast Cancer Irradiation Using Biology: From Bench to the Accelerator. <i>Frontiers in Oncology</i> , 2018, 8, 83.	1.3	5
1562	Management of the Axilla in the Era of Breast Cancer Heterogeneity. <i>Frontiers in Oncology</i> , 2018, 8, 84.	1.3	6
1563	Precision Medicine in Hormone Receptor-Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 144.	1.3	32
1564	Immune Landscape of Breast Cancers. <i>Biomedicines</i> , 2018, 6, 20.	1.4	81
1565	The Role of Chromosomal Instability in Cancer and Therapeutic Responses. <i>Cancers</i> , 2018, 10, 4.	1.7	128
1566	Bladder Cancer: New Insights into Its Molecular Pathology. <i>Cancers</i> , 2018, 10, 100.	1.7	77
1567	Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study. <i>Genes</i> , 2018, 9, 261.	1.0	4
1568	Dissecting Time- from Tumor-Related Gene Expression Variability in Bilateral Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 196.	1.8	0
1569	The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death. <i>International Journal of Molecular Sciences</i> , 2018, 19, 452.	1.8	22
1570	A Metabolomic Approach to Predict Breast Cancer Behavior and Chemotherapy Response. <i>International Journal of Molecular Sciences</i> , 2018, 19, 617.	1.8	31
1571	TASK-3 Downregulation Triggers Cellular Senescence and Growth Inhibition in Breast Cancer Cell Lines. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1033.	1.8	16
1572	Cytokeratin 19 (KRT19) has a Role in the Reprogramming of Cancer Stem Cell-Like Cells to Less Aggressive and More Drug-Sensitive Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1423.	1.8	38
1573	The Maxi-K (BK) Channel Antagonist Penitrem A as a Novel Breast Cancer-Targeted Therapeutic. <i>Marine Drugs</i> , 2018, 16, 157.	2.2	22
1574	Design, Synthesis and Docking Studies of Flavokawain B Type Chalcones and Their Cytotoxic Effects on MCF-7 and MDA-MB-231 Cell Lines. <i>Molecules</i> , 2018, 23, 616.	1.7	23
1575	Discovery of N-(Naphtho[1,2-b]Furan-5-Yl) Benzenesulfonamides as Novel Selective Inhibitors of Triple-Negative Breast Cancer (TNBC). <i>Molecules</i> , 2018, 23, 678.	1.7	4
1576	Nanoparticle-Mediated Therapeutic Agent Delivery for Treating Metastatic Breast Cancer—Challenges and Opportunities. <i>Nanomaterials</i> , 2018, 8, 361.	1.9	32

#	ARTICLE	IF	CITATIONS
1577	Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer. <i>Clinical Epigenetics</i> , 2018, 10, 88.	1.8	49
1578	LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer. <i>Oncogene</i> , 2018, 37, 6166-6179.	2.6	101
1579	Amino Acid Transporters and Glutamine Metabolism in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 907.	1.8	103
1580	The Inner and Outer Qualities of Extracellular Vesicles for Translational Purposes in Breast Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 584.	2.2	21
1581	Investigation on Physicochemical Characteristics of a Nanoliposome-Based System for Dual Drug Delivery. <i>Nanoscale Research Letters</i> , 2018, 13, 101.	3.1	27
1582	Cyclooxygenase and lipoxygenase gene expression in the inflammogenesis of breast cancer. <i>Inflammopharmacology</i> , 2018, 26, 909-923.	1.9	30
1583	Roles of flotillins in tumors. <i>Journal of Zhejiang University: Science B</i> , 2018, 19, 171-182.	1.3	23
1584	Trends in molecular subtypes of breast cancer: description of incidence rates between 2007 and 2012 from three French registries. <i>BMC Cancer</i> , 2018, 18, 161.	1.1	15
1585	The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours. <i>Breast Cancer Research</i> , 2018, 20, 21.	2.2	85
1586	Knockdown of lncRNA MAPT-AS1 inhibites proliferation and migration and sensitizes cancer cells to paclitaxel by regulating MAPT expression in ER-negative breast cancers. <i>Cell and Bioscience</i> , 2018, 8, 7.	2.1	37
1587	Gene expression in triple-negative breast cancer in relation to survival. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 199-207.	1.1	35
1588	When it comes to genomic analysis of tumours, don't buy in bulk. <i>British Journal of Cancer</i> , 2018, 118, 1281-1282.	2.9	0
1589	Thresher: determining the number of clusters while removing outliers. <i>BMC Bioinformatics</i> , 2018, 19, 9.	1.2	45
1590	Targeted learning ensembles for optimal individualized treatment rules with time-to-event outcomes. <i>Biometrika</i> , 2018, 105, 723-738.	1.3	10
1591	Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 111-120.	1.1	38
1592	Low serum gastrin associated with ER+ breast cancer development via inactivation of CCKBR/ERK/P65 signaling. <i>BMC Cancer</i> , 2018, 18, 824.	1.1	11
1593	Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs. <i>Current Oncology Reports</i> , 2018, 20, 76.	1.8	72
1594	Pituitary, Gonadal, Thyroid Hormones and Endocrine Disruptors in Pre and Postmenopausal Nigerian Women with ER-, PR- and HER-2-Positive and Negative Breast Cancers. <i>Medical Sciences (Basel)</i> Tj ETQq1 1 0.784314 rgBT /@verlock		

#	ARTICLE	IF	CITATIONS
1595	Co-expression in Single-Cell Analysis: Saving Grace or Original Sin?. Trends in Genetics, 2018, 34, 823-831.	2.9	34
1596	Establishment and characterization of three stable Basal/HER2-positive breast cancer cell lines derived from Chinese breast carcinoma with identical missense mutations in the DNA-binding domain of TP53. Cancer Cell International, 2018, 18, 118.	1.8	3
1597	Germline and Somatic <i>NF1</i> Alterations Are Linked to Increased HER2 Expression in Breast Cancer. Cancer Prevention Research, 2018, 11, 655-664.	0.7	4
1598	Increased β -actinin-1 destabilizes E-cadherin-based adhesions and associates with poor prognosis in basal-like breast cancer. PLoS ONE, 2018, 13, e0196986.	1.1	39
1599	Somatic loss of WWOX is associated with TP53 perturbation in basal-like breast cancer. Cell Death and Disease, 2018, 9, 832.	2.7	26
1600	ICAM1 expression is induced by proinflammatory cytokines and associated with TLS formation in aggressive breast cancer subtypes. Scientific Reports, 2018, 8, 11720.	1.6	71
1601	The clinical applications of The Cancer Genome Atlas project for bladder cancer. Expert Review of Anticancer Therapy, 2018, 18, 973-980.	1.1	12
1602	Survival Study of Triple-Negative and Non-“Triple-Negative Breast Cancer in a Brazilian Cohort. Clinical Medicine Insights: Oncology, 2018, 12, 117955491879056.	0.6	83
1603	A combined approach with gene-wise normalization improves the analysis of RNA-seq data in human breast cancer subtypes. PLoS ONE, 2018, 13, e0201813.	1.1	6
1604	Systematic identification of non-coding pharmacogenomic landscape in cancer. Nature Communications, 2018, 9, 3192.	5.8	73
1605	Integrative analysis of the inter-tumoral heterogeneity of triple-negative breast cancer. Scientific Reports, 2018, 8, 11807.	1.6	43
1606	Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer. PLoS Genetics, 2018, 14, e1007571.	1.5	33
1607	Subtyping Of Triple Negative Breast Carcinoma On The Basis Of RTK Expression. Journal of Cancer, 2018, 9, 2589-2602.	1.2	3
1608	Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy. World Journal of Clinical Oncology, 2018, 9, 33-41.	0.9	23
1609	Molecular Subtypes of Bladder Cancer. Current Oncology Reports, 2018, 20, 77.	1.8	111
1610	The association between Notch4 expression, and clinicopathological characteristics and clinical outcomes in patients with breast cancer. Oncology Letters, 2018, 15, 8749-8755.	0.8	29
1611	The role of abemaciclib in treatment of advanced breast cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877692.	1.4	14
1612	Immunity drives <i>TET1</i> regulation in cancer through NF- κ B. Science Advances, 2018, 4, eaap7309.	4.7	64

#	ARTICLE	IF	CITATIONS
1613	Reporters to mark and eliminate basal or luminal epithelial cells in culture and in vivo. <i>PLoS Biology</i> , 2018, 16, e2004049.	2.6	17
1614	Association between expression of random gene sets and survival is evident in multiple cancer types and may be explained by sub-classification. <i>PLoS Computational Biology</i> , 2018, 14, e1006026.	1.5	21
1615	Breast cancer treatment and its effects on aging. <i>Journal of Geriatric Oncology</i> , 2019, 10, 346-355.	0.5	51
1616	Dual role for miR-34a in the control of early progenitor proliferation and commitment in the mammary gland and in breast cancer. <i>Oncogene</i> , 2019, 38, 360-374.	2.6	39
1617	The role of PIP5K1 β /pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1 β inhibitor. <i>Oncogene</i> , 2019, 38, 375-389.	2.6	29
1618	Association of Genetic Variants in NF- κ B with Susceptibility to Breast Cancer: a Case Control Study. <i>Pathology and Oncology Research</i> , 2019, 25, 1395-1400.	0.9	5
1619	Pan-Cancer and Single-Cell Modeling of Genomic Alterations Through Gene Expression. <i>Frontiers in Genetics</i> , 2019, 10, 671.	1.1	22
1620	Artificial intelligence-directed prognostication of breast cancer. <i>EBioMedicine</i> , 2019, 46, 6-7.	2.7	2
1621	The genomic landscape of estrogen receptor β binding sites in mouse mammary gland. <i>PLoS ONE</i> , 2019, 14, e0220311.	1.1	25
1622	A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers. <i>Cancers</i> , 2019, 11, 1158.	1.7	6
1623	LSD1 suppresses invasion, migration and metastasis of luminal breast cancer cells via activation of GATA3 and repression of TRIM37 expression. <i>Oncogene</i> , 2019, 38, 7017-7034.	2.6	48
1624	Regulation of Immunity in Breast Cancer. <i>Cancers</i> , 2019, 11, 1080.	1.7	43
1625	Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses. <i>Npj Breast Cancer</i> , 2019, 5, 21.	2.3	43
1626	Serum amyloid A predisposes inflammatory tumor microenvironment in triple negative breast cancer. <i>Oncotarget</i> , 2019, 10, 511-526.	0.8	28
1627	Depletion of the Transcriptional Coactivator Amplified in Breast Cancer 1 (AIB1) Uncovers Functionally Distinct Subpopulations in Triple-Negative Breast Cancer. <i>Neoplasia</i> , 2019, 21, 963-973.	2.3	2
1628	HMGA1 promotes breast cancer angiogenesis supporting the stability, nuclear localization and transcriptional activity of FOXM1. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 313.	3.5	67
1629	Identification of long non-coding RNA-mediated transcriptional dysregulation triplets reveals global patterns and prognostic biomarkers for ER+/PR+, HER2- and triple negative breast cancer. <i>International Journal of Molecular Medicine</i> , 2019, 44, 1015-1025.	1.8	5
1630	Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study. <i>PLoS ONE</i> , 2019, 14, e0218434.	1.1	18

#	ARTICLE	IF	CITATIONS
1631	CONFIGURE: A pipeline for identifying context specific regulatory modules from gene expression data and its application to breast cancer. <i>BMC Medical Genomics</i> , 2019, 12, 97.	0.7	5
1632	Molecular profile of breast cancers in Guinean oncological settings. <i>Pan African Medical Journal</i> , 2019, 33, 22.	0.3	9
1633	Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer. <i>BMC Cancer</i> , 2019, 19, 695.	1.1	4
1634	Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials. <i>Frontiers in Oncology</i> , 2019, 9, 510.	1.3	49
1635	Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer. <i>Theranostics</i> , 2019, 9, 4935-4945.	4.6	36
1636	The effect of modifiable risk factors on breast cancer aggressiveness among black and white women. <i>American Journal of Surgery</i> , 2019, 218, 689-694.	0.9	5
1637	TUFT1 Promotes Triple Negative Breast Cancer Metastasis, Stemness, and Chemoresistance by Up-Regulating the Rac1/ β 2-Catenin Pathway. <i>Frontiers in Oncology</i> , 2019, 9, 617.	1.3	23
1638	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. <i>Cancers</i> , 2019, 11, 1033.	1.7	160
1639	Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression. <i>Npj Breast Cancer</i> , 2019, 5, 20.	2.3	31
1640	In Vivo Assessment of VCAM-1 Expression by SPECT/CT Imaging in Mice Models of Human Triple Negative Breast Cancer. <i>Cancers</i> , 2019, 11, 1039.	1.7	3
1641	Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19. <i>Histochemistry and Cell Biology</i> , 2019, 152, 281-291.	0.8	45
1642	HR+/HER2 \sim Metastatic Breast Cancer: Epidemiology, Prescription Patterns, Healthcare Resource Utilisation and Costs from a Large Italian Real-World Database. <i>Clinical Drug Investigation</i> , 2019, 39, 945-951.	1.1	8
1643	Interrogation of Phenotypic Plasticity between Epithelial and Mesenchymal States in Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 893.	1.0	45
1644	LobSig is a multigene predictor of outcome in invasive lobular carcinoma. <i>Npj Breast Cancer</i> , 2019, 5, 18.	2.3	28
1645	<p>Candidate tumor suppressor gene IRF6 is involved in human breast cancer pathogenesis via modulating PI3K-regulatory subunit PIK3R2 expression</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 5557-5572.	0.9	14
1646	Long non-coding RNA (lncRNA) transcriptional landscape in breast cancer identifies LINC01614 as non-favorable prognostic biomarker regulated by TGF β 2 and focal adhesion kinase (FAK) signaling. <i>Cell Death Discovery</i> , 2019, 5, 109.	2.0	63
1647	Halogen-Substituted Derivatives of Dictyostelium Differentiation-Inducing Factor-1 Suppress Serum-Induced Cell Migration of Human Breast Cancer MDA-MB-231 Cells in Vitro. <i>Biomolecules</i> , 2019, 9, 256.	1.8	6
1648	Predicting prognosis of endometrioid endometrial adenocarcinoma on the basis of gene expression and clinical features using Random Forest. <i>Oncology Letters</i> , 2019, 18, 1597-1606.	0.8	7

#	ARTICLE	IF	CITATIONS
1649	Chemoresistance in the Human Triple-Negative Breast Cancer Cell Line MDA-MB-231 Induced by Doxorubicin Gradient Is Associated with Epigenetic Alterations in Histone Deacetylase. <i>Journal of Oncology</i> , 2019, 2019, 1-12.	0.6	44
1650	MicroRNA and Oxidative Stress Interplay in the Context of Breast Cancer Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5143.	1.8	30
1651	The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. <i>Cell Reports</i> , 2019, 29, 889-903.e10.	2.9	40
1652	The LQB-223 Compound Modulates Antiapoptotic Proteins and Impairs Breast Cancer Cell Growth and Migration. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5063.	1.8	1
1653	Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells. <i>Vaccines</i> , 2019, 7, 149.	2.1	63
1654	Integrated Transcriptome and Pathway Analyses Revealed Multiple Activated Pathways in Breast Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 910.	1.3	44
1655	Cyclin D1 is Associated with Radiosensitivity of Triple-Negative Breast Cancer Cells to Proton Beam Irradiation. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4943.	1.8	17
1656	<p>Genetic association of XRCC5 gene polymorphisms with breast cancer among Jordanian women</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7923-7928.	1.0	7
1657	Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast Cancers. <i>IScience</i> , 2019, 21, 341-358.	1.9	29
1658	Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance. <i>BMC Cancer</i> , 2019, 19, 1039.	1.1	77
1659	Shared and distinct mechanisms of fibrosis. <i>Nature Reviews Rheumatology</i> , 2019, 15, 705-730.	3.5	331
1660	Relationship between Diabetes and Diabetes Medications and Risk of Different Molecular Subtypes of Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1802-1808.	1.1	20
1661	Coupled Genome-Wide DNA Methylation and Transcription Analysis Identified Rich Biomarkers and Drug Targets in Triple-Negative Breast Cancer. <i>Cancers</i> , 2019, 11, 1724.	1.7	8
1662	PKC± Modulates Epithelial-to-Mesenchymal Transition and Invasiveness of Breast Cancer Cells Through ZEB1. <i>Frontiers in Oncology</i> , 2019, 9, 1323.	1.3	26
1663	Two Distinct Subtypes Revealed in Blood Transcriptome of Breast Cancer Patients With an Unsupervised Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 985.	1.3	16
1664	Surface-Enhanced Raman Spectroscopy Characterization of Breast Cell Phenotypes: Effect of Nanoparticle Geometry. <i>ACS Applied Nano Materials</i> , 2019, 2, 6960-6970.	2.4	5
1665	Molecular subtyping of mammary Paget's disease using immunohistochemistry. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2019, 40, 440-446.	0.5	8
1666	Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 21715-21726.	3.3	122

#	ARTICLE	IF	CITATIONS
1667	First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β -Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1916-1925.	1.9	21
1668	BC200 overexpression contributes to luminal and triple negative breast cancer pathogenesis. <i>BMC Cancer</i> , 2019, 19, 994.	1.1	14
1669	The trans-DATA study: aims and design of a translational breast cancer prognostic marker identification study. <i>Diagnostic and Prognostic Research</i> , 2019, 3, 20.	0.8	1
1670	Hyper-Activation of STAT3 Sustains Progression of Non-Papillary Basal-Type Bladder Cancer via FOSL1 Regulome. <i>Cancers</i> , 2019, 11, 1219.	1.7	32
1671	Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge. <i>Cells</i> , 2019, 8, 957.	1.8	467
1672	Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer. <i>Frontiers in Genetics</i> , 2019, 10, 815.	1.1	35
1673	High WDR34 mRNA expression as a potential prognostic biomarker in patients with breast cancer as determined by integrated bioinformatics analysis. <i>Oncology Letters</i> , 2019, 18, 3177-3187.	0.8	13
1674	An integrated bioinformatics analysis of potential therapeutic targets among matrix metalloproteinases in breast cancer. <i>Oncology Letters</i> , 2019, 18, 2985-2994.	0.8	2
1675	Dietary Inflammatory Index and Risk of Breast Cancer Based on Hormone Receptor Status: A Case-Control Study in Korea. <i>Nutrients</i> , 2019, 11, 1949.	1.7	23
1676	Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 459-467.	1.1	23
1677	Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFN γ -Driven Antitumor Immunity. <i>Cancer Research</i> , 2019, 79, 5394-5406.	0.4	55
1678	Impact of chemotherapy on the expression of claudins and cadherins in invasive breast cancer. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 3014-3024.	0.8	6
1679	Phenotypic, structural, and ultrastructural analysis of triple-negative breast cancer cell lines and breast cancer stem cell subpopulation. <i>European Biophysics Journal</i> , 2019, 48, 673-684.	1.2	4
1680	Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer. <i>Metallomics</i> , 2019, 11, 1579-1592.	1.0	18
1681	Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC. <i>Npj Precision Oncology</i> , 2019, 3, 21.	2.3	23
1682	WNT5B governs the phenotype of basal-like breast cancer by activating WNT signaling. <i>Cell Communication and Signaling</i> , 2019, 17, 109.	2.7	45
1683	Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer. <i>PLoS ONE</i> , 2019, 14, e0221785.	1.1	31
1684	Shining a Light on the Effects of the Combination of (–)-Epigallocatechin-3-gallate and Tapentadol on the Growth of Human Triple-negative Breast Cancer Cells. <i>In Vivo</i> , 2019, 33, 1463-1468.	0.6	13

#	ARTICLE	IF	CITATIONS
1685	Mechanisms and Implications of Metabolic Heterogeneity in Cancer. <i>Cell Metabolism</i> , 2019, 30, 434-446.	7.2	355
1686	MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis. <i>Neoplasia</i> , 2019, 21, 1015-1035.	2.3	76
1687	Pathways to Endocrine Therapy Resistance in Breast Cancer. <i>Frontiers in Endocrinology</i> , 2019, 10, 573.	1.5	100
1688	Targeting transcription factors in cancer “from undruggable to reality. <i>Nature Reviews Cancer</i> , 2019, 19, 611-624.	12.8	515
1689	Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification. <i>BMC Cancer</i> , 2019, 19, 897.	1.1	14
1690	Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness. <i>Cancers</i> , 2019, 11, 1334.	1.7	150
1691	Subtype-Based Prognostic Analysis of Cell-in-Cell Structures in Early Breast Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 895.	1.3	35
1692	Generation of in situ sequencing based OncoMaps to spatially resolve gene expression profiles of diagnostic and prognostic markers in breast cancer. <i>EBioMedicine</i> , 2019, 48, 212-223.	2.7	29
1693	Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database. <i>PLoS ONE</i> , 2019, 14, e0222358.	1.1	35
1694	Association of <i>ESR1</i> Mutations and Visceral Metastasis in Patients with Estrogen Receptor-Positive Advanced Breast Cancer from Brazil. <i>Journal of Oncology</i> , 2019, 2019, 1-5.	0.6	9
1695	Robust and interpretable PAM50 reclassification exhibits survival advantage for myoepithelial and immune phenotypes. <i>Npj Breast Cancer</i> , 2019, 5, 30.	2.3	25
1697	The intracellular redox environment modulates the cytotoxic efficacy of single and combination chemotherapy in breast cancer cells using photochemical internalisation. <i>RSC Advances</i> , 2019, 9, 25861-25874.	1.7	3
1698	Tumor homing peptide modified liposomes of capecitabine for improved apoptotic activity and HER2 targeted therapy in breast cancer: <i>in vitro</i> studies. <i>RSC Advances</i> , 2019, 9, 24987-24994.	1.7	13
1699	Hybrid 18F-FDG-PET/MRI Measurement of Standardized Uptake Value Coupled with Yin Yang 1 Signature in Metastatic Breast Cancer. A Preliminary Study. <i>Cancers</i> , 2019, 11, 1444.	1.7	25
1700	Stem Cells and Cellular Origins of Breast Cancer: Updates in the Rationale, Controversies, and Therapeutic Implications. <i>Frontiers in Oncology</i> , 2019, 9, 820.	1.3	54
1701	Histone deacetylase inhibitors reinforce the phenotypical markers of breast epithelial or mesenchymal cancer cells but inhibit their migratory properties. <i>Cancer Management and Research</i> , 2019, Volume 11, 8345-8358.	0.9	14
1702	Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells. <i>Cancers</i> , 2019, 11, 1430.	1.7	15
1703	Epidermal growth factor receptor (EGFR) gene alteration and protein overexpression in Malaysian triple-negative breast cancer (TNBC) cohort. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7749-7756.	1.0	24

#	ARTICLE	IF	CITATIONS
1704	A Novel Panel of 80 RNA Biomarkers with Differential Expression in Multiple Human Solid Tumors against Healthy Blood Samples. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4894.	1.8	2
1705	SP1 and STAT3 Functionally Synergize to Induce the RhoU Small GTPase and a Subclass of Non-canonical WNT Responsive Genes Correlating with Poor Prognosis in Breast Cancer. <i>Cancers</i> , 2019, 11, 101.	1.7	21
1706	Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 795-805.	1.1	37
1707	Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier. <i>Breast Cancer Research</i> , 2019, 21, 14.	2.2	5
1708	Hope4Genes: a Hopfield-like class prediction algorithm for transcriptomic data. <i>Scientific Reports</i> , 2019, 9, 337.	1.6	24
1709	Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study. <i>PLoS ONE</i> , 2019, 14, e0211488.	1.1	10
1710	Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 53-69.	1.0	63
1711	Predicting Breast Cancer Molecular Subtype with MRI Dataset Utilizing Convolutional Neural Network Algorithm. <i>Journal of Digital Imaging</i> , 2019, 32, 276-282.	1.6	73
1712	Profiling of Invasive Breast Carcinoma Circulating Tumour Cells—Are We Ready for the “Liquid” Revolution?. <i>Cancers</i> , 2019, 11, 143.	1.7	8
1713	Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 129-139.	1.1	14
1714	Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. <i>Cancer Discovery</i> , 2019, 9, 176-198.	7.7	778
1715	HER2 overexpression and correlation with other significant clinicopathologic parameters in Ivorian breast cancer women. <i>BMC Clinical Pathology</i> , 2019, 19, 1.	1.8	19
1716	Precision medicine for locally advanced breast cancer: frontiers and challenges in Latin America. <i>Ecancermedicalscience</i> , 2019, 13, 896.	0.6	8
1717	MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors. <i>Breast Cancer Research</i> , 2019, 21, 20.	2.2	52
1718	<p>Metastasis inhibition in breast cancer by targeting cancer cell extravasation</p>. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 165-178.	1.0	19
1719	Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node. , 2019, 7, 133.		32
1720	<p>Personalized medicine in breast cancer: pharmacogenomics approaches</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2019, Volume 12, 59-73.	0.4	39
1721	Cardiotoxicities of Modern Treatments in Breast Cancer. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 34.	0.4	2

#	ARTICLE	IF	CITATIONS
1722	A systematic analysis of genomics-based modeling approaches for prediction of drug response to cytotoxic chemotherapies. <i>BMC Medical Genomics</i> , 2019, 12, 87.	0.7	10
1723	The MMTV-Wnt1 murine model produces two phenotypically distinct subtypes of mammary tumors with unique therapeutic responses to an EGFR inhibitor. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	1.2	8
1724	Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 569-587.	1.1	21
1725	How to Choose a Mouse Model of Breast Cancer, a Genomic Perspective. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2019, 24, 231-243.	1.0	7
1726	Patient-Derived Xenograft Models of Breast Cancer and Their Application. <i>Cells</i> , 2019, 8, 621.	1.8	93
1727	Tumor-infiltrating M2-like macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer. <i>Oncology Reports</i> , 2019, 42, 581-594.	1.2	86
1728	GECKO is a genetic algorithm to classify and explore high throughput sequencing data. <i>Communications Biology</i> , 2019, 2, 222.	2.0	16
1729	Refinement of breast cancer molecular classification by miRNA expression profiles. <i>BMC Genomics</i> , 2019, 20, 503.	1.2	75
1730	GATA3 Truncating Mutations Promote Cistromic Re-Programming In Vitro, but Not Mammary Tumor Formation in Mice. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2019, 24, 271-284.	1.0	3
1731	Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases. <i>BMC Cancer</i> , 2019, 19, 549.	1.1	7
1732	Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample. <i>Annals of Surgical Oncology</i> , 2019, 26, 2779-2786.	0.7	13
1733	ROR1 Potentiates FGFR Signaling in Basal-Like Breast Cancer. <i>Cancers</i> , 2019, 11, 718.	1.7	9
1734	Expression Concordance of 325 Novel RNA Biomarkers between Data Generated by NanoString nCounter and Affymetrix GeneChip. <i>Disease Markers</i> , 2019, 2019, 1-12.	0.6	5
1735	Array comparative genomic hybridization analysis discloses chromosome copy number alterations as indicators of patient outcome in lymph node-negative breast cancer. <i>BMC Cancer</i> , 2019, 19, 521.	1.1	10
1736	FGFs/FGFRs-dependent signalling in regulation of steroid hormone receptors – implications for therapy of luminal breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 230.	3.5	33
1737	Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series. <i>BMC Genomics</i> , 2019, 20, 452.	1.2	36
1738	Transcriptome profiling revealed multiple genes and ECM-receptor interaction pathways that may be associated with breast cancer. <i>Cellular and Molecular Biology Letters</i> , 2019, 24, 38.	2.7	191
1739	FOXA1 is Prognostic of Triple Negative Breast Cancers by Transcriptionally Suppressing <i>SOD2</i> and <i>IL6</i> . <i>International Journal of Biological Sciences</i> , 2019, 15, 1030-1041.	2.6	18

#	ARTICLE	IF	CITATIONS
1740	Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 627-644.	2.1	29
1741	Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer. <i>BMC Cancer</i> , 2019, 19, 465.	1.1	13
1742	Reclassification of breast cancer: Towards improved diagnosis and outcome. <i>PLoS ONE</i> , 2019, 14, e0217036.	1.1	4
1743	The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 13-23.	1.4	27
1744	Quantitative assessment of breast cancer liver metastasis expansion with patient-derived xenografts. <i>Clinical and Experimental Metastasis</i> , 2019, 36, 257-269.	1.7	9
1745	Emerging Role of SOX Proteins in Breast Cancer Development and Maintenance. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2019, 24, 213-230.	1.0	24
1746	Proteins with Evolutionarily Hypervariable Domains are Associated with Immune Response and Better Survival of Basal-like Breast Cancer Patients. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 430-440.	1.9	27
1747	Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer. <i>Cancers</i> , 2019, 11, 646.	1.7	37
1748	Oncotype DX for Comprehensive Treatment in Male Breast Cancer: A Case Report and Literature Review. <i>American Journal of Men's Health</i> , 2019, 13, 155798831984785.	0.7	2
1749	Decoding the link between WWOX and p53 in aggressive breast cancer. <i>Cell Cycle</i> , 2019, 18, 1177-1186.	1.3	18
1750	Molecular Mechanisms of Breast Cancer Metastasis to the Lung: Clinical and Experimental Perspectives. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2272.	1.8	143
1751	In-Cell Determination of Lactate Dehydrogenase Activity in a Luminal Breast Cancer Model " ex vivo Investigation of Excised Xenograft Tumor Slices Using dDNP Hyperpolarized [1-13C]pyruvate. <i>Sensors</i> , 2019, 19, 2089.	2.1	11
1752	Imaging Biomarkers as Predictors for Breast Cancer Death. <i>Journal of Oncology</i> , 2019, 2019, 1-12.	0.6	8
1753	New Insights into the Implication of Epigenetic Alterations in the EMT of Triple Negative Breast Cancer. <i>Cancers</i> , 2019, 11, 559.	1.7	67
1754	Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells. <i>PLoS ONE</i> , 2019, 14, e0215894.	1.1	21
1755	Multi-Omic Data Interpretation to Repurpose Subtype Specific Drug Candidates for Breast Cancer. <i>Frontiers in Genetics</i> , 2019, 10, 420.	1.1	36
1756	A four-gene signature for prognosis in breast cancer patients with hypermethylated IL15RA. <i>Oncology Letters</i> , 2019, 17, 4245-4254.	0.8	11
1757	ARPC2 promotes breast cancer proliferation and metastasis. <i>Oncology Reports</i> , 2019, 41, 3189-3200.	1.2	21

#	ARTICLE	IF	CITATIONS
1758	Flavonoids: New Frontier for Immuno-Regulation and Breast Cancer Control. <i>Antioxidants</i> , 2019, 8, 103.	2.2	64
1759	Phosphoâ€RNAâ€seq: a modified small RNAâ€seq method that reveals circulating mRNA and lncRNA fragments as potential biomarkers in human plasma. <i>EMBO Journal</i> , 2019, 38, .	3.5	72
1760	Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers. <i>Npj Breast Cancer</i> , 2019, 5, 15.	2.3	16
1761	Overexpression of ASPM, CDC20, and TTK Confer a Poorer Prognosis in Breast Cancer Identified by Gene Co-expression Network Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 310.	1.3	56
1762	Development and characterisation of acquired radioresistant breast cancer cell lines. <i>Radiation Oncology</i> , 2019, 14, 64.	1.2	72
1763	Cell Reprogramming in Tumorigenesis and Its Therapeutic Implications for Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1827.	1.8	14
1764	Functional Variant rs4442975 Modulating FOXA1 Binding Affinity Can Influence Bone Marrow Suppression during Neoadjuvant Chemotherapy for Luminal A Type Breast Cancer. <i>BioMed Research International</i> , 2019, 2019, 1-6.	0.9	3
1765	MGSEA â€ a multivariate Gene set enrichment analysis. <i>BMC Bioinformatics</i> , 2019, 20, 145.	1.2	11
1766	Î²2-microglobulin has a different regulatory molecular mechanism between ER+ and ERâ” breast cancer with HER2â”. <i>BMC Cancer</i> , 2019, 19, 223.	1.1	8
1767	MicroRNA-Mediated Suppression of the TGF-Î² Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance. <i>Cell Reports</i> , 2019, 26, 2667-2680.e7.	2.9	101
1768	The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation. <i>Science Advances</i> , 2019, 5, eaat9820.	4.7	95
1769	Molecular mechanism of tripleâ€negative breast cancerâ€associated BRCA1 and the identification of signaling pathways. <i>Oncology Letters</i> , 2019, 17, 2905-2914.	0.8	22
1770	MicroRNAs and Androgen Receptor: Emerging Players in Breast Cancer. <i>Frontiers in Genetics</i> , 2019, 10, 203.	1.1	19
1771	Luteolin inhibits cell cycle progression and induces apoptosis of breast cancer cells through downregulation of human telomerase reverse transcriptase. <i>Oncology Letters</i> , 2019, 17, 3842-3850.	0.8	51
1772	The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines. <i>Journal of Clinical Medicine</i> , 2019, 8, 397.	1.0	8
1773	PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1468-1477.	3.3	107
1774	Differences in intra-tumoral macrophage infiltration and radiotherapy response among intrinsic subtypes in pT1-T2 breast cancers treated with breast-conserving surgery. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 151-162.	1.4	15
1775	Predictability of human differential gene expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 6491-6500.	3.3	103

#	ARTICLE	IF	CITATIONS
1776	Separation of breast cancer and organ microenvironment transcriptomes in metastases. <i>Breast Cancer Research</i> , 2019, 21, 36.	2.2	36
1777	Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive study. <i>EBioMedicine</i> , 2019, 42, 352-362.	2.7	35
1778	FOXM1 Deubiquitination by USP21 Regulates Cell Cycle Progression and Paclitaxel Sensitivity in Basal-like Breast Cancer. <i>Cell Reports</i> , 2019, 26, 3076-3086.e6.	2.9	60
1779	FLOT2 overexpression is associated with the progression and prognosis of human colorectal cancer. <i>Oncology Letters</i> , 2019, 17, 2802-2808.	0.8	7
1780	Drug Combinations in Breast Cancer Therapy. <i>Pharmaceutical Nanotechnology</i> , 2019, 7, 3-23.	0.6	213
1781	Association between digital breast tomosynthesis and molecular subtypes of breast cancer. <i>Oncology Letters</i> , 2019, 17, 2669-2676.	0.8	6
1782	Association of FOSL1 copy number alteration and triple negative breast tumors. <i>Genetics and Molecular Biology</i> , 2019, 42, 26-31.	0.6	7
1783	Classifying Breast Cancer Subtypes Using Multiple Kernel Learning Based on Omics Data. <i>Genes</i> , 2019, 10, 200.	1.0	34
1784	Reduction in milk fat globule-EGF factor 8 inhibits triple-negative breast cancer cell viability and migration. <i>Oncology Letters</i> , 2019, 17, 3457-3465.	0.8	5
1785	Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab. <i>Translational Oncology</i> , 2019, 12, 739-748.	1.7	5
1786	Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity. <i>Cancers</i> , 2019, 11, 363.	1.7	35
1787	Identification of lncRNAs associated with early-stage breast cancer and their prognostic implications. <i>Molecular Oncology</i> , 2019, 13, 1342-1355.	2.1	43
1788	New analogs of SYA013 as sigma-2 ligands with anticancer activity. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 2629-2636.	1.4	12
1789	Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists. <i>Journal of Drug Assessment</i> , 2019, 8, 62-69.	1.1	0
1790	The Role of ZNF143 in Breast Cancer Cell Survival Through the NAD(P)H Quinone Dehydrogenase 1-p53-Beclin1 Axis Under Metabolic Stress. <i>Cells</i> , 2019, 8, 296.	1.8	15
1791	Integrative Analysis Reveals Subtype-Specific Regulatory Determinants in Triple Negative Breast Cancer. <i>Cancers</i> , 2019, 11, 507.	1.7	10
1792	Intratumoral Heterogeneity: More Than Just Mutations. <i>Trends in Cell Biology</i> , 2019, 29, 569-579.	3.6	157
1793	Biochemical pathways mediated by KLK6 protease in breast cancer. <i>Molecular Oncology</i> , 2019, 13, 2329-2343.	2.1	12

#	ARTICLE	IF	CITATIONS
1794	Combinatorial Detection of Conserved Alteration Patterns for Identifying Cancer Subnetworks. <i>GigaScience</i> , 2019, 8, .	3.3	9
1795	A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. <i>Cell</i> , 2019, 177, 1330-1345.e18.	13.5	547
1796	Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. , 2019, 7, 90.		80
1797	A Machine Learning Classifier for Assigning Individual Patients With Systemic Sclerosis to Intrinsic Molecular Subsets. <i>Arthritis and Rheumatology</i> , 2019, 71, 1701-1710.	2.9	56
1798	Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer. <i>Cancer Biology and Therapy</i> , 2019, 20, 1105-1112.	1.5	22
1799	Recent advances in understanding tumor stroma-mediated chemoresistance in breast cancer. <i>Molecular Cancer</i> , 2019, 18, 67.	7.9	120
1800	Pokemon Inhibits Transforming Growth Factor β 2-Smad4-Related Cell Proliferation Arrest in Breast Cancer through Specificity Protein 1. <i>Journal of Breast Cancer</i> , 2019, 22, 15.	0.8	10
1801	The Endocannabinoid System as a Target in Cancer Diseases: Are We There Yet?. <i>Frontiers in Pharmacology</i> , 2019, 10, 339.	1.6	91
1802	circTADA2As suppress breast cancer progression and metastasis via targeting miR-203a-3p/SOCS3 axis. <i>Cell Death and Disease</i> , 2019, 10, 175.	2.7	187
1803	Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 100.	3.5	18
1804	<p>Attenuated ZHX3 expression serves as a potential biomarker that predicts poor clinical outcomes in breast cancer patients</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 1199-1210.	0.9	13
1805	Triple-negative breast cancer: the reality in Chile and in Latin America. <i>Ecancermedalscience</i> , 2019, 13, 893.	0.6	8
1806	A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses. <i>Scientific Reports</i> , 2019, 9, 1538.	1.6	46
1807	The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 667.	1.8	19
1808	<p>Identification of key pathways and hub genes in basal-like breast cancer using bioinformatics analysis</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1319-1331.	1.0	50
1809	Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 487-497.	1.1	15
1810	A high-risk luminal A dominant breast cancer subtype with increased mobility. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 459-472.	1.1	26
1811	Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 287-295.	1.1	18

#	ARTICLE	IF	CITATIONS
1812	HR-MAS NMR Based Quantitative Metabolomics in Breast Cancer. <i>Metabolites</i> , 2019, 9, 19.	1.3	31
1813	Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer. <i>Nature Communications</i> , 2019, 10, 766.	5.8	99
1814	Radiomics analysis of MRI for predicting molecular subtypes of breast cancer in young women. , 2019, 10950, .		1
1815	Genomics applied to the treatment of breast cancer. <i>Oncotarget</i> , 2019, 10, 4786-4801.	0.8	20
1816	ILC2s: New Actors in Tumor Immunity. <i>Frontiers in Immunology</i> , 2019, 10, 2801.	2.2	30
1817	Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications. <i>Frontiers in Oncology</i> , 2019, 9, 1124.	1.3	52
1818	Immune gene expression profiling reveals heterogeneity in luminal breast tumors. <i>Breast Cancer Research</i> , 2019, 21, 147.	2.2	43
1819	<p>Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10353-10373.	0.9	8
1820	Identifying Biomarkers to Pair with Targeting Treatments within Triple Negative Breast Cancer for Improved Patient Stratification. <i>Cancers</i> , 2019, 11, 1864.	1.7	5
1821	MicroRNAs Involved in Carcinogenesis, Prognosis, Therapeutic Resistance, and Applications in Human Triple-Negative Breast Cancer. <i>Cells</i> , 2019, 8, 1492.	1.8	102
1822	Historical Biobanks in Breast Cancer Metabolomicsâ€™ Challenges and Opportunities. <i>Metabolites</i> , 2019, 9, 278.	1.3	5
1823	RAS as Supporting Actor in Breast Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1199.	1.3	46
1824	Targeted Therapies for Triple-Negative Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2019, 20, 82.	1.3	237
1825	Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study. <i>BMC Cancer</i> , 2019, 19, 1158.	1.1	31
1826	Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer. <i>International Journal of Medical Sciences</i> , 2019, 16, 1188-1198.	1.1	19
1827	<p>The Exosome And Breast Cancer Cell Plasticity</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 9817-9825.	1.0	10
1828	TZAP Mutation Leads to Poor Prognosis of Patients with Breast Cancer â€™. <i>Medicina (Lithuania)</i> , 2019, 55, 748.	0.8	7
1829	MiR-205 Dysregulations in Breast Cancer: The Complexity and Opportunities. <i>Non-coding RNA</i> , 2019, 5, 53.	1.3	44

#	ARTICLE	IF	CITATIONS
1830	Differential impact of classical and non-canonical NF- κ B pathway-related gene expression on the survival of breast cancer patients. <i>Journal of Cancer</i> , 2019, 10, 5191-5211.	1.2	11
1831	Intra-tumor heterogeneity for endometrial cancer and its clinical significance. <i>Chinese Medical Journal</i> , 2019, 132, 1550-1562.	0.9	8
1832	Molecular subtyping of bladder cancer. <i>Current Opinion in Urology</i> , 2019, 29, 198-202.	0.9	4
1833	Clinical implications of molecular subtyping in bladder cancer. <i>Current Opinion in Urology</i> , 2019, 29, 350-356.	0.9	20
1834	Genetic determinants of the molecular portraits of epithelial cancers. <i>Nature Communications</i> , 2019, 10, 5666.	5.8	21
1835	A transcriptome-based signature of pathological angiogenesis predicts breast cancer patient survival. <i>PLoS Genetics</i> , 2019, 15, e1008482.	1.5	12
1836	Tumor suppressor HIC1 is synergistically compromised by cancer-associated fibroblasts and tumor cells through the IL-6/pSTAT3 axis in breast cancer. <i>BMC Cancer</i> , 2019, 19, 1180.	1.1	20
1837	Upregulation Of miR-153 Inhibits Triple-Negative Breast Cancer Progression By Targeting ZEB2-Mediated EMT And Contributes To Better Prognosis. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 9611-9625.	1.0	25
1838	Pannexin1 Is Associated with Enhanced Epithelial-To-Mesenchymal Transition in Human Patient Breast Cancer Tissues and in Breast Cancer Cell Lines. <i>Cancers</i> , 2019, 11, 1967.	1.7	27
1839	Functionalized Upconversion Nanoparticles for Targeted Labelling of Bladder Cancer Cells. <i>Biomolecules</i> , 2019, 9, 820.	1.8	13
1840	SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 64-74.	1.2	16
1841	KLP-PI: a new prognostic index for luminal B HER-2-negative breast cancer. <i>Human Cell</i> , 2019, 32, 172-184.	1.2	2
1842	Increases in Tumor N-glycan Polylactosamines Associated with Advanced HER2-Positive and Triple-Negative Breast Cancer Tissues. <i>Proteomics - Clinical Applications</i> , 2019, 13, e1800014.	0.8	50
1843	Quantitative in vivo proton MR spectroscopic assessment of lipid metabolism: Value for breast cancer diagnosis and prognosis. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 239-249.	1.9	34
1844	Oncogenic activity of poly (ADP-ribose) glycohydrolase. <i>Oncogene</i> , 2019, 38, 2177-2191.	2.6	21
1845	The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers. <i>Oncogene</i> , 2019, 38, 2020-2041.	2.6	70
1846	Clinical target sequencing for precision medicine of breast cancer. <i>International Journal of Clinical Oncology</i> , 2019, 24, 131-140.	1.0	14
1847	PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 9.	1.8	43

#	ARTICLE	IF	CITATIONS
1848	Single Cell Omics of Breast Cancer: An Update on Characterization and Diagnosis. Indian Journal of Clinical Biochemistry, 2019, 34, 3-18.	0.9	14
1849	Molecular features of premenopausal breast cancers in Latin American women: Pilot results from the PRECAMA study. PLoS ONE, 2019, 14, e0210372.	1.1	12
1850	Tumor grade and molecular subtypes on local control in breast cancer radiotherapy: Does fractionation really matter? A retrospective control study group. Clinical and Translational Radiation Oncology, 2019, 15, 7-12.	0.9	3
1851	PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA. Molecular Cancer, 2019, 18, 9.	7.9	139
1852	Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours. Breast Cancer Research, 2019, 21, 2.	2.2	29
1853	Transcriptional regulation of normal human mammary cell heterogeneity and its perturbation in breast cancer. EMBO Journal, 2019, 38, e100330.	3.5	35
1854	Breast Cancer Mortality in Older and Younger Patients in California. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 303-310.	1.1	16
1855	Long non-coding RNAs as monitoring tools and therapeutic targets in breast cancer. Cellular Oncology (Dordrecht), 2019, 42, 1-12.	2.1	50
1856	Radiomic Phenotypes of Mammographic Parenchymal Complexity: Toward Augmenting Breast Density in Breast Cancer Risk Assessment. Radiology, 2019, 290, 41-49.	3.6	63
1857	A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics. Molecular Cancer Therapeutics, 2019, 18, 204-212.	1.9	17
1858	Integrative cancer patient stratification via subspace merging. Bioinformatics, 2019, 35, 1653-1659.	1.8	20
1859	ITCH nuclear translocation and H1.2 polyubiquitination negatively regulate the DNA damage response. Nucleic Acids Research, 2019, 47, 824-842.	6.5	19
1860	A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer. Breast Cancer Research and Treatment, 2019, 174, 143-155.	1.1	18
1861	Functional Role of miRNAs in the Progression of Breast Ductal Carcinoma in Situ. American Journal of Pathology, 2019, 189, 966-974.	1.9	11
1862	Proteomics and phosphoproteomics in precision medicine: applications and challenges. Briefings in Bioinformatics, 2019, 20, 767-777.	3.2	34
1863	Chemical genomics reveals inhibition of breast cancer lung metastasis by Ponatinib via c-Jun. Protein and Cell, 2019, 10, 161-177.	4.8	24
1864	Identification of aberrant gene expression during breast ductal carcinoma <i>in situ</i> progression to invasive ductal carcinoma. Journal of International Medical Research, 2020, 48, 030006051881536.	0.4	7
1865	Double-positive in triple-negative? How significant is basal cytokeratin expression in breast cancer?. Medical Journal Armed Forces India, 2020, 76, 63-70.	0.3	3

#	ARTICLE	IF	CITATIONS
1866	Subtype-specific transcriptional regulators in breast tumors subjected to genetic and epigenetic alterations. <i>Bioinformatics</i> , 2020, 36, 994-999.	1.8	6
1867	Adenoid Cystic Carcinoma of the Breast: A Case Report. <i>Case Reports in Oncology</i> , 2020, 12, 698-703.	0.3	9
1868	What Can We Learn About Drug Safety and Other Effects in the Era of Electronic Health Records and Big Data That We Would Not Be Able to Learn From Classic Epidemiology?. <i>Journal of Surgical Research</i> , 2020, 246, 599-604.	0.8	4
1869	Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy. <i>Oncology and Therapy</i> , 2020, 8, 1-11.	1.0	37
1870	Imaging Phenotypes of Breast Cancer Heterogeneity in Preoperative Breast Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) Scans Predict 10-Year Recurrence. <i>Clinical Cancer Research</i> , 2020, 26, 862-869.	3.2	50
1871	CNTs mediated CD44 targeting; a paradigm shift in drug delivery for breast cancer. <i>Genes and Diseases</i> , 2020, 7, 205-216.	1.5	7
1872	Identification of potential key genes for HER-2 positive breast cancer based on bioinformatics analysis. <i>Medicine (United States)</i> , 2020, 99, e18445.	0.4	19
1873	Glutathione peroxidase-1 regulates adhesion and metastasis of triple-negative breast cancer cells via FAK signaling. <i>Redox Biology</i> , 2020, 29, 101391.	3.9	28
1874	Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer. <i>British Journal of Cancer</i> , 2020, 122, 94-101.	2.9	35
1875	Molecular classification of breast cancer: A retrospective cohort study. <i>Annals of Medicine and Surgery</i> , 2020, 49, 44-48.	0.5	94
1876	The GEFâ€”1/PKD3 signaling pathway promotes the maintenance of tripleâ€”negative breast cancer stem cells. <i>International Journal of Cancer</i> , 2020, 146, 3423-3434.	2.3	13
1877	Serine-Arginine Protein Kinase 1 (SRPK1) as a Prognostic Factor and Potential Therapeutic Target in Cancer: Current Evidence and Future Perspectives. <i>Cells</i> , 2020, 9, 19.	1.8	23
1878	A Machine-Learning Tool Concurrently Models Single Omics and Phenome Data for Functional Subtyping and Personalized Cancer Medicine. <i>Cancers</i> , 2020, 12, 2811.	1.7	0
1879	Transcriptional regulators and alterations that drive melanoma initiation and progression. <i>Oncogene</i> , 2020, 39, 7093-7105.	2.6	20
1880	Time-Resolved Profiling Reveals ATF3 as a Novel Mediator of Endocrine Resistance in Breast Cancer. <i>Cancers</i> , 2020, 12, 2918.	1.7	10
1881	TRIM27 Functions as a Novel Oncogene in Non-Triple-Negative Breast Cancer by Blocking Cellular Senescence through p21â€”Ubiquitination. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 22, 910-923.	2.3	27
1882	Identification of key genes unique to the luminal a and basal-like breast cancer subtypes via bioinformatic analysis. <i>World Journal of Surgical Oncology</i> , 2020, 18, 268.	0.8	15
1883	The Prognostic Impact of Age at Diagnosis Upon Breast Cancer of Different Immunohistochemical Subtypes: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1729.	1.3	12

#	ARTICLE	IF	CITATIONS
1884	Cancer-Associated Fibroblasts: Epigenetic Regulation and Therapeutic Intervention in Breast Cancer. <i>Cancers</i> , 2020, 12, 2949.	1.7	32
1885	Transcriptional Expressions of CXCL9/10/12/13 as Prognosis Factors in Breast Cancer. <i>Journal of Oncology</i> , 2020, 2020, 1-15.	0.6	11
1886	PIWI-Like 1 and PIWI-Like 2 Expression in Breast Cancer. <i>Cancers</i> , 2020, 12, 2742.	1.7	4
1887	Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. <i>Npj Breast Cancer</i> , 2020, 6, 54.	2.3	181
1888	Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer. <i>Cancer Cell International</i> , 2020, 20, 501.	1.8	11
1889	Understanding PD-L1 Testing in Breast Cancer: A Practical Approach. <i>Breast Care</i> , 2020, 15, 481-490.	0.8	34
1890	A deep learning and similarity-based hierarchical clustering approach for pathological stage prediction of papillary renal cell carcinoma. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 2639-2646.	1.9	11
1891	Dissociated Response in Metastatic Cancer: An Atypical Pattern Brought Into the Spotlight With Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 566297.	1.3	39
1892	Future perspectives of surgical treatment of breast cancer. <i>Annals of Medicine and Surgery</i> , 2020, 59, 93-95.	0.5	2
1893	ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 2758.	1.7	33
1894	Identification of a Profile of Neutrophil-Derived Granule Proteins in the Surface of Gold Nanoparticles after Their Interaction with Human Breast Cancer Sera. <i>Nanomaterials</i> , 2020, 10, 1223.	1.9	12
1895	Metabolomic profiling of mouse mammary tumor-derived cell lines reveals targeted therapy options for cancer subtypes. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 1117-1127.	2.1	3
1896	High PKC δ expression is required for ALDH1-positive cancer stem cell function and indicates a poor clinical outcome in late-stage breast cancer patients. <i>PLoS ONE</i> , 2020, 15, e0235747.	1.1	8
1897	The Premature Senescence in Breast Cancer Treatment Strategy. <i>Cancers</i> , 2020, 12, 1815.	1.7	23
1898	Histology of Luminal Breast Cancer. <i>Breast Care</i> , 2020, 15, 327-336.	0.8	15
1899	A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 76.	2.2	41
1900	Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Cancers</i> , 2020, 12, 1820.	1.7	31
1901	Mitochondrial DNA Mutation Analysis in Breast Cancer: Shifting From Germline Heteroplasmy Toward Homoplasmy in Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 572954.	1.3	19

#	ARTICLE	IF	CITATIONS
1902	Quadruple-negative breast cancer: novel implications for a new disease. <i>Breast Cancer Research</i> , 2020, 22, 127.	2.2	17
1903	ZFH3 Promotes the Proliferation and Tumor Growth of ER-Positive Breast Cancer Cells Likely by Enhancing Stem-Like Features and MYC and TBX3 Transcription. <i>Cancers</i> , 2020, 12, 3415.	1.7	13
1904	Immune-related lncRNAs as predictors of survival in breast cancer: a prognostic signature. <i>Journal of Translational Medicine</i> , 2020, 18, 442.	1.8	72
1905	<p>Prognostic Significance of a Novel Score Model Based on Preoperative Indicators in Patients with Breast Cancer Spine Metastases (BCSM)</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 11501-11513.	0.9	4
1906	Hypofractionated radiation therapy for early breast cancer: Follow up of a new treatment standard. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 886-889.	0.3	2
1907	Modulatory Role of microRNAs in Triple Negative Breast Cancer with Basal-Like Phenotype. <i>Cancers</i> , 2020, 12, 3298.	1.7	15
1908	Curcumin Treatment Identifies Therapeutic Targets within Biomarkers of Liver Colonization by Highly Invasive Mesothelioma Cellsâ€™Potential Links with Sarcomas. <i>Cancers</i> , 2020, 12, 3384.	1.7	7
1909	Viroimmunotherapy for breast cancer: promises, problems and future directions. <i>Cancer Gene Therapy</i> , 2021, 28, 757-768.	2.2	13
1910	Breast Cancer Heterogeneity and Response to Novel Therapeutics. <i>Cancers</i> , 2020, 12, 3271.	1.7	40
1911	RNA-Seq-Based Breast Cancer Subtypes Classification Using Machine Learning Approaches. <i>Computational Intelligence and Neuroscience</i> , 2020, 2020, 1-13.	1.1	14
1912	Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Journal of Cancer</i> , 2020, 11, 7127-7136.	1.2	11
1913	Enhance PARPi Application beyond BRCA-Mutant Breast Cancer (BC): Facts Are Facts. <i>Journal of Clinical Medicine</i> , 2020, 9, 2377.	1.0	1
1914	Recent advances in siRNA delivery mediated by lipid-based nanoparticles. <i>Advanced Drug Delivery Reviews</i> , 2020, 154-155, 64-78.	6.6	192
1915	<p>Long Non-Coding RNAs in Drug Resistance of Breast Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7075-7087.	1.0	20
1916	Androgen receptor expression is useful to predict the therapeutic effect in HER2-positive breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 277-285.	1.1	11
1917	Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer. <i>Cancers</i> , 2020, 12, 1959.	1.7	244
1918	Gene Co-expression Is Distance-Dependent in Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1232.	1.3	25
1919	Impact of Eukaryotic Translation Initiation Factors on Breast Cancer: Still Much to Investigate. <i>Cancers</i> , 2020, 12, 1984.	1.7	6

#	ARTICLE	IF	CITATIONS
1920	Exploring the Metabolic Vulnerabilities of Epithelialâ€“Mesenchymal Transition in Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 655.	1.8	15
1921	Comprehensive Cohort Analysis of Mutational Spectrum in Early Onset Breast Cancer Patients. <i>Cancers</i> , 2020, 12, 2089.	1.7	9
1922	The Emerging Role of MicroRNAs in Breast Cancer. <i>Journal of Oncology</i> , 2020, 2020, 1-7.	0.6	31
1923	Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1390.	3.4	115
1924	Understanding the Role of Innate Immune Cells and Identifying Genes in Breast Cancer Microenvironment. <i>Cancers</i> , 2020, 12, 2226.	1.7	21
1925	An integrative deep learning framework for classifying molecular subtypes of breast cancer. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 2185-2199.	1.9	40
1926	Metastatic Breast Cancer and Pre-Diagnostic Blood Gene Expression Profilesâ€“The Norwegian Women and Cancer (NOWAC) Post-Genome Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 575461.	1.3	9
1927	The UPR Transducer IRE1 Promotes Breast Cancer Malignancy by Degrading Tumor Suppressor microRNAs. <i>IScience</i> , 2020, 23, 101503.	1.9	25
1928	Pathology of Hereditary Breast and Ovarian Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 531790.	1.3	30
1929	MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer. <i>ESMO Open</i> , 2020, 5, e000937.	2.0	10
1930	Three-Dimensional Models as a New Frontier for Studying the Role of Proteoglycans in the Normal and Malignant Breast Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 569454.	1.8	10
1931	Screening and Identification of Key Biomarkers in Acquired Lapatinib-Resistant Breast Cancer. <i>Frontiers in Pharmacology</i> , 2020, 11, 577150.	1.6	4
1932	Comprehensive analysis of structural variants in breast cancer genomes using single-molecule sequencing. <i>Genome Research</i> , 2020, 30, 1258-1273.	2.4	72
1933	Genomic Signatures in Luminal Breast Cancer. <i>Breast Care</i> , 2020, 15, 355-365.	0.8	20
1934	Circulating MicroRNAs as Prognostic and Therapeutic Biomarkers in Breast Cancer Molecular Subtypes. <i>Journal of Personalized Medicine</i> , 2020, 10, 98.	1.1	16
1935	Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. <i>Cancers</i> , 2020, 12, 2392.	1.7	171
1936	Vitamin D Effects on Cell Differentiation and Stemness in Cancer. <i>Cancers</i> , 2020, 12, 2413.	1.7	41
1937	LIMK2 promotes the metastatic progression of triple-negative breast cancer by activating SRPK1. <i>Oncogenesis</i> , 2020, 9, 77.	2.1	24

#	ARTICLE	IF	CITATIONS
1938	Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis. <i>Oncogene</i> , 2020, 39, 6589-6605.	2.6	50
1939	Dietary effects on breast cancer molecular subtypes, a 1:2 paired case-control study. <i>Food Science and Nutrition</i> , 2020, 8, 5545-5549.	1.5	0
1940	Cyclin E expression is associated with high levels of replication stress in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 40.	2.3	27
1941	Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials. <i>Cancers</i> , 2020, 12, 2497.	1.7	17
1942	High accuracy gene expression profiling of sorted cell subpopulations from breast cancer PDX model tissue. <i>PLoS ONE</i> , 2020, 15, e0238594.	1.1	1
1943	Management of early breast cancer during the COVID-19 pandemic in Brazil. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 637-647.	1.1	20
1944	STAT3 and GR Cooperate to Drive Gene Expression and Growth of Basal-Like Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2020, 80, 4355-4370.	0.4	17
1945	Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 1415.	1.3	31
1946	Multi-Omics Analysis Detects Novel Prognostic Subgroups of Breast Cancer. <i>Frontiers in Genetics</i> , 2020, 11, 574661.	1.1	18
1947	<p>LncRNA ADAMTS9-AS1 Restrains the Aggressive Traits of Breast Carcinoma Cells via Sponging miR-513a-5p</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 10693-10703.	0.9	15
1948	Analysis of the Gene Expression Profile of Stromal Pro-Tumor Factors in Cancer-Associated Fibroblasts from Luminal Breast Carcinomas. <i>Diagnostics</i> , 2020, 10, 865.	1.3	7
1949	Metagenomic characterization of lysine acetyltransferases in human cancer and their association with clinicopathologic features. <i>Cancer Science</i> , 2020, 111, 1829-1839.	1.7	15
1950	Clinicopathological and prognostic significance of nestin expression in patients with breast cancer: a systematic review and meta-analysis. <i>Cancer Cell International</i> , 2020, 20, 169.	1.8	10
1951	Antiproliferative and Carbonic Anhydrase II Inhibitory Potential of Chemical Constituents from <i>Lycium shawii</i> and <i>Aloe vera</i> : Evidence from In Silico Target Fishing and In Vitro Testing. <i>Pharmaceuticals</i> , 2020, 13, 94.	1.7	20
1952	Tumor Necrosis Factor Î± Blockade: An Opportunity to Tackle Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 584.	1.3	96
1953	Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 628.	1.3	34
1954	Hormone Receptor-Status Prediction in Breast Cancer Using Gene Expression Profiles and Their Macroscopic Landscape. <i>Cancers</i> , 2020, 12, 1165.	1.7	4
1955	EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both <i>in vitro</i> and <i>in vivo</i>. <i>Clinical and Translational Immunology</i> , 2020, 9, e01135.	1.7	48

#	ARTICLE	IF	CITATIONS
1956	Breast Cancer Health Disparities in Hispanics/Latinas. <i>Current Breast Cancer Reports</i> , 2020, 12, 175-184.	0.5	10
1957	Association between Lymph Node Status and Expression Levels of Androgen Receptor, miR-185, miR-205, and miR-21 in Breast Cancer Subtypes. <i>International Journal of Breast Cancer</i> , 2020, 2020, 1-7.	0.6	14
1958	In silico analyses identify lncRNAs: WDFY3-AS2, BDNF-AS and AFAP1-AS1 as potential prognostic factors for patients with triple-negative breast tumors. <i>PLoS ONE</i> , 2020, 15, e0232284.	1.1	17
1959	Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance. <i>Oncologist</i> , 2020, 25, e1481-e1491.	1.9	92
1960	Naturally-Occurring Canine Mammary Tumors as a Translational Model for Human Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 617.	1.3	78
1961	Triple-negative breast cancer molecular subtyping and treatment progress. <i>Breast Cancer Research</i> , 2020, 22, 61.	2.2	1,022
1962	Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 63.	2.2	8
1963	Identification of Potential Key Genes Associated With the Pathogenesis, Metastasis, and Prognosis of Triple-Negative Breast Cancer on the Basis of Integrated Bioinformatics Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 856.	1.3	5
1964	Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy. <i>Cancers</i> , 2020, 12, 1511.	1.7	9
1965	Long Noncoding RNAs Involved in the Endocrine Therapy Resistance of Breast Cancer. <i>Cancers</i> , 2020, 12, 1424.	1.7	13
1966	Epithelial-Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance. <i>Molecular Cancer Research</i> , 2020, 18, 1257-1270.	1.5	86
1967	<p>Î²-Elemene Enhances the Chemotherapeutic Effect of 5-Fluorouracil in Triple-Negative Breast Cancer via PI3K/AKT, RAF-MEK-Erk, and NF-Î²B Signaling Pathways</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5207-5222.	1.0	23
1968	Biology of the Triple-Negative Breast Cancer: Immunohistochemical, RNA, and DNA Features. <i>Breast Care</i> , 2020, 15, 208-216.	0.8	6
1969	ALDH1+ stem cells demonstrate more stem cell-like characteristics than CD44+/CD24<sup>-</sup>/low stem cells in different molecular subtypes of breast cancer. <i>Translational Cancer Research</i> , 2020, 9, 1652-1659.	0.4	2
1970	The Burden and Trends of Breast Cancer From 1990 to 2017 at the Global, Regional, and National Levels: Results From the Global Burden of Disease Study 2017. <i>Frontiers in Oncology</i> , 2020, 10, 650.	1.3	56
1971	DGM-CM6: A New Model to Predict Distant Recurrence Risk in Operable Endocrine-Responsive Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 783.	1.3	4
1972	Multi-Omic Regulation of the PAM50 Gene Signature in Breast Cancer Molecular Subtypes. <i>Frontiers in Oncology</i> , 2020, 10, 845.	1.3	15
1973	Insights into the Role of Estrogen Receptor Î² in Triple-Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 1477.	1.7	33

#	ARTICLE	IF	CITATIONS
1974	A mixed-model approach for powerful testing of genetic associations with cancer risk incorporating tumor characteristics. <i>Biostatistics</i> , 2020, 22, 772-788.	0.9	11
1975	Calcium Homeostasis: A Potential Vicious Cycle of Bone Metastasis in Breast Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 293.	1.3	25
1976	Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 719.	1.7	15
1977	A bioinformatics approach to identify novel long, non-coding RNAs in breast cancer cell lines from an existing RNA-sequencing dataset. <i>Non-coding RNA Research</i> , 2020, 5, 48-59.	2.4	14
1978	PIWI-interacting RNAs: new biomarkers for diagnosis and treatment of breast cancer. <i>Cell and Bioscience</i> , 2020, 10, 44.	2.1	20
1979	Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. <i>Medical Sciences (Basel, Switzerland)</i> , 2020, 8, 18.	1.3	72
1980	Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes. <i>Cancers</i> , 2020, 12, 819.	1.7	61
1981	Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Oncology</i> , 2020, 2020, 1-13.	0.6	16
1982	Genomic Subtyping in Bladder Cancer. <i>Current Urology Reports</i> , 2020, 21, 9.	1.0	18
1983	Improved Outcome Prediction for Appendiceal Pseudomyxoma Peritonei by Integration of Cancer Cell and Stromal Transcriptional Profiles. <i>Cancers</i> , 2020, 12, 1495.	1.7	6
1984	Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 950.	1.3	15
1985	Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration. <i>Breast Cancer Research</i> , 2020, 22, 73.	2.2	29
1986	Comparison of unsupervised machine-learning methods to identify metabolomic signatures in patients with localized breast cancer. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 1509-1524.	1.9	21
1987	Impact of mRNA-Assessed Molecular Subtype Conversion, Intact and Apoptotic Circulating Tumor Cells on Survival of Metastatic Breast Cancer Patients: Proof of Principle. <i>Diagnostics</i> , 2020, 10, 369.	1.3	2
1988	Non-Coding RNAs as Regulators and Markers for Targeting of Breast Cancer and Cancer Stem Cells. <i>Cancers</i> , 2020, 12, 351.	1.7	30
1989	The Fluoro-Thiazolylhydrazone Compound TSC-3C Inhibits Triple Negative Breast Cancer (TNBC) Cell Line Activity by Promoting Apoptosis, Regulating the MAPK Pathway and Inducing Mitochondrial Dysfunction. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1038.	1.8	6
1990	Comprehensive Analysis of Competitive Endogenous RNAs Network, Being Associated With Esophageal Squamous Cell Carcinoma and Its Emerging Role in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 1474.	1.3	20
1991	Omission of postoperative radiation after breast conserving surgery: A progressive paradigm shift towards precision medicine. <i>Clinical and Translational Radiation Oncology</i> , 2020, 21, 112-119.	0.9	27

#	ARTICLE	IF	CITATIONS
1992	BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study. <i>Diagnostics</i> , 2020, 10, 119.	1.3	6
1993	Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer. <i>Nature Cancer</i> , 2020, 1, 163-175.	5.7	209
1994	Î±-Santalol functionalized chitosan nanoparticles as efficient inhibitors of polo-like kinase in triple negative breast cancer. <i>RSC Advances</i> , 2020, 10, 5487-5501.	1.7	17
1995	Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy. <i>Frontiers in Molecular Biosciences</i> , 2019, 6, 160.	1.6	596
1996	Commercially Available Gene Expression Assays as Predictive Tools for Adjuvant Radiotherapy? A Critical Review. <i>Breast Care</i> , 2020, 15, 118-127.	0.8	10
1997	Lipid Transfer Proteins and Membrane Contact Sites in Human Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 371.	1.8	33
1998	MAG11, a New Potential Tumor Suppressor Gene in Estrogen Receptor Positive Breast Cancer. <i>Cancers</i> , 2020, 12, 223.	1.7	15
1999	TTF-1/p63-Positive Poorly Differentiated NSCLC: A Histogenetic Hypothesis from the Basal Reserve Cell of the Terminal Respiratory Unit. <i>Diagnostics</i> , 2020, 10, 25.	1.3	15
2000	The need for rapid therapeutic efficacy testing for cancer therapy. <i>Experimental and Molecular Pathology</i> , 2020, 113, 104382.	0.9	0
2001	Nitric Oxide and S-Nitrosylation in Cancers: Emphasis on Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2020, 14, 117822341988268.	0.6	32
2002	The Association of IL-1 and HRAS Gene Polymorphisms with Breast Cancer Susceptibility in a Jordanian Population of Arab Descent: A Genotypeâ€“Phenotype Study. <i>Cancers</i> , 2020, 12, 283.	1.7	13
2003	Triple-Negative Primary Breast Tumors Induce Supportive Premetastatic Changes in the Extracellular Matrix and Soluble Components of the Lung Microenvironment. <i>Cancers</i> , 2020, 12, 172.	1.7	19
2004	ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 903.	1.8	26
2005	Cyclin-dependent kinase 4/6 inhibitor in combination with endocrine therapy versus endocrine therapy only for advanced breast cancer: a systematic review and meta-analysis. <i>Translational Cancer Research</i> , 2020, 9, 657-668.	0.4	3
2006	Targeting triple-negative breast cancers with the Smac-mimetic birinapant. <i>Cell Death and Differentiation</i> , 2020, 27, 2768-2780.	5.0	31
2007	3â€²-UTR Shortening Contributes to Subtype-Specific Cancer Growth by Breaking Stable ceRNA Crosstalk of Housekeeping Genes. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 334.	2.0	8
2008	Salicylate suppresses the oncogenic hyaluronan network in metastatic breast cancer cells. <i>Matrix Biology Plus</i> , 2020, 6-7, 100031.	1.9	15
2009	The Application of Radiomics in Breast MRI: A Review. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382091619.	0.8	46

#	ARTICLE	IF	CITATIONS
2010	Human Breast Cancer Cells Demonstrate Electrical Excitability. <i>Frontiers in Neuroscience</i> , 2020, 14, 404.	1.4	28
2011	Mechanistic Pathways of Malignancy in Breast Cancer Stem Cells. <i>Frontiers in Oncology</i> , 2020, 10, 452.	1.3	37
2012	Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer. <i>Frontiers in Genetics</i> , 2020, 11, 219.	1.1	21
2013	TIE2 Induces Breast Cancer Cell Dormancy and Inhibits the Development of Osteolytic Bone Metastases. <i>Cancers</i> , 2020, 12, 868.	1.7	9
2014	The Landscape of Targeted Therapies in TNBC. <i>Cancers</i> , 2020, 12, 916.	1.7	232
2015	Isoliquiritigenin Derivative Regulates miR-374a/BAX Axis to Suppress Triple-Negative Breast Cancer Tumorigenesis and Development. <i>Frontiers in Pharmacology</i> , 2020, 11, 378.	1.6	23
2016	High Galectin-7 and Low Galectin-8 Expression and the Combination of both are Negative Prognosticators for Breast Cancer Patients. <i>Cancers</i> , 2020, 12, 953.	1.7	17
2017	Reproductive Risk Factors Associated with Breast Cancer Molecular Subtypes among Young Women in Northern China. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	9
2018	PathME: pathway based multi-modal sparse autoencoders for clustering of patient-level multi-omics data. <i>BMC Bioinformatics</i> , 2020, 21, 146.	1.2	38
2019	Sphingosine Kinase 1 in Breast Cancer—A New Molecular Marker and a Therapy Target. <i>Frontiers in Oncology</i> , 2020, 10, 289.	1.3	18
2020	Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine. <i>Cancers</i> , 2020, 12, 821.	1.7	10
2021	BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 828.	1.7	27
2022	Morphologic and Genomic Heterogeneity in the Evolution and Progression of Breast Cancer. <i>Cancers</i> , 2020, 12, 848.	1.7	14
2023	FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy. <i>Journal of Clinical Medicine</i> , 2020, 9, 994.	1.0	14
2024	Identifying Heterogeneous Effect Using Latent Supervised Clustering With Adaptive Fusion. <i>Journal of Computational and Graphical Statistics</i> , 2021, 30, 43-54.	0.9	7
2025	Integrating Multidimensional Data for Clustering Analysis With Applications to Cancer Patient Data. <i>Journal of the American Statistical Association</i> , 2021, 116, 14-26.	1.8	7
2026	Prevalence of Molecular Subtypes of Breast Cancer in India: a Systematic Review and Meta-analysis. <i>Indian Journal of Surgical Oncology</i> , 2021, 12, 152-163.	0.3	6
2027	Prognostic and predictive parameters in breast pathology: a pathologist's primer. <i>Modern Pathology</i> , 2021, 34, 94-106.	2.9	14

#	ARTICLE	IF	CITATIONS
2028	The correlation of 18F-FDG PET/CT metabolic parameters, clinicopathological factors, and prognosis in breast cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 620-627.	1.2	17
2029	The prevalence of luminal B subtype is higher in older postmenopausal women with ER+/HER2- breast cancer and is associated with inferior outcomes. <i>Journal of Geriatric Oncology</i> , 2021, 12, 219-226.	0.5	3
2030	Breast Cancer-Specific Mortality in Small-Sized Tumor with Stage IV Breast Cancer: A Population-Based Study. <i>Oncologist</i> , 2021, 26, e241-e250.	1.9	10
2031	The Value of Nomograms in Pre-Operative Prediction of Lymphovascular Invasion in Primary Breast Cancer Undergoing Modified Radical Surgery: Based on Multiparametric Ultrasound and Clinicopathologic Indicators. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 517-526.	0.7	10
2032	The lingering mysteries of metastatic recurrence in breast cancer. <i>British Journal of Cancer</i> , 2021, 124, 13-26.	2.9	263
2033	High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers. <i>Molecular Oncology</i> , 2021, 15, 429-461.	2.1	19
2035	An approach for normalization and quality control for NanoString RNA expression data. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	67
2036	Triple-negative breast cancer: new treatment strategies in the era of precision medicine. <i>Science China Life Sciences</i> , 2021, 64, 372-388.	2.3	26
2037	Molecular Biology in the Breast Clinics—Current status and future perspectives. <i>Indian Journal of Surgical Oncology</i> , 2021, 12, 7-20.	0.3	0
2038	Research advances and new challenges in overcoming triple-negative breast cancer. , 2021, 4, 517-542.		11
2039	Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer. <i>Science Advances</i> , 2021, 7, .	4.7	38
2040	An <i>In Silico</i> Analysis Identified FZD9 as a Potential Prognostic Biomarker in Triple-Negative Breast Cancer Patients. <i>The Journal of Breast Health</i> , 2021, 17, 42-52.	0.4	2
2041	ZNF703 gene copy number and protein expression in breast cancer; associations with proliferation, prognosis and luminal subtypes. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 65-77.	1.1	5
2042	Breast cancer molecular subtypes and receptor status among women at Potchefstroom Hospital: a cross-sectional study. <i>Pan African Medical Journal</i> , 2021, 38, 85.	0.3	8
2043	Postmastectomy radiation therapy can improve survival for breast cancer patients with 1–3 positive axillary lymph nodes: a retrospective cohort study using the SEER database. <i>Translational Cancer Research</i> , 2021, 10, 1984-2001.	0.4	0
2044	Insights Into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 574813.	1.3	13
2045	KCTD12 is a prognostic marker of breast cancer and correlates with tumor immune cell infiltration. <i>Translational Cancer Research</i> , 2021, 10, 261-272.	0.4	1
2046	Molecular Subtype May Be More Associated With Prognosis and Chemotherapy Benefit Than Tumor Size in T1N0 Breast Cancer Patients: An Analysis of 2,168 Patients for Possible De-Escalation Treatment. <i>Frontiers in Oncology</i> , 2021, 11, 636266.	1.3	4

#	ARTICLE	IF	CITATIONS
2047	DeCompress: tissue compartment deconvolution of targeted mRNA expression panels using compressed sensing. <i>Nucleic Acids Research</i> , 2021, 49, e48-e48.	6.5	4
2048	The Dual Function of KDM5C in Both Gene Transcriptional Activation and Repression Promotes Breast Cancer Cell Growth and Tumorigenesis. <i>Advanced Science</i> , 2021, 8, 2004635.	5.6	26
2049	Impact of between-tissue differences on pan-cancer predictions of drug sensitivity. <i>PLoS Computational Biology</i> , 2021, 17, e1008720.	1.5	5
2050	Molecular Subtyping and Outlier Detection in Human Disease Using the Paraclique Algorithm. <i>Algorithms</i> , 2021, 14, 63.	1.2	1
2051	Mitotic kinases as drivers of the epithelial-to-mesenchymal transition and as therapeutic targets against breast cancers. <i>Experimental Biology and Medicine</i> , 2021, 246, 1036-1044.	1.1	5
2052	Advanced Approaches to Breast Cancer Classification and Diagnosis. <i>Frontiers in Pharmacology</i> , 2020, 11, 632079.	1.6	86
2053	Raloxifene as a treatment option for viral infections. <i>Journal of Microbiology</i> , 2021, 59, 124-131.	1.3	30
2054	FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1. <i>Breast Cancer Research</i> , 2021, 23, 21.	2.2	22
2055	Correlation of prognostic and predictive indicators in breast cancer patients from the eastern province of Saudi Arabia. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2021, 42, 293-298.	0.5	1
2056	Better overall survival in patients who achieve pathological complete response after neoadjuvant chemotherapy for breast cancer in a Chilean public hospital. <i>Ecancermedalscience</i> , 2021, 15, 1185.	0.6	3
2057	Random Forest Modelling of High-Dimensional Mixed-Type Data for Breast Cancer Classification. <i>Cancers</i> , 2021, 13, 991.	1.7	21
2058	New immunological potential markers for triple negative breast cancer: IL18R1, CD53, TRIM, Jaw1, LTB, PTPRCAP. <i>Discover Oncology</i> , 2021, 12, 6.	0.8	10
2059	Transferring MINDACT to Daily Routine: Implementation of the 70-Gene Signature in Luminal Early Breast Cancer “ Results from a Prospective Registry of the Austrian Group Medical Tumor Therapy (AGMT). <i>Breast Care</i> , 2022, 17, 1-9.	0.8	3
2060	Identification of markers associated with brain metastasis from breast cancer through bioinformatics analysis and verification in clinical samples. <i>Gland Surgery</i> , 2021, 10, 924-942.	0.5	4
2061	Postpartum breast cancer: mechanisms underlying its worse prognosis, treatment implications, and fertility preservation. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 412-422.	1.2	14
2062	Frequency-dependent interactions determine outcome of competition between two breast cancer cell lines. <i>Scientific Reports</i> , 2021, 11, 4908.	1.6	21
2063	Mechanistic Targets and Nutritionally Relevant Intervention Strategies to Break Obesity“Breast Cancer Links. <i>Frontiers in Endocrinology</i> , 2021, 12, 632284.	1.5	7
2064	Dynamic roles of inflammasomes in inflammatory tumor microenvironment. <i>Npj Precision Oncology</i> , 2021, 5, 18.	2.3	31

#	ARTICLE	IF	CITATIONS
2065	FOXQ1 is Differentially Expressed Across Breast Cancer Subtypes with Low Expression Associated with Poor Overall Survival. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 171-188.	1.0	5
2066	Laboratory Models for Investigating Breast Cancer Therapy Resistance and Metastasis. <i>Frontiers in Oncology</i> , 2021, 11, 645698.	1.3	22
2067	Model-based feature selection and clustering of RNA-seq data for unsupervised subtype discovery. <i>Annals of Applied Statistics</i> , 2021, 15, 481-508.	0.5	6
2068	Fuzheng Yiliu Formula Regulates Tumor Invasion and Metastasis through Inhibition of WAVE3 Expression. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-14.	0.5	0
2069	Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses. <i>Npj Breast Cancer</i> , 2021, 7, 46.	2.3	6
2070	High Expression of microRNA-223 Indicates a Good Prognosis in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 630432.	1.3	11
2071	Control of Breast Cancer Pathogenesis by Histone Methylation and the Hairless Histone Demethylase. <i>Endocrinology</i> , 2021, 162, .	1.4	7
2072	Expression and Prognosis of Sperm-Associated Antigen 1 in Human Breast Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2689-2698.	1.0	3
2073	SphK2/S1P Promotes Metastasis of Triple-Negative Breast Cancer Through the PAK1/LIMK1/Cofilin1 Signaling Pathway. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 598218.	1.6	19
2074	The microRNA analysis portal is a next-generation tool for exploring and analyzing miRNA-focused data in the literature. <i>Scientific Reports</i> , 2021, 11, 9007.	1.6	8
2075	Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. <i>British Journal of Cancer</i> , 2021, 125, 164-175.	2.9	177
2076	Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1080-1092.	2.0	15
2077	Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 618767.	1.3	12
2078	Serum HER2 levels predict treatment efficacy and prognosis in patients with HER2-positive breast cancer undergoing neoadjuvant treatment. <i>Gland Surgery</i> , 2021, 10, 1300-1314.	0.5	4
2079	PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. <i>The Cochrane Library</i> , 2021, 2021, CD011395.	1.5	19
2080	The Proper Ki-67 Cut-Off in Hormone Responsive Breast Cancer: A Monoinstitutional Analysis with Long-Term Follow-Up. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 213-217.	1.0	10
2081	Breast cancer disparities in outcomes; unmasking biological determinants associated with racial and genetic diversity. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 7-14.	1.7	14
2082	Cancer Progress and Priorities: Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 822-844.	1.1	47

#	ARTICLE	IF	CITATIONS
2083	Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5207.	1.8	20
2084	C(3)1-TAg in C57BL/6 J background as a model to study mammary tumor development. <i>Histochemistry and Cell Biology</i> , 2021, 156, 165-182.	0.8	8
2085	Cancer microenvironment and genomics: evolution in process. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 85-99.	1.7	11
2086	Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 1797-1809.	0.8	7
2087	Analysis of Increased EGFR and IGF-1R Signaling and Its Correlation with Socio-Epidemiological Features and Biological Profile in Breast Cancer Patients: A Study in Northern Brazil. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 325-339.	1.0	1
2088	Mammary epithelial cells have lineage-rooted metabolic identities. <i>Nature Metabolism</i> , 2021, 3, 665-681.	5.1	24
2089	Bioinformatics analysis on enrichment analysis of potential hub genes in breast cancer. <i>Translational Cancer Research</i> , 2021, 10, 2399-2408.	0.4	5
2090	The LINC01119-SOCS5 axis as a critical theranostic in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 69.	2.3	7
2091	FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. <i>Npj Breast Cancer</i> , 2021, 7, 51.	2.3	11
2092	RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4883-4897.	3.2	11
2093	Apatinib enhances the anti-tumor effect of paclitaxel via the PI3K/p65/Bcl-xl pathway in triple-negative breast cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 1001-1001.	0.7	12
2094	Undercutting efforts of precision medicine: roadblocks to minority representation in breast cancer clinical trials. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 605-611.	1.1	4
2095	Targeting of lactate dehydrogenase C dysregulates the cell cycle and sensitizes breast cancer cells to DNA damage response targeted therapy. <i>Molecular Oncology</i> , 2022, 16, 885-903.	2.1	11
2096	BlackSheep: A Bioconductor and Bioconda Package for Differential Extreme Value Analysis. <i>Journal of Proteome Research</i> , 2021, 20, 3767-3773.	1.8	6
2097	Suboptimal therapy following breast conserving surgery in triple-negative and HER2-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 509-520.	1.1	5
2098	Pan-cancer network disorders revealed by overall and local signaling entropy. <i>Journal of Molecular Cell Biology</i> , 2021, 13, 622-635.	1.5	2
2099	Computer-Aided Diagnosis Evaluation of the Correlation Between Magnetic Resonance Imaging With Molecular Subtypes in Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 693339.	1.3	5
2100	Co-expression of transcription factor AP-2beta (TFAP2B) and GATA3 in human mammary epithelial cells with intense, apicobasal immunoreactivity for CK8/18. <i>Journal of Molecular Histology</i> , 2021, 52, 1257-1264.	1.0	2

#	ARTICLE	IF	CITATIONS
2101	Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6483.	1.8	11
2102	SOX factors as cell-state regulators in the mammary gland and breast cancer. <i>Seminars in Cell and Developmental Biology</i> , 2021, 114, 126-133.	2.3	14
2103	The association between molecular type and prognosis of patients with stage IV breast cancer: an observational study based on SEER database. <i>Gland Surgery</i> , 2021, 10, 1889-1898.	0.5	5
2104	Cancer Grade Model: a multi-gene machine learning-based risk classification for improving prognosis in breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 748-758.	2.9	15
2105	Mammary gland development from a single cell omics view. <i>Seminars in Cell and Developmental Biology</i> , 2021, 114, 171-185.	2.3	18
2106	The rate of estrogen receptor conversion associated with tumor progression in estrogen receptor-positive breast cancer patients following adjuvant Tamoxifen administration. <i>Cancer Reports</i> , 2021, , e1431.	0.6	2
2107	Multimiomics analysis reveals CT83 is the most specific gene for triple negative breast cancer and its hypomethylation is oncogenic in breast cancer. <i>Scientific Reports</i> , 2021, 11, 12172.	1.6	12
2108	FBXO15 plays a critical suppressive functional role in regulation of breast cancer progression. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 211.	7.1	1
2109	Imitating evolution's tinkering by protein engineering reveals extension of human galectin-7 activity. <i>Histochemistry and Cell Biology</i> , 2021, 156, 253-272.	0.8	7
2110	Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer. <i>ELife</i> , 2021, 10, .	2.8	18
2111	Breast cancer heterogeneity through the lens of single-cell analysis and spatial pathologies. <i>Seminars in Cancer Biology</i> , 2022, 82, 3-10.	4.3	23
2112	Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment. <i>Nature Cancer</i> , 2021, 2, 680-692.	5.7	56
2113	Bulk and single-cell transcriptome profiling reveal the metabolic heterogeneity in human breast cancers. <i>Molecular Therapy</i> , 2021, 29, 2350-2365.	3.7	49
2114	Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 6622-6637.	3.2	7
2115	Endocrine therapy with accelerated Partial breast irradiation or exclusive ultra-accelerated Partial breast irradiation for women aged 60 years with Early-stage breast cancer (EPOPE): The rationale for a GEC-ESTRO randomized phase III-controlled trial. <i>Clinical and Translational Radiation Oncology</i> , 2021, 29, 1-8.	0.9	5
2116	Identification of a Three-RNA Binding Proteins (RBPs) Signature Predicting Prognosis for Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 663556.	1.3	16
2117	Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer. <i>Molecular Oncology</i> , 2022, 16, 2413-2431.	2.1	3
2118	A chemokine regulatory loop induces cholesterol synthesis in lung-colonizing triple-negative breast cancer cells to fuel metastatic growth. <i>Molecular Therapy</i> , 2022, 30, 672-687.	3.7	11

#	ARTICLE	IF	CITATIONS
2119	Acid-base transporters and pH dynamics in human breast carcinomas predict proliferative activity, metastasis, and survival. <i>ELife</i> , 2021, 10, .	2.8	21
2120	Revisiting social MPE: an integration of molecular pathological epidemiology and social science in the new era of precision medicine. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 869-886.	1.5	2
2121	Tissue mechanics in stem cell fate, development, and cancer. <i>Developmental Cell</i> , 2021, 56, 1833-1847.	3.1	71
2122	Accurate prediction of breast cancer survival through coherent voting networks with gene expression profiling. <i>Scientific Reports</i> , 2021, 11, 14645.	1.6	3
2123	Theory, methods, and operational results of the Young Women's Health History Study: a study of young-onset breast cancer incidence in Black and White women. <i>Cancer Causes and Control</i> , 2021, 32, 1129-1148.	0.8	4
2124	Expression of Ki67 in Triple Negative Breast Carcinoma and Its Correlation with Clinicopathological Variables – A Study from a Tertiary Care Center in Thrissur, Kerala. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2021, 8, 2439-2443.	0.0	0
2125	Comprehensive Analysis of the Expression, Prognosis, and Biological Significance of OVOLs in Breast Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 3951-3960.	0.8	12
2126	ZEB2 regulates endocrine therapy sensitivity and metastasis in luminal a breast cancer cells through a non-canonical mechanism. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 25-37.	1.1	4
2127	Breast Cancer Characteristics in the Population of Survivors Participating in the World Trade Center Environmental Health Center Program 2002–2019. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7555.	1.2	4
2128	Individual- and neighborhood-level socioeconomic status and risk of aggressive breast cancer subtypes in a pooled cohort of women from Kaiser Permanente Northern California. <i>Cancer</i> , 2021, 127, 4602-4612.	2.0	13
2129	The role of connexins in breast cancer: from misregulated cell communication to aberrant intracellular signaling. <i>Tissue Barriers</i> , 2022, 10, 1962698.	1.6	3
2130	Prediction and interpretation of cancer survival using graph convolution neural networks. <i>Methods</i> , 2021, 192, 120-130.	1.9	29
2131	Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 621-630.	1.1	6
2132	Prevalence and Molecular Profile of Breast Carcinoma Using Immunohistochemistry Markers in Mexican Women. <i>World Journal of Oncology</i> , 2021, 12, 119-123.	0.6	9
2133	Single-cell evaluation reveals shifts in the tumor-immune niches that shape and maintain aggressive lesions in the breast. <i>Nature Communications</i> , 2021, 12, 5024.	5.8	11
2134	Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer: A Systematic Literature Review. <i>Cancer Management and Research</i> , 2021, Volume 13, 6537-6566.	0.9	14
2135	Immunotherapy Treatment for Triple Negative Breast Cancer. <i>Pharmaceuticals</i> , 2021, 14, 763.	1.7	30
2136	Proteomic profiling dataset of chemical perturbations in multiple biological backgrounds. <i>Scientific Data</i> , 2021, 8, 226.	2.4	9

#	ARTICLE	IF	CITATIONS
2137	A novel lncRNA derived from an ultraconserved region: lnc-uc.147, a potential biomarker in luminal A breast cancer. <i>RNA Biology</i> , 2021, , 1-14.	1.5	9
2138	Impacts of LOC105371267 Variants on Breast Cancer Susceptibility in Northern Chinese Han Females: A Population-Based Case-Control Study. <i>Journal of Oncology</i> , 2021, 2021, 1-10.	0.6	0
2139	ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer. <i>Nature Communications</i> , 2021, 12, 4867.	5.8	97
2140	Risk factors for breast cancer subtypes among Black women undergoing screening mammography. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 827-835.	1.1	12
2141	A systematic review of datasets that can help elucidate relationships among gene expression, race, and immunohistochemistry-defined subtypes in breast cancer. <i>Cancer Biology and Therapy</i> , 2021, 22, 1-13.	1.5	2
2142	Heterogeneity within molecular subtypes of breast cancer. <i>American Journal of Physiology - Cell Physiology</i> , 2021, 321, C343-C354.	2.1	43
2143	Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx [®] Digital Spatial Profiler. <i>Cancers</i> , 2021, 13, 4456.	1.7	50
2144	miRNome Profiling Reveals Shared Features in Breast Cancer Subtypes and Highlights miRNAs That Potentially Regulate MYB and EZH2 Expression. <i>Frontiers in Oncology</i> , 2021, 11, 710919.	1.3	1
2145	lncRNA BORG:TRIM28 Complexes Drive Metastatic Progression by Inducing \uparrow Integrin/CD49f Expression in Breast Cancer Stem Cells. <i>Molecular Cancer Research</i> , 2021, 19, 2068-2080.	1.5	9
2146	Common tumor-suppressive signaling of thyroid hormone receptor beta in breast and thyroid cancer cells. <i>Molecular Carcinogenesis</i> , 2021, 60, 874-885.	1.3	8
2147	Targeting the Transcriptome Through Globally Acting Components. <i>Frontiers in Genetics</i> , 2021, 12, 749850.	1.1	1
2148	Prognostic and tumor-immune infiltration cell signatures in tamoxifen-resistant breast cancers. <i>Gland Surgery</i> , 2021, 10, 2766-2779.	0.5	2
2149	A single-cell and spatially resolved atlas of human breast cancers. <i>Nature Genetics</i> , 2021, 53, 1334-1347.	9.4	535
2150	Molecular Pathology of Breast Tumors. <i>Surgical Pathology Clinics</i> , 2021, 14, 455-471.	0.7	2
2151	Gold Nanoparticles in Triple-Negative Breast Cancer Therapeutics. <i>Current Medicinal Chemistry</i> , 2023, 30, 316-334.	1.2	9
2152	Improving Prognosis of Surrogate Assay for Breast Cancer Patients by Absolute Quantitation of Ki67 Protein Levels Using Quantitative Dot Blot (QDB) Method. <i>Frontiers in Oncology</i> , 2021, 11, 737781.	1.3	7
2153	A ferroptosis-associated gene signature for the prediction of prognosis and therapeutic response in luminal-type breast carcinoma. <i>Scientific Reports</i> , 2021, 11, 17610.	1.6	4
2154	A common goal to CARE: Cancer Advocates, Researchers, and Clinicians Explore current treatments and clinical trials for breast cancer brain metastases. <i>Npj Breast Cancer</i> , 2021, 7, 121.	2.3	6

#	ARTICLE	IF	CITATIONS
2155	Classification and immune invasion analysis of breast cancer based on m6A genes. <i>Annals of Translational Medicine</i> , 2021, 9, 1418-1418.	0.7	6
2156	Clinical Features and Serological Markers Risk Model Predicts Overall Survival in Patients Undergoing Breast Cancer and Bone Metastasis Surgeries. <i>Frontiers in Oncology</i> , 2021, 11, 693689.	1.3	6
2157	Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives. <i>Obesity Reviews</i> , 2022, 23, e13358.	3.1	20
2158	Breast adipose regulation of premenopausal breast epithelial phenotype involves interleukin 10. <i>Journal of Molecular Endocrinology</i> , 2021, 67, 173-188.	1.1	5
2159	Basal-like breast cancer with low TGF β 2 and high TNF α pathway activity is rich in activated memory CD4 T cells and has a good prognosis. <i>International Journal of Biological Sciences</i> , 2021, 17, 670-682.	2.6	12
2160	Gene expression comparison between primary estrogen receptor α -positive and triple α -negative breast cancer with paired axillary lymph node metastasis. <i>Breast Journal</i> , 2021, 27, 432-440.	0.4	3
2161	Differential Angiogenic Responses of Human Endothelial Colony-Forming Cells to Different Molecular Subtypes of Breast Cancer Cells. <i>Journal of Lipid and Atherosclerosis</i> , 2021, 10, 111.	1.1	6
2162	Keratin 19 maintains E-cadherin localization at the cell surface and stabilizes cell-cell adhesion of MCF7 cells. <i>Cell Adhesion and Migration</i> , 2021, 15, 1-17.	1.1	12
2163	Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 2-7.	1.0	13
2164	Statistical and Bioinformatics Analysis of Data from Bulk and Single-Cell RNA Sequencing Experiments. <i>Methods in Molecular Biology</i> , 2021, 2194, 143-175.	0.4	12
2165	Mouse Models of Breast Cancer. <i>Methods in Molecular Biology</i> , 2015, 1267, 47-71.	0.4	26
2166	Pharmacokinetics and Pharmacodynamics in Breast Cancer Animal Models. <i>Methods in Molecular Biology</i> , 2016, 1406, 271-287.	0.4	3
2167	MicroRNAs in regulation of triple-negative breast cancer progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1401-1411.	1.2	121
2168	Prediction of clinical outcome with microarray data: a partial least squares discriminant analysis (PLS-DA) approach. <i>Human Genetics</i> , 2003, 112, 581-92.	1.8	325
2169	The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences. <i>Nature Communications</i> , 2020, 11, 6433.	5.8	37
2170	Identification of synergistic drug combinations using breast cancer patient-derived xenografts. <i>Scientific Reports</i> , 2020, 10, 1493.	1.6	34
2171	P63 modulates the expression of the WDFY2 gene which is implicated in cancer regulation and limb development. <i>Bioscience Reports</i> , 2019, 39, .	1.1	5
2172	Ki67 Immunohistochemistry Quantification in Breast Carcinoma: A Comparison of Visual Estimation, Counting, and ImmunoRatio. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 105-111.	0.6	16

#	ARTICLE	IF	CITATIONS
2173	aWCluster: A Novel Integrative Network-Based Clustering of Multiomics for Subtype Analysis of Cancer Data. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2022, 19, 1472-1483.	1.9	11
2174	Targeting DNA binding proteins for cancer therapy. <i>Cancer Science</i> , 2020, 111, 1058-1064.	1.7	17
2175	Combining multiparametric MRI with receptor information to optimize prediction of pathologic response to neoadjuvant therapy in breast cancer: preliminary results. <i>Journal of Medical Imaging</i> , 2017, 5, 1.	0.8	4
2176	High quality RNA isolation from tumours with low cellularity and high extracellular matrix component for cDNA microarrays: application to chondrosarcoma. <i>Journal of Clinical Pathology</i> , 2001, 54, 778-782.	1.0	80
2177	Identification of 5-Gene Signature Improves Lung Adenocarcinoma Prognostic Stratification Based on Differential Expression Invasion Genes of Molecular Subtypes. <i>BioMed Research International</i> , 2020, 2020, 1-22.	0.9	20
2178	Colonic epithelial miR-31 associates with the development of Crohn's phenotypes. <i>JCI Insight</i> , 2018, 3, .	2.3	20
2179	Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients. <i>JCI Insight</i> , 2019, 4, .	2.3	83
2180	Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism. <i>JCI Insight</i> , 2016, 1, .	2.3	41
2181	microRNA-143/145 loss induces Ras signaling to promote aggressive Pten-deficient basal-like breast cancer. <i>JCI Insight</i> , 2017, 2, .	2.3	22
2182	TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination. <i>Journal of Clinical Investigation</i> , 2020, 130, 958-973.	3.9	53
2183	Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. <i>Journal of Clinical Investigation</i> , 2002, 110, 633-641.	3.9	142
2184	Src promotes estrogen-dependent estrogen receptor β proteolysis in human breast cancer. <i>Journal of Clinical Investigation</i> , 2007, 117, 2205-2215.	3.9	76
2185	β -Crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. <i>Journal of Clinical Investigation</i> , 2005, 116, 261-270.	3.9	256
2186	Is the small heat shock protein β -crystallin an oncogene?. <i>Journal of Clinical Investigation</i> , 2005, 116, 30-32.	3.9	43
2187	Targeting TACE-dependent EGFR ligand shedding in breast cancer. <i>Journal of Clinical Investigation</i> , 2007, 117, 337-345.	3.9	224
2188	The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. <i>Journal of Clinical Investigation</i> , 2007, 117, 1370-1380.	3.9	236
2189	RASAL2 activates RAC1 to promote triple-negative breast cancer progression. <i>Journal of Clinical Investigation</i> , 2014, 124, 5291-5304.	3.9	72
2190	Role of steroid receptor and coregulator mutations in hormone-dependent cancers. <i>Journal of Clinical Investigation</i> , 2017, 127, 1126-1135.	3.9	42

#	ARTICLE	IF	CITATIONS
2191	Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. <i>Journal of Clinical Investigation</i> , 2017, 127, 3472-3483.	3.9	130
2192	Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis. <i>Journal of Clinical Investigation</i> , 2017, 128, 531-544.	3.9	38
2193	PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity. <i>Journal of Clinical Investigation</i> , 2018, 128, 2787-2801.	3.9	28
2194	Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 1371-1383.	3.9	126
2195	Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. <i>Journal of Clinical Investigation</i> , 2019, 129, 1785-1800.	3.9	266
2196	EZH2 inhibitors-mediated epigenetic reactivation of FOSB inhibits triple-negative breast cancer progress. <i>Cancer Cell International</i> , 2020, 20, 175.	1.8	15
2197	Clinical Value of miR-101-3p and Biological Analysis of its Prospective Targets in Breast Cancer: A Study Based on The Cancer Genome Atlas (TCGA) and Bioinformatics. <i>Medical Science Monitor</i> , 2017, 23, 1857-1871.	0.5	25
2198	Downregulation of TBC1 Domain Family Member 24 (BC1D24) Inhibits Breast Carcinoma Growth via IGF1R/PI3K/AKT Pathway. <i>Medical Science Monitor</i> , 2018, 24, 3987-3996.	0.5	6
2199	Abnormal expression of ATP1A1 and ATP1A2 in breast cancer. <i>F1000Research</i> , 2017, 6, 10.	0.8	17
2200	Determination of Stromal Signatures in Breast Carcinoma. <i>PLoS Biology</i> , 2005, 3, e187.	2.6	180
2201	A trans-acting Variant within the Transcription Factor RIM101 Interacts with Genetic Background to Determine its Regulatory Capacity. <i>PLoS Genetics</i> , 2016, 12, e1005746.	1.5	11
2202	Heterologous Tissue Culture Expression Signature Predicts Human Breast Cancer Prognosis. <i>PLoS ONE</i> , 2007, 2, e145.	1.1	8
2203	Induction of ErbB-3 Expression by $\alpha 6 \beta 4$ Integrin Contributes to Tamoxifen Resistance in ER ⁺ 1-Negative Breast Carcinomas. <i>PLoS ONE</i> , 2008, 3, e1592.	1.1	47
2204	Comparative Analysis of Viral Gene Expression Programs during Poxvirus Infection: A Transcriptional Map of the Vaccinia and Monkeypox Genomes. <i>PLoS ONE</i> , 2008, 3, e2628.	1.1	54
2205	The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer. <i>PLoS ONE</i> , 2010, 5, e9499.	1.1	35
2206	Cancer Biomarker Discovery: The Entropic Hallmark. <i>PLoS ONE</i> , 2010, 5, e12262.	1.1	46
2207	Longitudinal Study of Mammary Epithelial and Fibroblast Co-Cultures Using Optical Coherence Tomography Reveals Morphological Hallmarks of Pre-Malignancy. <i>PLoS ONE</i> , 2012, 7, e49148.	1.1	33
2208	MicroRNA-7 Inhibits Multiple Oncogenic Pathways to Suppress HER2 ⁺ 16 Mediated Breast Tumorigenesis and Reverse Trastuzumab Resistance. <i>PLoS ONE</i> , 2014, 9, e114419.	1.1	51

#	ARTICLE	IF	CITATIONS
2209	Location of Triple-Negative Breast Cancers: Comparison with Estrogen Receptor-Positive Breast Cancers on MR Imaging. PLoS ONE, 2015, 10, e0116344.	1.1	9
2210	LSD1 Overexpression Is Associated with Poor Prognosis in Basal-Like Breast Cancer, and Sensitivity to PARP Inhibition. PLoS ONE, 2015, 10, e0118002.	1.1	67
2211	Exome Analysis Reveals Differentially Mutated Gene Signatures of Stage, Grade and Subtype in Breast Cancers. PLoS ONE, 2015, 10, e0119383.	1.1	19
2212	Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib. PLoS ONE, 2015, 10, e0125232.	1.1	27
2213	Association of Protein Translation and Extracellular Matrix Gene Sets with Breast Cancer Metastasis: Findings Uncovered on Analysis of Multiple Publicly Available Datasets Using Individual Patient Data Approach. PLoS ONE, 2015, 10, e0129610.	1.1	5
2214	Overweight as a Prognostic Factor for Triple-Negative Breast Cancers in Chinese Women. PLoS ONE, 2015, 10, e0129741.	1.1	40
2215	Semi-Supervised Projective Non-Negative Matrix Factorization for Cancer Classification. PLoS ONE, 2015, 10, e0138814.	1.1	18
2216	Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes. PLoS ONE, 2016, 11, e0142047.	1.1	16
2217	Molecular Subtype-Specific Expression of MicroRNA-29c in Breast Cancer Is Associated with CpG Dinucleotide Methylation of the Promoter. PLoS ONE, 2015, 10, e0142224.	1.1	20
2218	DNA Methylation Patterns Can Estimate Nonequivalent Outcomes of Breast Cancer with the Same Receptor Subtypes. PLoS ONE, 2015, 10, e0142279.	1.1	17
2219	Newly Constructed Network Models of Different WNT Signaling Cascades Applied to Breast Cancer Expression Data. PLoS ONE, 2015, 10, e0144014.	1.1	19
2220	Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers. PLoS ONE, 2016, 11, e0158259.	1.1	16
2221	Abundant NDRG2 Expression Is Associated with Aggressiveness and Unfavorable Patientsâ€™ Outcome in Basal-Like Breast Cancer. PLoS ONE, 2016, 11, e0159073.	1.1	12
2222	Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery. PLoS ONE, 2016, 11, e0159888.	1.1	15
2223	Discretization of Gene Expression Data Unmasks Molecular Subgroups Recurring in Different Human Cancer Types. PLoS ONE, 2016, 11, e0161514.	1.1	4
2224	Galectin-7 Expression Potentiates HER-2-Positive Phenotype in Breast Cancer. PLoS ONE, 2016, 11, e0166731.	1.1	13
2225	Mutant PIK3CA Induces EMT in a Cell Type Specific Manner. PLoS ONE, 2016, 11, e0167064.	1.1	5
2226	Claudin-Low Breast Cancer; Clinical & Pathological Characteristics. PLoS ONE, 2017, 12, e0168669.	1.1	111

#	ARTICLE	IF	CITATIONS
2227	Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study. PLoS ONE, 2016, 11, e0168730.	1.1	16
2228	Prospects of Targeting the Gastrin Releasing Peptide Receptor and Somatostatin Receptor 2 for Nuclear Imaging and Therapy in Metastatic Breast Cancer. PLoS ONE, 2017, 12, e0170536.	1.1	8
2229	Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA. PLoS ONE, 2017, 12, e0172351.	1.1	10
2230	Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer. PLoS ONE, 2017, 12, e0177331.	1.1	40
2231	Immunohistochemical subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis. PLoS ONE, 2017, 12, e0179602.	1.1	24
2232	Tumor tissue protein signatures reflect histological grade of breast cancer. PLoS ONE, 2017, 12, e0179775.	1.1	8
2233	Nipple sparing mastectomy in breast cancer patients and long-term survival outcomes: An analysis of the SEER database. PLoS ONE, 2017, 12, e0183448.	1.1	30
2234	Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1. PLoS ONE, 2017, 12, e0183917.	1.1	15
2235	Validation of the 18-gene classifier as a prognostic biomarker of distant metastasis in breast cancer. PLoS ONE, 2017, 12, e0184372.	1.1	38
2236	Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers. PLoS ONE, 2017, 12, e0185753.	1.1	15
2237	Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer. PLoS ONE, 2017, 12, e0186658.	1.1	34
2238	MicroRNA-10b expression in breast cancer and its clinical association. PLoS ONE, 2018, 13, e0192509.	1.1	42
2239	Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells. PLoS ONE, 2018, 13, e0194913.	1.1	9
2240	Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures. PLoS ONE, 2020, 15, e0239197.	1.1	13
2241	Ultrasonographic features of pure ductal carcinoma in situ of the breast: correlations with pathologic features and biological markers. Ultrasonography, 2018, 37, 307-314.	1.0	11
2242	Synergistic effects induced by combined treatments of aqueous extract of propolis and venom. Medicine and Pharmacy Reports, 2016, 89, 104-109.	0.2	5
2243	Clinical applications of mouse models for breast cancer engaging HER2/neu. Integrative Cancer Science and Therapeutics, 2016, 3, 593-603.	0.1	19
2244	FOXF2 differentially regulates expression of metabolic genes in non-cancerous and cancerous breast epithelial cells. Trends in Diabetes and Metabolism, 2018, 1, .	0.1	6

#	ARTICLE	IF	CITATIONS
2245	Review of Triple Negative Breast Cancer and the Impact of Inducible Nitric Oxide Synthase on Tumor Biology and Patient Outcomes. <i>Critical Reviews in Oncogenesis</i> , 2016, 21, 333-351.	0.2	44
2246	Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL. <i>Tomography</i> , 2016, 2, 378-387.	0.8	20
2247	Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer. <i>Tomography</i> , 2020, 6, 216-222.	0.8	11
2248	Expressions of miR-21 and miR-210 in Breast Cancer and Their Predictive Values for Prognosis. <i>Iranian Journal of Public Health</i> , 0, , .	0.3	13
2249	Pyridoxine 5â€²-phosphate oxidase is correlated with human breast invasive ductal carcinoma development. <i>Aging</i> , 2019, 11, 2151-2176.	1.4	18
2250	Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies. <i>Oncoscience</i> , 2015, 2, 81-90.	0.9	27
2251	HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer. <i>Oncoscience</i> , 2015, 2, 207-224.	0.9	21
2252	Conserved E2F mediated metastasis in mouse models of breast cancer and HER2 positive patients. <i>Oncoscience</i> , 2015, 2, 867-871.	0.9	16
2253	Identification of new miRNA biomarkers associated with HER2-positive breast cancers. <i>Oncoscience</i> , 2015, 2, 924-929.	0.9	20
2254	Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers. <i>Oncotarget</i> , 2016, 7, 44395-44405.	0.8	25
2255	The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer. <i>Oncotarget</i> , 2016, 7, 49859-49877.	0.8	48
2256	Induction of HOXA9 expression in three-dimensional organotypic culture of the Claudin-low breast cancer cells. <i>Oncotarget</i> , 2016, 7, 51503-51514.	0.8	11
2257	Triple negative breast cancer: shedding light onto the role of pi3k/akt/mTOR pathway. <i>Oncotarget</i> , 2016, 7, 60712-60722.	0.8	103
2258	Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs). <i>Oncotarget</i> , 2016, 7, 55458-55472.	0.8	19
2259	Î²Np63 drives metastasis in breast cancer cells via PI3K/CD44v6 axis. <i>Oncotarget</i> , 2016, 7, 54157-54173.	0.8	25
2260	Association mining of mutated cancer genes in different clinical stages across 11 cancer types. <i>Oncotarget</i> , 2016, 7, 68270-68277.	0.8	9
2261	Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer. <i>Oncotarget</i> , 2016, 7, 69111-69123.	0.8	26
2262	Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes. <i>Oncotarget</i> , 2016, 7, 74966-74978.	0.8	61

#	ARTICLE	IF	CITATIONS
2263	Stat3 accelerates Myc induced tumor formation while reducing growth rate in a mouse model of breast cancer. <i>Oncotarget</i> , 2016, 7, 65797-65807.	0.8	9
2264	<i>ERBB2</i> mutations associated with solid variant of high-grade invasive lobular breast carcinomas. <i>Oncotarget</i> , 2016, 7, 73337-73346.	0.8	34
2265	Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells. <i>Oncotarget</i> , 2016, 7, 73697-73710.	0.8	23
2266	Identification of novel prognostic indicators for triple-negative breast cancer patients through integrative analysis of cancer genomics data and protein interactome data. <i>Oncotarget</i> , 2016, 7, 71620-71634.	0.8	12
2267	Epithelial cells captured from ductal carcinoma in situ reveal a gene expression signature associated with progression to invasive breast cancer. <i>Oncotarget</i> , 2016, 7, 75672-75684.	0.8	5
2268	FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort. <i>Oncotarget</i> , 2016, 7, 75729-75738.	0.8	10
2269	Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. <i>Oncotarget</i> , 2016, 7, 79428-79441.	0.8	11
2270	Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer. <i>Oncotarget</i> , 2017, 8, 30477-30494.	0.8	17
2271	Microenvironmental networks promote tumor heterogeneity and enrich for metastatic cancer stem-like cells in Luminal-A breast tumor cells. <i>Oncotarget</i> , 2016, 7, 81123-81143.	0.8	23
2272	Common profiles of Notch signaling differentiate disease-free survival in luminal type A and triple negative breast cancer. <i>Oncotarget</i> , 2016, 8, 6013-6032.	0.8	16
2273	DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival. <i>Oncotarget</i> , 2017, 8, 1074-1082.	0.8	16
2274	Genomic regulation of invasion by STAT3 in triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 8226-8238.	0.8	69
2275	Integrative genomic and transcriptomic analysis for pinpointing recurrent alterations of plant homeodomain genes and their clinical significance in breast cancer. <i>Oncotarget</i> , 2017, 8, 13099-13115.	0.8	19
2276	The effect of androgen receptor expression on clinical characterization of metastatic breast cancer. <i>Oncotarget</i> , 2017, 8, 8693-8706.	0.8	7
2277	Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance. <i>Oncotarget</i> , 2017, 8, 17819-17832.	0.8	44
2278	Lymph node status in different molecular subtype of breast cancer: triple negative tumours are more likely lymph node negative. <i>Oncotarget</i> , 2017, 8, 55534-55543.	0.8	22
2279	TNBC invasion: downstream of STAT3. <i>Oncotarget</i> , 2017, 8, 20517-20518.	0.8	5
2280	Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors. <i>Oncotarget</i> , 2017, 8, 21733-21740.	0.8	18

#	ARTICLE	IF	CITATIONS
2281	Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients. <i>Oncotarget</i> , 2017, 8, 38706-38716.	0.8	31
2282	BI-RADS 3-5 microcalcifications: prediction of lymph node metastasis of breast cancer. <i>Oncotarget</i> , 2017, 8, 30190-30198.	0.8	6
2283	GD2 expression in breast cancer. <i>Oncotarget</i> , 2017, 8, 31592-31600.	0.8	38
2284	Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 37172-37185.	0.8	6
2285	Post-operative radiotherapy is beneficial for T1/T2 triple negative breast cancer patients with four or more positive lymph nodes. <i>Oncotarget</i> , 2017, 8, 42917-42925.	0.8	8
2286	The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer. <i>Oncotarget</i> , 2017, 8, 44870-44880.	0.8	17
2287	Identification of a novel p53 target, COL17A1, that inhibits breast cancer cell migration and invasion. <i>Oncotarget</i> , 2017, 8, 55790-55803.	0.8	58
2288	Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis. <i>Oncotarget</i> , 2017, 8, 72031-72043.	0.8	6
2289	A pathways-based prediction model for classifying breast cancer subtypes. <i>Oncotarget</i> , 2017, 8, 58809-58822.	0.8	16
2290	Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes. <i>Oncotarget</i> , 2017, 8, 70481-70495.	0.8	14
2291	Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification. <i>Oncotarget</i> , 2017, 8, 59023-59035.	0.8	79
2292	Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer. <i>Oncotarget</i> , 2017, 8, 74391-74405.	0.8	40
2293	Transcriptional signature of lymphoblastoid cell lines of <i>BRCA1</i> and non- <i>BRCA1/2</i> high risk breast cancer families. <i>Oncotarget</i> , 2017, 8, 78691-78712.	0.8	8
2294	The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 76974-76986.	0.8	34
2295	Down-regulation of traditional oncomiRs in plasma of breast cancer patients. <i>Oncotarget</i> , 2017, 8, 77369-77384.	0.8	32
2296	Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems. <i>Oncotarget</i> , 2017, 8, 80804-80819.	0.8	24
2297	A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib. <i>Oncotarget</i> , 2017, 8, 104894-104912.	0.8	28
2298	Survival rate variation with different histological subtypes of poor prognostic male anal squamous cell carcinoma: a population-based study. <i>Oncotarget</i> , 2017, 8, 84349-84359.	0.8	3

#	ARTICLE	IF	CITATIONS
2299	The exon 38-containing ARHGEF11 splice isoform is differentially expressed and is required for migration and growth in invasive breast cancer cells. <i>Oncotarget</i> , 2017, 8, 92157-92170.	0.8	15
2300	Downregulation of miR-221-3p and upregulation of its target gene PARP1 are prognostic biomarkers for triple negative breast cancer patients and associated with poor prognosis. <i>Oncotarget</i> , 2017, 8, 108712-108725.	0.8	44
2301	YAP1 inhibition radiosensitizes triple negative breast cancer cells by targeting the DNA damage response and cell survival pathways. <i>Oncotarget</i> , 2017, 8, 98495-98508.	0.8	34
2302	Post-menopausal breast cancer: from estrogen to androgen receptor. <i>Oncotarget</i> , 2017, 8, 102739-102758.	0.8	26
2303	Structural determinant of BST-2-mediated regulation of breast cancer cell motility: a role for cytoplasmic tail tyrosine residues. <i>Oncotarget</i> , 2017, 8, 110221-110233.	0.8	7
2304	Clinicopathological and prognostic significance of SDC1 overexpression in breast cancer. <i>Oncotarget</i> , 2017, 8, 111444-111455.	0.8	33
2305	FRK inhibits breast cancer cell migration and invasion by suppressing epithelial-mesenchymal transition. <i>Oncotarget</i> , 2017, 8, 113034-113065.	0.8	14
2306	Prognostic impact of AnxA1 and AnxA2 gene expression in triple-negative breast cancer. <i>Oncotarget</i> , 2018, 9, 2697-2704.	0.8	28
2307	Molecular characterization of breast cancer cell response to metabolic drugs. <i>Oncotarget</i> , 2018, 9, 9645-9660.	0.8	22
2308	Metabolic profiles of triple-negative and luminal A breast cancer subtypes in African-American identify key metabolic differences. <i>Oncotarget</i> , 2018, 9, 11677-11690.	0.8	46
2309	Effect of postmastectomy radiotherapy on triple-negative breast cancer with T1-2 and 1-3 positive axillary lymph nodes: a population-based study using the SEER 18 database. <i>Oncotarget</i> , 2019, 10, 5245-5252.	0.8	6
2310	Genetic rearrangements, hotspot mutations, and microRNA expression in the progression of metastatic adenoid cystic carcinoma of the salivary gland. <i>Oncotarget</i> , 2018, 9, 19675-19687.	0.8	15
2311	The versatile nature of miR-9/9* in human cancer. <i>Oncotarget</i> , 2018, 9, 20838-20854.	0.8	64
2312	PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer. <i>Oncotarget</i> , 2018, 9, 23208-23219.	0.8	14
2313	The TGF β -EGFR-Akt signaling axis plays a role in enhancing proinflammatory chemokines in triple-negative breast cancer cells. <i>Oncotarget</i> , 2018, 9, 29286-29303.	0.8	12
2314	Probabilistic graphical models relate immune status with response to neoadjuvant chemotherapy in breast cancer. <i>Oncotarget</i> , 2018, 9, 27586-27594.	0.8	8
2315	Global metabolite profiling analysis of lipotoxicity in HER2/neu-positive breast cancer cells. <i>Oncotarget</i> , 2018, 9, 27133-27150.	0.8	8
2316	Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity. <i>Oncotarget</i> , 2018, 9, 30115-30127.	0.8	25

#	ARTICLE	IF	CITATIONS
2317	SIRT1-dependent epigenetic regulation of H3 and H4 histone acetylation in human breast cancer. <i>Oncotarget</i> , 2018, 9, 30661-30678.	0.8	44
2318	Assessing the efficacy of androgen receptor and Sox10 as independent markers of the triple-negative breast cancer subtype by transcriptome profiling. <i>Oncotarget</i> , 2018, 9, 33348-33359.	0.8	13
2319	ATR suppresses the pro-tumorigenic functions of breast stromal fibroblasts. <i>Oncotarget</i> , 2018, 9, 34681-34690.	0.8	4
2320	Integrated landscape of copy number variation and RNA expression associated with nodal metastasis in invasive ductal breast carcinoma. <i>Oncotarget</i> , 2018, 9, 36836-36848.	0.8	8
2321	FGFR1 ^{Δ2} is a driver isoform of FGFR1 alternative splicing in breast cancer cells. <i>Oncotarget</i> , 2019, 10, 30-44.	0.8	13
2322	Large-scale in-silico identification of a tumor-specific antigen pool for targeted immunotherapy in triple-negative breast cancer. <i>Oncotarget</i> , 2019, 10, 2515-2529.	0.8	11
2323	CpG promoter hypo-methylation and up-regulation of microRNA-190b in hormone receptor-positive breast cancer. <i>Oncotarget</i> , 2019, 10, 4664-4678.	0.8	3
2324	Distinct pattern of one-carbon metabolism, a nutrient-sensitive pathway, in invasive breast cancer: A metabolomic study. <i>Oncotarget</i> , 2020, 11, 1637-1652.	0.8	2
2325	Induction of phenotypic changes in HER2-positive breast cancer cells in vivo and in vitro. <i>Oncotarget</i> , 2020, 11, 2919-2929.	0.8	2
2326	PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects. <i>Oncotarget</i> , 2015, 6, 4299-4314.	0.8	87
2327	Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant Basal-HER2 subtype of breast cancer. <i>Oncotarget</i> , 2015, 6, 7104-7122.	0.8	17
2328	Cell type of origin as well as genetic alterations contribute to breast cancer phenotypes. <i>Oncotarget</i> , 2015, 6, 9018-9030.	0.8	19
2329	Low spinophilin expression enhances aggressive biological behavior of breast cancer. <i>Oncotarget</i> , 2015, 6, 11191-11202.	0.8	10
2330	Difference between observed and expected number of involved lymph nodes reflects the metastatic potential of breast cancer independent to intrinsic subtype. <i>Oncotarget</i> , 2015, 6, 16686-16697.	0.8	7
2331	Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome. <i>Oncotarget</i> , 2015, 6, 17261-17275.	0.8	44
2332	Pit-1 inhibits BRCA1 and sensitizes human breast tumors to cisplatin and vitamin D treatment. <i>Oncotarget</i> , 2015, 6, 14456-14471.	0.8	12
2333	Targeting lactate transport suppresses <i>in vivo</i> breast tumour growth. <i>Oncotarget</i> , 2015, 6, 19177-19189.	0.8	92
2334	Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells. <i>Oncotarget</i> , 2015, 6, 20902-20920.	0.8	96

#	ARTICLE	IF	CITATIONS
2335	CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome. <i>Oncotarget</i> , 2015, 6, 17462-17478.	0.8	168
2336	Identification and evaluation of network modules for the prognosis of basal-like breast cancer. <i>Oncotarget</i> , 2015, 6, 17713-17724.	0.8	3
2337	Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis. <i>Oncotarget</i> , 2015, 6, 23944-23958.	0.8	21
2338	Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy. <i>Oncotarget</i> , 2015, 6, 18174-18182.	0.8	21
2339	Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer. <i>Oncotarget</i> , 2015, 6, 27923-27937.	0.8	24
2340	Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways. <i>Oncotarget</i> , 2015, 6, 29143-29160.	0.8	44
2341	Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications. <i>Oncotarget</i> , 2015, 6, 33306-33318.	0.8	31
2342	Distinct breast cancer stem/progenitor cell populations require either HIF1 α or loss of PHD3 to expand under hypoxic conditions. <i>Oncotarget</i> , 2015, 6, 31721-31739.	0.8	46
2343	miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers. <i>Oncotarget</i> , 2015, 6, 32115-32137.	0.8	20
2344	Increased metastasis with loss of <i>E2F2</i> in <i>Myc</i> -driven tumors. <i>Oncotarget</i> , 2015, 6, 38210-38224.	0.8	27
2345	The molecular effect of metastasis suppressors on Src signaling and tumorigenesis: new therapeutic targets. <i>Oncotarget</i> , 2015, 6, 35522-35541.	0.8	43
2346	A novel gammaretroviral shuttle vector insertional mutagenesis screen identifies <i>SHARPIN</i> as a breast cancer metastasis gene and prognostic biomarker. <i>Oncotarget</i> , 2015, 6, 39507-39520.	0.8	25
2347	Understanding the role of the kynurenine pathway in human breast cancer immunobiology. <i>Oncotarget</i> , 2016, 7, 6506-6520.	0.8	109
2348	Towards understanding the breast cancer epigenome: a comparison of genome-wide DNA methylation and gene expression data. <i>Oncotarget</i> , 2016, 7, 3002-3017.	0.8	19
2349	Differential expression of neurogenes among breast cancer subtypes identifies high risk patients. <i>Oncotarget</i> , 2016, 7, 5313-5326.	0.8	24
2350	STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers. <i>Oncotarget</i> , 2016, 7, 7055-7065.	0.8	47
2351	Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer. <i>Oncotarget</i> , 2016, 7, 15460-15473.	0.8	103
2352	Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition. <i>Oncotarget</i> , 2016, 7, 10522-10535.	0.8	24

#	ARTICLE	IF	CITATIONS
2353	mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials. <i>Oncotarget</i> , 2016, 7, 27055-27066.	0.8	14
2354	MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating <i>BRCA1</i> expression. <i>Oncotarget</i> , 2016, 7, 20068-20079.	0.8	42
2355	MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer. <i>Oncotarget</i> , 2016, 7, 20381-20394.	0.8	52
2356	Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. <i>Oncotarget</i> , 2016, 7, 22543-22555.	0.8	11
2357	Comparative genomic analysis of primary tumors and metastases in breast cancer. <i>Oncotarget</i> , 2016, 7, 27208-27219.	0.8	69
2358	Pattern of <i>RECK</i> CpG methylation as a potential marker for predicting breast cancer prognosis and drug-sensitivity. <i>Oncotarget</i> , 2016, 7, 82158-82169.	0.8	4
2359	Intratumoral expression of CCR3 in breast cancer is associated with improved relapse-free survival in luminal-like disease. <i>Oncotarget</i> , 2016, 7, 28570-28578.	0.8	13
2360	Mitochondrial DNA content in breast cancer: Impact on <i>in vitro</i> and <i>in vivo</i> phenotype and patient prognosis. <i>Oncotarget</i> , 2016, 7, 29166-29176.	0.8	33
2361	Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers. <i>Oncotarget</i> , 2016, 7, 43124-43149.	0.8	52
2362	Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer. <i>Oncotarget</i> , 2016, 7, 36632-36644.	0.8	15
2363	Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer. <i>Oncotarget</i> , 0, 7, 41559-41574.	0.8	15
2364	Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor <i>RARRES1</i> . <i>Oncotarget</i> , 2016, 7, 44096-44112.	0.8	26
2365	Centrosome aberrations and chromosome instability contribute to tumorigenesis and intra-tumor heterogeneity. <i>Journal of Cancer Metastasis and Treatment</i> , 2018, 4, 43.	0.5	23
2366	Studies of postpartum mammary gland involution reveal novel pro-metastatic mechanisms. <i>Journal of Cancer Metastasis and Treatment</i> , 2019, 2019, .	0.5	21
2367	Cellular plasticity and metastasis in breast cancer: a pre- and post-malignant problem. <i>Journal of Cancer Metastasis and Treatment</i> , 2019, 2019, .	0.5	11
2368	Network rewiring, adaptive resistance and combating strategies in breast cancer. , 2019, 2, 1106-1126.		5
2369	Downregulation of hexokinase 2 improves radiosensitivity of breast cancer. <i>Translational Cancer Research</i> , 2019, 8, 290-297.	0.4	11
2370	Evaluation of human epidermal growth factor receptor 2 status of breast cancer using preoperative multidetector computed tomography with deep learning and handcrafted radiomics features. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 175-185.	0.7	17

#	ARTICLE	IF	CITATIONS
2371	Circulating MicroRNAs and Blood-Brain-Barrier Function in Breast Cancer Metastasis. <i>Current Pharmaceutical Design</i> , 2020, 26, 1417-1427.	0.9	11
2372	Translation of a Tissue-Selective Rexinoid, UAB30, to the Clinic for Breast Cancer Prevention. <i>Current Topics in Medicinal Chemistry</i> , 2017, 17, 676-695.	1.0	11
2373	PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies. <i>Reviews on Recent Clinical Trials</i> , 2015, 10, 238-245.	0.4	18
2374	Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises. <i>Cancer Genomics and Proteomics</i> , 2017, 14, 299-313.	1.0	46
2375	Chronic Low-Dose Exposure to Xenoestrogen Ambient Air Pollutants and Breast Cancer Risk: XENAIR Protocol for a Case-Control Study Nested Within the French E3N Cohort. <i>JMIR Research Protocols</i> , 2020, 9, e15167.	0.5	7
2376	Association between ERCC1 Polymorphism and the Risk and Clinicopathological Features of Breast Cancer in Thai Women in the Lower Northeastern Region. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 2999-3002.	0.5	2
2377	PAX6 Promoter Methylation Correlates with MDA-MB-231 Cell Migration, and Expression of MMP2 and MMP9. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 2859-2866.	0.5	9
2378	Prognostic Value of Lymphangiogenesis Determinants in Luminal and Non-luminal Breast Carcinomas. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 2461-2467.	0.5	4
2379	LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state. <i>Life Science Alliance</i> , 2018, 1, e201800171.	1.3	26
2380	Overview on Epigenetic Re-programming: A Potential Therapeutic Intervention in Triple Negative Breast Cancers. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 3341-3351.	0.5	8
2381	Prognostic Value of BCL2 in Women Patients with Invasive Breast Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 3557-3564.	0.5	3
2382	Nottingham Prognostic Index is an Applicable Prognostic Tool in Non-Metastatic Triple-Negative Breast Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 59-63.	0.5	7
2383	Immunohistochemical Evaluation of Ki-67 and Comparison with Clinicopathologic Factors in Breast Carcinomas. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 73-79.	0.5	29
2384	Revealing the Complexity of Breast Cancer by Next Generation Sequencing. <i>Cancers</i> , 2015, 7, 2183-2200.	1.7	28
2385	Distinct expression patterns in hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2008, 14, 6072.	1.4	34
2386	Gene expression profiling of gastric cancer by microarray combined with laser capture microdissection. <i>World Journal of Gastroenterology</i> , 2005, 11, 7405.	1.4	29
2388	Aldehyde dehydrogenase 1, a target of miRâ€222, is expressed at elevated levels in cervical cancer. <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 1673-1680.	0.8	4
2389	Identification of new cancer stem cell markers and signaling pathways in HERâ€2â€positive breast cancer by transcriptome sequencing. <i>International Journal of Oncology</i> , 2019, 55, 1003-1018.	1.4	12

#	ARTICLE	IF	CITATIONS
2390	Circulating non-coding RNA-biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?. <i>International Journal of Oncology</i> , 2020, 56, 47-68.	1.4	20
2391	Survival-related risk score of lung adenocarcinoma identified by weight gene co-expression network analysis. <i>Oncology Letters</i> , 2019, 18, 4441-4448.	0.8	5
2392	Screening of core genes and pathways in breast cancer development via comprehensive analysis of multi gene expression datasets. <i>Oncology Letters</i> , 2019, 18, 5821-5830.	0.8	9
2393	Prognostic phenotypic classification for canine mammary tumors. <i>Oncology Letters</i> , 2019, 18, 6545-6553.	0.8	24
2394	Cathepsin-1/2L interacts with CDK2-AP1 as a potential predictor of prognosis in patients with breast cancer. <i>Oncology Letters</i> , 2020, 19, 167-176.	0.8	7
2395	Three-microRNA expression signature predicts survival in triple-negative breast cancer. <i>Oncology Letters</i> , 2020, 19, 301-308.	0.8	21
2396	Biglycan as a potential diagnostic and prognostic biomarker in multiple human cancers. <i>Oncology Letters</i> , 2020, 19, 1673-1682.	0.8	25
2397	Identification of candidate RNA signatures in triple-negative breast cancer by the construction of a competing endogenous RNA network with integrative analyses of Gene Expression Omnibus and The Cancer Genome Atlas data. <i>Oncology Letters</i> , 2020, 19, 1915-1927.	0.8	5
2398	The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab-paclitaxel chemotherapy. <i>Oncology Letters</i> , 2020, 19, 2705-2712.	0.8	13
2399	Icaritin enhances the efficacy of cetuximab against triple-negative breast cancer cells. <i>Oncology Letters</i> , 2020, 19, 3950-3958.	0.8	9
2400	Prognostic and predictive value of monocarboxylate transporter 4 in patients with breast cancer. <i>Oncology Letters</i> , 2020, 20, 2143-2152.	0.8	10
2401	Circulating microRNAs and their role in the immune response in triple-negative breast cancer (Review). <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	13
2402	Black-White Disparities in Breast Cancer Subtype: The Intersection of Socially Patterned Stress and Genetic Expression. <i>AIMS Public Health</i> , 2017, 4, 526-556.	1.1	52
2403	Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. <i>Annals of Translational Medicine</i> , 2014, 2, 122.	0.7	32
2404	Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review. <i>World Journal of Oncology</i> , 2013, 4, 137-141.	0.6	6
2405	TNBC vs. Non-TNBC: A Five-Year Retrospective Review of Differences in Mean Age, Family History, Smoking History and Stage at Diagnosis at an Inner City University Program. <i>World Journal of Oncology</i> , 2013, 4, 241-247.	0.6	10
2406	Prognostic Role of Androgen Receptor Expression in Surgically Resected Early Breast Cancer Patients. <i>Journal of Breast Cancer</i> , 2020, 23, 182.	0.8	12
2407	Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer. <i>Journal of Carcinogenesis</i> , 2019, 18, 5.	2.5	4

#	ARTICLE	IF	CITATIONS
2408	Deep Learning to Estimate Human Epidermal Growth Factor Receptor 2 Status from Hematoxylin and Eosin-Stained Breast Tissue Images. <i>Journal of Pathology Informatics</i> , 2020, 11, 19.	0.8	32
2409	Therapeutic impacts of microRNAs in breast cancer by their roles in regulating processes involved in this disease. <i>Journal of Research in Medical Sciences</i> , 2017, 22, 130.	0.4	35
2410	Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling. <i>South Asian Journal of Cancer</i> , 2018, 07, 096-101.	0.2	7
2411	Estrogen receptor, Progesterone receptor, and human epidermal growth factor receptor-2 status in breast cancer: A retrospective study of 5436 women from a regional cancer center in South India. <i>South Asian Journal of Cancer</i> , 2018, 07, 07-10.	0.2	22
2412	Interobserver Variability of Ki-67 Measurement in Breast Cancer. <i>Journal of Pathology and Translational Medicine</i> , 2016, 50, 129-137.	0.4	24
2413	Prognostic Significance of a Micropapillary Pattern in Pure Mucinous Carcinoma of the Breast: Comparative Analysis with Micropapillary Carcinoma. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 403-409.	0.4	19
2414	Young Age Is Associated with Increased Locoregional Recurrence in Node-Positive Breast Cancer with Luminal Subtypes. <i>Cancer Research and Treatment</i> , 2017, 49, 484-493.	1.3	12
2415	Incorporating Risk Factors to Identify the Indication of Post-mastectomy Radiotherapy in N1 Breast Cancer Treated with Optimal Systemic Therapy: A Multicenter Analysis in Korea (KROG 14-23). <i>Cancer Research and Treatment</i> , 2017, 49, 739-747.	1.3	27
2416	Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance. <i>Cancer Research and Treatment</i> , 2019, 51, 737-747.	1.3	53
2417	Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers. <i>The Journal of Breast Health</i> , 2019, 15, 125-129.	0.4	5
2418	Novel applications of COX-2 inhibitors, metformin, and statins for the primary chemoprevention of breast cancer. <i>Journal of the Turkish German Gynecology Association</i> , 2016, 17, 214-223.	0.2	9
2419	Correlation between 18F-FDG Positron-Emission Tomography 18F-FDG Uptake Levels at Diagnosis and Histopathologic and Immunohistochemical Factors in Patients with Breast Cancer. <i>Journal of Breast Health</i> , 2016, 12, 112-118.	0.9	10
2420	Paradigm Shift From Halstedian Radical Mastectomy to Personalized Medicine. <i>Journal of Breast Health</i> , 2017, 13, 50-53.	0.9	6
2421	Emerging gene-based prognostic tools in early breast cancer: First steps to personalised medicine. <i>World Journal of Clinical Oncology</i> , 2014, 5, 795.	0.9	10
2422	Lymphocyte subsets predictive value and possible involvement of human papilloma virus infection on breast cancer molecular subtypes. <i>World Journal of Clinical Oncology</i> , 2018, 9, 123-132.	0.9	5
2423	Cancer stem cells and early stage basal-like breast cancer. <i>World Journal of Obstetrics and Gynecology</i> , 2016, 5, 150.	0.5	5
2424	Zinc finger protein 143 expression is closely related to tumor malignancy via regulating cell motility in breast cancer. <i>BMB Reports</i> , 2017, 50, 621-627.	1.1	15
2425	A chemical conjugate between HER2-targeting antibody fragment and Pseudomonas exotoxin A fragment demonstrates cytotoxic effects on HER2-expressing breast cancer cells. <i>BMB Reports</i> , 2019, 52, 496-501.	1.1	11

#	ARTICLE	IF	CITATIONS
2426	Predictive markers of endocrine response in breast cancer. <i>World Journal of Experimental Medicine</i> , 2018, 8, 1-7.	0.9	18
2427	Classification of Genes Based on Age-Related Differential Expression in Breast Cancer. <i>Genomics and Informatics</i> , 2017, 15, 156-161.	0.4	16
2428	Immunohistochemical Subtypes of Breast Cancer: Correlation with Clinicopathological and Radiological Factors. <i>Iranian Journal of Radiology</i> , 2016, 13, e31386.	0.1	10
2429	Novel aromatase inhibitors selection using induced fit docking and extra precision methods: Potential clinical use in ER-alpha-positive breast cancer. <i>Bioinformatics</i> , 2016, 12, 324-331.	0.2	8
2430	Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ. <i>Clinics</i> , 2013, 68, 638-643.	0.6	13
2431	Immunohistochemical profile of high-grade ductal carcinoma in situ of the breast. <i>Clinics</i> , 2013, 68, 674-678.	0.6	9
2432	Transcriptional control of subtype switching ensures adaptation and growth of pancreatic cancer. <i>ELife</i> , 2019, 8, .	2.8	66
2433	RNA-seq analysis identified hormone-related genes associated with prognosis of triple negative breast cancer. <i>Journal of Biomedical Research</i> , 2020, 34, 129.	0.7	21
2434	Formal modeling and analysis of ER- α -associated Biological Regulatory Network in breast cancer. <i>PeerJ</i> , 2016, 4, e2542.	0.9	6
2435	The prognostic impact of age in different molecular subtypes of breast cancer: a population-based study. <i>PeerJ</i> , 2019, 7, e7252.	0.9	21
2436	qtQDA: quantile transformed quadratic discriminant analysis for high-dimensional RNA-seq data. <i>PeerJ</i> , 2019, 7, e8260.	0.9	5
2437	Pan-cancer systematic identification of lncRNAs associated with cancer prognosis. <i>PeerJ</i> , 2020, 8, e8797.	0.9	3
2438	Transcription levels and prognostic significance of the NFI family members in human cancers. <i>PeerJ</i> , 2020, 8, e8816.	0.9	14
2439	Bladder Metastasis from Breast Cancer: A Systematic Review. <i>Cureus</i> , 2020, 12, e7408.	0.2	10
2440	Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype. <i>Cureus</i> , 2016, 8, e924.	0.2	59
2441	Breast Cancer Incidence and Mortality by Molecular Subtype: Statewide Age and Racial/Ethnic Disparities in New Jersey. <i>Cancer Health Disparities</i> , 2019, 3, e1-e17.	0.5	15
2442	Expression and functions of long non-coding RNA NEAT1 and isoforms in breast cancer. <i>British Journal of Cancer</i> , 2022, 126, 551-561.	2.9	26
2443	Patient-Derived Organoids Can Guide Personalized Therapies for Patients with Advanced Breast Cancer. <i>Advanced Science</i> , 2021, 8, e2101176.	5.6	42

#	ARTICLE	IF	CITATIONS
2444	The impact of Oncotype <sc>DX</sc> testing on adjuvant chemotherapy decision making in 1â€“3 node positive breast cancer. <i>Cancer Reports</i> , 2022, 5, e1546.	0.6	3
2445	Fatty acid oxidation is a druggable gateway regulating cellular plasticity for driving metastasis in breast cancer. <i>Science Advances</i> , 2021, 7, eabh2443.	4.7	42
2446	RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs). <i>Genes</i> , 2021, 12, 1686.	1.0	0
2447	Halophilic Carotenoids and Breast Cancer: From Salt Marshes to Biomedicine. <i>Marine Drugs</i> , 2021, 19, 594.	2.2	10
2448	Assessment of programmed death-ligand 1 receptor immunohistochemical expression and its association with tumor-infiltrating lymphocytes and p53 status in triple-negative breast cancer. <i>Romanian Journal of Morphology and Embryology</i> , 2021, 62, 63-71.	0.4	1
2449	3D tumor angiogenesis models: recent advances and challenges. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3477-3494.	1.2	32
2450	Presence of high-risk HPVs, EBV, and MMTV in human triple-negative breast cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4457-4466.	1.4	13
2451	NRIP1 is activated by C-JUN/C-FOS and activates the expression of PGR, ESR1 and CCND1 in luminal A breast cancer. <i>Scientific Reports</i> , 2021, 11, 21159.	1.6	8
2452	A Case-Control Study of TP53 R72P Polymorphism in the Breast Cancer Patients of Ethnic Kashmiri Population. <i>World Journal of Oncology</i> , 2010, 1, 236-241.	0.6	4
2453	Carcinoma in situ to invasive breast cancer. <i>Oncoscience</i> , 2015, 2, 570-571.	0.9	0
2454	Palbociclib: A New Option for Front-Line Treatment of Metastatic, Hormone Receptorâ€“Positive, HER2-Negative Breast Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2015, 6, .	0.2	0
2455	Gene modules associated with breast cancer distant metastasis-free survival in the PAM50 molecular subtypes. <i>Oncotarget</i> , 2016, 7, 21686-21698.	0.8	2
2456	The Clock Is Ticking: Countdown to Metastases. <i>PLoS Genetics</i> , 2016, 12, e1006299.	1.5	2
2457	Breast Metaplastic Squamous Cell Carcinoma Diagnosed with Fine Needle and Core Biopsy: A Case Study. <i>American Journal of Case Reports</i> , 2018, 19, 203-206.	0.3	7
2458	Clinical and cyto-morphological characterization of triple negative breast cancer. <i>Journal of Cytology</i> , 2019, 36, 84.	0.2	5
2459	Insights into breast cancer phenotyping through molecular omics approaches and therapy response. , 2019, 2, 527-538.		2
2460	T1â€“2N1M0 tripleâ€“negative breast cancer patients from the SEER database showed potential benefit from postâ€“mastectomy radiotherapy. <i>Oncology Letters</i> , 2020, 19, 735-744.	0.8	5
2461	RAB6C is an independent prognostic factor of estrogen receptorâ€“positive/progesterone receptorâ€“negative breast cancer. <i>Oncology Letters</i> , 2020, 19, 52-60.	0.8	5

#	ARTICLE	IF	CITATIONS
2462	UNC5Câ€knockdown enhances the growth and metastasis of breast cancer cells by potentiating the integrinâ€ signaling pathway. International Journal of Oncology, 2020, 56, 139-150.	1.4	4
2463	Regulation and New Treatment Strategies in Breast Cancer. Journal of Life Sciences (Westlake Village,) Tj ETQq1 1 0.784314 ggBT /Over	1.8	2
2464	Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer. Clinical and Translational Oncology, 2020, 22, 2275-2285.	1.2	4
2465	Personalized analysis of breast cancer using sample-specific networks. PeerJ, 2020, 8, e9161.	0.9	4
2466	Moonlight human ribosomal protein L13a downregulation is associated with p53 and HER2/neu expression in breast cancer. Journal of Applied Biomedicine, 2020, 18, 46-53.	0.6	1
2467	Hypercluster: a flexible tool for parallelized unsupervised clustering optimization. BMC Bioinformatics, 2020, 21, 428.	1.2	6
2468	Analysis of Sociodemographic, Clinical, and Genomic Factors Associated With Breast Cancer Mortality in the Linked Surveillance, Epidemiology, and End Results and Medicare Database. JAMA Network Open, 2021, 4, e2131020.	2.8	4
2469	Role of formin INF2 in human diseases. Molecular Biology Reports, 2022, 49, 735-746.	1.0	8
2470	Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 731148.	1.3	5
2471	Current advances in immune checkpoint inhibitor combinations with radiation therapy or cryotherapy for breast cancer. Breast Cancer Research and Treatment, 2022, 191, 229-241.	1.1	12
2472	The age-specific differences in histopathological tumor characteristics and TNM classification of breast carcinomas in Quality assured mamma diagnostic (QuaMaDi) program in the state of Schleswigâ€Holstein in Germany. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	1.2	0
2473	Assessment of the Risk of Breast Cancer Development Applying NCI Tool among Iraqi Women. Asian Pacific Journal of Cancer Prevention, 2021, 22, 3121-3126.	0.5	0
2474	Magnetic resonance imaging system for intraoperative margin assessment for DCIS and invasive breast cancer using the ClearSightâ„¢ system in breastâ€conserving surgeryâ€Results from a postmarketing study. Journal of Surgical Oncology, 2022, 125, 361-368.	0.8	4
2475	DNAJB4 identified as a potential breast cancer marker: evidence from bioinformatics analysis and basic experiments. Gland Surgery, 2020, 9, 1955-1972.	0.5	9
2476	Detection and analysis of stable and flexible genes towards a genome signature framework in cancer. Bioinformation, 2019, 15, 772-779.	0.2	2
2477	Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99. BMC Cancer, 2020, 20, 114.	1.1	5
2478	Implementation of Next-Generation Sequencing in Saudi Arabia for HER2-Positive Breast Cancer. Saudi Journal of Biological Sciences, 2022, 29, 1808-1812.	1.8	1
2479	Targeted and systemic insights into the crosstalk between DNA-dependent protein kinase catalytic subunit and receptors of estrogen, progesterone and epidermal growth factor in the context of cancer. Molecular Biology Reports, 2021, , 1.	1.0	1

#	ARTICLE	IF	CITATIONS
2480	Circulating <scp>microRNAs</scp> as indicators in the prediction of neoadjuvant chemotherapy response in luminal <scp>B</scp> breast cancer. <i>Thoracic Cancer</i> , 2021, 12, 3396-3406.	0.8	16
2481	Estrogen receptor variant ER β 46 and insulin receptor drive in primary breast cancer cells growth effects and interleukin 11 induction prompting the motility of cancer-associated fibroblasts. <i>Clinical and Translational Medicine</i> , 2021, 11, e516.	1.7	3
2482	Mechanobiology of Bone Metastatic Cancer. <i>Current Osteoporosis Reports</i> , 2021, 19, 580-591.	1.5	6
2483	Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 737794.	1.3	4
2484	Resistance to endocrine therapy in HR α and/or HER2 α breast cancer: the most promising predictive biomarkers. <i>Molecular Biology Reports</i> , 2022, 49, 717-733.	1.0	15
2485	Should we target intermediate expression of HER2 in older estrogen receptor positive patients?. <i>Translational Cancer Research</i> , 2020, 9, 4056-4059.	0.4	1
2487	Differential Association of the Lifestyle-Related Risk Factors Smoking and Obesity with Triple Negative Breast Cancer in a Brazilian Population. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 1585-1593.	0.5	9
2488	Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 955-959.	0.5	6
2489	Proteomics and its applications in breast cancer. <i>American Journal of Cancer Research</i> , 2021, 11, 4006-4049.	1.4	0
2490	Receptor-Mediated Targeted Delivery of Surface-Modified Nanomedicine in Breast Cancer: Recent Update and Challenges. <i>Pharmaceutics</i> , 2021, 13, 2039.	2.0	14
2491	Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis. <i>Cancers</i> , 2021, 13, 5694.	1.7	41
2492	CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer. <i>MedComm</i> , 2021, 2, 514-530.	3.1	12
2493	Evaluation of PD-L1 and tumor infiltrating lymphocytes in paired pretreatment biopsies and post neoadjuvant chemotherapy surgical specimens of breast carcinoma. <i>Scientific Reports</i> , 2021, 11, 22478.	1.6	8
2494	Compressive stress-mediated p38 activation required for ER α phenotype in breast cancer. <i>Nature Communications</i> , 2021, 12, 6967.	5.8	22
2495	3-D vascularized breast cancer model to study the role of osteoblast in formation of a pre-metastatic niche. <i>Scientific Reports</i> , 2021, 11, 21966.	1.6	8
2496	Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments. <i>Cell Death and Disease</i> , 2021, 12, 1118.	2.7	9
2497	Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression. <i>Oncogenesis</i> , 2021, 10, 77.	2.1	14
2498	Periostin gene expression in neu-positive breast cancer cells is regulated by a FGFR signaling cross talk with TGF β /PI3K/AKT pathways. <i>Breast Cancer Research</i> , 2021, 23, 107.	2.2	12

#	ARTICLE	IF	CITATIONS
2499	The matricellular protein CCN6 differentially regulates mitochondrial metabolism in normal epithelium and in metaplastic breast carcinomas. <i>Journal of Cell Communication and Signaling</i> , 2022, 16, 433-445.	1.8	2
2500	CD40LG as a Prognostic Molecular Marker Regulates Tumor Microenvironment Through Immune Process in Breast Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 8833-8846.	0.8	5
2501	Folliculin impairs breast tumor growth by repressing TFE3-dependent induction of the Warburg effect and angiogenesis. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	15
2502	What is beyond LncRNAs in breast cancer: A special focus on colon cancer-associated Transcript-1 (CCAT-1). <i>Non-coding RNA Research</i> , 2021, 6, 174-186.	2.4	14
2503	Population-genetic Aspects of Breast Cancers and Association with Rh Factor in Selected Sample. <i>Medicinski Arhiv = Medical Archives = Archives De MĂ©decine</i> , 2021, 75, 413.	0.4	0
2504	Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110595.	1.4	10
2505	Loss of function of GATA3 induces basal-like mammary tumors. <i>Theranostics</i> , 2022, 12, 720-733.	4.6	8
2506	A Pan-Cancer Analysis of Tumor-Infiltrating B Cell Repertoires. <i>Frontiers in Immunology</i> , 2021, 12, 790119.	2.2	7
2507	Breast cancer treatment patterns by age and time since last pregnancy in the Carolina Breast Cancer Study Phase III. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 435-445.	1.1	0
2508	Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy. <i>Cancers</i> , 2022, 14, 279.	1.7	12
2509	The Impact of Reproductive Factors on the Risk of Breast Cancer by ER/PR and HER2: A Multicenter Case-Control Study in Northern and Eastern China. <i>Oncologist</i> , 2022, 27, e1-e8.	1.9	5
2510	Chrysin impairs genomic stability by suppressing DNA double-strand break repair in breast cancer cells. <i>Cell Cycle</i> , 2022, 21, 379-391.	1.3	8
2511	Effect of node status on breast cancer survival by subtype: a single-center retrospective cohort study. <i>Translational Cancer Research</i> , 2020, 9, 5900-5908.	0.4	1
2512	Comprehensive analysis of the NME gene family functions in breast cancer. <i>Translational Cancer Research</i> , 2020, 9, 6369-6382.	0.4	3
2513	Flimma: a federated and privacy-aware tool for differential gene expression analysis. <i>Genome Biology</i> , 2021, 22, 338.	3.8	10
2514	The TSH/Thyroid Hormones Axis and Breast Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 687.	1.0	4
2515	Lineage-specific silencing of PSAT1 induces serine auxotrophy and sensitivity to dietary serine starvation in luminal breast tumors. <i>Cell Reports</i> , 2022, 38, 110278.	2.9	14
2516	Brain metastases originating in breast cancer: clinical-pathological analysis and immunohistochemical profile. <i>Romanian Journal of Morphology and Embryology</i> , 2022, 62, 435-444.	0.4	3

#	ARTICLE	IF	CITATIONS
2517	KRT13 promotes stemness and drives metastasis in breast cancer through a plakoglobin/c-Myc signaling pathway. <i>Breast Cancer Research</i> , 2022, 24, 7.	2.2	23
2518	Lympho-vascular invasion impacts the prognosis in breast-conserving surgery: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2022, 22, 102.	1.1	16
2519	Breast Cancer Classification Based on Tumor Budding and Stem Cell-Related Signatures Facilitate Prognosis Evaluation. <i>Frontiers in Oncology</i> , 2021, 11, 818869.	1.3	6
2520	RSL1D1 promotes the progression of colorectal cancer through RAN-mediated autophagy suppression. <i>Cell Death and Disease</i> , 2022, 13, 43.	2.7	14
2521	Influence of Olive Oil and Its Components on Breast Cancer: Molecular Mechanisms. <i>Molecules</i> , 2022, 27, 477.	1.7	35
2522	Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies. <i>Oncologist</i> , 2022, 27, 30-39.	1.9	10
2523	Transcriptional changes in the mammary gland during lactation revealed by single cell sequencing of cells from human milk. <i>Nature Communications</i> , 2022, 13, 562.	5.8	34
2524	A deep learning model for breast ductal carcinoma in situ classification in whole slide images. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 1009-1022.	1.4	16
2525	The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study. <i>International Journal of Clinical Oncology</i> , 2022, 27, 707-716.	1.0	8
2526	Involvement of Mitochondrial Mechanisms and Cyclooxygenase-2 Activation in the Effect of Desethylamidarone on 4T1 Triple-Negative Breast Cancer Line. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1544.	1.8	2
2527	A comprehensive long-read isoform analysis platform and sequencing resource for breast cancer. <i>Science Advances</i> , 2022, 8, eabg6711.	4.7	30
2528	Identification of long non-coding RNAs and RNA binding proteins in breast cancer subtypes. <i>Scientific Reports</i> , 2022, 12, 693.	1.6	14
2529	A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients. <i>Molecular Cancer</i> , 2022, 21, 22.	7.9	7
2530	Pathogenesis of Triple-Negative Breast Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2022, 17, 181-204.	9.6	132
2531	The Role of Progesterone Receptors in Breast Cancer. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 305-314.	2.0	47
2532	Unveiling the Potential of Liquid Biopsy in HER2-Positive Breast Cancer Management. <i>Cancers</i> , 2022, 14, 587.	1.7	8
2533	SEC61G regulates breast cancer cell proliferation and metastasis by affecting the Epithelial-Mesenchymal Transition. <i>Journal of Cancer</i> , 2022, 13, 831-846.	1.2	6
2534	Extracellular Vesicles as Mediators of Therapy Resistance in the Breast Cancer Microenvironment. <i>Biomolecules</i> , 2022, 12, 132.	1.8	7

#	ARTICLE	IF	CITATIONS
2535	Lipid Changes During Endocrine Therapy in Breast Cancer Patients: The Results of a 5-Year Real-World Retrospective Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 670897.	1.3	4
2536	Transcribed Ultraconserved Regions Are Associated with Clinicopathological Features in Breast Cancer. <i>Biomolecules</i> , 2022, 12, 214.	1.8	3
2537	Breast cancer recurrence: factors impacting occurrence and survival. <i>Irish Journal of Medical Science</i> , 2022, 191, 2501-2510.	0.8	12
2538	Influence of progesterone receptor on metastasis and prognosis in breast cancer patients with negative HER-2. <i>Gland Surgery</i> , 2022, 11, 77-90.	0.5	4
2539	The expression of HOXC10 is correlated with tumor-infiltrating immune cells in basal-like breast cancer and serves as a prognostic biomarker. <i>Annals of Translational Medicine</i> , 2022, 10, 81-81.	0.7	1
2540	Degraders: The Ultimate Weapon Against Amplified Driver Kinases in Cancer. <i>Molecular Pharmacology</i> , 2022, 101, 191-200.	1.0	5
2541	The role of mineralocorticoids and glucocorticoids under the impact of 11 β -hydroxysteroid dehydrogenase in human breast lesions. <i>Medical Molecular Morphology</i> , 2022, , .	0.4	0
2542	The DNA damage repair landscape in Black women with breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210754.	1.4	6
2543	Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 465-484.	1.1	6
2544	Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature. <i>Cureus</i> , 2022, 14, e21970.	0.2	9
2545	A framework to predict the applicability of Oncotype DX, MammaPrint, and E2F4 gene signatures for improving breast cancer prognostic prediction. <i>Scientific Reports</i> , 2022, 12, 2211.	1.6	4
2546	Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 529-539.	1.1	11
2547	Decoding Insulin-Like Growth Factor Signaling Pathway From a Non-coding RNAs Perspective: A Step Towards Precision Oncology in Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2022, 27, 79-99.	1.0	13
2548	From Mouse to Human: Cellular Morphometric Subtype Learned From Mouse Mammary Tumors Provides Prognostic Value in Human Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 819565.	1.3	5
2549	Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1493-1499.	3.2	22
2550	Prognosis of Tumor Microenvironment in Luminal B-Type Breast Cancer. <i>Disease Markers</i> , 2022, 2022, 1-21.	0.6	2
2551	The 3D in vivo chorioallantoic membrane model and its role in breast cancer research. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1.	1.2	2
2552	MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers. <i>Diagnostic Pathology</i> , 2022, 17, 24.	0.9	6

#	ARTICLE	IF	CITATIONS
2553	Quantitative single-cell analysis of immunofluorescence protein multiplex images illustrates biomarker spatial heterogeneity within breast cancer subtypes. <i>Breast Cancer Research</i> , 2021, 23, 114.	2.2	3
2554	SRIQ clustering: A fusion of Random Forest, QT clustering, and KNN concepts. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 1567-1579.	1.9	1
2555	SENPI1 promotes triple-negative breast cancer invasion and metastasis via enhancing CSN5 transcription mediated by GATA1 deSUMOylation. <i>International Journal of Biological Sciences</i> , 2022, 18, 2186-2201.	2.6	9
2556	<i>Karanahan</i>: A Potential New Treatment Option for Human Breast Cancer and Its Validation in a Clinical Setting. <i>Breast Cancer: Basic and Clinical Research</i> , 2022, 16, 117822342110599.	0.6	3
2557	Predictive value of DNA repair gene expression for response to neoadjuvant chemotherapy in breast cancer. <i>Brazilian Journal of Medical and Biological Research</i> , 2022, 55, e11857.	0.7	0
2558	Co-Relation of Hormonal Profile and BRCA1 in Sporadic Breast Carcinoma: A Single Institutional Experience of 303 Patients. <i>BMC Clinical Pathology</i> , 2022, 15, 2632010X2210763.	0.7	1
2559	Effects of Ruxolitinib and Calcitriol Combination Treatment on Various Molecular Subtypes of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2535.	1.8	8
2560	Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer. <i>Open Biology</i> , 2022, 12, 210373.	1.5	21
2561	A Complex Radiomic Signature in Luminal Breast Cancer from a Weighted Statistical Framework: A Pilot Study. <i>Diagnostics</i> , 2022, 12, 499.	1.3	11
2562	MCTS1 as a Novel Prognostic Biomarker and Its Correlation With Immune Infiltrates in Breast Cancer. <i>Frontiers in Genetics</i> , 2022, 13, 825901.	1.1	10
2563	Multiomics Topic Modeling for Breast Cancer Classification. <i>Cancers</i> , 2022, 14, 1150.	1.7	4
2564	Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021. <i>Cancers</i> , 2022, 14, 1253.	1.7	69
2565	Transcriptional Factor Repertoire of Breast Cancer in 3D Cell Culture Models. <i>Cancers</i> , 2022, 14, 1023.	1.7	9
2566	Imaging Cancer-Associated Fibroblasts (CAFs) with FAPI PET. <i>Biomedicines</i> , 2022, 10, 523.	1.4	32
2567	Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes. <i>Nature Communications</i> , 2022, 13, 896.	5.8	46
2568	Breast Cancer; Discovery of Novel Diagnostic Biomarkers, Drug Resistance, and Therapeutic Implications. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 783450.	1.6	32
2569	Breast Cancer Incidence, Hormone Receptor Status, Historical Redlining, and Current Neighborhood Characteristics in Massachusetts, 2005-2015. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	11
2570	Outcome analysis of primary breast cancer patients who declined adjuvant chemotherapyâ€”results from the prospective multi-center BRENDA II study. <i>Breast Cancer</i> , 2022, , 1.	1.3	0

#	ARTICLE	IF	CITATIONS
2571	Development and Validation of a Novel Stemness-Index-Related Long Noncoding RNA Signature for Breast Cancer Based on Weighted Gene Co-Expression Network Analysis. <i>Frontiers in Genetics</i> , 2022, 13, 760514.	1.1	5
2572	Hyperactivation of MAPK Induces Tamoxifen Resistance in SPRED2-Deficient ER \pm -Positive Breast Cancer. <i>Cancers</i> , 2022, 14, 954.	1.7	14
2573	Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics. <i>Cancer Research</i> , 2022, 82, 1174-1192.	0.4	21
2574	Glycosphingolipids in human embryonic stem cells and breast cancer stem cells, and potential cancer therapy strategies based on their structures and functions. <i>Glycoconjugate Journal</i> , 2022, 39, 177-195.	1.4	5
2575	Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society. <i>Breast Cancer Research</i> , 2022, 24, 22.	2.2	80
2576	Identification of Differentially Expressed Hub Genes Associated With Immune Cell Recruitment in Claudin-Low Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 848206.	1.3	2
2577	Elaeagnus angustifolia Plant Extract Induces Apoptosis via P53 and Signal Transducer and Activator of Transcription 3 Signaling Pathways in Triple-Negative Breast Cancer Cells. <i>Frontiers in Nutrition</i> , 2022, 9, 871667.	1.6	8
2578	Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. <i>JCO Precision Oncology</i> , 2022, 6, e2000368.	1.5	9
2579	Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 \pm early breast cancer (PHAEDRA). <i>BMC Cancer</i> , 2022, 22, 269.	1.1	0
2580	Biodegradable and biocompatible subcutaneous implants consisted of pH-sensitive mebendazole-loaded/folic acid-targeted chitosan nanoparticles for murine triple-negative breast cancer treatment. <i>Journal of Nanobiotechnology</i> , 2022, 20, 169.	4.2	19
2581	A Motif-Based Network Analysis of Regulatory Patterns in Doxorubicin Effects on Treating Breast Cancer, a Systems Biology Study. <i>Avicenna Journal of Medical Biotechnology</i> , 0, , .	0.2	0
2582	The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer. <i>Current Oncology</i> , 2022, 29, 1761-1772.	0.9	1
2583	Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 813462.	1.3	2
2584	Development of a Model System to Study Expression Profile of RAC2 Gene in Breast Cancer MDA-MB-231 Cell Line. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-8.	0.5	2
2585	NRG1/ERBB3/ERBB2 Axis Triggers Anchorage-Independent Growth of Basal-like/Triple-Negative Breast Cancer Cells. <i>Cancers</i> , 2022, 14, 1603.	1.7	6
2586	Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 21-35.	1.1	4
2587	Epigenetic Factors as Etiological Agents, Diagnostic Markers, and Therapeutic Targets for Luminal Breast Cancer. <i>Biomedicines</i> , 2022, 10, 748.	1.4	0
2588	A single-cell analysis of breast cancer cell lines to study tumour heterogeneity and drug response. <i>Nature Communications</i> , 2022, 13, 1714.	5.8	65

#	ARTICLE	IF	CITATIONS
2589	27-Hydroxycholesterol Binds GPER and Induces Progression of Estrogen Receptor-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 1521.	1.7	7
2590	Inositol (1,4,5)-Trisphosphate Receptors in Invasive Breast Cancer: A New Prognostic Tool?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2962.	1.8	6
2591	Breast Cancer Mortality Trends and Predictions to 2030 and Its Attributable Risk Factors in East and South Asian Countries. <i>Frontiers in Nutrition</i> , 2022, 9, 847920.	1.6	12
2592	Canine and murine models of osteosarcoma. <i>Veterinary Pathology</i> , 2022, 59, 399-414.	0.8	22
2593	The early-stage triple-negative breast cancer landscape derives a novel prognostic signature and therapeutic target. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 319-330.	1.1	4
2594	Association Between Vascular Index Measured via Superb Microvascular Imaging and Molecular Subtype of Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 861151.	1.3	5
2595	Natural Small Molecules in Breast Cancer Treatment: Understandings from a Therapeutic Viewpoint. <i>Molecules</i> , 2022, 27, 2165.	1.7	47
2596	Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy. <i>Molecular Biomedicine</i> , 2022, 3, 8.	1.7	38
2597	XGboost Prediction Model Based on 3.0T Diffusion Kurtosis Imaging Improves the Diagnostic Accuracy of MRI BiRADS 4 Masses. <i>Frontiers in Oncology</i> , 2022, 12, 833680.	1.3	2
2598	In Vitro Anti-cancer Effect of <i>Crataegus oxyacantha</i> Berry Extract on Hormone Receptor Positive and Triple Negative Breast Cancers via Regulation of Canonical Wnt Signaling Pathway. <i>Applied Biochemistry and Biotechnology</i> , 2023, 195, 2687-2708.	1.4	5
2599	IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 866014.	1.3	87
2600	Breast Cancer Subtype-Specific miRNAs: Networks, Impacts, and the Potential for Intervention. <i>Biomedicines</i> , 2022, 10, 651.	1.4	12
2601	Molecular subtyping reveals uniqueness of prognosis in breast ductal carcinoma in situ patients with lumpectomy. <i>Breast</i> , 2022, 64, 1-6.	0.9	2
2602	BTG2 as a tumor target for the treatment of luminal breast cancer. <i>Experimental and Therapeutic Medicine</i> , 2022, 23, 339.	0.8	3
2603	Body size in early life and the risk of postmenopausal breast cancer. <i>BMC Cancer</i> , 2022, 22, 232.	1.1	4
2604	Spatial collagen stiffening promotes collective breast cancer cell invasion by reinforcing extracellular matrix alignment. <i>Oncogene</i> , 2022, 41, 2458-2469.	2.6	47
2605	Estrogen Receptor and the Unfolded Protein Response: Double-Edged Swords in Therapy for Estrogen Receptor-Positive Breast Cancer. <i>Targeted Oncology</i> , 2022, 17, 111-124.	1.7	7
2606	Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 4141-4152.	0.7	5

#	ARTICLE	IF	CITATIONS
2607	Deciphering HER2-HER3 Dimerization at the Single CTC Level: A Microfluidic Approach. <i>Cancers</i> , 2022, 14, 1890.	1.7	2
2608	Brain Microvascular Pericytes—More than Bystanders in Breast Cancer Brain Metastasis. <i>Cells</i> , 2022, 11, 1263.	1.8	4
2609	Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 265-279.	1.1	10
2610	Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. <i>Cell Reports</i> , 2022, 39, 110595.	2.9	25
2611	Comparative Proteomic Profiling of Secreted Extracellular Vesicles from Breast Fibroadenoma and Malignant Lesions: A Pilot Study. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3989.	1.8	6
2612	Enhancer RNA Transcription Is Essential for a Novel CSF1 Enhancer in Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 1852.	1.7	3
2613	Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4314.	1.2	5
2614	Subclonal heterogeneity and evolution in breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 155.	2.3	23
2615	Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments. <i>Clinical Cancer Research</i> , 2022, 28, 960-971.	3.2	4
2616	Unmet challenges in systemic therapy for early stage breast cancer. <i>Breast</i> , 2022, 62, S67-S69.	0.9	1
2617	The FoxQ1 transcription factor is a novel regulator of electron transport chain complex I subunits in human breast cancer cells. <i>Molecular Carcinogenesis</i> , 2022, 61, 372-381.	1.3	4
2618	AI in spotting high-risk characteristics of medical imaging and molecular pathology. <i>Precision Clinical Medicine</i> , 2021, 4, 271-286.	1.3	2
2619	Can Systems Biology Advance Clinical Precision Oncology?. <i>Cancers</i> , 2021, 13, 6312.	1.7	10
2620	Joint and individual analysis of breast cancer histologic images and genomic covariates. <i>Annals of Applied Statistics</i> , 2021, 15, 1697-1722.	0.5	4
2621	Design and synthesis of chromone-nitrogen mustard derivatives and evaluation of anti-breast cancer activity. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 437-450.	2.5	10
2622	Molecular analysis of TCGA breast cancer histologic types. <i>Cell Genomics</i> , 2021, 1, 100067.	3.0	37
2624	CoMI: consensus mutual information for tissue-specific gene signatures. <i>BMC Bioinformatics</i> , 2021, 22, 624.	1.2	0
2625	Challenges and Gaps in Clinical Trial Genomic Data Management. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100193.	1.0	0

#	ARTICLE	IF	CITATIONS
2626	Immunotherapy in triple-negative breast cancer: A literature review and new advances. <i>World Journal of Clinical Oncology</i> , 2022, 13, 219-236.	0.9	16
2627	Breast cancer in the era of integrating "Omics" approaches. <i>Oncogenesis</i> , 2022, 11, 17.	2.1	23
2628	Definition of High-Risk Early Hormone-Positive HER2~Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898.	1.7	20
2629	Evolution of gene expression signature in mammary gland stem cells from neonatal to old mice. <i>Cell Death and Disease</i> , 2022, 13, 335.	2.7	2
2630	Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1145-1153.	1.0	8
2631	ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. <i>Nature Communications</i> , 2022, 13, 2011.	5.8	29
2632	Value of the 21-gene expression assay in predicting locoregional recurrence rates in estrogen receptor-positive breast cancer: a systematic review and network meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 535-544.	1.1	7
2633	Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review. <i>Frontiers in Medicine</i> , 2022, 9, 881551.	1.2	11
2634	Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers. <i>Npj Breast Cancer</i> , 2022, 8, 51.	2.3	9
2635	"On the Spot"™ Digital Pathology of Breast Cancer Based on Single-Cell Mass Spectrometry Imaging. <i>Analytical Chemistry</i> , 2022, 94, 6180-6190.	3.2	21
2636	Identifying a confused cell identity for esophageal squamous cell carcinoma. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 122.	7.1	19
2637	Construction and Validation of Angiogenesis-Related Prognostic Risk Signature to Facilitate Survival Prediction and Biomarker Excavation of Breast Cancer Patients. <i>Journal of Oncology</i> , 2022, 2022, 1-21.	0.6	6
2638	Clinical Impact of 11q13.3 Amplification on Immune Cell Infiltration and Prognosis in Breast Cancer. <i>International Journal of General Medicine</i> , 2022, Volume 15, 4037-4052.	0.8	4
2639	The ELEANOR noncoding RNA expression contributes to cancer dormancy and predicts late recurrence of estrogen receptor~positive breast cancer. <i>Cancer Science</i> , 2022, 113, 2336-2351.	1.7	10
2640	Breast tumor microenvironment structures are associated with genomic features and clinical outcome. <i>Nature Genetics</i> , 2022, 54, 660-669.	9.4	88
2641	Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells. <i>Breast Cancer: Basic and Clinical Research</i> , 2022, 16, 117822342210805.	0.6	0
2642	Inverse correlation between Ki67 expression as a continuous variable and outcomes in luminal HER2-negative breast cancer.. , 2019, 5, 72-78.		3
2643	Differences in clinicopathologic features and subtype distribution of invasive breast cancer between women older and younger than 40 years.. , 2019, 5, 92-97.		2

#	ARTICLE	IF	CITATIONS
2644	Differences in clinicopathologic features and subtype distribution of invasive breast cancer between elderly and non-elderly women.. , 2021, 7, 59-64.		0
2645	Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes.. , 2021, 7, 130-135.		1
2655	Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature. JCO Precision Oncology, 2022, 6, e2100463.	1.5	10
2656	Density-Dependent Migration Characteristics of Cancer Cells Driven by Pseudopod Interaction. Frontiers in Cell and Developmental Biology, 2022, 10, 854721.	1.8	6
2657	PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives. Cancers, 2022, 14, 2161.	1.7	15
2658	Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC). Pharmaceuticals, 2022, 15, 542.	1.7	14
2659	The importance of targeting signalling mechanisms of the SLC39A family of zinc transporters to inhibit endocrine resistant breast cancer. Exploration of Targeted Anti-tumor Therapy, 2022, 3, 224-239.	0.5	4
2660	Leveraging Deep Learning Techniques and Integrated Omics Data for Tailored Treatment of Breast Cancer. Journal of Personalized Medicine, 2022, 12, 674.	1.1	6
2661	Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer. Npj Breast Cancer, 2022, 8, 56.	2.3	3
2662	Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin. Cancers, 2022, 14, 2404.	1.7	2
2663	Muscarinic Receptors Associated with Cancer. Cancers, 2022, 14, 2322.	1.7	8
2664	Mouse Mammary Tumor Virus (MMTV) and MMTV-like Viruses: An In-depth Look at a Controversial Issue. Viruses, 2022, 14, 977.	1.5	12
2665	CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer. Nature Communications, 2022, 13, 2642.	5.8	15
2666	Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer. Cancers, 2022, 14, 2405.	1.7	1
2667	A hierarchical approach to combine histological grade and immunohistochemical factors to identify high-risk luminal breast cancers. Ecancermedicinescience, 0, 16, .	0.6	0
2668	Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2022, 28, 3127-3140.	3.2	11
2669	Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2. Biomedicines, 2022, 10, 1061.	1.4	1
2670	Association between tumor 18F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer. Scientific Reports, 2022, 12, 7858.	1.6	3

#	ARTICLE	IF	CITATIONS
2671	Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer. <i>BMC Cancer</i> , 2022, 22, 548.	1.1	2
2672	Plasma membrane proteoglycans syndecan-2 and syndecan-4 engage with EGFR and RON kinase to sustain carcinoma cell cycle progression. <i>Journal of Biological Chemistry</i> , 2022, 298, 102029.	1.6	4
2673	Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer. <i>Scientific Reports</i> , 2022, 12, 8176.	1.6	2
2674	Breast Cancer-Stromal Interactions: Adipose-Derived Stromal/Stem Cell Age and Cancer Subtype Mediated Remodeling. <i>Stem Cells and Development</i> , 2022, 31, 604-620.	1.1	3
2675	Mir-4728 is a Valuable Biomarker for Diagnostic and Prognostic Assessment of HER2-Positive Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	1.6	3
2676	Fractionated irradiation of MCF7 breast cancer cells rewires a gene regulatory circuit towards a treatment-resistant stemness phenotype. <i>Molecular Oncology</i> , 2022, 16, 3410-3435.	2.1	2
2677	Transcriptional Repression by FoxM1 Suppresses Tumor Differentiation and Promotes Metastasis of Breast Cancer. <i>Cancer Research</i> , 2022, 82, 2458-2471.	0.4	17
2678	Socioeconomic, Clinical, and Molecular Features of Breast Cancer Influence Overall Survival of Latin American Women. <i>Frontiers in Oncology</i> , 2022, 12, 845527.	1.3	6
2679	The regulatory function of piRNA/PIWI complex in cancer and other human diseases: The role of DNA methylation. <i>International Journal of Biological Sciences</i> , 2022, 18, 3358-3373.	2.6	26
2680	Adenoid Cystic Carcinoma of the Breast: A Case Report. <i>Cureus</i> , 2022, , .	0.2	0
2681	Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 2509.	1.7	22
2682	Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	2
2683	Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population-based analysis. <i>Cancer Medicine</i> , 0, , .	1.3	3
2684	The AKT1E17K Allele Promotes Breast Cancer in Mice. <i>Cancers</i> , 2022, 14, 2645.	1.7	1
2685	Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study. <i>Cancers</i> , 2022, 14, 2615.	1.7	7
2686	Molecular Diagnostic and Prognostication Assays for the Subtyping of Urinary Bladder Cancer Are on the Way to Illuminating Our Vision. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5620.	1.8	0
2687	Wnt Signaling in the Breast: From Development to Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	10
2688	Exploring BODIPY-Based Sensor for Imaging of Intracellular Microviscosity in Human Breast Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5687.	1.8	2

#	ARTICLE	IF	CITATIONS
2689	Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping. <i>Cancers</i> , 2022, 14, 2571.	1.7	2
2690	Molecular Subtypes As Emerging Predictors of Clinicopathological Response to Neoadjuvant Chemotherapy (NACT) in Locally Advanced Breast Cancer (LABC): A Single-Centre Experience in Western India. <i>Cureus</i> , 2022, , .	0.2	0
2691	Necroptosis-Related LncRNAs Signature and Subtypes for Predicting Prognosis and Revealing the Immune Microenvironment in Breast Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2692	High expression of SLC20A1 is less effective for endocrine therapy and predicts late recurrence in ER-positive breast cancer. <i>PLoS ONE</i> , 2022, 17, e0268799.	1.1	2
2693	Epsteinâ€Barr Virus Association with Breast Cancer: Evidence and Perspectives. <i>Biology</i> , 2022, 11, 799.	1.3	5
2694	Breast Cancer Therapy: The Potential Role of Mesenchymal Stem Cells in Translational Biomedical Research. <i>Biomedicines</i> , 2022, 10, 1179.	1.4	3
2695	CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	14
2696	EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6122.	1.8	7
2697	Metabolomics and EMT Markers of Breast Cancer: A Crosstalk and Future Perspective. <i>Pathophysiology</i> , 2022, 29, 200-222.	1.0	11
2698	Dihydropyrazole-Carbohydrazide Derivatives with Dual Activity as Antioxidant and Anti-Proliferative Drugs on Breast Cancer Targeting the HDAC6. <i>Pharmaceuticals</i> , 2022, 15, 690.	1.7	1
2699	Identification of Crucial lncRNAs for Luminal A Breast Cancer through RNA Sequencing. <i>International Journal of Endocrinology</i> , 2022, 2022, 1-14.	0.6	6
2700	Breast cancer incidence and survival in Scotland by socio-economic deprivation and tumour subtype. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	3
2701	Cellular Senescence in Normal Mammary Gland and Breast Cancer. Implications for Cancer Therapy. <i>Genes</i> , 2022, 13, 994.	1.0	7
2702	Breast cancer recurrence and survival rates in patients who underwent breastâ€conserving surgery under nonâ€mechanically ventilated anesthesia. <i>Cancer Reports</i> , 2023, 6, .	0.6	2
2703	Polo-Like Kinase 1 Regulates Chromosomal Instability and Paclitaxel Resistance in Breast Cancer Cells. <i>Journal of Breast Cancer</i> , 2022, 25, 178.	0.8	3
2704	miR-638 Serves as a Biomarker of 5-Fluorouracil Sensitivity to Neoadjuvant Chemotherapy in Breast Cancer. <i>Journal of Breast Cancer</i> , 0, 25, .	0.8	2
2705	Transcriptional coactivator MED1 in the interface of anti-estrogen and anti-HER2 therapeutic resistance. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 498-510.	0.9	1
2706	Genome-wide cross-cancer analysis illustrates the critical role of bimodal miRNA in patient survival and drug responses to PI3K inhibitors. <i>PLoS Computational Biology</i> , 2022, 18, e1010109.	1.5	1

#	ARTICLE	IF	CITATIONS
2707	Evaluation of the Prognostic Value of CD56 (140 kDa Isoform) Expression in Breast Cancer Tissues: an Eight-Year Retrospective Study. <i>Iranian Biomedical Journal</i> , 2022, 26, 175-182.	0.4	0
2708	Circulating tumor cell assay to non-invasively evaluate PD-L1 and other therapeutic targets in multiple cancers. <i>PLoS ONE</i> , 2022, 17, e0270139.	1.1	1
2709	Breast Cancer Genomics: Primary and Most Common Metastases. <i>Cancers</i> , 2022, 14, 3046.	1.7	3
2710	Differential Private Deep Learning Models for Analyzing Breast Cancer Omics Data. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
2711	Classification of triple negative breast cancer by epithelial mesenchymal transition and the tumor immune microenvironment. <i>Scientific Reports</i> , 2022, 12, .	1.6	10
2712	Glioma Subtypes Based on the Activity Changes of Immunologic and Hallmark Gene Sets in Cancer. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
2713	Upregulated GATA3/miR205-5p Axis Inhibits MFNG Transcription and Reduces the Malignancy of Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 3057.	1.7	2
2714	Construction of ceRNA Networks Associated With CD8 T Cells in Breast Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	11
2715	The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis. <i>Antioxidants</i> , 2022, 11, 1195.	2.2	8
2716	Global Trends in Research of Androgen Receptor Associated With Breast Cancer From 2011 to 2020: A Scientometric Analysis. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	5
2717	Nanotechnological Approaches for the Treatment of Triple-Negative Breast Cancer: A Comprehensive Review. <i>Current Drug Metabolism</i> , 2022, 23, 781-799.	0.7	2
2718	Advances in the Prevention and Treatment of Obesity-Driven Effects in Breast Cancers. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	52
2719	Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	21
2720	Euclidean distance-optimized data transformation for cluster analysis in biomedical data (EDOtrans). <i>BMC Bioinformatics</i> , 2022, 23, .	1.2	6
2721	Breast cancer in the era of precision medicine. <i>Molecular Biology Reports</i> , 2022, 49, 10023-10037.	1.0	19
2722	Intra- and Peritumoral Radiomics Model Based on Early DCE-MRI for Preoperative Prediction of Molecular Subtypes in Invasive Ductal Breast Carcinoma: A Multitask Machine Learning Study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
2723	Association of Obesity and Diabetes With the Incidence of Breast Cancer in Louisiana. <i>American Journal of Preventive Medicine</i> , 2022, 63, S83-S92.	1.6	5
2724	Clinical Application of Next-Generation Sequencing in Patients With Breast Cancer: Real-World Data. <i>Journal of Breast Cancer</i> , 2022, 25, 366.	0.8	8

#	ARTICLE	IF	CITATIONS
2725	A Novel YTHDF3-Based Model to Predict Prognosis and Therapeutic Response in Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	4
2726	A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis. <i>Rheumatology</i> , 0, , .	0.9	5
2727	Relationship of micro-RNA, mRNA and eIF Expression in Tamoxifen-Adapted MCF-7 Breast Cancer Cells: Impact of miR-1972 on Gene Expression, Proliferation and Migration. <i>Biomolecules</i> , 2022, 12, 916.	1.8	4
2728	MicroRNAs miR-142-5p, miR-150-5p, miR-320a-3p, and miR-4433b-5p in Serum and Tissue: Potential Biomarkers in Sporadic Breast Cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	10
2729	Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2730	Association of Serum Levels of Plasticizers Compounds, Phthalates and Bisphenols, in Patients and Survivors of Breast Cancer: A Real Connection?. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8040.	1.2	5
2731	Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer. <i>BioMed Research International</i> , 2022, 2022, 1-10.	0.9	4
2732	Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	7
2733	Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes. <i>BMC Women's Health</i> , 2022, 22, .	0.8	2
2734	Update of the 100 Most Cited Articles on Breast Cancer: A Bibliometric Analysis. <i>The Journal of Breast Health</i> , 2022, 18, 258-270.	0.4	0
2735	A Novel Surrogate Nomogram Capable of Predicting OncotypeDX Recurrence Score. <i>Journal of Personalized Medicine</i> , 2022, 12, 1117.	1.1	0
2736	Machine learning techniques for identification of carcinogenic mutations, which cause breast adenocarcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	11
2737	From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine. <i>Cancers</i> , 2022, 14, 3469.	1.7	5
2738	Anti-breast cancer sinomenine derivatives via mechanisms of apoptosis induction and metastasis reduction. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 1870-1883.	2.5	6
2739	Loss of RPTP ³ primes breast tissue for acid extrusion, promotes malignant transformation and results in early tumour recurrence and shortened survival. <i>British Journal of Cancer</i> , 2022, 127, 1226-1238.	2.9	4
2740	ALYREF, a novel factor involved in breast carcinogenesis, acts through transcriptional and post-transcriptional mechanisms selectively regulating the short NEAT1 isoform. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	17
2741	High SLC20A1 Expression Is Associated With Poor Prognosis for Radiotherapy of Estrogen Receptor-positive Breast Cancer. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 429-442.	0.3	1
2742	EBF1 promotes triple-negative breast cancer progression by surveillance of the HIF1 ¹ pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	4

#	ARTICLE	IF	CITATIONS
2743	Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 517-529.	1.1	5
2744	CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models. <i>Cancers</i> , 2022, 14, 3361.	1.7	6
2745	The development of molecular typing in canine mammary carcinomas. <i>Molecular Biology Reports</i> , 2022, 49, 8943-8951.	1.0	2
2746	Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3618-3629.	3.2	12
2747	Triple-Negative Breast Cancer circRNAome Reveals Hsa_circ_0072309 as a Potential Risk Biomarker. <i>Cancers</i> , 2022, 14, 3280.	1.7	3
2748	LncRNAs in breast cancer: a link to future approaches. <i>Cancer Gene Therapy</i> , 2022, 29, 1866-1877.	2.2	19
2749	Comparative Efficacy of Tyrosine Kinase Inhibitors and Antibody-Drug Conjugates in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A Systematic Review and Network Meta-Analysis. <i>Cancers</i> , 2022, 14, 3372.	1.7	4
2750	Circulating proteins as predictive and prognostic biomarkers in breast cancer. <i>Clinical Proteomics</i> , 2022, 19, .	1.1	20
2751	Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	4
2752	Metabolomics of Breast Cancer: A Review. <i>Metabolites</i> , 2022, 12, 643.	1.3	16
2753	Clinical trials of immunotherapy in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 1-15.	1.1	19
2754	Concordance between Ki-67 index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint. <i>Molecular and Clinical Oncology</i> , 2022, 17, .	0.4	3
2755	Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies. <i>Current Oncology</i> , 2022, 29, 4768-4778.	0.9	14
2756	Inflammation-Driven Regulation of PD-L1 and PD-L2, and Their Cross-Interactions with Protective Soluble TNF± Receptors in Human Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 3513.	1.7	2
2757	A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	30
2758	Radiogenomics analysis reveals the associations of dynamic contrast-enhanced MRI features with gene expression characteristics, PAM50 subtypes, and prognosis of breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
2759	Personalized Approaches for the Prevention and Treatment of Breast Cancer. <i>Journal of Personalized Medicine</i> , 2022, 12, 1201.	1.1	0
2760	Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine. <i>Cancers</i> , 2022, 14, 3876.	1.7	20

#	ARTICLE	IF	CITATIONS
2761	Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8716.	1.8	5
2762	Dual Function of Secreted APE1/Ref-1 in TNBC Tumorigenesis: An Apoptotic Initiator and a Regulator of Chronic Inflammatory Signaling. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9021.	1.8	2
2763	PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?. <i>Cancers</i> , 2022, 14, 4039.	1.7	16
2764	A signature constructed with mitophagy-related genes to predict the prognosis and therapy response for breast cancer. <i>Aging</i> , 2022, 14, 6169-6186.	1.4	9
2765	HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer. <i>EBioMedicine</i> , 2022, 83, 104205.	2.7	8
2766	Application of Fluorescence In Situ Hybridization Assisted by Fluorescence Microscope in Detection of Her2 Gene in Breast Cancer Patients. <i>Contrast Media and Molecular Imaging</i> , 2022, 2022, 1-6.	0.4	2
2767	Triple negative breast cancer: approved treatment options and their mechanisms of action. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3701-3719.	1.2	13
2768	PACT promotes the metastasis of basal-like breast cancer through Rac1 SUMOylation and activation. <i>Oncogene</i> , 2022, 41, 4282-4294.	2.6	4
2769	STAT family of transcription factors in breast cancer: Pathogenesis and therapeutic opportunities and challenges. <i>Seminars in Cancer Biology</i> , 2022, 86, 84-106.	4.3	31
2770	Elevated insulin-like growth factor 2 mRNA binding protein 1 levels predict a poor prognosis in patients with breast carcinoma using an integrated multi-omics data analysis. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
2771	Ovo Like Zinc Finger 2 (OVOL2) Suppresses Breast Cancer Stem Cell Traits and Correlates with Immune Cells Infiltration. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 14, 211-227.	1.0	1
2772	Triple negative breast cancer: Pitfalls and progress. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	110
2773	Triple-negative breast cancer metastasis involves complex epithelial-mesenchymal transition dynamics and requires vimentin. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	43
2774	Accurate determination of CRISPR-mediated gene fitness in transplantable tumours. <i>Nature Communications</i> , 2022, 13, .	5.8	1
2775	Left sided breast cancer is associated with aggressive biology and worse outcomes than right sided breast cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	10
2776	A novel age-related gene expression signature associates with proliferation and disease progression in breast cancer. <i>British Journal of Cancer</i> , 2022, 127, 1865-1875.	2.9	5
2777	Breast cancer stage prediction: a computational approach guided by transcriptome analysis. <i>Molecular Genetics and Genomics</i> , 0, , .	1.0	0
2778	Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	17

#	ARTICLE	IF	CITATIONS
2779	Distinctive gene expression patterns in pregnancy-associated breast cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
2780	Connecting omics signatures and revealing biological mechanisms with iLINCS. <i>Nature Communications</i> , 2022, 13, .	5.8	24
2781	Impact on breast cancer susceptibility and clinicopathological traits of common genetic polymorphisms in <i>TP53</i> , <i>MDM2</i> and <i>ATM</i> genes in Sardinian women. <i>Oncology Letters</i> , 2022, 24, .	0.8	3
2782	Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features. <i>Journal of Zhejiang University: Science B</i> , 2022, 23, 617-624.	1.3	6
2783	BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 263-274.	1.1	5
2784	Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents. <i>Cancers</i> , 2022, 14, 4064.	1.7	11
2785	Fate decisions of breast cancer stem cells in cancer progression. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2786	Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer—A Review of Molecular Characterisation, Therapeutic Targets and Future Trends. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
2787	Functional Characterization of <i>lncRNA152</i> as an Angiogenesis-Inhibiting Tumor Suppressor in Triple-Negative Breast Cancers. <i>Molecular Cancer Research</i> , 2022, 20, 1623-1635.	1.5	6
2788	CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
2789	Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 453-459.	1.1	3
2790	Comparative analysis of the molecular subtype landscape in canine and human mammary gland tumors. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2022, 27, 171-183.	1.0	9
2791	Depletion of Mdig Changes Proteomic Profiling in Triple Negative Breast Cancer Cells. <i>Biomedicines</i> , 2022, 10, 2021.	1.4	0
2792	<i>In Vitro</i> and <i>In Silico</i> Study to Assess Toxic Mechanisms of Hybrid Molecules of Quinone-Benzocaine as Plastoquinone Analogues in Breast Cancer Cells. <i>ACS Omega</i> , 2022, 7, 30250-30264.	1.6	11
2793	Noncanonical Wnt/Ror2 signaling regulates cellâ€‘matrix adhesion to prompt directional tumor cell invasion in breast cancer. <i>Molecular Biology of the Cell</i> , 2022, 33, .	0.9	2
2794	Sâ€™phase fraction, lymph node status and disease staging as the main prognostic factors to differentiate between young and older patients with invasive breast carcinoma. <i>Oncology Letters</i> , 2022, 24, .	0.8	1
2795	Racial Disparity in Quadruple Negative Breast Cancer: Aggressive Biology and Potential Therapeutic Targeting and Prevention. <i>Cancers</i> , 2022, 14, 4484.	1.7	5
2796	Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 14, 259-280.	1.0	3

#	ARTICLE	IF	CITATIONS
2797	Pilot Study of Combination Gemogenovatumel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492211105.	0.6	4
2798	Age-Dependent Heterogeneity of Lymph Node Metastases and Survival Identified by Analysis of a National Breast Cancer Registry. <i>Journal of Pharmacy and Pharmacology Research</i> , 2022, 06, .	0.1	1
2799	Using classification and K-means methods to predict breast cancer recurrence in gene expression data. <i>Journal of Medical Signals and Sensors</i> , 2022, 12, 122.	0.5	1
2800	Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 171-194.	0.8	2
2801	Breast Carcinoma Receptor Expression in a Caribbean Population. <i>The Surgery Journal</i> , 2022, 08, e262-e265.	0.3	0
2802	Clustering Molecular Subtypes in Breast Cancer, Immunohistochemical Parameters and Risk of Axillary Nodal Involvement. <i>Journal of Personalized Medicine</i> , 2022, 12, 1404.	1.1	2
2803	The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets. <i>Genes</i> , 2022, 13, 1555.	1.0	2
2804	Stabilization of c-Myc by the atypical cell cycle regulator, Spy1, decreases efficacy of breast cancer treatments. <i>Breast Cancer Research and Treatment</i> , 2022, 196, 17-30.	1.1	1
2805	Rational Approach to Finding Genes Encoding Molecular Biomarkers: Focus on Breast Cancer. <i>Genes</i> , 2022, 13, 1538.	1.0	0
2806	LncRNA SEMA3B-AS1 inhibits breast cancer progression by targeting miR-3940/KLLN axis. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	15
2807	Time tracking and multidimensional influencing factors analysis on female breast cancer mortality: Evidence from urban and rural China between 1994 to 2019. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
2808	Invasive ductal breast cancer molecular subtype prediction by MRI radiomic and clinical features based on machine learning. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
2809	Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	35
2810	Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes “an observational cohort study in Sweden. <i>BMC Cancer</i> , 2022, 22, .	1.1	6
2811	Development and validation of nomograms for predicting overall survival and cancer specific survival in locally advanced breast cancer patients: A SEER population-based study. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
2812	Comparison of dual mTORC1/2 inhibitor AZD8055 and mTORC1 inhibitor rapamycin on the metabolism of breast cancer cells using proton nuclear magnetic resonance spectroscopy metabolomics. <i>Investigational New Drugs</i> , 2022, 40, 1206-1215.	1.2	1
2813	Overexpression of PBK/TOPK relates to poor prognosis of patients with breast cancer: a retrospective analysis. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	2
2814	Downregulation of Elov15 promotes breast cancer metastasis through a lipid-droplet accumulation-mediated induction of TGF- β 2 receptors. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	8

#	ARTICLE	IF	CITATIONS
2815	Challenges for Triple Negative Breast Cancer Treatment: Defeating Heterogeneity and Cancer Stemness. <i>Cancers</i> , 2022, 14, 4280.	1.7	17
2816	Regulatory mechanisms and function of hypoxia-induced long noncoding RNA NDRG1-OT1 in breast cancer cells. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	3
2817	Five decades of progress in surgical oncology: Breast. <i>Journal of Surgical Oncology</i> , 2022, 126, 852-859.	0.8	0
2818	Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	15
2819	Loss of SNAI1 induces cellular plasticity in invasive triple-negative breast cancer cells. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	4
2820	A vicious circle in breast cancer: The interplay between inflammation, reactive oxygen species, and microRNAs. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
2821	Molecular Classification of Breast Carcinoma in a Tertiary Hospital of India: the Recent Trends. <i>Indian Journal of Surgical Oncology</i> , 0, , .	0.3	0
2822	Effects of Combined Pentadecanoic Acid and Tamoxifen Treatment on Tamoxifen Resistance in MCFâ~7/SC Breast Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11340.	1.8	8
2823	CmPn signaling networks in the tumorigenesis of breast cancer. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	9
2824	Reproductive history differs by molecular subtypes of breast cancer among women agedâ€%â%â€%50Âyears in Scotland diagnosed 2009â€“2016: a cross-sectional study. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	0
2825	Immune depletion of the methylated phenotype of colon cancer is closely related to resistance to immune checkpoint inhibitors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
2826	Terminal differentiation and anti-tumorigenic effects of prolactin in breast cancer. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	0
2827	Comprehensive Transcriptomic and Proteomic Analyses Identify a Candidate Gene Set in Cross-Resistance for Endocrine Therapy in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10539.	1.8	1
2828	Delving into the Heterogeneity of Different Breast Cancer Subtypes and the Prognostic Models Utilizing scRNA-Seq and Bulk RNA-Seq. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9936.	1.8	8
2829	Removing unwanted variation from large-scale RNA sequencing data with PRPS. <i>Nature Biotechnology</i> , 2023, 41, 82-95.	9.4	20
2830	Current landscape of personalized clinical treatments for triple-negative breast cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	11
2831	Investigation of the Role of PUFA Metabolism in Breast Cancer Using a Rank-Based Random Forest Algorithm. <i>Cancers</i> , 2022, 14, 4663.	1.7	3
2832	The roles of small extracellular vesicles as prognostic biomarkers and treatment approaches in triple-negative breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2

#	ARTICLE	IF	CITATIONS
2833	Hypoxia Triggers TAZ Phosphorylation in Basal A Triple Negative Breast Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10119.	1.8	2
2834	Current Molecular Combination Therapies Used for the Treatment of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11046.	1.8	19
2835	Salvage Mastectomy Is not the Treatment of Choice for Aggressive Subtypes of Ipsilateral Breast Cancer Recurrence: A Single-Institution Retrospective Study. <i>The Journal of Breast Health</i> , 2022, 18, 315-322.	0.4	4
2836	Machine learning-assisted elucidation of CD81â€“CD44 interactions in promoting cancer stemness and extracellular vesicle integrity. <i>ELife</i> , 0, 11, .	2.8	12
2837	Modulatory role of miRNAs in thyroid and breast cancer progression and insights into their therapeutic manipulation. <i>Current Research in Pharmacology and Drug Discovery</i> , 2022, 3, 100131.	1.7	5
2838	Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy. <i>Annals of Medicine</i> , 2022, 54, 2580-2596.	1.5	7
2839	Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	10
2840	Expression of MiRNA-29b and MiRNA-31 and their diagnostic and prognostic values in Egyptian females with breast cancer. <i>Non-coding RNA Research</i> , 2022, 7, 248-257.	2.4	6
2841	Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 0, 5, 971-80.	0.9	9
2842	Caveolin-1-deficient fibroblasts promote migration, invasion, and stemness via activating the TGF- β /Smad signaling pathway in breast cancer cells. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, 54, 1587-1598.	0.9	2
2843	Transcriptomic profiling of Indian breast cancer patients revealed subtype-specific mRNA and lncRNA signatures. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
2844	A genome-wide cell-free DNA methylation analysis identifies an epsignature associated with metastatic luminal B breast cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	3
2845	Spatial Transcriptomic Analysis of a Diverse Patient Cohort Reveals a Conserved Architecture in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2023, 83, 34-48.	0.4	9
2846	NSMCE2, a novel super-enhancer-regulated gene, is linked to poor prognosis and therapy resistance in breast cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
2847	Sabizabulin, a Potent Orally Bioavailable Colchicine Binding Site Agent, Suppresses HER2+ Breast Cancer and Metastasis. <i>Cancers</i> , 2022, 14, 5336.	1.7	8
2848	A living biobank of canine mammary tumor organoids as a comparative model for human breast cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	12
2849	The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2850	Differential Cytotoxicity of Curcumin-Loaded Micelles on Human Tumor and Stromal Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12362.	1.8	6

#	ARTICLE	IF	CITATIONS
2851	A gene expression signature in HER2+ breast cancer patients related to neoadjuvant chemotherapy resistance, overall survival, and disease-free survival. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
2852	Gene expression profile suggests different mechanisms underlying sporadic and familial mesial temporal lobe epilepsy. <i>Experimental Biology and Medicine</i> , 2022, 247, 2233-2250.	1.1	2
2853	Cellular Plasticity and Heterotypic Interactions during Breast Morphogenesis and Cancer Initiation. <i>Cancers</i> , 2022, 14, 5209.	1.7	3
2854	The Transcriptomic Landscape of Pediatric Astrocytoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12696.	1.8	3
2855	Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform. <i>Cancers</i> , 2022, 14, 4859.	1.7	0
2856	Hypoxia and ER α Transcriptional Crosstalk Is Associated with Endocrine Resistance in Breast Cancer. <i>Cancers</i> , 2022, 14, 4934.	1.7	4
2857	Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	0
2858	Myricetin-induced apoptosis in triple-negative breast cancer cells through inhibition of the PI3K/Akt/mTOR pathway. , 2022, 39, .		12
2859	A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming. <i>Oncogene</i> , 2022, 41, 5076-5091.	2.6	5
2860	The Role of miRNA-182 and FOXO3 Expression in Breast Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 3361-3370.	0.5	7
2861	Recurrence Score $\text{\textcircled{R}}$ Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting $\text{\textcircled{R}}$ Results of the IRMA Trial. <i>Cancers</i> , 2022, 14, 5365.	1.7	6
2862	Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent $\langle scp \rangle$ TP53 $\langle /scp \rangle$ mutation and $\langle scp \rangle$ MYC $\langle /scp \rangle$ amplification. <i>Thoracic Cancer</i> , 0, , .	0.8	2
2863	Intrinsic subtypes in Ethiopian breast cancer patient. <i>Breast Cancer Research and Treatment</i> , 2022, 196, 495-504.	1.1	4
2864	Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 4829.	1.7	8
2865	Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 205-214.	1.9	2
2866	A genomic and transcriptomic study toward breast cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
2867	The Role of MicroRNAs in HER2-Positive Breast Cancer: Where We Are and Future Prospective. <i>Cancers</i> , 2022, 14, 5326.	1.7	6
2868	Identification of miRNA biomarkers for breast cancer by combining ensemble regularized multinomial logistic regression and Cox regression. <i>BMC Bioinformatics</i> , 2022, 23, .	1.2	4

#	ARTICLE	IF	CITATIONS
2869	Identifying enhancer-driven subtype-specific prognostic markers in breast cancer based on multi-omics data. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
2870	Mass spectroscopy-based proteomics and metabolomics analysis of triple-positive breast cancer cells treated with tamoxifen and/or trastuzumab. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 467-488.	1.1	3
2871	USP7 Induces Chemoresistance in Triple-Negative Breast Cancer via Deubiquitination and Stabilization of ABCB1. <i>Cells</i> , 2022, 11, 3294.	1.8	8
2872	Classification of Subgroups with Immune Characteristics Based on DNA Methylation in Luminal Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12747.	1.8	0
2873	K-RAS Associated Gene-Mutation-Based Algorithm for Prediction of Treatment Response of Patients with Subtypes of Breast Cancer and Especially Triple-Negative Cancer. <i>Cancers</i> , 2022, 14, 5322.	1.7	1
2874	Strong prognostic value of SLAMF7 protein expression in patients with lymph node- positive breast cancer. <i>Oncology Letters</i> , 2022, 24, .	0.8	2
2875	Identification of a prognostic risk-scoring model and risk signatures based on glycosylation-associated cluster in breast cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
2876	Breast Cancer Metastatic Dormancy and Relapse: An Enigma of Microenvironment(s). <i>Cancer Research</i> , 2022, 82, 4497-4510.	0.4	14
2877	Crosstalk between CXCR4/ACKR3 and EGFR Signaling in Breast Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11887.	1.8	1
2878	Breast Cancer Cells Reprogram the Oncogenic lncRNAs/mRNAs Coexpression Networks in Three-Dimensional Microenvironment. <i>Cells</i> , 2022, 11, 3458.	1.8	3
2879	Circular RNAs: New layer of complexity evading breast cancer heterogeneity. <i>Non-coding RNA Research</i> , 2023, 8, 60-74.	2.4	20
2880	Exploring the Integrated Role of AKT2, CD44v6, And MT1-MMP as Predictors of Axillary Lymph Node Metastasis in Invasive Breast Carcinoma of No Special Type. <i>Iranian Journal of Pathology</i> , 2022, 17, 475-485.	0.2	0
2881	The Monocyte, a Maestro in the Tumor Microenvironment (TME) of Breast Cancer. <i>Cancers</i> , 2022, 14, 5460.	1.7	14
2882	Detecting the expression of HRs and BCL2 via IHC can help identify luminal A-like subtypes of triple-positive breast cancers. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	0
2883	Unsupervised Analysis Based on DCE-MRI Radiomics Features Revealed Three Novel Breast Cancer Subtypes with Distinct Clinical Outcomes and Biological Characteristics. <i>Cancers</i> , 2022, 14, 5507.	1.7	6
2884	Effects of hirsuteine on MDA-453 breast cancer cell proliferation. <i>Oncology Letters</i> , 2022, 25, .	0.8	2
2885	Zinc's Association with the CmPn/CmP Signaling Network in Breast Cancer Tumorigenesis. <i>Biomolecules</i> , 2022, 12, 1672.	1.8	7
2886	Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4

#	ARTICLE	IF	CITATIONS
2887	Epigenetic Mechanisms in Breast Adenocarcinoma: Novel DNA Methylation Patterns. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 603-608.	0.3	0
2888	Breast Cancer Sera Changes in Alu Element Methylation Predict Metastatic Disease Progression. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 731-738.	0.3	0
2889	Circulating miRNA Expression Profiling in Breast Cancer Molecular Subtypes: Applying Machine Learning Analysis in Bioinformatics. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 739-749.	0.3	4
2890	SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXR \pm /FOXO1 pathway independently of REV-ERBs. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	7
2891	MLSP: A bioinformatics tool for predicting molecular subtypes and prognosis in patients with breast cancer. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 6412-6426.	1.9	0
2892	Protein disulfide isomerase A3 activity promotes extracellular accumulation of proteins relevant to basal breast cancer outcomes in human MDA-MB-A231 breast cancer cells. <i>American Journal of Physiology - Cell Physiology</i> , 2023, 324, C113-C132.	2.1	2
2893	Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer. <i>Genes</i> , 2022, 13, 2065.	1.0	19
2894	The molecular profile of breast cancer: primary tumor versus corresponding lymph node metastases. <i>Romanian Journal of Morphology and Embryology</i> , 2022, 63, 421-429.	0.4	0
2895	Classic and New Markers in Diagnostics and Classification of Breast Cancer. <i>Cancers</i> , 2022, 14, 5444.	1.7	18
2896	Association between Obesity, Race or Ethnicity, and Luminal Subtypes of Breast Cancer. <i>Biomedicines</i> , 2022, 10, 2931.	1.4	6
2897	The application of exosomes in the treatment of triple-negative breast cancer. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	8
2898	Loss of Brca1 and Trp53 in adult mouse mammary ductal epithelium results in development of hormone receptor-positive or hormone receptor-negative tumors, depending on inactivation of Rb family proteins. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	0
2899	Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts. <i>Cancer Cell</i> , 2022, 40, 1521-1536.e7.	7.7	23
2900	Signatures of Breast Cancer Progression in the Blood: What Could Be Learned from Circulating Tumor Cell Transcriptomes. <i>Cancers</i> , 2022, 14, 5668.	1.7	3
2901	Omission of chemotherapy for hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer: patterns of treatment and outcomes from the Korean Breast Cancer Society Registry. <i>Annals of Surgical Treatment and Research</i> , 2022, 103, 313.	0.4	1
2902	Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study. <i>Breast Journal</i> , 2022, 2022, 1-11.	0.4	2
2903	High SURF4 expression is associated with poor prognosis of breast cancer. <i>Aging</i> , 2022, 14, 9317-9337.	1.4	4
2904	Establishment and Validation of a Model for Disease-Free Survival Rate Prediction Using the Combination of microRNA-381 and Clinical Indicators in Patients with Breast Cancer. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 14, 375-389.	1.0	1

#	ARTICLE	IF	CITATIONS
2905	The deubiquitinating enzyme STAMBP is a newly discovered driver of triple-negative breast cancer progression that maintains RAI14 protein stability. <i>Experimental and Molecular Medicine</i> , 2022, 54, 2047-2059.	3.2	7
2906	ERK MAP Kinase Signaling Regulates RAR Signaling to Confer Retinoid Resistance on Breast Cancer Cells. <i>Cancers</i> , 2022, 14, 5890.	1.7	0
2907	The POLR3G Subunit of Human RNA Polymerase III Regulates Tumorigenesis and Metastasis in Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 5732.	1.7	7
2908	Choice of High-Throughput Proteomics Method Affects Data Integration with Transcriptomics and the Potential Use in Biomarker Discovery. <i>Cancers</i> , 2022, 14, 5761.	1.7	1
2909	The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target. <i>Life</i> , 2022, 12, 1992.	1.1	18
2910	Multiparametric MRI Features of Breast Cancer Molecular Subtypes. <i>Medicina (Lithuania)</i> , 2022, 58, 1716.	0.8	5
2911	Suicide risk among female breast cancer survivors: A population-based study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2912	Correlations between serum lipid and Ki67 levels in different breast cancer molecular subcategories. <i>Oncology Letters</i> , 2022, 25, .	0.8	3
2913	A 5-Pathway Signature Predicts Prognosis Based on Immune-Derived lncRNAs in Patients with Breast Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-17.	0.6	1
2914	Transcriptomic pan-cancer analysis using rank-based Bayesian inference. <i>Molecular Oncology</i> , 2023, 17, 548-563.	2.1	0
2915	Identifying Associations between DCE-MRI Radiomic Features and Expression Heterogeneity of Hallmark Pathways in Breast Cancer: A Multi-Center Radiogenomic Study. <i>Genes</i> , 2023, 14, 28.	1.0	1
2916	Long term trends of breast cancer incidence according to proliferation status. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
2917	Identification of a minimum number of genes to predict triple-negative breast cancer subgroups from gene expression profiles. <i>Human Genomics</i> , 2022, 16, .	1.4	2
2918	MicroRNAs: A Link between Mammary Gland Development and Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15978.	1.8	3
2919	Immune subtype identification and multi-layer perceptron classifier construction for breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
2920	Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression. <i>ESMO Open</i> , 2022, 7, 100636.	2.0	4
2921	Lipid Metabolism Heterogeneity and Crosstalk with Mitochondria Functions Drive Breast Cancer Progression and Drug Resistance. <i>Cancers</i> , 2022, 14, 6267.	1.7	6
2922	Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer. <i>Cancers</i> , 2022, 14, 6034.	1.7	6

#	ARTICLE	IF	CITATIONS
2923	Predictive and Prognostic Value of TRIM58 Protein Expression in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 14, 475-487.	1.0	0
2924	Hydroxychavicol as a potential anticancer agent (Review). <i>Oncology Letters</i> , 2022, 25, .	0.8	2
2925	Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5417-5428.	1.2	3
2926	Blockade of store-operated calcium entry sensitizes breast cancer cells to cisplatin therapy via modulating inflammatory response. <i>Saudi Pharmaceutical Journal</i> , 2023, 31, 245-254.	1.2	3
2927	Adipocytes secretome from normal and tumor breast favor breast cancer invasion by metabolic reprogramming. <i>Clinical and Translational Oncology</i> , 2023, 25, 1389-1401.	1.2	2
2928	Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases. <i>European Journal of Medical Research</i> , 2023, 28, .	0.9	3
2929	Apoptosis-modulatory miR-361-3p as a novel treatment target in endocrine-responsive and endocrine-resistant breast cancer. <i>Journal of Endocrinology</i> , 2023, 256, .	1.2	1
2930	Impact of age on indication for chemotherapy in early breast cancer patients: results from 104 German institutions from 2008 to 2017. <i>Archives of Gynecology and Obstetrics</i> , 2023, 308, 219-229.	0.8	3
2932	Prognostic significance of pretreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with T2N1 hormone receptor-positive, ERBB2-negative breast cancer who underwent adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	3
2933	<scp>PRMT3</scp> regulates the progression of invasive micropapillary carcinoma of the breast. <i>Cancer Science</i> , 2023, 114, 1912-1928.	1.7	6
2934	Clinicopathological characteristics and features of molecular subtypes of breast cancer at high altitudes. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
2935	NTF4 plays a dual role in breast cancer in mammary tumorigenesis and metastatic progression. <i>International Journal of Biological Sciences</i> , 2023, 19, 641-657.	2.6	0
2936	Learning from small medical dataâ€”robust semi-supervised cancer prognosis classifier with Bayesian variational autoencoder. <i>Bioinformatics Advances</i> , 2023, 3, .	0.9	2
2937	Construction of a DNA damage repair gene signature for predicting prognosis and immune response in breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
2938	Targeting Breast Cancer Stem Cells. <i>International Journal of Biological Sciences</i> , 2023, 19, 552-570.	2.6	18
2939	Analysis of Changes in the Expression of Selected Genes from the ABC Family in Patients with Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1257.	1.8	0
2940	Obesity and Breast Cancer: Interaction or Interference with the Response to Therapy?. <i>Current Oncology</i> , 2023, 30, 1220-1231.	0.9	5
2941	On data normalization and batch-effect correction for tumor subtyping with microRNA data. <i>NAR Genomics and Bioinformatics</i> , 2023, 5, .	1.5	1

#	ARTICLE	IF	CITATIONS
2942	Clinicopathological and prognostic value of Ki-67 expression in oral malignant melanoma: A systematic review and meta-analysis. <i>Journal of Dental Research, Dental Clinics, Dental Prospects</i> , 2022, 16, 140-146.	0.4	1
2943	Evaluating the Role of Circulating MicroRNAs in Predicting Long-Term Survival Outcomes in Breast Cancer: A Prospective, Multicenter Clinical Trial. <i>Journal of the American College of Surgeons</i> , 2023, 236, 317-327.	0.2	8
2944	Expression and prognosis analyses of the fibronectin type-III domain-containing (FNDC) protein family in human cancers: A Review. <i>Medicine (United States)</i> , 2022, 101, e31854.	0.4	2
2945	Analysis of Tumor Microenvironment Heterogeneity among Breast Cancer Subtypes to Identify Subtype-Specific Signatures. <i>Genes</i> , 2023, 14, 44.	1.0	4
2946	The Prognostic and Predictive Value of Genomic Assays in Guiding Adjuvant Breast Radiation Therapy. <i>Biomedicines</i> , 2023, 11, 98.	1.4	2
2947	Radiotherapeutic Strategies to Overcome Resistance of Breast Cancer Brain Metastases by Considering Immunogenic Aspects of Cancer Stem Cells. <i>Cancers</i> , 2023, 15, 211.	1.7	2
2948	Special Techniques of Adjuvant Breast Carcinoma Radiotherapy. <i>Cancers</i> , 2023, 15, 298.	1.7	1
2949	Ezrin accelerates breast cancer liver metastasis through promoting furin-like convertase-mediated cleavage of Notch1. <i>Cellular Oncology (Dordrecht)</i> , 2023, 46, 571-587.	2.1	4
2950	The Role of PPARs in Breast Cancer. <i>Cells</i> , 2023, 12, 130.	1.8	16
2951	Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	1
2952	Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
2953	Proliferative epithelial changes in tumour adjacent tissue in Sri Lankan women with breast carcinoma: do morphological changes support molecular models of breast carcinogenesis?. <i>Diagnostic Pathology</i> , 2022, 17, .	0.9	0
2954	Mebendazole prevents distant organ metastases in part by decreasing ITGÎ24 expression and cancer stemness. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	3
2955	Combination of Conventional Drugs with Biocompounds Derived from Cinnamic Acid: A Promising Option for Breast Cancer Therapy. <i>Biomedicines</i> , 2023, 11, 275.	1.4	5
2956	Identification and validation of immunohistochemical marker panels to predict the prognosis of muscle invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2023, 12, 176-186.	0.6	1
2957	Bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with HER2 low expression breast cancer. <i>Gland Surgery</i> , 2023, .	0.5	0
2958	Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis. <i>Diagnostics</i> , 2023, 13, 372.	1.3	4
2959	The tamoxifen-regulated, long non-coding RNA LINC00992 affects proliferation, migration, and expression of tamoxifen resistance-associated genes in MCF-7 breast cancer cells. <i>Wspolczesna Onkologia</i> , 0, , .	0.7	0

#	ARTICLE	IF	CITATIONS
2960	TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis. <i>Cancer Research</i> , 2023, 83, 997-1015.	0.4	1
2961	Zebrafish Cancer Avatars: A Translational Platform for Analyzing Tumor Heterogeneity and Predicting Patient Outcomes. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2288.	1.8	5
2962	Tumorigenicity of EGFR- and/or HER2-Positive Breast Cancers Is Mediated by Recruitment of Tumor-Associated Macrophages. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1443.	1.8	3
2963	Systemically Identifying Triple-Negative Breast Cancer Subtype-Specific Prognosis Signatures, Based on Single-Cell RNA-Seq Data. <i>Cells</i> , 2023, 12, 367.	1.8	1
2964	Establishment and characterization of a HER2-enriched canine mammary cancerous myoepithelial cell line. <i>BMC Veterinary Research</i> , 2023, 19, .	0.7	1
2965	GRHL2-controlled gene expression networks in luminal breast cancer. <i>Cell Communication and Signaling</i> , 2023, 21, .	2.7	3
2966	The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis. <i>EJNMMI Research</i> , 2023, 13, .	1.1	7
2967	The potential role of nanomedicine in the treatment of breast cancer to overcome the obstacles of current therapies. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	3
2968	Progranulin and Breast Cancer Mortality: 13-Year Follow-Up of a Cohort Study. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 15, 251-261.	1.0	0
2969	A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6834.	1.8	23
2970	Estrogen receptor targeting with genistein radiolabeled Technetium-99m as radiotracer of breast cancer: Its optimization, characterization, and predicting stability constants by DFT calculation. <i>Heliyon</i> , 2023, 9, e13169.	1.4	2
2971	Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer Reveals TP53 Aneuploidy-driven Metabolic Reprogramming. <i>Cancer Research Communications</i> , 2023, 3, 281-296.	0.7	0
2972	MiR-221 and miR-222 regulate cell cycle progression and affect chemosensitivity in breast cancer by targeting ANXA3. <i>Experimental and Therapeutic Medicine</i> , 2023, 25, .	0.8	6
2973	Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 2903.	1.2	6
2974	Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 583-598.	1.9	4
2975	A bibliometric analysis of 16,826 triple-negative breast cancer publications using multiple machine learning algorithms: Progress in the past 17 years. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	0
2976	Rise of Deep Learning Clinical Applications and Challenges in Omics Data: A Systematic Review. <i>Diagnostics</i> , 2023, 13, 664.	1.3	2
2978	Early Assessment of Neoadjuvant Chemotherapy Response Using Multiparametric Magnetic Resonance Imaging in Luminal B-like Subtype of Breast Cancer Patients: A Single-Center Prospective Study. <i>Diagnostics</i> , 2023, 13, 694.	1.3	0

#	ARTICLE	IF	CITATIONS
2980	The activation of <i>EP300</i> by <i>F11R</i> leads to <i>EMT</i> and acts as a prognostic factor in triple-negative breast cancers. <i>Journal of Pathology: Clinical Research</i> , 2023, 9, 165-181.	1.3	1
2981	Recent advances of small extracellular vesicle biomarkers in breast cancer diagnosis and prognosis. <i>Molecular Cancer</i> , 2023, 22, .	7.9	19
2982	Breast cancer subtype and clinical characteristics in women from Peru. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
2983	Characteristics of recurrence, predictors for relapse and prognosis of rapid relapse triple-negative breast cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
2984	Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	6
2985	Immunohistochemical subtype and its relationship with 5-year overall survival in breast cancer patients. <i>Ecanermedalscience</i> , 0, 17, .	0.6	0
2986	The RUNX/CBF β Complex in Breast Cancer: A Conundrum of Context. <i>Cells</i> , 2023, 12, 641.	1.8	2
2987	Galectin functions in cancer-associated inflammation and thrombosis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	3
2988	The role of LncRNAs in tumor immunotherapy. <i>Cancer Cell International</i> , 2023, 23, .	1.8	11
2989	Variable Intrinsic Expression of Immunoregulatory Biomarkers in Breast Cancer Cell Lines, Mammospheres, and Co-Cultures. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4478.	1.8	2
2990	CRISPR/Cas9 screen uncovers functional translation of cryptic lncRNA-encoded open reading frames in human cancer. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	10
2991	Contrast subgraphs allow comparing homogeneous and heterogeneous networks derived from omics data. <i>GigaScience</i> , 2022, 12, .	3.3	3
2992	Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2023, 32, 708-717.	1.1	0
2993	Lineage plasticity enables low-ER luminal tumors to evolve and gain basal-like traits. <i>Breast Cancer Research</i> , 2023, 25, .	2.2	3
2994	Molecular Profiling in Early ER+ Breast Cancer to Aid Systemic Therapy Decisions. <i>Current Oncology Reports</i> , 2023, 25, 491-500.	1.8	1
2995	Tumor senescence leads to poor survival and therapeutic resistance in human breast cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
2996	Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2023, 199, 1-12.	1.1	4
2997	Editorial: Cancer stem cells as attractive targets for breast cancer therapy. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0

#	ARTICLE	IF	CITATIONS
2999	Psychotic disorders as a framework for precision psychiatry. <i>Nature Reviews Neurology</i> , 0, , .	4.9	3
3000	Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs. <i>Cancers</i> , 2023, 15, 1582.	1.7	4
3001	<scp>RANK</scp> is a poor prognosis marker and a therapeutic target in <scp>ER</scp> â€negative postmenopausal breast cancer. <i>EMBO Molecular Medicine</i> , 2023, 15, .	3.3	2
3002	Evaluation of the efficacy of chemotherapy for tubular carcinoma of the breast: A Surveillance, Epidemiology, and End Results cohort study. <i>Cancer Medicine</i> , 0, , .	1.3	1
3003	Leveraging transcriptomics for precision diagnosis: Lessons learned from cancer and sepsis. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	7
3004	MMR Deficiency Defines Distinct Molecular Subtype of Breast Cancer with Histone Proteomic Networks. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5327.	1.8	1
3005	The Chorioallantoic Membrane Xenograft Assay as a Reliable Model for Investigating the Biology of Breast Cancer. <i>Cancers</i> , 2023, 15, 1704.	1.7	2
3006	Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5474.	1.8	4
3007	Multiplex imaging of breast cancer lymph node metastases identifies prognostic single-cell populations independent of clinical classifiers. <i>Cell Reports Medicine</i> , 2023, 4, 100977.	3.3	6
3008	Female breast cancer subtypes in the Romagna Unit of the Emilia-Romagna cancer registry, and estimated incident cases by subtypes and age in Italy in 2020. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
3009	Role of RUNX2 in breast cancer development and drug resistance (Review). <i>Oncology Letters</i> , 2023, 25, .	0.8	1
3010	Revisiting the Syndecans: Master Signaling Regulators with Prognostic and Targetable Therapeutic Values in Breast Carcinoma. <i>Cancers</i> , 2023, 15, 1794.	1.7	4
3011	Intratumoral heterogeneity, treatment response, and survival outcome of <scp>ER</scp> â€positive <scp>HER2</scp> â€positive breast cancer. <i>Cancer Medicine</i> , 0, , .	1.3	1
3012	GE11-antigen-loaded hepatitis B virus core antigen virus-like particles efficiently bind to TNBC tumor. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
3013	Estrogen Receptor β 24 Regulates Chemotherapy Resistance and Induces Cancer Stem Cells in Triple Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5867.	1.8	5
3014	Identification of Breast Cancer Subtypes by Integrating Genomic Analysis with the Immune Microenvironment. <i>ACS Omega</i> , 2023, 8, 12217-12231.	1.6	5
3015	The WAVE3/ β 2-catenin oncogenic signaling regulates chemoresistance in triple negative breast cancer. <i>Breast Cancer Research</i> , 2023, 25, .	2.2	2
3016	The Association between Early-Onset Diagnosis and Clinical Outcomes in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2023, 15, 1923.	1.7	1

#	ARTICLE	IF	CITATIONS
3017	S1P1 Threonine 236 Phosphorylation Mediates the Invasiveness of Triple-Negative Breast Cancer and Sensitivity to FTY720. <i>Cells</i> , 2023, 12, 980.	1.8	2
3018	Reproducibility and intratumoral heterogeneity of the PAM50 breast cancer assay. <i>Breast Cancer Research and Treatment</i> , 2023, 199, 147-154.	1.1	1
3019	Recent advances in lab-on-a-chip systems for breast cancer metastasis research. <i>Nanoscale Advances</i> , 2023, 5, 2375-2393.	2.2	2
3020	Triphenyltin(IV) Carboxylates with Exceptionally High Cytotoxicity against Different Breast Cancer Cell Lines. <i>Biomolecules</i> , 2023, 13, 595.	1.8	3
3021	High expression of RTN4IP1 predicts adverse prognosis for patients with breast cancer. <i>Translational Cancer Research</i> , 2023, 12, 859-872.	0.4	1
3022	TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2023, 482, 861-868.	1.4	2
3023	Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer. <i>Nature Cancer</i> , 2023, 4, 716-733.	5.7	5
3024	Altered Expression of CYSLTR1 is Associated With Adverse Clinical Outcome in Triple Negative Breast Tumors: An <i>&lt;i>in Silico</i> Approach. <i>The Journal of Breast Health</i> , 2023, 19, 148-158.	0.4	0
3025	Molecular landscape and emerging therapeutic strategies in breast cancer brain metastasis. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311659.	1.4	0
3026	Integrated pancancer analysis reveals the oncogene characteristics and prognostic value of DIP2B in breast cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	0
3028	Cytokeratin 6 identifies basal-like subtypes of pancreatic ductal adenocarcinoma with decreased survival. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 7539-7546.	1.2	2
3029	Homotypic Entosis as a Potential Novel Diagnostic Marker in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6819.	1.8	4
3030	SRPKs: a promising therapeutic target in cancer. <i>Clinical and Experimental Medicine</i> , 2023, 23, 3093-3112.	1.9	0
3031	Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far. <i>OncoTargets and Therapy</i> , 0, Volume 16, 235-247.	1.0	3
3032	Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type. <i>Cancers</i> , 2023, 15, 2204.	1.7	10
3033	Role of Secreted Frizzled-Related Protein 1 in Early Breast Carcinogenesis and Breast Cancer Aggressiveness. <i>Cancers</i> , 2023, 15, 2251.	1.7	1
3034	Claudin-4-adhesion signaling drives breast cancer metabolism and progression via liver X receptor β . <i>Breast Cancer Research</i> , 2023, 25, .	2.2	2
3035	Multimodal ultrasound features of breast cancers: correlation with molecular subtypes. <i>BMC Medical Imaging</i> , 2023, 23, .	1.4	3

#	ARTICLE	IF	CITATIONS
3036	Diffusion-time dependent diffusion MRI: effect of diffusion-time on microstructural mapping and prediction of prognostic features in breast cancer. <i>European Radiology</i> , 0, , .	2.3	0
3037	COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	3
3038	Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis. <i>ESMO Open</i> , 2023, 8, 101216.	2.0	0
3039	spongEffects: ceRNA modules offer patient-specific insights into the miRNA regulatory landscape. <i>Bioinformatics</i> , 2023, 39, .	1.8	2